
<html lang="en"     class="pb-page"  data-request-id="303a5621-cf94-43af-999e-efb6a6196ee1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b01468;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2017.60.issue-7"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer" /></meta><meta name="dc.Creator" content="Heather E.  Burks" /></meta><meta name="dc.Creator" content="Tinya  Abrams" /></meta><meta name="dc.Creator" content="Christina A.  Kirby" /></meta><meta name="dc.Creator" content="Jason  Baird" /></meta><meta name="dc.Creator" content="Alexander  Fekete" /></meta><meta name="dc.Creator" content="Lawrence G.  Hamann" /></meta><meta name="dc.Creator" content="Sunkyu  Kim" /></meta><meta name="dc.Creator" content="Franco  Lombardo" /></meta><meta name="dc.Creator" content="Alice  Loo" /></meta><meta name="dc.Creator" content="Danuta  Lubicka" /></meta><meta name="dc.Creator" content="Kaitlin  Macchi" /></meta><meta name="dc.Creator" content="Donald P.  McDonnell" /></meta><meta name="dc.Creator" content="Yuji  Mishina" /></meta><meta name="dc.Creator" content="John D.  Norris" /></meta><meta name="dc.Creator" content="Jill  Nunez" /></meta><meta name="dc.Creator" content="Chitra  Saran" /></meta><meta name="dc.Creator" content="Yingchuan  Sun" /></meta><meta name="dc.Creator" content="Noel M.  Thomsen" /></meta><meta name="dc.Creator" content="Chunrong  Wang" /></meta><meta name="dc.Creator" content="Jianling  Wang" /></meta><meta name="dc.Creator" content="Stefan  Peukert" /></meta><meta name="dc.Description" content="Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity..." /></meta><meta name="Description" content="Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 15, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01468" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01468" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01468" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01468" /></link>
        
    
    

<title>Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01468" /></meta><meta property="og:title" content="Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0028.jpeg" /></meta><meta property="og:description" content="Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo. We outline the discovery and chemical optimization of the THIQ scaffold leading to THIQ 40 and showcase the racemization of the scaffold, pharmacokinetic studies in preclinical species, and the in vivo efficacy of THIQ 40 in a MCF-7 human breast cancer xenograft model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01468"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01468">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01468&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01468&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01468&amp;href=/doi/10.1021/acs.jmedchem.6b01468" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 2790-2818</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01592" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01665" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Heather+E.++Burks">Heather E. Burks</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-9115-9970" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tinya++Abrams">Tinya Abrams</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christina+A.++Kirby">Christina A. Kirby</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Baird">Jason Baird</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander++Fekete">Alexander Fekete</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lawrence+G.++Hamann">Lawrence G. Hamann</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sunkyu++Kim">Sunkyu Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Franco++Lombardo">Franco Lombardo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alice++Loo">Alice Loo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Danuta++Lubicka">Danuta Lubicka</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kaitlin++Macchi">Kaitlin Macchi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Donald+P.++McDonnell">Donald P. McDonnell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuji++Mishina">Yuji Mishina</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+D.++Norris">John D. Norris</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jill++Nunez">Jill Nunez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chitra++Saran">Chitra Saran</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yingchuan++Sun">Yingchuan Sun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Noel+M.++Thomsen">Noel M. Thomsen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chunrong++Wang">Chunrong Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianling++Wang">Jianling Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Peukert">Stefan Peukert</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina 27710, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 617-871-3803. E-mail: <a href="/cdn-cgi/l/email-protection#92faf7f3e6faf7e0bcf0e7e0f9e1d2fcfde4f3e0e6fbe1bcf1fdff"><span class="__cf_email__" data-cfemail="a0c8c5c1d4c8c5d28ec2d5d2cbd3e0cecfd6c1d2d4c9d38ec3cfcd">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01468&amp;href=/doi/10.1021%2Facs.jmedchem.6b01468" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 2790–2818</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 15, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 November 2016</li><li><span class="item_label"><b>Published</b> online</span>15 March 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 April 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01468" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01468</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2790%26pageCount%3D29%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHeather%2BE.%2BBurks%252C%2BTinya%2BAbrams%252C%2BChristina%2BA.%2BKirby%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D7%26contentID%3Dacs.jmedchem.6b01468%26title%3DDiscovery%2Bof%2Ban%2BAcrylic%2BAcid%2BBased%2BTetrahydroisoquinoline%2Bas%2Ban%2BOrally%2BBioavailable%2BSelective%2BEstrogen%2BReceptor%2BDegrader%2Bfor%2BER%25CE%25B1%252B%2BBreast%2BCancer%26numPages%3D29%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2818%26publicationDate%3DApril%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01468"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2358</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">21</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01468" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Heather&quot;,&quot;last_name&quot;:&quot;E. Burks&quot;},{&quot;first_name&quot;:&quot;Tinya&quot;,&quot;last_name&quot;:&quot;Abrams&quot;},{&quot;first_name&quot;:&quot;Christina&quot;,&quot;last_name&quot;:&quot;A. Kirby&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Baird&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;Fekete&quot;},{&quot;first_name&quot;:&quot;Lawrence&quot;,&quot;last_name&quot;:&quot;G. Hamann&quot;},{&quot;first_name&quot;:&quot;Sunkyu&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Franco&quot;,&quot;last_name&quot;:&quot;Lombardo&quot;},{&quot;first_name&quot;:&quot;Alice&quot;,&quot;last_name&quot;:&quot;Loo&quot;},{&quot;first_name&quot;:&quot;Danuta&quot;,&quot;last_name&quot;:&quot;Lubicka&quot;},{&quot;first_name&quot;:&quot;Kaitlin&quot;,&quot;last_name&quot;:&quot;Macchi&quot;},{&quot;first_name&quot;:&quot;Donald&quot;,&quot;last_name&quot;:&quot;P. McDonnell&quot;},{&quot;first_name&quot;:&quot;Yuji&quot;,&quot;last_name&quot;:&quot;Mishina&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;D. Norris&quot;},{&quot;first_name&quot;:&quot;Jill&quot;,&quot;last_name&quot;:&quot;Nunez&quot;},{&quot;first_name&quot;:&quot;Chitra&quot;,&quot;last_name&quot;:&quot;Saran&quot;},{&quot;first_name&quot;:&quot;Yingchuan&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Noel&quot;,&quot;last_name&quot;:&quot;M. Thomsen&quot;},{&quot;first_name&quot;:&quot;Chunrong&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jianling&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Peukert&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;2790-2818&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01468&quot;},&quot;abstract&quot;:&quot;Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo. We outline the discovery and chemical optimization of the THIQ scaffold leading to THIQ 40 and showcase the racemization of the scaffold, pharmacokinetic studies in preclinical species, and the in vivo efficacy of THIQ 40 in a MCF-7 human breast cancer xenograft model.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01468&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01468" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01468&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01468" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01468&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01468" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01468&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01468&amp;href=/doi/10.1021/acs.jmedchem.6b01468" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01468" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01468" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01468%26sid%3Dliteratum%253Aachs%26pmid%3D28296398%26genre%3Darticle%26aulast%3DBurks%26date%3D2017%26atitle%3DDiscovery%2Bof%2Ban%2BAcrylic%2BAcid%2BBased%2BTetrahydroisoquinoline%2Bas%2Ban%2BOrally%2BBioavailable%2BSelective%2BEstrogen%2BReceptor%2BDegrader%2Bfor%2BER%25CE%25B1%252B%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D7%26spage%3D2790%26epage%3D2818%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/jmcmar.2017.60.issue-7/20170413/jmcmar.2017.60.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Tetrahydroisoquinoline <b>40</b> has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo. We outline the discovery and chemical optimization of the THIQ scaffold leading to THIQ <b>40</b> and showcase the racemization of the scaffold, pharmacokinetic studies in preclinical species, and the in vivo efficacy of THIQ <b>40</b> in a MCF-7 human breast cancer xenograft model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57685" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57685" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Breast cancer is the most prevalent cancer and the second leading cause of cancer mortality in women with estrogen receptor α-positive (ERα+) disease being the most prevalent (∼70%).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Tamoxifen, a selective estrogen receptor modulator (SERM), was the first endocrine therapy approved for the treatment of metastatic breast cancer and for use as an adjuvant therapy in postmenopausal women with ERα+ breast cancer (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In the setting of advanced disease, a large proportion of patients with ERα+ disease respond positively to tamoxifen, although de novo and acquired resistance to this drug remains an impediment to durable clinical responses.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Initially, it was believed that resistance to tamoxifen signaled the end of the therapeutic utility of ERα, although the clinical success of aromatase inhibitors (AIs) like anastrozole, when used in this setting, highlighted the continued engagement of the receptor in processes of pathological importance in this disease.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Considering this (re)validation of ERα as a target, it is surprising that despite extensive clinical testing of many SERMs of diverse chemical structures like raloxifene, none have been shown to be effective in advanced disease.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Indeed, the lone ER-modulator that has shown to be effective in tamoxifen/aromatase inhibitor refractory disease is the selective estrogen receptor degrader (SERD) fulvestrant, a high affinity competitive antagonist that distinguishes itself from other ER-ligands in that upon binding it denatures the receptor and targets it for proteasomal degradation.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Currently, fulvestrant is the only SERD approved for use in patients with breast cancer. However, this molecule has poor pharmaceutical properties and has to be administered monthly by intramuscular injection. Even with improved dosing regimens it is not clear that the intratumoral levels of fulvestrant are sufficient to occupy the receptor.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0001.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Clinically approved SERMs, SERDs, and AIs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Initially, it was unclear why removal of ERα was required for efficacy in advanced disease. However, it is now known that ERα has the ability to activate transcription in the absence of a canonical small molecule ligand.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> This process termed “ligand independent activation” is thought to arise as a result of (a) direct phosphorylation of the receptor or (b) alterations in the expression and/or activity of the receptor associated coregulatory proteins. Thus, once on DNA the receptor has the potential to be activated by pathways and/or proteins that are overexpressed and or hyperactivated in cancer. Additionally, gain-of-function mutations in ESR1, the gene encoding the ER, have been observed in patients with metastatic breast cancer resulting in resistance to endocrine therapy.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> SERD-dependent removal of the ERα blocks this escape mechanism and is likely to be the most effective way of targeting the receptor in breast cancer.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">After the discovery of fulvestrant, the field has shifted toward the development of novel SERDs with improved pharmacokinetic properties to avoid monthly intramuscular injections and increase exposure levels. A compound that possesses ERα antagonistic properties as well as the degradation phenotype is (<i>E</i>)-3-(4-((<i>E</i>)-1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid <b>1</b> (GW7604),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> which is the 4-hydroxylated variant of (<i>E</i>)-3-(4-((<i>Z</i>)-1,2-diphenylbut-1-en-1-yl)phenyl)acrylic acid <b>2</b> (GW5638) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> While <b>1</b> has remained in the preclinical setting; it has been extensively studied since its discovery.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Previously published structural information on the ERα ligand binding domain (LBD) in complex with <b>2</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=IR5K">IR5K</a>)<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> as well as rat ERβLBD in complex with <i>N</i>-(<i>n</i>-butyl)-11-[3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl]<i>N</i>-methylundecanamide <b>3</b> (ICI164,384) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=IHJ1">IHJ1</a>),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> a compound structurally similar to fulvestrant, gave insight into the important structural features of SERDs. ERα contains two activation regions, activating function 1 (AF1) and activating function 2 (AF2) which control transcription activation. AF1 is located at the amino terminus of ERα and is regulated by growth factors through phosphorylation.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> AF2 is located in the carboxy terminus of the LBD, and its function is dependent on the positioning of Helix 12 (H12). In turn, the position of H12 is influenced by the ligand which is bound to ERα. In the case of ERα agonist estradiol, H12 is able to position itself as a cap over the LBD, completing the docking groove for coactivators. On the contrary, antiestrogens such as tamoxifen do not allow for H12 to bind in the same orientation, thereby disrupting coactivator binding and blocking transcriptional activity. The structure of the ERαLBD in complex with <b>2</b> reveals that H12 lies in a similar position to that of H12 of ERαLBD in complex with other antiestrogens but also suggests that a twist of H12 increases the surface hydrophobicity and, therefore, decreases stability. A more extreme result is seen in the structure of ERβLBD in complex with <b>3</b> where there is no electron density for H12. Instead, it reveals that the bulky side chain of the compound lies along the coactivator recruitment site, blocking the interaction of H12 at this location. We sought to exploit the positioning of H12 as a means to promote ERα degradation and develop an orally bioavailable low molecular weight antagonist for the treatment of ERα+ tamoxifen-resistant breast cancer. We envisioned that the previously reported orally bioavailable tetrahydroisoquinoline (THIQ) scaffold <b>4</b> described in the literature as a SERM could serve as an effective starting point (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Triphenyl-based and THIQ-based SERMs and SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">During the course of our studies, several new entities of ERα antagonists and degraders have been reported in the literature (ARN-810, AZD9496, THIQ-phenol), indicating the surging interest in front line therapies needed for the treatment of ERα+ tamoxifen-resistant breast cancer in the clinic.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We hypothesized that the scaffold of THIQ <b>4</b> could be chemically tuned to afford a SERD phenotype with the introduction of an acrylate moiety in a similar fashion to the SERM to SERD modulation that was observed with 4-hydroxytamoxifen and <b>1</b> (<a class="ref internalNav" href="#fig1" aria-label="Figures 1">Figures 1</a> and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). We proposed that the installation of an acrylic acid moiety in place of the pendent aminoethoxy in <b>4</b> offered a tool molecule for an initial proof of concept toward determining if the THIQ scaffold could be amenable to an ERα degradation phenotype.</div><div class="NLM_p">In order to incorporate the acrylate moiety onto the THIQ scaffold, we needed to establish a chemical route that would provide prompt access to the core and also enable the rapid preparation of a number of analogs for further biological profiling. The synthesis of the acrylate derived THIQ analog began with the condensation of <i>p</i>-bromophenyllithium to 2-(4-fluorophenyl)-3,4-dihydro-6-methoxy-1(2<i>H</i>)-isoquinolinone <b>5</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> The monolithiated <i>p</i>-bromophenyllithium species was prepared by the treatment of 1-bromo-4-iodobenzene in pentanes with 2.5 M <i>n</i>-butyllithium at room temperature.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> After the formation of <i>p</i>-bromophenyllithium, the lithiate was added to a chilled solution of isoquinoline <b>5</b> at −78 °C. Perchloric acid was utilized to generate the iminium ion, which was intercepted with methylmagnesium bromide to form <b>6</b>. Heck coupling of methyl acrylate to <b>6</b> introduced the acrylate moiety which afforded α,β-unsaturated ester <b>7</b>. Lewis acid mediated demethylation of <b>7</b> followed by saponification of <b>8</b> provided cinnamic acid containing THIQ <b>9</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) (i) 1-bromo-4-iodobenzene (3 equiv), 2.5 M <i>n</i>-BuLi in hexanes (3.01 equiv), pentanes (0.12 M), 1 h, rt; (ii) <b>5</b> in THF (0.2 M), −78 °C, 1 h; (iii) HClO<sub>4</sub>, 1 h; (b) 1.4 M MeMgBr (3 equiv) in THF, 16 h, rt, 95% yield; (c) methyl acrylate (10 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (15 mol %), Et<sub>3</sub>N (5 equiv), DMF (0.15 M), 120 °C, 1 h, 63% yield; (d) AlCl<sub>3</sub> (4 equiv), EtSH (10 equiv), DCM (0.1 M), 0 °C, 1 h, 52% yield; (e) LiOH (16 equiv), dioxanes, H<sub>2</sub>O, 50 °C, 2 h, quantitative yield.</p></p></figure><div class="NLM_p">We utilized four assays to evaluate the biological properties of THIQ <b>9</b>. The affinity for ERα was evaluated with an ERα scintillation proximity binding assay (SPA). The anti-estrogen activity was evaluated using an estrogen-responsive reporter gene in ER+ MCF-7 breast cancer cells (ERα transcription IC<sub>50</sub>) (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). ERα degradation was assessed in two different in-cell Western assays; MCF-7 cells were treated with compounds for 18 h, followed by fixation and processing for in-cell visualization using an anti-ER-α antibody which monitored the amount of receptor remaining. The first in-cell Western assay assessed the remaining ERα levels when compounds were added at 10 μM (% ERα remaining). The second assay evaluated a dose range of the compounds to determine the concentration at which half of the ERα receptor level remained (ERα degradation IC<sub>50</sub>). The activity of the THIQ analogs <b>4</b> and <b>9</b> were evaluated alongside known SERMs and SERDs to benchmark their activities within these assays (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). THIQ <b>9</b> demonstrated affinity for the ERαLBD on par with that observed for 4-hydroxytamoxifen, fulvestrant, and <b>1</b>. The ERα antagonist activity observed with THIQ <b>9</b> was weaker than the activity of aminoethoxy-derived THIQ <b>4</b> (ERα transcription IC<sub>50</sub> of 202 nM vs 3 nM) but similar to that observed with <b>1</b> (ERα transcription IC<sub>50</sub> of 242 nM). Fulvestrant at 10 μM induced ERα degradation with 18% ERα remaining. A dose–response analysis of fulvestrant activity revealed an ERα degradation IC<sub>50</sub> of 1 nM. GW analogs <b>1</b> and <b>2</b> were also efficient at reducing the ERα receptor levels at 10 μM, with 24% and 22% ERα remaining. As expected, tamoxifen and 4-hydroxytamoxifen, which lacked the acrylic acid motif, were not effective at reducing ERα receptor levels, with 90% and 94% ERα remaining. The acrylic acid proves effective as an ERα degradation motif when comparing the aminoethoxy moiety on the tamoxifen scaffold to the acrylic acid moiety on the GW scaffold. This observation extends to the THIQ scaffold as well; aminoethoxy-containing THIQ <b>4</b> was less effective at promoting ERα degradation (81% ERα remaining) when compared to acrylic acid containing THIQ <b>9</b> (19% ERα remaining). ERα degradation was not investigated in a dose–response study for THIQ <b>4</b>; however THIQ <b>9</b> was equipotent to <b>1</b> (ERα degradation IC<sub>50</sub> of 7 nM). While the introduction of the acrylic acid motif on THIQ <b>9</b> provided insight that this motif reduced ERα protein levels within the cell, we sought further chemical refinement of the THIQ scaffold to better understand the ERα antagonistic and degradation properties.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial Biological Data of THIQs <b>4</b> and <b>9</b> Compared to Known SERDs/SERMs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">ERα binding IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">ERα transcription IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">% ERα remaining</th><th class="colsep0 rowsep0" align="center">ERα degradation IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tamoxifen</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1605</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4-hydroxytamoxifen</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fulvestrant</td><td class="colsep0 rowsep0" align="left">8.4</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">9.2</td><td class="colsep0 rowsep0" align="left">242</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">260</td><td class="colsep0 rowsep0" align="left">12825</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">264</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">202</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">nd = not determined.</p></div></div></div><div class="NLM_p">We wondered if we could further manipulate the acrylate group to provide a more effective motif to reduce ERα degradation. We initially evaluated this concept by preparing a small set of analogs that were accessed through intermediates obtained in the synthesis of <b>9</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The rigidity of the cinnamic acid was evaluated by saturating the olefin in THIQ <b>9</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, compound <b>11</b>). Saturated THIQ <b>11</b> was prepared from the saponification of <b>7</b>, followed by reduction of the α,β-unsaturated olefin of <b>10</b> with cobalt borohydride and methyl ether deprotection with boron tribromide. Amide analogs were accessed through either a HATU-mediated coupling to <b>9</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, compound <b>12</b> and <b>14</b>) or a HATU-mediated coupling to <b>10</b> and subsequent boron tribromide deprotection (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, compound <b>13</b>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) 2 M LiOH, THF (0.1 M), 60 °C, 30 min, quantitative; (b) CoCl<sub>2</sub>·6H<sub>2</sub>O (0.02 equiv)/NaBH<sub>4</sub> (2 equiv), EtOH (0.1 M), 90% yield; (c) AlCl<sub>3</sub> (7 equiv), EtSH (18 equiv), DCM (0.04 M), 0 °C, 37% yield; (d) HATU (1.5 equiv), 2,2-difluoroethanamine (2 equiv), Et<sub>3</sub>N (2 equiv), DCM (0.05 M), 90% yield; (e) 1 M BBr<sub>3</sub> in DCM (0.4 equiv), DCM (0.1 M), 0 °C, 30 min, 38% yield.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Acrylate-Based Modifications of THIQ <b>9</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0017.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0018.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">nd = not determined.</p></div></div><div></div></div><div class="NLM_p">The THIQ analogs highlighted in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> were evaluated for solubility, permeability, transcriptional activity, and ERα degradation at 10 μM. The saturated THIQ <b>11</b> was equipotent when compared to cinnamic acid THIQ <b>9</b> as an antagonist although appeared less effective in terms of ERα degradation at 10 μM (32% ERα remaining) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). The methylamide THIQ <b>12</b> was more potent in the transcription assay when compared to <b>9</b> and also afforded comparable ERα levels at 10 μM (24% ERα remaining). Extension of the amide tail with fluorinated analogs <b>13</b> and <b>14</b> impacted the level of ERα degradation at 10 μM when compared to <b>12</b> and <b>9</b>. From the small set of analogs highlighted in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, the acrylic acid remained the most effective ERα degradation motif.</div><div class="NLM_p">We further expanded the search for alternative degradation motifs by examining heterocyclic replacements of the carboxylic acid of THIQ <b>9</b>. Imidazole-derived THIQ <b>18</b> was prepared from a palladium-catalyzed Heck coupling between triflate <b>15</b> and a mixture of 1-((2-(trimethylsilyl)ethoxy)methyl)-4-vinyl-1<i>H</i>-imidazole and 1-((2-(trimethylsilyl)ethoxy)methyl)-5-vinyl-1<i>H</i>-imidazole (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The Heck product <b>17</b> was then subjected to methyl ether deprotection with boron tribromide to provide the parent imidazole THIQ <b>18</b>. Substitution on the imidazole was explored by employing bromide <b>16</b> in a Heck coupling with a mixture of 1-methyl-4-vinylimidazole and 1-methyl-5-vinylimidazole. The <i>N</i>-methyl THIQ analogs were then separated to afford <b>19</b> and <b>20</b>. Tetrazole-containing THIQ analogs were obtained from the cross coupling of bromide <b>6</b> to acrylonitrile which afforded α,β-unsaturated nitrile <b>21</b>. A tin-mediated cyclization with <b>21</b> and azidotrimethylsilane enabled access to tetrazole <b>22</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The methyl ether of tetrazole <b>22</b> was removed with aluminum trichloride and ethanethiol to afford phenol <b>23</b>. Alkylation of methyl ether tetrazole <b>22</b> with methyl iodide afforded a regiosiomeric mixture of products which were separated and deprotected with aluminum trichloride and ethanethiol to afford <b>24</b> and <b>25</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) <b>15</b>, 1-((2-(trimethylsilyl)ethoxy)methyl)-4-vinyl-1<i>H</i>-imidazole and 1-((2-(trimethylsilyl)ethoxy)methyl)-5-vinyl-1<i>H</i>-imidazole (15.7 equiv), Et<sub>3</sub>N (236 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (0.78 equiv), DMF (0.01 M), 80 °C, 16 h, 35% yield; (b) 1 M BBr<sub>3</sub> in DCM (4 equiv), DCM (0.035 M), −78 to 0 °C, 30 min, 46% yield; (c) <b>16</b>, 1-methyl-4-vinylimidazole and 1-methyl-5-vinylimidazole (3.3 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (15 mol %), Et<sub>3</sub>N (5 equiv), DMF (0.15 M), 120 °C, 1 h, 5% yield; (d) <b>6</b>, acrylonitrile (10 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (15 mol %), Et<sub>3</sub>N (5 equiv), DMF (0.15 M), microwave, 150 °C, 1 h, 46% yield; (e) Bu<sub>2</sub>SnO (0.1 equiv), TMSN<sub>3</sub> (6 equiv), DME (0.1 M), microwave, 2 h, 180 °C, quant; (f) AlCl<sub>3</sub> (4 equiv), EtSH (10 equiv), DCM (0.1 M) 0 °C, 1 h, 21% yield; (g) MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, 29% yield; (h) AlCl<sub>3</sub> (4 equiv), EtSH (10 equiv), DCM (0.1 M) 0 °C, 1 h, 49% yield.</p></p></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Heterocycle-Based Acrylate Replacements for the Carboxylic Acid of THIQ <b>9</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0019.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0020.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">nd = not determined.</p></div></div><div></div></div><div class="NLM_p">Oxadiazole replacements for the carboxylic acid of THIQ <b>9</b> were obtained in three steps highlighted in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The synthesis began with a HATU-mediated coupling between acid intermediate <b>10</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) and substituted acylhydrazides which afforded <b>26</b> in excellent yields. Treatment of <b>26</b> with triphenylphosphine and hexachloroethane promoted the cyclization of <b>26</b> to afford oxadiazoles<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a><b>27</b>, and deprotection with aluminum trichloride and ethanethiol afforded substituted oxadiazoles <b>28</b>–<b>30</b>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) HATU (1.2 equiv), NMM (5 equiv), DMF (0.1 M), 76–88% yield; (b) PPh<sub>3</sub> (1.8 equiv), EtN-<i>i</i>-Pr<sub>2</sub> (5.75 equiv), Cl<sub>3</sub>CCCl<sub>3</sub> (1.3 equiv), MeCN (0.05 M), 82–87%; (c) AlCl<sub>3</sub> (4 equiv), EtSH (10 equiv), DCM (0.1 M), 38–49% yield.</p></p></figure><div class="NLM_p">The heterocycle-containing THIQs were evaluated for their antagonistic properties in the ERα transcription assay and for their ability to degrade ERα (tested at 10 μM in the in-cell Western) (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). We anticipated that the solubility and permeability of the newly synthesized analogs would be hampered by the replacement of the carboxylic acid but anticipated being able to mitigate these properties should a new degradation motif be identified. Imidazole-derived THIQs <b>18</b>–<b>20</b> did not afford an improved level of ERα degradation (30–68% ERα remaining) when compared to THIQ <b>9</b> (19% ERα remaining). Tetrazole THIQ <b>23</b> afforded ERα degradation levels (18% ERα remaining) comparable to that of THIQ <b>9</b>, but the ERα antagonistic properties were significantly reduced (ERα transcription IC<sub>50</sub> of 1030 nM). Alkylated tetrazoles <b>24</b> and <b>25</b> were less efficient at degrading ERα, with 39% and 63% ERα remaining, respectively. Oxadiazole THIQs <b>28</b>–<b>30</b> were also less efficient (28–38% ERα remaining). With these modifications in hand, we prioritized the acrylic acid of THIQ <b>9</b> as an ERα degradation motif and sought to further refine the scaffold to increase the ERα antagonistic abilities.</div><div class="NLM_p">Using the cocrystal structure of THIQ <b>4</b> in the ERαLBD, the <i>N</i>-aryl ring of the THIQ core has been modeled to overlay with the D-ring of known ERα ligands like raloxifene and the GW series.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> We directed our chemistry efforts around the optimization of the <i>N</i>-aryl moiety on the THIQ scaffold as a means to improve the ERα antagonistic properties of the scaffold and maintained the acrylic acid as the ERα degradation motif. The route that was established for the synthesis of THIQ <b>9</b> in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> was adopted to access the <i>N</i>-aryl modifications on the core (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). The <i>N</i>-aryl moiety was introduced by a copper(I)-mediated Ullmann coupling between <b>31</b> and aryl bromides or aryl iodides. The <i>p</i>-bromophenyllithium addition developed for THIQ <b>9</b> was applied to <i>N</i>-aryl isoquinolines <b>32</b> affording the tetrahydroisoquinoline core <b>33</b>, after iminium ion formation with perchloric acid and methyl Grignard addition. Heck coupling to bromide <b>33</b> provided α,β-unsaturated ester THIQ <b>34</b>, which was then treated with BBr<sub>3</sub> or AlCl<sub>3</sub> with ethanethiol and lithium hydroxide to offer carboxylate-derived THIQs described by <b>35</b>.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) Cu(I)I, ArX, base, Δ; (b) LiC<sub>6</sub>H<sub>4</sub>Br; HClO<sub>4</sub>; (c) MeMgBr; (d) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (cat.), Et<sub>3</sub>N, methyl acrylate, Δ; (e) BBr<sub>3</sub> or AlCl<sub>3</sub>/EtSH; (f) LiOH.</p></p></figure><div class="NLM_p">Modifications on the <i>N</i>-aryl ring or D-ring would directly impact the affinity of the ligand for ERα. Newly synthesized analogs were evaluated in the ERα binding (SPA) assay to measure their affinity for the ERαLBD in addition to the previously described cellular assays (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The solubility and permeability of the newly synthesized analogs were also captured, as these are factors that would impact the interpretation of cellular activity. Initially, we removed the <i>p</i>-fluoro substituent from the <i>N</i>-aryl ring to afford <b>36</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) and observed weaker antagonistic activity when compared to <b>9</b>. We then investigated the migration of the <i>p-</i>fluoro substituent on the <i>N</i>-aryl ring to the <i>m</i>-position to obtain THIQ <b>37</b> and found that <b>37</b> afforded a near equipotent analog to <b>9</b> with respect to ERα binding while also maintaining solubility and permeability but cellular antagonistic potency was reduced. Unfortunately, the corresponding THIQ analog containing an <i>o</i>-fluoro substituted <i>N</i>-aryl ring was not synthetically accessible and we were unable to evaluate the impact of this substitution on activity. As the ERα ligand binding pocket is known to be hydrophobic and dynamic, we probed the flexible nature of the pocket by introducing hydrophobicity on the ligand to maximize hydrophobic interactions between the ligand and ERαLBD. We envisioned that the introduction of an <i>o</i>-isopropyl substituent on the <i>N</i>-aryl ring should occupy similar space as the ethyl group in <b>2</b> and enable exploration of the dynamic nature of a portion of the ERαLBD. The <i>o</i>-isopropyl substituted <i>N</i>-aryl ring on THIQ <b>38</b> proved to be detrimental for ERα binding affinity (ERα binding IC<sub>50</sub> of 1200 nM) and significantly reduced the activity in the cellular assays. Placement of the isopropyl group at the <i>m</i>-position of the <i>N</i>-aryl ring (<b>39</b>) restored the affinity of the ligand for ERα (ERα binding IC<sub>50</sub> of 76 nM). The antagonistic nature of <b>39</b> (ERα transcription IC<sub>50</sub> of 466 nM) was reduced when compared to <b>9</b>, but the remaining ERα levels were comparable at 10 μM (22% ERα remaining). The incorporation of the isopropyl substituent at the <i>p</i>-position of the <i>N</i>-aryl ring (<b>40</b>) offered an improvement in ERα affinity (ERα binding IC<sub>50</sub> of 17 nM) and the most potent analog to date in the ERα transcription assay (ERα transcription IC<sub>50</sub> of 30 nM) as well as the ERα degradation assays (15% ERα remaining, ERα degradation IC<sub>50</sub> of 0.9 nM). The improved antagonistic activity obtained with <b>40</b> was surprising when considering the raloxifene scaffold where the D-ring occupies the same spatial region as the <i>N</i>-aryl ring of <b>40</b> and contains a hydroxyl that forms a hydrogen bond with His524 (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). To probe the significance of the methyl substituent in the benzylic position for activity, we prepared the des-methyl analogue of <b>36</b> (compound not shown) and determined its potency to be weaker than the one for <b>36</b>. We hypothesize that the better potency of <b>36</b> over its des-methyl analogue is due to optimized van der Waals interactions between the methyl substituent and Leu346 of the receptor (see also <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Thus, we did not pursue compounds without a substituent in this position in our further SAR exploration.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>N</i>-Aryl Modifications of the THIQ Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0021.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0022.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">nd = not determined.</p></div></div><div></div></div><div class="NLM_p">To gain an understanding of how a sterically demanding substituent at the <i>p</i>-position may dramatically influence the binding of <b>40</b> to the ERαLBD, we attempted to identify structural differences within the ERαLBD through X-ray crystallographic studies (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). The structures of ERαLDB (301–553) in complex with <b>9</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T92">5T92</a>) and <b>40</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T97">5T97</a>) were solved to 2.2 and 3.0 Å, respectively. The overall fold of the ERαLBD structures compare well with that of the previously described structures,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> with rmsd values of 0.379 and 0.521 Å when including residues 310–525. Consistent among structures containing a hydroxyl moiety on the A-ring is the hydrogen bonding network among residues Arg394, Glu353, a structurally conserved water, and the hydroxyl. This network is well described in previously reported structures.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> A less common feature that the two structures share and that was interesting to us in terms of developing a SERD is the lack of clear electron density for helix 12 (H12). The acrylate moieties of both THIQ <b>9</b> and <b>40</b> extend out of the ligand binding pocket between helices 3 (H3) and 11 (H11), exposing it to H12. This exposure results in displacement of H12, eliminating the possibility of coactivator binding and likely leading to the instability of ERα and degradation.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> A notable difference between the two structures includes rearrangement of hydrophobic residues, namely, Met421 and His524, within the binding pocket. The bulky and hydrophobic isopropyl substitution at the <i>p</i>-position of the <i>N</i>-aryl ring of <b>40</b> demands conformational adjustments that are seen within the binding pocket of <b>40</b>. This results in an altered van der Waals interaction network (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) that likely allows for less flexibility within the typical dynamic hydrophobic core. Arrangement of this network with <b>40</b> mimics that seen in the structure of ERαLDB in complex with <b>2</b>.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The highly hydrophobic ligand binding pocket has been described previously as being adaptable to various ligand configurations.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> While the cellular potency of <b>40</b> was superior to analogs synthesized thus far, we used the insights offered in the crystal structures of <b>9</b> and <b>40</b> to attempt to understand the structural limitations of the THIQ scaffold and further optimize the core.</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structures of THIQs <b>9</b> (green) and <b>40</b> (yellow) (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T92">5T92</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T97">5T97</a>, respectively).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The THIQ analogs that probed the structural limitations of the <i>p</i>-position on the <i>N</i>-aryl ring were synthesized using the route established in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Affinity for the ERαLBD was used to understand the scope of the substitution that could be tolerated in this position. However, the prioritization of compounds for progression toward an orally bioavailable SERD scaffold was driven by the cellular activity profile. The incorporation of a methyl substituent (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, compounds <b>41</b> and <b>42)</b> afforded binding affinities (ERα binding IC<sub>50</sub> of 12–47 nM) in the previously observed range; however, reduced antagonistic activity was observed (ERα transcription IC<sub>50</sub> of 111–207 nM). Increasing steric encumbrance beyond isopropyl to <i>tert</i>-butyl (compound <b>43</b>) and trifluoromethyl (compound <b>44</b>) reduced the binding affinity when compared to <b>40</b>, suggesting that an increase in bulk of the compound in this area results in a spatial limit with the ligand likely causing nonideal interactions with the LBD. The transcriptional activityies of <b>43</b> and <b>44</b> (ERα transcription IC<sub>50</sub> of 119–302 nM) were also reduced when compared to THIQ <b>9</b>. A straight chain <i>n</i>-butyl aliphatic extension on the <i>p</i>-substituent of the <i>N</i>-aryl ring (compound <b>45</b>) proved advantageous for the ERα affinity (ERα binding IC<sub>50</sub> of 24 nM) as well as transcriptional potency (ERα transcription IC<sub>50</sub> of 23 nM) when compared to THIQ <b>40</b>. The one-carbon extension of <b>45</b> to <b>46</b> revealed a limit observed with ERα affinity (ERα binding IC<sub>50</sub> of 110 nM) when compared to <b>40</b>. The orientation of a highly dynamic aliphatic chain as in <b>46</b> in a hydrophobic pocket like the ERαLBD would be challenging to model to understand the reason for the reduction in ERα affinity. However, one may conclude that dynamic substitutions as long flexible chains in the <i>p</i>-position of the <i>N</i>-aryl ring are less likely to maintain a maximal van der Waals interaction network. Cyclic substituents (entries <b>47</b>, <b>48</b>) were accommodated within the ERαLBD with binding affinities ranging from 31 to 53 nM. Ligands <b>47</b> and <b>48</b> maintained antagonistic activity (ERα transcription IC<sub>50</sub> of 39–53 nM) slightly diminished from those observed with <b>40</b> but exhibited a similar ability to degrade ERα (at 10 μM, 14–16% ERα remaining, ERα degradation IC<sub>50</sub> of 0.4–0.6 nM). We explored hydrophilic substituents such as a hydroxyl, morpholine, and oxetane on the <i>N</i>-aryl ring (structures not disclosed) and observed that these compounds were weak antagonists in the transcriptional assay. Overall, the <i>p</i>-position on the <i>N-</i>aryl ring of the THIQ core was amenable to substitution with preference exhibited for THIQs <b>40</b>, <b>41</b>, <b>45</b>, and <b>47</b> as determined by ERα affinity. When considering the impact of the modifications on the cellular activities, THIQs <b>40</b> and <b>45</b> stood out for antagonistic activity in combination with their ability to degrade ERα.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Investigation of the Structural Scope of the <i>p</i>-Position of the <i>N</i>-Aryl Ring of the THIQ Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0023.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0024.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">nd = not determined.</p></div></div><div></div></div><div class="NLM_p">With a better understanding of the optimized spatial scope of the THIQ scaffold in the ERαLBD, we sought to fine-tune THIQ <b>40</b> to improve cellular potency (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). We envisioned that homologation of the isopropyl substituent of <b>40</b> would further optimize van der Waals interactions between the ligand and His524 and Met421, in a similar fashion as achieved with <b>45</b>. While isobutyl-substituted THIQ <b>49</b> afforded reduced ERα affinity (ERα binding IC<sub>50</sub> of 48 nM) when compared to <b>40</b> and <b>45</b>, the antagonistic potency was improved (ERα transcription IC<sub>50</sub> of 11 nM). Refinement of the isopropyl moiety to an ethyl cyclopropane (<b>50</b>) at the <i>p</i>-position proved advantageous for ERα affinity (ERα binding IC<sub>50</sub> of 5.2 nM), offering an improvement when compared to <b>47</b>. We inferred from this boost in affinity that the combination of the cyclopropyl moiety with a one carbon homologation maximized the van der Waals interactions obtained with the repositioning of His524 and Met421. THIQ <b>50</b> also afforded an improvement in antagonistic potency (ERα transcription IC<sub>50</sub> of 6.5 nM) with comparable levels of ERα remaining at 10 μM (12% ERα remaining, ERα degradation IC<sub>50</sub> of 0.6 nM). Introduction of 2-isopropylpyridine (<b>52</b>) as the <i>N</i>-aryl ring imparted an improvement in ERα affinity (ERα binding IC<sub>50</sub> of 6.8 nM) but a reduction in cellular activities. The <i>sec-</i>butyl derived THIQ <b>53</b> offered advantageous ERα binding but a reduction in cellular activity. Fluorination of <b>40</b> to afford compounds <b>54</b> and <b>55</b> were advantageous with respect to increasing ERα affinity, but these modifications limited the antagonistic potency of the scaffold. However, fluorination of <b>49</b> in the ortho-position to afford <b>56</b> was effective at improving affinity (ERα binding IC<sub>50</sub> of 0.5 nM) and the antagonistic potency (ERα transcription IC<sub>50</sub> of 7 nM) while maintaining ERα receptor levels comparable to those observed thus far (12% ERα remaining at 10 μM, ERα degradation IC<sub>50</sub> of 0.4 nM). Overall, refinements of the <i>p</i>-position of the <i>N</i>-aryl ring lead to improvements in ERα affinity with several analogs highlighted in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. With the aim to develop an orally bioavailable ERα antagonist and degrader, we coupled cell based activities to affinity and prioritized <b>49</b>, <b>50</b>, and <b>56</b> for further in vivo profiling.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Refinement of the <i>p</i>-Position of the <i>N</i>-Aryl Ring of the THIQ Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0025.gif" alt="" id="fx9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0026.gif" alt="" id="fx10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">nd = not determined.</p></div></div><div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Racemization of <b>40</b></h3><div class="NLM_p">While the optimization of the THIQ scaffold was ongoing, THIQ <b>40</b> was profiled in downstream assays to evaluate the early developability of this racemic scaffold.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> From the crystal structure, we knew that the (<i>R</i>)-enantiomer of the <b>40</b> would be favored to bind in the ERαLBD (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). The cinnamic acid portion of <b>(</b><i><b>R</b></i><b>)-40</b> positions itself to exit the LBD between H3 and H11. When <b>(</b><i><b>S</b></i><b>)-40</b> is modeled into the cocrystal of <b>(</b><i><b>R</b></i><b>)-40</b> and the ERαLBD with alignment of <b>(</b><i><b>S</b></i><b>)-40</b> on the A-ring of <b>(</b><i><b>R</b></i><b>)-40</b>, a steric clash between the cinnamic acid moiety of <b>(</b><i><b>S</b></i><b>)-40</b> and H3 is observed. Multiple crystal structures of the ERαLBD show a consistent positioning of H3, suggesting inflexibility of this helix and supporting the idea that <b>(</b><i><b>S</b></i><b>)-40</b> cannot be accommodated in the pocket, resulting in a transcriptionally inactive compound.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Model of <b>(</b><i><b>S</b></i><b>)-40</b> (yellow) superimposed onto the cocrystal of <b>(</b><i><b>R</b></i><b>)-40</b> (orange) and the ERαLBD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To evaluate the activities of <b>(</b><i><b>R</b></i><b>)-</b> and <b>(</b><i><b>S</b></i><b>)-40</b>, we separated a racemic mixture of <b>40</b> by chiral SFC into the two enantiomers with of >95:5 enantiopurity (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Both <b>(</b><i><b>R</b></i><b>)-</b> and <b>(</b><i><b>S</b></i><b>)-40</b> were evaluated for ERα affinity and cell based activity. Surprisingly, both enantiomers bound to the ERαLBD and exhibited activity in the ERα transcriptional assay, which is inconsistent with our hypothesis that <b>(</b><i><b>S</b></i><b>)-40</b> would be inactive (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). As the enantiomers of <b>40</b> were active, we proposed that <b>(</b><i><b>R</b></i><b>)-</b> and <b>(</b><i><b>S</b></i><b>)-40</b> must be interconverting.</div><figure id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0014.jpeg" id="gr6" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We first investigated the solution stability of <b>(</b><i><b>R</b></i><b>)-</b> and <b>(</b><i><b>S</b></i><b>)-40</b> in aqueous buffer to replicate the environment present in an in vitro setting as well as protic organic solvent (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a). Starting with a >95:5 ratio, at pH 6.8 and 7.4, the erosion of enantiopurity of <b>(</b><i><b>R</b></i><b>)-40</b> is observed within minutes. In methanol at room temperature, the rate of erosion of enantiopurity for <b>(</b><i><b>R</b></i><b>)-40</b> is reduced when compared to physiological conditions but erosion is observed within 1 h. The rates of conversion for <b>(</b><i><b>R</b></i><b>)-</b> and <b>(</b><i><b>S</b></i><b>)-40</b> are nearly identical under physiological conditions, and racemization occurs within minutes at pH 6.8 and 7.4; the data for <b>(</b><i><b>S</b></i><b>)-40</b> are contained within the <a href="/doi/suppl/10.1021/acs.jmedchem.6b01468/suppl_file/jm6b01468_si_001.pdf" class="ext-link">Supporting Information</a>. The extent of racemization was also analyzed in the plasma of various species (human, monkey, dog, rat, and mouse) and found to be within minutes (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>b). With the fast interconversion observed with <b>(</b><i><b>R</b></i><b>)-40</b> and <b>(</b><i><b>S</b></i><b>)-40</b>, we anticipated that the fast interconversion should result in consistent exposure to a 50:50 enantiomeric mixture at all times in vivo.</div><figure id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0005.jpeg" id="GRAPHIC-d88e2185-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Stability of <b>(</b><i><b>R</b></i><b>)</b>-<b>40</b> in aqueous buffer at pH 6.8 and 7.4 and methanol. (b) Stability of <b>(</b><i><b>R</b></i><b>)-40</b> in mouse, human, rat, dog, and monkey plasma.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We propose the following mechanism for racemization of <b>(</b><i><b>S</b></i><b>)-</b> and <b>(</b><i><b>R</b></i><b>)-40</b> under pH neutral conditions or in protic solvent; a ring opened quinoline <b>57</b> is formed which enables addition of the aniline to form the opposite enantiomer (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). To support this mechanism, we prepared a pair of enantiomers of <b>10</b> where the phenol hydroxyl group is methylated. These methyl ethers did not show measurable racemization (structures and data in <a href="/doi/suppl/10.1021/acs.jmedchem.6b01468/suppl_file/jm6b01468_si_001.pdf" class="ext-link">Supporting Information</a>). Thus, bioisosteres of the phenol could possibly prevent the racemization observed with our scaffold.</div><figure id="sch7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0015.jpeg" id="gr7" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We sought chemical optimization of the scaffold to limit the racemization. As the hydroxyl on the A-ring is important for ERα affinity we were unable to remove this functional group. Therefore, the methyl moiety of the THIQ scaffold was targeted as this would impact the partial positive charge on the benzylic carbon formed during ring opening that would be generated in the formation of <b>57</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). We sought to introduce a trifluoromethyl and difluoromethyl substituent at this position. The route to install the trifluoromethyl substituent was analogous to that described in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>, with the exception that the iminium ion that forms from the treatment of 2-(4-isopropylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>58</b>) with <i>p</i>-bromophenyllithium and perchloric acid was intercepted with sodium acetate and trimethyl(trifluoromethyl)silane.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The racemic compound was synthesized (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, <b>rac-59</b>), and the enantiomers were separated by chiral SFC to <b>(</b><i><b>R</b></i><b>)-59</b> and <b>(</b><i><b>S</b></i><b>)-59</b>. The difluoromethyl substituent was incorporated by intercepting the analogous iminium ion with potassium fluoride and ethyl 2,2-difluoro-2-(trimethylsilyl)acetate which installed the difluoroacetate <b>60</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Saponification of <b>60</b> followed by decarboxylation afforded difluoride <b>61</b>. Heck coupling with <b>61</b> and methyl acrylate installed the acrylate moiety to obtain <b>62</b>. Lewis acid mediated deprotection followed by saponification afforded <b>rac-63</b>. The enantiomers of <b>rac-63</b> were separated by chiral SFC to <b>(</b><i><b>R</b></i><b>)-63</b> and <b>(</b><i><b>S</b></i><b>)-63</b>.</div><figure id="sch8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0016.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 8. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) 1-bromo-4-iodobenzene (3 equiv), 2.5 M <i>n</i>-BuLi in hexanes (3.01 equiv), pentanes (0.12 M), 1 h, rt; (ii) <b>58</b> in THF (0.2 M), −78 °C, 1 h; (iii) HClO<sub>4</sub>, 1 h; (b) KF (3 equiv), 0.38 M 2,2-difluoro-2-(trimethylsilyl)acetate in DMF, 30 min, rt, 77% yield; (c) 1 M LiOH (2.5 equiv), 1,4-dioxane (0.1 M), 2 h, 40 °C (carried forward crude); (d) CsF (5 equiv), NMP (0.2 M), 192 °C, 24 h, 80% yield; (e) methyl acrylate (20 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (50 mol %), NEt<sub>3</sub> (5 equiv), DMF (0.15 M), 130 °C, 1 h, 15% yield; (f) AlCl<sub>3</sub> (8 equiv), EtSH (20 equiv), DCM (0.01 M), 2 h, rt, 84% yield; (g) 1 M LiOH (10 equiv), 1,4-dioxane (0.02 M), 3 h, rt, 44% yield.</p></p></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Methyl-Substituted THIQ Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0027.gif" alt="" id="fx11" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">ERα binding IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">ERα transcription IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">% ERα remaining</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>rac-59</b></td><td class="colsep0 rowsep0" align="left">rac-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">139</td><td class="colsep0 rowsep0" align="char" char=".">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(</b><i><b>R</b></i><b>)-59</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">61</td><td class="colsep0 rowsep0" align="char" char=".">125</td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(</b><i><b>S</b></i><b>)-59</b></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">880</td><td class="colsep0 rowsep0" align="char" char=".">1138</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>rac-63</b></td><td class="colsep0 rowsep0" align="left">rac-CF<sub>2</sub>H</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(</b><i><b>R</b></i><b>)-63</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-CF<sub>2</sub>H</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(</b><i><b>S</b></i><b>)-63</b></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-CF<sub>2</sub>H</td><td class="colsep0 rowsep0" align="char" char=".">1100</td><td class="colsep0 rowsep0" align="char" char=".">37500</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr></tbody></table></div></div><div class="NLM_p last">Solvent was removed from each enantiomer immediately, and the enantiopurity was characterized postcondensation to ensure purity >95:5. The compounds were evaluated in the ERα binding and cellular assays utilized thus far (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). For <b>(</b><i><b>R</b></i><b>)-59</b> and <b>(</b><i><b>S</b></i><b>)-59</b>, ERα affinity (ERα IC<sub>50</sub> of 61 and 880 nM) was observed as well as antagonistic activity suggesting some degree of racemization. The racemic difluoro analog <b>rac-63</b> had higher affinity for ERα when compared to trifluoromethyl analog <b>rac-59</b> and comparable levels of antagonistic activity. The enantiomers <b>(<i>R</i>)-</b> and <b>(</b><i><b>S</b></i><b>)-63</b> demonstrated a larger window for binding affinity and antagonistic activity when compared to <b>(</b><i><b>R</b></i><b>)-59</b> and <b>(</b><i><b>S</b></i><b>)-59</b>. ERα degradation was observed with all compounds in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. Interestingly, under the conditions of this assay, <b>(</b><i><b>S</b></i><b>)-63</b> appeared significantly less active suggesting that if racemization occurs, it may be a slower process. Overall with the results in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, the observed biological activity in the binding and transcription assays confirms this observation: nearly all biologically activity resides with the <i>R</i>-enantiomer whereas the <i>S</i>-enantiomer is almost inactive, consistent with slow racemization during in vitro testing. We incorporated substituents larger than those described in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>; however, those derivatives were significantly less active (data not disclosed). Ultimately, we were not able to eliminate racemization completely by modification of the methyl group of <b>40</b>, and considering the rapid rate of conversion of its two enantiomers, we chose to continue to profile the racemic mixture in additional studies.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Pharmacokinetics and Pharmacodynamics</h3><div id="secz" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Pharmacokinetics</h4><div class="NLM_p">Since oral bioavailability had been observed with THIQ <b>4</b>, this and other pharmacokinetic properties were determined for THIQ <b>40</b> in C57BL/6 mice (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>). Dosing of a 3 mg/kg solution of <b>40</b> afforded 78% oral bioavailability, with the maximal plasma concentrations at 7864 nM and an AUC of 13589 nM·h. As more potent THIQ analogs were identified (THIQs <b>45</b>, <b>49</b>, <b>50</b>, and <b>56</b>), pharmacokinetic parameters were examined in mice. However, the additional THIQ analogs tested had either significantly higher clearance (compound <b>45</b>), lower bioavailability (compounds <b>49</b> and <b>50</b>), or both (compound <b>56</b>), resulting in significantly reduced overall exposure from oral administration in comparison to <b>40</b>. These results in conjunction with the good in vitro activity warranted further characterization of <b>40</b>.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Pharmacokinetic Parameters of Select THIQs in C57/BL6 Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dose iv/po (mg/kg)</th><th class="colsep0 rowsep0" align="center">formulation</th><th class="colsep0 rowsep0" align="center" char=".">oral BAV<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> po dn<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–7h</sub> po dn<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a> (nM h/mg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–7h</sub> iv dn<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a> (nM h/mg)</th><th class="colsep0 rowsep0" align="center" char=".">clearance (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">terminal half-life for elimination (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">1/3</td><td class="colsep0 rowsep0" align="left">solution<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">78</td><td class="colsep0 rowsep0" align="char" char=".">2621</td><td class="colsep0 rowsep0" align="char" char=".">4533</td><td class="colsep0 rowsep0" align="char" char=".">5808</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">0.2/2</td><td class="colsep0 rowsep0" align="left">solution<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">246</td><td class="colsep0 rowsep0" align="char" char=".">612</td><td class="colsep0 rowsep0" align="char" char=".">1095</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">0.4/2</td><td class="colsep0 rowsep0" align="left">solution<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">282</td><td class="colsep0 rowsep0" align="char" char=".">598</td><td class="colsep0 rowsep0" align="char" char=".">2682</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">1/3</td><td class="colsep0 rowsep0" align="left">solution<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">299</td><td class="colsep0 rowsep0" align="char" char=".">403</td><td class="colsep0 rowsep0" align="char" char=".">3471</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">0.4/2</td><td class="colsep0 rowsep0" align="left">solution<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">274</td><td class="colsep0 rowsep0" align="char" char=".">1385</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">BAV = bioavailability.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">dn = dose normalized.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Vehicle: 1% 1 N NaOH, 10% PEG300, 25% (of 20% Cremophor), PBS, 1 N HCl for pH adjustment.</p></div><div class="footnote" id="t8fn4"><sup>d</sup><p class="last">Vehicle: 1% 1 N NaOH, 20% PEG300, 25% (of 20% Solutol), PBS, 1 N HCl for pH adjustment.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> In Vitro Pharmacodynamics</h4><div class="NLM_p">To evaluate the SERD properties of <b>40</b> in vitro, the assessment of <b>40</b> to induce ERα degradation was evaluated in an in-cell Western assay with 4-hydroxytamoxifen and fulvestrant included in the evaluation. As expected, 4-hydroxytamoxifen did not induce ERα degradation, consistent with it being known to stabilize ERα protein levels.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In this assay, THIQ <b>40</b> (IC<sub>50</sub> of 1.8 nM) was equipotent to fulvestrant (IC<sub>50</sub> of 1.2 nM) at inducing a downregulation of ERα levels (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Consistent with our observation that increasing <b>40</b> or fulvestrant treatment did not fully degrade ERα levels, it has been reported that fulvestrant-mediated degradation of ERα is saturable in cells, resulting in a low level of remaining ERα, which may not be accessible in the cell to proteolytic degradation.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0006.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Measurement of ERα reduction by THIQ <b>40</b>, fulvestrant, and 4-hydroxytamoxifen in MCF-7 cells grown in 10% charcoal dextran-stripped serum supplemented media. For the in-cell Western, cells were incubated with compounds for 18 h followed by fixation and processing to determine the amount of ERα protein remaining.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One mechanism of resistance that emerges with tamoxifen or estrogen deprivation treatment for ER-positive breast cancer is an upregulation of growth factor signaling pathways that results in ligand-independent growth even while ERα remains expressed.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> To further evaluate the SERD-like properties of <b>40</b>, an estradiol-independent proliferation assay in MCF-7 cells was conducted where proliferation was driven by insulin instead of estrogen. In this assay, a compound that possesses SERD activity will block growth factor mediated cell proliferation, while SERMs will not block such activity and therefore be inactive (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). As expected, 4-hydroxytamoxifen was inactive, consistent with its SERM properties, while fulvestrant was potent [(IC<sub>50</sub> of 0.06 nM ± 0.05 (<i>n</i> = 2)]. Likewise, <b>40</b> inhibited insulin driven proliferation in MCF-7 cells [IC<sub>50</sub> of 2.1 nM ± 0.6 (n = 2)], although to a lesser extent than fulvestrant. The ability to downregulate ERα protein levels and inhibit MCF-7 proliferation in an estradiol-independent manner demonstrates the SERD properties of <b>40</b>.</div><figure id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0007.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Insulin-mediated proliferation of MCF-7 cells. Cells were incubated in DMEM (without phenol red) plus 8% charcoal dextran-stripped serum with insulin (20 nM) and compound treatment for 6 d. Cellular proliferation was quantified by measuring DNA content. IC<sub>50</sub> values were determined using GraphPad Prism software and are defined as the inflection point of the fitted inhibition curves.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> In Vivo Pharmacodynamics</h4><div class="NLM_p">To characterize the in vivo antitumor activity of <b>40</b>, efficacy and ERα degradation were evaluated in the MCF-7 human breast cancer xenograft model in immunocompromised nude mice supplemented with estradiol to support tumor growth. Administration of <b>40</b> once daily at 20 mg/kg resulted in robust antitumor efficacy, corresponding to 78% tumor growth inhibition as compared to the control group treated with the vehicle alone [day 108, <i>p</i> < 0.05, Kruskal–Wallis analysis of variance (ANOVA), Dunn’s post hoc test]. Tamoxifen and fulvestrant were included as positive control compounds in this ER dependent model, with treatment levels and schedules selected based on preexisting literature.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Tamoxifen and fulvestrant demonstrated similar efficacy to <b>40</b>, inducing 86% and 83% tumor growth inhibition, respectively (day 108, <i>p</i> < 0.05, Kruskal–Wallis ANOVA, Dunn’s post hoc test) (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>a and <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>b). THIQ <b>40</b> was well tolerated and demonstrated no body weight loss in the mice.</div><figure id="fig8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0008.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo efficacy and ERα degradation by <b>40</b> in the MCF-7 xenograft model in female nude mice. Tumors were established by injection of 10 million cells in 50% Matrigel into the axillary mammary fat pad area. Mice were implanted with a 0.36 mg estradiol/90-day release pellet 2 days prior to cell implantation. When tumors reached an average of approximately 230 mm<sup>3</sup>, mice were randomized according to tumor volume into treatment groups (<i>n</i> = 6). THIQ <b>40</b> (20 mg/kg) or its vehicle alone were orally (po) treated once daily, and tamoxifen was orally treated (60 mg/kg) 5 times a week. Fulvestrant was administered subcutaneously (sc) once a week (250 mg/mouse). (a) Caliper measurements of tumor length and width were used to determine tumor volumes of treatment groups, which are graphed over time: (∗) <i>p</i> < 0.05, Kruskal–Wallis ANOVA, Dunn’s pos thoc test, versus vehicle control on day 108 after implantation. (b) Individual tumor volumes are plotted for values on day 108. (c) At the end of the efficacy study on day 108, MCF-7 tumors (<i>n</i> = 3–5) were collected at 7 and 24 h after last dose of THIQ <b>40</b> or 24 h after last dose of fulvestrant, and ER-α protein levels were analyzed from tumor lysates by ELISA (DuoSet, R&D System, catalog no. DYC5715-5) to detect ERα levels. The percent of ERα remaining was determined by comparing tumors from the treated mice versus those from the vehicle control group ((∗) <i>p</i> < 0.05, one-way ANOVA, Holm–Sidak method post hoc test, versus vehicle control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">ERα degradation in MCF-7 tumors from the end of the efficacy study in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>c was compared between groups treated with the vehicle alone, <b>40</b>, and fulvestrant. Tumors were collected 7 or 24 h after last dose on day 108 to assess ERα levels from the end of the efficacy study. THIQ <b>40</b> at 7 and 24 h postdose and fulvestrant at 24 h postdose similarly reduced ERα protein levels in the tumors by 56%, 51%, and 62% (all <i>p</i> < 0.05, one-way ANOVA, Holm–Sidak post hoc test), respectively. These data demonstrate a maintained pharmacodynamic effect during the daily <b>40</b> dosing interval and provide support that <b>40</b> demonstrated SERD activity at tolerated and efficacious exposures in vivo.</div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pharmacokinetics in Advanced Preclinical Species</h3><div class="NLM_p">Pharmacokinetic parameters of <b>40</b> were subsequently evaluated in rats and dogs (<a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>) to assess if sufficient exposure for toxicological studies could be achieved. Dosing of a 3 mg/kg solution of <b>40</b> to rats resulted in 60% bioavailability and a clearance of 14.9 mL min<sup>–1</sup> kg<sup>–1</sup> (27% of hepatic blood flow), confirming the favorable PK profile observed before in mice. A separate dose-escalation study in rats using a suspension of crystalline material demonstrated excellent dose linearity by AUC and an under proportional increase in <i>C</i><sub>max</sub>. Comparing solution and suspension formulation at the 3 mg/kg dose the solution formulation showed a 66% higher exposure. In dogs, <b>40</b> showed good exposure upon oral administration with a comparable bioavailability of 56%. The study yielded also a low clearance of 2.3 mL min<sup>–1</sup> kg<sup>–1</sup> (7% of hepatic blood flow).</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Pharmacokinetic Parameters for THIQ <b>40</b> in Sprague Dawley Rats and Beagle Dogs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">dose iv/po (mg/kg)</th><th class="colsep0 rowsep0" align="center">formulation</th><th class="colsep0 rowsep0" align="center" char=".">oral BAV<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> po dn<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a> (nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> po (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–<i>t</i></sub> po dn<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a> (nM h/mg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–<i>t</i></sub> iv dn<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a> (nM h/mg)</th><th class="colsep0 rowsep0" align="center" char=".">clearance (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">terminal half-life for elimination (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">1/3</td><td class="colsep0 rowsep0" align="left">solution<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">1199</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">1586</td><td class="colsep0 rowsep0" align="char" char=".">2627</td><td class="colsep0 rowsep0" align="char" char=".">14.9</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">–/3</td><td class="colsep0 rowsep0" align="left">suspension<a class="ref internalNav" href="#t9fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">602</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">955</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">–/30</td><td class="colsep0 rowsep0" align="left">suspension<a class="ref internalNav" href="#t9fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">346</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1125</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">–/100</td><td class="colsep0 rowsep0" align="left">suspension<a class="ref internalNav" href="#t9fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">202</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">918</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">0.3/10</td><td class="colsep0 rowsep0" align="left">solution<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">1311</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">7994</td><td class="colsep0 rowsep0" align="char" char=".">14347</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">BAV = bioavailability.</p></div><div class="footnote" id="t9fn2"><sup>b</sup><p class="last">dn = dose normalized.</p></div><div class="footnote" id="t9fn3"><sup>c</sup><p class="last">Vehicle: 1% 1 N NaOH, 20% PEG300, 25% (of 20% Solutol), PBS, 1 N HCl for pH adjustment.</p></div><div class="footnote" id="t9fn4"><sup>d</sup><p class="last">Vehicle: 0.1% Tween 80, 0.5% methylcellulose.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81452" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81452" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Chemistry efforts afforded acrylate-based THIQ <b>40</b> which was found to be a potent ERα antagonist and degrader. Scaffold optimization afforded insight into the dynamic nature of the ERαLBD by modulation of the <i>p</i>-position of the <i>N</i>-aryl ring of the THIQ core which required the maximization of van der Waals interactions between the ligand and His524 and Met421 residues. Racemization of the THIQ core was observed with most of the biological activity residing in the (<i>R</i>)-enantiomer. THIQ <b>40</b> was similarly potent to fulvestrant in an in-cell Western assay measuring ERα degradation but was less potent in an insulin-driven proliferation assay. THIQ <b>40</b> exhibited antitumor efficacy in the MCF-7 human breast cancer xenograft model and demonstrated SERD activity at tolerated and efficacious exposures in vivo. The good pharmacokinetic properties, in particular oral bioavailability, of THIQ <b>40</b> together with its robust antagonistic and ERα degradation properties provide a favorable profile for this compound as a SERD.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80541" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80541" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Chemical Methods</h3><div class="NLM_p last">Starting materials, reagents, and solvents were obtained from commercial sources and used as received. THF and diethyl ether were anhydrous grade. Compounds <b>5</b>, <b>58</b>, <b>64</b>, <b>65</b>, and <b>67</b>–<b>68</b> were prepared as described in ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a>. Progress of the reactions was monitored by analytical LC/MS using an Agilent 1100 series with UV detection at 214 and 254 nm and an electrospray mode (ESI) coupled with a Waters ZQ single quad mass detector. Progress of the reactions was also monitored by analytical LC/MS using a Waters Classic AcQuity UPLC with UV detection at 214 and 254 nm and an electrospray mode (ESI) coupled with a Waters SQ single quad mass detector. Purification of intermediates and final products was carried out on a normal phase using an ISCO CombiFlash system and prepacked SiO<sub>2</sub> cartridges eluted with optimized gradients of either ethyl acetate/heptane mixture or methanol/dichloromethane as described. Preparative high pressure liquid chromatography (HPLC) was performed on a Waters instrument. Systems were run with the described acetonitrile/water gradient with an <i>n</i>-propanol, NH<sub>4</sub>OH, or TFA modifier as described. Preparative SFC was perform a Thar-80 with UV detection based collection. Analytical chiral SFC was performed on a Waters/Thar SFC Investigator, with UV and MS detection. All compounds where biological data are presented have >95% purity as determined by HPLC. Resolution of racemates was carried out by chiral SFC using the conditions described with enantiopurity of >95:5. NMR spectra were recorded on a Bruker Ultrashield 400 Plus instrument. Chemical shifts (δ) are reported in parts per million (ppm) relative to deuterated solvent as the internal standard (CDCl<sub>3</sub> 7.26 ppm, DMSO-<i>d</i><sub>6</sub> 2.50 ppm, CD<sub>3</sub>OD 3.31 ppm), and coupling constants (<i>J</i>) are in hertz (Hz). Peak multiplicities are expressed as follows: singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet (q), multiplet (m), and broad singlet (br s).</div></div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 1-(4-Bromophenyl)-2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (<b>6</b>)</h3><div class="NLM_p"><i>Step 1.</i> To 1-bromo-4-iodobenzene (2.66 g, 9.40 mmol) and pentanes (24.9 mL) was added 2.5 M <i>n</i>-BuLi (3.77 mL, 9.43 mmol) in heptanes; a white precipitate formed immediately. This was stirred for 1 h at rt and then cooled to −78 °C. A solution of <b>5</b> (0.85 g, 3.13 mmol) in THF (17.5 mL) was added, and the reaction was stirred at −78 °C for 1 h. The reaction was quenched with water (39 mL) and EtOAc (39 mL), and to this was added perchloric acid (70% in water, 1.16 mL, 13.47 mmol). The mixture was then stirred for 30 min at rt. The reaction was partitioned between EtOAc and water. The organic layer was concentrated in vacuo to give crude iminium intermediate which was used directly in the next step. LC/MS (ESI) <i>m</i>/<i>z</i> 411.8 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 0.45 min.</div><div class="NLM_p last"><i>Step 2.</i> To the iminium intermediate in THF (20.3 mL) was added a 1.4 M MeMgBr (6.71 mL, 9.40 mmol) in THF at 0 °C. The mixture was stirred at 0 °C for 1 h. The reaction was quenched with saturated NH<sub>4</sub>Cl. The reaction was partitioned between DCM and water, and the organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–10% EtOAc/heptanes) to afford <b>6</b> (1.42 g, 95% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 427.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.53 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.68 (s, 3H), 2.96 (d, <i>J</i> = 15.66 Hz, 1H), 3.03–3.21 (m, 1H), 3.21–3.39 (m, 1H), 3.39–3.54 (m, 1H), 3.82 (s, 3H), 6.56–6.76 (m, 5H), 6.81 (t, <i>J</i> = 8.34 Hz, 2H), 7.09 (d, <i>J</i> = 8.08 Hz, 2H), 7.30–7.42 (m, 2H).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Methyl (<i>E</i>)-3-(4-(2-(4-Fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (<b>7</b>)</h3><div class="NLM_p last">To <b>6</b> (0.4 g, 0.94 mmol) were added Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (99 mg, 0.14 mmol), DMF (6.3 mL), TEA (0.65 mL, 4.69 mmol), and methyl acrylate (0.85 mL, 9.38 mmol). The mixture was microwaved for 1 h at 150 °C. The reaction was partitioned between water and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–20% EtOAc/heptanes) to afford <b>7</b> (255 mg, 63% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 432.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.14 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.65 (s, 3H), 2.83–2.98 (m, 1H), 3.03–3.20 (m, 1H), 3.23–3.35 (m, 1H), 3.35–3.45 (m, 1H), 3.75 (s, 3H), 3.77 (s, 3H), 6.38 (d, <i>J</i> = 16.17 Hz, 1H), 6.52–6.78 (m, 7H), 7.19 (d, <i>J</i> = 8.08 Hz, 2H), 7.35 (d, <i>J</i> = 8.59 Hz, 2H), 7.64 (d, <i>J</i> = 15.66 Hz, 1H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Methyl (<i>E</i>)-3-(4-(2-(4-Fluorophenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (<b>8</b>)</h3><div class="NLM_p last">To <b>7</b> (107 mg, 0.25 mmol) was added DCM (2.5 mL) at 0 °C. To this were added ethanethiol (0.18 mL, 2.48 mmol) and AlCl<sub>3</sub> (132 mg, 0.99 mmol). The reaction was stirred at 0 °C for 1 h and was warmed to rt and stirred for 3 h. The reaction was quenched with water and brought to pH 6 with saturated NaHCO<sub>3</sub>. The reaction was partitioned between saturated NaHCO<sub>3</sub> and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–50% EtOAc/heptanes) to afford <b>8</b> (54 mg, 52% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 418.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.48 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 1.60 (s, 3H), 2.80 (d, <i>J</i> = 16.67 Hz, 1H), 3.07 (br s, 1H), 3.20–3.28 (m, 1H), 3.41 (d, <i>J</i> = 8.59 Hz, 1H), 3.72 (s, 3H), 6.39–6.50 (m, 1H), 6.50–6.66 (m, 5H), 6.88 (t, <i>J</i> = 8.84 Hz, 2H), 7.26 (d, <i>J</i> = 8.59 Hz, 2H), 7.56–7.67 (m, 3H), 9.22 (s, 1H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>E</i>)-3-(4-(2-(4-Fluorophenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>9</b>)</h3><div class="NLM_p last">To <b>8</b> (54 mg, 0.13 mmol) were added 1,4-dioxanes (12 mL) and 1 M LiOH (2.07 mL, 2.07 mmol). The reaction was heated at 50 °C for 5 h, cooled to rt, and acidified to pH 1 with 1 M HCl. The reaction was partitioned between water and DCM. The organic layer was passed through a phase separator and concentrated in vacuo to afford <b>9</b> (53 mg, quantitative yield). LC/MS (ESI) <i>m</i>/<i>z</i> 404.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.02 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.67 (s, 3H), 2.85–2.91 (m, 1H), 3.07–3.12 (m, 1H), 3.26–3.29 (m, 1H), 3.42–3.48 (m, 1H), 6.45 (d, <i>J</i> = 15.9 Hz, 1H), 6.50 (dd, <i>J</i> = 8.6, 2.6 Hz, 1H), 6.56–6.69 (m, 4H), 6.73–6.81 (m, 2H), 7.24 (d, <i>J</i> = 8.3 Hz, 2H), 7.45 (d, <i>J</i> = 8.3 Hz, 2H), 7.63 (d, <i>J</i> = 16.0 Hz, 1H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>E</i>)-3-(4-(2-(4-Fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>10</b>)</h3><div class="NLM_p last">Prepared from <b>7</b> (3.42 mL, 0.62 mmol) as described for <b>9</b> to afford <b>10</b> as an orange oil (258 mg, quantitative). LC/MS (ESI) <i>m</i>/<i>z</i> 418.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.20 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.62 (s, 3H), 2.81–2.95 (m, 1H), 3.02–3.16 (m, 1H), 3.22–3.34 (m, 1H), 3.37–3.48 (m, 1H), 3.64–3.67 (m, 3H), 6.36 (d, <i>J</i> = 16.17 Hz, 1H), 6.48–6.56 (m, 1H), 6.56–6.66 (m, 4H), 6.67–6.75 (m, 2H), 7.12 (d, <i>J</i> = 8.59 Hz, 2H), 7.32 (d, <i>J</i> = 8.08 Hz, 2H), 7.55 (d, <i>J</i> = 15.66 Hz, 1H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 3-(4-(2-(4-Fluorophenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)propanoic Acid (<b>11</b>)</h3><div class="NLM_p"><i>Step 1.</i> To <b>10</b> (40 mg, 96 μmol) were added EtOH (958 μL) and CoCl<sub>2</sub>·6H<sub>2</sub>O (0.46 mg, 1.92 μmol) at 0 °C. Sodium borohydride (7.25 mg, 0.19 mmol) was added; the reaction was warmed to rt and stirred for 16 h. Partial conversion was observed; additional CoCl<sub>2</sub>·6H<sub>2</sub>O (0.46 mg, 1.92 μmol) and NaBH<sub>4</sub> (7.25 mg, 0.19 mmol) were added. The reaction was stirred for 1 h at rt. The reaction was partitioned between saturated NaHCO<sub>3</sub> and DCM. The organic layer was passed through a phase separator and concentrated in vacuo to afford crude 3-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)propanoic acid (36 mg, 90% yield) which was carried forward without further purification. LC/MS (ESI) <i>m</i>/<i>z</i> 420.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.24 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.53 (s, 3H), 2.79 (d, <i>J</i> = 16.17 Hz, 2H), 2.93–3.06 (m, 1H), 3.11–3.23 (m, 1H), 3.23–3.36 (m, 3H), 3.58–3.75 (m, 4H), 6.40–6.52 (m, 3H), 6.52–6.67 (m, 4H), 6.99 (d, <i>J</i> = 7.07 Hz, 2H), 7.21 (br s, 2H).</div><div class="NLM_p last"><i>Step 2.</i> To 3-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)propanoic acid (36 mg, 86 μmol) was added DCM (2 mL). At 0 °C, EtSH (118 μL, 1.60 mmol) and AlCl<sub>3</sub> (86 mg, 0.64 mmol) were added. The reaction was warmed to rt and stirred for 3 h. The reaction was quenched with water and brought to pH 6 with saturated NaHCO<sub>3</sub>. The reaction was partitioned between saturated NaHCO<sub>3</sub> and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by HPLC (5 mM NH<sub>4</sub>OH modifier, 15–40% MeCN/H<sub>2</sub>O) to afford <b>11</b> (13 mg, 37% yield) as a white solid. LC/MS (ESI) <i>m</i>/<i>z</i> 406.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.04 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.53 (s, 3H), 2.44 (t, <i>J</i> = 7.83 Hz, 2H), 2.71–2.81 (m, 3H), 2.90–3.01 (m, 1H), 3.14–3.20 (m, 1H), 3.27–3.35 (m, 1H), 6.36–6.42 (m, 1H), 6.44–6.52 (m, 4H), 6.61–6.68 (m, 2H), 6.92–7.00 (m, 4H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (9E)-3-(4-(2-(4-Fluorophenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)-<i>N</i>-methylacrylamide (<b>12</b>)</h3><div class="NLM_p last">To <b>9</b> (24 mg, 59 μmol) were added DCM (1 mL), HATU (33.9 mg, 89 μmol), and TEA (25 μL, 0.178 mmol). The mixture was stirred for 30 min at rt, and methylamine hydrochloride (12.05 mg, 0.178 mmol) was added. The reaction was stirred at rt for 16 h. The reaction was partitioned between DCM and water. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by HPLC (3% <i>n</i>-PrOH modifier, 20–100% MeCN/H<sub>2</sub>O) to afford <b>12</b> as a white solid (6 mg, 24% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 417.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.27 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.67 (s, 3H), 2.84 (s, 3H), 2.87–2.91 (m, 1H), 3.06–3.12 (m, 1H), 3.27–3.41 (m, 1H), 3.42–3.48 (m, 1H), 6.48–6.51 (m, 1H), 6.52–6.67 (m, 5H), 6.74–6.79 (m, 2H), 7.22 (d, <i>J</i> = 8.6 Hz, 2H), 7.41 (d, <i>J</i> = 8.6 Hz, 2H), 7.49 (d, <i>J</i> = 8.6 Hz, 1H).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>E</i>)-<i>N</i>-(2,2-Difluoroethyl)-3-(4-(2-(4-fluorophenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylamide (<b>13</b>)</h3><div class="NLM_p"><i>Step 1.</i> To <b>10</b> (38.8 mg, 0.093 mmol) were added DCM (2 mL), HATU (52.9 mg, 0.14 mmol), TEA (26 μL, 0.19 mmol), and 2,2-difluoroethanamine (15.02 mg, 0.19 mmol). The reaction was stirred at rt for 16 h. The reaction was partitioned between DCM and water. The organic layer was passed through a phase separator and concentrated. The crude material was purified by FCC (0–100% EtOAc/heptanes) to afford (<i>E</i>)-<i>N</i>-(2,2-difluoroethyl)-3-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylamide as a white solid (40 mg, 90% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 481.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.32 min.</div><div class="NLM_p last"><i>Step 2.</i> To (<i>E</i>)-<i>N</i>-(2,2-difluoroethyl)-3-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylamide (40 mg, 0.083 mmol) in DCM (2 mL) at −78 °C was added 1 M BBr<sub>3</sub> in DCM (250 μL, 0.250 mmol). The reaction was stirred at 0 °C for 30 min, cooled at −78 °C, quenched with MeOH, and concentrated in vacuo. The residue was basified with saturated NaHCO<sub>3</sub> to pH 9. The reaction was partitioned between saturated NaHCO<sub>3</sub> and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by HPLC (3% <i>n</i>-PrOH modifier, 15–95% MeCN/H<sub>2</sub>O) to afford <b>13</b> as a white solid (15 mg, 38% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 467.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.35 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.67 (s, 3H), 2.85–2.91 (m, 1H), 3.06–3.11 (m, 1H), 3.24–3.30 (m, 1H), 3.42–3.47 (m, 1H), 3.63–3.71 (m, 2H), 5.94 (t, <i>J</i> = 3.9 Hz, 1H), 6.50 (dd, <i>J</i> = 8.6, 2.6 Hz, 1H), 6.56–6.60 (m, 2H), 6.61–6.67 (m, 3H), 6.73–6.79 (m, 2H), 7.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.42 (d, <i>J</i> = 8.4 Hz, 2H), 7.55 (d, <i>J</i> = 15.8 Hz, 1H).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>E</i>)-3-(4-(2-(4-Fluorophenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)-<i>N</i>-(3,3,3-trifluoropropyl)acrylamide (<b>14</b>)</h3><div class="NLM_p last">To <b>9</b> (0.053 g, 0.131 mmol) in DMF (1.3 mL) were added HATU (60 mg, 0.16 mmol), 3,3,3-trifluoropropan-1-amine (14 μL, 0.15 mmol), and NMM (72 μL, 0.66 mmol). The reaction was stirred for 16 h at rt. The reaction was partitioned between saturated NH<sub>4</sub>Cl and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–50% EtOAc/heptanes) to obtain <b>14</b> (32 mg, 48% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 499.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.39 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.66 (s, 3H), 2.44–2.50 (m, 2H), 2.83–2.91 (m, 1H), 3.02–3.13 (m, 1H), 3.24–3.31 (m, 1H), 3.39–3.48 (m, 1H), 3.56 (t, <i>J</i> = 7.07 Hz, 2H), 6.48–6.53 (m, 1H), 6.56 (d, <i>J</i> = 15.66 Hz, 1H), 6.59–6.67 (m, 4H), 6.72–6.79 (m, 2 H), 7.21–7.23 (m, 2 H), 7.40–7.41 (m, 2H), 7.53 (d, <i>J</i> = 15.66 Hz, 1H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 4-(2-(4-Fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl Trifluoromethanesulfonate (<b>15</b>)</h3><div class="NLM_p last">To 4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenol<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> (250 mg, 0.688 mmol) was added DCM (3 mL). At 0 °C, TEA (115 μL, 825 μmol) and trifluoromethanesulfonic anhydride (139 μL, 825 μmol) were added. The reaction was partitioned between saturated NaHCO<sub>3</sub> and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–100% EtOAc/heptanes) to afford <b>15</b> as a colorless oil (280 mg, 82% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 496.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.36 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.71 (s, 3H), 2.94–3.01 (m, 1H), 3.09–3.16 (m, 1H), 3.27–3.32 (m, 1H), 3.41–3.47 (m, 1H), 3.84 (s, 3H), 6.58 (dd, <i>J</i> = 9.09, 5.05 Hz, 2H), 6.70–6.82 (m, 5H), 7.14 (d, <i>J</i> = 9.09 Hz, 2H), 7.28 (d, <i>J</i> = 8.59 Hz, 2H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −118.76 (s), −72.76 (s).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 1-(4-Bromophenyl)-2-(4-fluorophenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>16</b>)</h3><div class="NLM_p"><i>Step 1.</i> To <b>5</b> (0.5 g, 1.843 mmol) in DCM (9.22 mL) at 0 °C was added 1 M BBr<sub>3</sub> in heptanes (7.37 mL, 7.37 mmol). The reaction was stirred at 0 °C for 1 h. The reaction was quenched with MeOH (5 mL) and stirred for 10 min at rt. To the mixture was added Celite, volatiles were removed, and the crude material was purified by FCC (0–75% EtOAc/heptanes) to obtain 2-(4-fluorophenyl)-6-hydroxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (420 mg, 89% yield) as a white solid. LC/MS (ESI) <i>m</i>/<i>z</i> 258.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.04 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 3.02 (t, <i>J</i> = 6.32 Hz, 2H), 3.88 (t, <i>J</i> = 6.32 Hz, 2H), 6.69 (s, 1H), 6.74 (dd, <i>J</i> = 8.59, 2.53 Hz, 1H), 7.17–7.26 (m, 2H), 7.34–7.44 (m, 2H), 7.77 (d, <i>J</i> = 8.59 Hz, 1H), 10.14 (s, 1H).</div><div class="NLM_p"><i>Step 2.</i> To 2-(4-fluorophenyl)-6-hydroxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (420 mg, 1.63 mmol) in DMF (3.27 mL) were added <i>tert</i>-butylchlorodimethylsilane (369 mg, 2.45 mmol), DMAP (40 mg, 0.33 mmol), and imidazole (500 mg, 7.35 mmol). The reaction was stirred at rt for 16 h. The reaction was partitioned between water and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–10% EtOAc/heptanes) to obtain 6-((<i>tert</i>-butyldimethylsilyl)oxy)-2-(4-fluorophenyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (371 mg, 61% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 372.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.75 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.24–0.29 (m, 6H), 1.03 (s, 9H), 3.08 (t, <i>J</i> = 6.32 Hz, 2H), 3.93 (t, <i>J</i> = 6.57 Hz, 2H), 6.70 (d, <i>J</i> = 2.02 Hz, 1H), 6.83 (dd, <i>J</i> = 8.59, 2.53 Hz, 1H), 7.04–7.15 (m, 2H), 7.30–7.38 (m, 2H), 8.05 (d, <i>J</i> = 8.59 Hz, 1H).</div><div class="NLM_p last"><i>Step 3.</i> 6-((<i>tert</i>-Butyldimethylsilyl)oxy)-2-(4-fluorophenyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one was used to prepare <b>16</b> as described for <b>6</b>. Purification by FCC (0–20% EtOAc/heptanes) to afford <b>16</b> (404 mg, 98% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 414.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.58 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.75 (s, 3H), 2.90–3.06 (m, 1H), 3.06–3.24 (m, 1H), 3.31–3.42 (m, 1H), 3.46–3.50 (m, 1H), 6.61–6.77 (m, 5H), 6.88 (t, <i>J</i> = 8.84 Hz, 2H), 7.08–7.18 (m, 2H), 7.38–7.44 (m, 2H).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>E</i>)-2-(4-Fluorophenyl)-6-methoxy-1-methyl-1-(4-(2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-4-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinoline (<b>17</b>)</h3><div class="NLM_p"><i>Step 1.</i> To 4-vinyl-1<i>H</i>-imidazole (260 mg, 2.76 mmol) in DMF (4 mL) was added NaH (60% dispersion in mineral oil, 331 mg, 8.29 mmol). The reaction was stirred at rt for 15 min and was charged with SEMCl (490 μL, 2.76 mmol). After 90 min at rt, the reaction was cooled to 0 °C and quenched with saturated NH<sub>4</sub>Cl. The reaction was partitioned between saturated NH<sub>4</sub>Cl and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–100% EtOAc/heptanes) to afford a regioisomeric mixture of 1-((2-(trimethylsilyl)ethoxy)methyl)-4-vinyl-1<i>H</i>-imidazole as a white solid (540 mg, 87% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 225.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.35 min.</div><div class="NLM_p last"><i>Step 2.</i> To <b>15</b> (90 mg, 0.023 mmol) was added 1-((2-(trimethylsilyl)ethoxy)methyl)-4-vinyl-1<i>H</i>-imidazole (82 mg, 0.363 mmol), DMF (2 mL), TEA (760 μL, 5.45 mmol), and Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (12.75 mg, 0.018 mmol). The reaction was heated at 80 °C for 16 h. The crude mixture was directly purified by FCC (0–70% EtOAc/heptanes) to afford <b>17</b> as a white solid (40 mg, 35% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 570.6 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.39 min.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>E</i>)-1-(4-(2-(1<i>H</i>-Imidazol-4-yl)vinyl)phenyl)-2-(4-fluorophenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>18</b>)</h3><div class="NLM_p last">To <b>17</b> (40 mg, 70 μmol) in DCM (2 mL) at −78 °C was added 1 M BBr<sub>3</sub> in DCM (281 μL, 0.281 mmol). The reaction was stirred at 0 °C for 30 min and was cooled to −78 °C and quenched with MeOH and concentrated in vacuo. The residue was basified with saturated NaHCO<sub>3</sub> to pH 9 and partitioned with DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by HPLC (3% <i>n</i>-PrOH modifier,15–100% MeCN/H<sub>2</sub>O) to afford <b>18</b> as a white solid (14 mg, 46% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 426.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.39 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.66 (s, 3H), 2.85–2.91 (m, 1H), 3.05–3.13 (m, 1H), 3.25–3.33 (m, 1H), 3.41–3.47 (m, 1H), 6.49–6.52 (m, 1H), 6.57–6.58 (m, 1H), 6.62–6.67 (m, 3H), 6.74–6.78 (m, 2H), 7.02 (br s, 2H), 7.13–7.15 (m, 3H), 7.33–7.35 (m, 2H), 7.67–7.67 (m, 1H).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>E</i>)-2-(4-Fluorophenyl)-1-methyl-1-(4-(2-(1-methyl-1<i>H</i>-imidazol-4-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>19</b>) and (<i>E</i>)-2-(4-Fluorophenyl)-1-methyl-1-(4-(2-(1-methyl-1<i>H</i>-imidazol-5-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>20</b>)</h3><div class="NLM_p">Prepared as described for <b>7</b> with <b>16</b> (100 mg, 0.24 mmol) and 1-methyl-4-vinyl-1<i>H</i>-imidazole and 1-methyl-5-vinyl-1<i>H</i>-imidazole (1.46 mL, 0.79 mmol). The crude material was purified by SFC (10 mM NH<sub>4</sub>OH modifier, 5–10% MeOH in CO<sub>2</sub>, flow rate of 80 g/min) to afford as a white solid <b>19</b> (2.4 mg, 2% yield) and <b>20</b> (4 mg, 3% yield) as a yellow solid.</div><div class="NLM_p"><b>19</b>, (<i>E</i>)-2-(4-fluorophenyl)-1-methyl-1-(4-(2-(1-methyl-1<i>H</i>-imidazol-4-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol: LC/MS (ESI) <i>m</i>/<i>z</i> 440.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.35 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.56 (s, 3H), 2.78 (d, <i>J</i> = 16.17 Hz, 1H), 2.92–3.05 (m, 1H), 3.16 (br s, 1H), 3.30–3.40 (m, 1H), 3.65 (s, 3H), 6.36–6.41 (m, 1H), 6.44–6.59 (m, 4H), 6.63–6.71 (m, 2H), 6.92 (s, 2H), 7.07 (d, <i>J</i> = 8.59 Hz, 2H), 7.15 (s, 1H), 7.29 (d, <i>J</i> = 8.59 Hz, 2H), 7.50 (s, 1H).</div><div class="NLM_p last"><b>20</b>, (<i>E</i>)-2-(4-fluorophenyl)-1-methyl-1-(4-(2-(1-methyl-1<i>H</i>-imidazol-5-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol: LC/MS (ESI) <i>m</i>/<i>z</i> 440.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.34 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.64–1.70 (m, 3H), 2.84–2.95 (m, 1H), 3.05–3.17 (m, 1H), 3.26–3.31 (m, 1H), 3.41–3.49 (m, 1H), 3.73 (s, 3H), 6.49–6.56 (m, 1H), 6.56–6.70 (m, 4H), 6.73–6.81 (m, 2H), 6.94–7.01 (m, 1H), 7.06–7.18 (m, 4H), 7.34 (d, <i>J</i> = 8.08 Hz, 2H), 7.60 (s, 1H).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>E</i>)-3-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylonitrile (<b>21</b>)</h3><div class="NLM_p last">To <b>6</b> (400 mg, 0.94 mmol) in DMF (6.26 mL), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (99 mg, 0.14 mmol), TEA (654 μL, 4.69 mmol), and acrylonitrile (618 μL, 9.38 mmol) were added. The reaction was microwaved for 1 h at 150 °C. The reaction was partitioned between water and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–20% EtOAc/heptanes) to afford <b>21</b> (173 mg, 46% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 399.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.60 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.69–1.75 (m, 3H), 2.93–3.03 (m, 1H), 3.12–3.25 (m, 1H), 3.28–3.39 (m, 1H), 3.44–3.48 (m, 1H), 3.80–3.84 (m, 3H), 5.86 (d, <i>J</i> = 16.67 Hz, 1H), 6.59–6.85 (m, 7H), 7.25–7.36 (m, 3H), 7.40 (d, <i>J</i> = 16.67 Hz, 1H), 7.71 (d, <i>J</i> = 8.59 Hz, 1H).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (<i>E</i>)-1-(4-(2-(2<i>H</i>-Tetrazol-5-yl)vinyl)phenyl)-2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (<b>22</b>)</h3><div class="NLM_p last">To <b>21</b> (173 mg, 0.43 mmol) in DME (4.34 mL) was added dibutylstannanone (10.81 mg, 43 μmol) and azidotrimethylsilane (346 μL, 2.60 mmol). The reaction was microwaved for 2 h at 180 °C. The reaction mixture was filtered over Celite and concentrated in vacuo to afford <b>22</b>; the material was not purified. LC/MS (ESI) <i>m</i>/<i>z</i> 442.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.18 min.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>E</i>)-1-(4-(2-(2H-Tetrazol-5-yl)vinyl)phenyl)-2-(4-fluorophenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>23</b>)</h3><div class="NLM_p last">(<i>E</i>)-1-(4-(2-(2<i>H</i>-Tetrazol-5-yl)vinyl)phenyl)-2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (3.2 mg, 7.25 μmol) <b>22</b> was deprotected as described for <b>8</b>. The crude material was purified by HPLC (3% TFA modifier, 30–100% MeCN/H<sub>2</sub>O) to afford <b>23</b> (0.85 mg, 21% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 428.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.15 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.69 (s, 3H), 2.87–2.97 (m, 1H), 3.10 (br s, 1H), 3.38 (t, <i>J</i> = 1.52 Hz, 1H), 3.54 (br s, 1H), 6.43–6.49 (m, 1H), 6.52–6.58 (m, 2H), 6.66 (br s, 2H), 6.77 (t, <i>J</i> = 8.59 Hz, 2H), 7.08–7.18 (m, 3H), 7.45 (d, <i>J</i> = 8.59 Hz, 2H), 7.55 (d, <i>J</i> = 16.67 Hz, 1H).</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>E</i>)-2-(4-Fluorophenyl)-1-methyl-1-(4-(2-(2-methyl-2<i>H</i>-tetrazol-5-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>24</b>) and (<i>E</i>)-2-(4-Fluorophenyl)-1-methyl-1-(4-(2-(1-methyl-1<i>H</i>-tetrazol-5-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>25</b>)</h3><div class="NLM_p"><i>Step 1.</i> To <b>22</b> (58 mg, 0.13 mmol) in DMF (2.63 mL) were added K<sub>2</sub>CO<sub>3</sub> (54 mg, 0.39 mmol) and MeI (9.04 μL, 0.15 mmol). The reaction was stirred for 16 h at rt. The reaction was partitioned between saturated NH<sub>4</sub>Cl and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by HPLC (5 mM NH<sub>4</sub>OH modifier, 45–70% MeCN/H<sub>2</sub>O) to afford (<i>E</i>)-2-(4-fluorophenyl)-6-methoxy-1-methyl-1-(4-(2-(1-methyl-1<i>H</i>-tetrazol-5-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinoline (5 mg, 8% yield) and (<i>E</i>)-2-(4-fluorophenyl)-6-methoxy-1-methyl-1-(4-(2-(2-methyl-2<i>H</i>-tetrazol-5-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinoline (13 mg, 21% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 456.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.61 min, 1.73 min.</div><div class="NLM_p last"><i>Step 2.</i> The products from the previous step were deprotected as described for <b>8</b>. (<i>E</i>)-2-(4-Fluorophenyl)-1-methyl-1-(4-(2-(2-methyl-2<i>H</i>-tetrazol-5-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>24</b>): purified by SFC (10 mM NH<sub>4</sub>OH modifier, 10% <i>i</i>-PrOH in CO<sub>2</sub>, flow rate 75 g/min) to afford <b>24</b> (4 mg, 29% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 442.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.48 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.57 (s, 3H), 2.74–2.83 (m, 1H), 2.94–3.04 (m, 1H), 3.13–3.19 (m, 1H), 3.31–3.40 (m, 1H), 4.24–4.28 (m, 3H), 6.37–6.43 (m, 1H), 6.46–6.61 (m, 4H), 6.63–6.70 (m, 2H), 7.03–7.08 (m, 1H), 7.11–7.15 (m, 2H), 7.32–7.40 (m, 2H), 7.55 (d, <i>J</i> = 16.17 Hz, 1H). (<i>E</i>)-2-(4-Fluorophenyl)-1-methyl-1-(4-(2-(1-methyl-1<i>H</i>-tetrazol-5-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>25</b>): purified by HPLC (0.1% TFA modifier, 25–50% acetonitrile/water) to afford 1 mg (20% yield) as a white film. LC/MS (ESI) <i>m</i>/<i>z</i> 442.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.40 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.72 (s, 3H), 3.02 (d, <i>J</i> = 7.07 Hz, 1H), 3.09–3.17 (m, 1H), 3.47 (br s, 1H), 3.60 (d, <i>J</i> = 19.20 Hz, 1H), 3.74 (s, 3H), 6.45–6.52 (m, 2H), 6.52–6.58 (m, 2H), 6.70 (br s, 2H), 6.87 (t, <i>J</i> = 8.59 Hz, 2H), 6.97–7.07 (m, 4H), 7.19 (d, <i>J</i> = 12.13 Hz, 1H).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>E</i>)-<i>N</i>′-Acetyl-3-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylohydrazide (<b>26</b>)</h3><div class="NLM_p last">To <b>10</b> (35 mg, 84 μmol) in DMF (836 μL) was added HATU (38 mg, 0.100 mmol) followed by acetohydrazide (7.43 mg, 0.100 mmol) and NMM (46 μL, 0.418 mmol). The reaction was stirred for 16 h at rt. The reaction was partitioned between saturated NH<sub>4</sub>Cl and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–75% EtOAc/heptanes) to obtain <b>26</b> (31.2 mg, 79% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 474.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.40 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.66 (br s, 3H), 2.11 (s, 3H), 2.97–3.03 (m, 1H), 3.13 (d, <i>J</i> = 6.06 Hz, 1H), 3.33 (br s, 1H), 3.43 (br s, 1H), 3.78 (s, 3H), 6.53–6.83 (m, 8H), 7.16 (d, <i>J</i> = 7.58 Hz, 2H), 7.33 (d, <i>J</i> = 8.59 Hz, 2H), 7.64 (d, <i>J</i> = 15.66 Hz, 1H), 9.86 (d, <i>J</i> = 7.07 Hz, 2H).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>E</i>)-2-(4-(2-(4-Fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)styryl)-5-methyl-1,3,4-oxadiazole (<b>27</b>)</h3><div class="NLM_p last">To <b>26</b> (31.2 mg, 66 μmol) in MeCN (1.3 mL) were added PPh<sub>3</sub> (31 mg, 0.12 mmol), DIEA (67 μL, 0.38 mmol), and hexachloroethane (20 mg, 86 μmol). The reaction was stirred for 4 h at rt. The reaction was concentrated in vacuo and partitioned between water and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–20% EtOAc/heptanes) to afford <b>27</b> as a clear oil (26 mg, 87% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 456.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.65 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.66 (br s, 3H), 2.55 (s, 3H), 2.85–3.01 (m, 1H), 3.12 (br s, 1H), 3.32 (br s, 1H), 3.42 (br s, 1H), 3.77 (s, 3H), 6.52–6.80 (m, 7H), 6.89–6.98 (m, 1H), 7.15–7.24 (m, 2H), 7.37 (d, <i>J</i> = 8.59 Hz, 2H), 7.40–7.47 (m, 1H).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>E</i>)-2-(4-Fluorophenyl)-1-methyl-1-(4-(2-(5-methyl-1,3,4-oxadiazol-2-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>28</b>)</h3><div class="NLM_p last">Prepared from <b>27</b> (26 mg, 57 μmol) as described for <b>8</b>. Purified by HPLC (5 mM NH<sub>4</sub>OH modifier, 35–60% MeCN/H<sub>2</sub>O) to afford <b>28</b> (9.6 mg, 38% yield) as a white solid. LC/MS (ESI) <i>m</i>/<i>z</i> 442.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.41 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.58 (s, 3H), 2.48 (s, 3H), 2.76–2.80 (m, 1H), 2.94–3.05 (m, 1H), 3.14–3.19 (m, 1H), 3.32–3.40 (m, 1H), 6.40 (dd, <i>J</i> = 8.59, 2.53 Hz, 1H), 6.48 (d, <i>J</i> = 2.53 Hz, 1H), 6.51 (d, <i>J</i> = 8.59 Hz, 1H), 6.55–6.60 (m, 2H), 6.63–6.71 (m, 2H), 6.97 (d, <i>J</i> = 16.67 Hz, 1H), 7.17 (d, <i>J</i> = 8.59 Hz, 2H), 7.41 (d, <i>J</i> = 8.59 Hz, 2H), 7.48 (d, <i>J</i> = 16.17 Hz, 1H).</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>E</i>)-2-(4-Fluorophenyl)-1-methyl-1-(4-(2-(5-propyl-1,3,4-oxadiazol-2-yl)vinyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>29</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared as described for <b>26</b> with <b>10</b> (0.36 mL, 72 μmol) and butyrohydrazide (8.81 mg, 86 μmol). The crude material was purified by FCC (0–50% EtOAc/heptanes) to afford (<i>E</i>)-<i>N</i>′-(3-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acryloyl)butyrohydrazide (31.7 mg, 88% yield) as a clear oil. LC/MS (ESI) <i>m</i>/<i>z</i> 502.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.50 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.94–1.02 (m, 3H), 1.60–1.82 (m, 5H), 2.35 (t, <i>J</i> = 7.33 Hz, 2H), 2.96 (br s, 1H), 3.13 (br s, 1H), 3.33 (br s, 1H), 3.44 (br s, 1H), 3.73–3.83 (m, 3H), 6.53–6.82 (m, 8H), 7.17 (d, <i>J</i> = 7.07 Hz, 2H), 7.30–7.39 (m, 2H), 7.67 (d, <i>J</i> = 15.66 Hz, 1H), 9.64 (d, <i>J</i> = 6.06 Hz, 1H), 9.89 (br s, 1H).</div><div class="NLM_p"><i>Step 2.</i> Prepared as described for <b>27</b> with (<i>E</i>)-<i>N</i>′-(3-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acryloyl)butyrohydrazide (31.7 mg, 63 μmol). The crude material was purified by FCC (0–20% EtOAc/heptanes) to afford (<i>E</i>)-2-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)styryl)-5-propyl-1,3,4-oxadiazole as a clear solid (25 mg, 82% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 484.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.73 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.98 (t, <i>J</i> = 7.33 Hz, 3H), 1.55–1.65 (m, 3H), 1.75–1.84 (m, 2H), 2.79 (t, <i>J</i> = 7.33 Hz, 2H), 2.87 (d, <i>J</i> = 15.66 Hz, 1H), 3.00–3.17 (m, 1H), 3.19–3.31 (m, 1H), 3.32–3.45 (m, 1H), 3.72 (s, 3H), 6.48–6.73 (m, 7H), 6.90 (d, <i>J</i> = 16.67 Hz, 1H), 7.16 (d, <i>J</i> = 7.58 Hz, 2H), 7.32 (d, <i>J</i> = 8.59 Hz, 2H), 7.35–7.43 (m, 1H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared as described for <b>8</b> with (<i>E</i>)-2-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)styryl)-5-propyl-1,3,4-oxadiazole (25 mg, 52 μmol). The crude material was purified by HPLC (5 mM NH<sub>4</sub>OH modifier, 45–70% MeCN/H<sub>2</sub>O) to afford <b>29</b> (12 mg, 49% yield) as a white solid. LC/MS (ESI) <i>m</i>/<i>z</i> 470.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.60 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 0.97 (t, <i>J</i> = 7.33 Hz, 3H), 1.60 (s, 3H), 1.72–1.81 (m, 2H), 2.76–2.90 (m, 3H), 3.01–3.14 (m, 1H), 3.19–3.29 (m, 1H), 3.38–3.47 (m, 1H), 6.40–6.50 (m, 1H), 6.50–6.66 (m, 4H), 6.88 (t, <i>J</i> = 8.84 Hz, 2H), 7.12–7.31 (m, 3H), 7.49 (d, <i>J</i> = 16.67 Hz, 1H), 7.63 (d, <i>J</i> = 8.59 Hz, 2H), 9.21 (br s, 1H).</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>E</i>)-2-(4-Fluorophenyl)-1-(4-(2-(5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl)vinyl)phenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-6-ol (<b>30</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared as described for <b>26</b> with <b>10</b> (0.36 mL, 72 μmol) and 2-methoxyacetohydrazide (8.98 mg, 86 μmol). The crude material was purified by FCC (0–50% EtOAc/heptanes) to obtain (<i>E</i>)-3-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)-<i>N</i>′-(2-methoxyacetyl)acrylohydrazide (27.5 mg, 76% yield) as a clear oil. LC/MS (ESI) <i>m</i>/<i>z</i> 504.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.44 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.68 (br s, 3H), 2.90–2.96 (m, 1H), 3.14 (br s, 1H), 3.35 (br s, 1H), 3.39–3.51 (m, 4H), 3.80 (s, 3H), 4.08 (s, 2H), 6.51–6.80 (m, 8H), 7.18 (d, <i>J</i> = 8.08 Hz, 2H), 7.33 (d, <i>J</i> = 8.59 Hz, 2H), 7.64 (d, <i>J</i> = 15.66 Hz, 1H), 9.22 (d, <i>J</i> = 5.56 Hz, 1H), 9.47 (d, <i>J</i> = 5.05 Hz, 1H).</div><div class="NLM_p"><i>Step 2.</i> Prepared as described for <b>27</b> with (<i>E</i>)-3-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)-<i>N</i>′-(2-methoxyacetyl)acrylohydrazide (27.5 mg, 55 μmol). The crude material was purified by FCC (0–20% EtOAc/heptanes) to afford (<i>E</i>)-2-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)styryl)-5-(methoxymethyl)-1,3,4-oxadiazole as a clear oil (23 mg, 87% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 486.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.65 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.71 (s, 3H), 2.97 (d, <i>J</i> = 15.66 Hz, 1H), 3.11–3.23 (m, 1H), 3.35 (d, <i>J</i> = 13.64 Hz, 1H), 3.46 (d, <i>J</i> = 8.08 Hz, 1H), 3.51 (s, 3H), 3.82 (s, 3H), 4.70 (s, 2H), 6.59–6.73 (m, 4H), 6.73–6.83 (m, 3H), 7.02 (d, <i>J</i> = 16.67 Hz, 1H), 7.23–7.32 (m, 2H), 7.43 (d, <i>J</i> = 8.08 Hz, 2H), 7.59 (d, <i>J</i> = 16.17 Hz, 1H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared as described for <b>8</b> with (<i>E</i>)-2-(4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)styryl)-5-(methoxymethyl)-1,3,4-oxadiazole (0.23 mL, 23 μmol). The crude material was purified by HPLC (5 mM NH<sub>4</sub>OH modifier, 45–70% MeCN/H<sub>2</sub>O) to afford <b>30</b> (4.2 mg, 40% yield) as a white fluffy solid. LC/MS (ESI) <i>m</i>/<i>z</i> 458.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.31 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.59 (s, 3H), 2.79 (d, <i>J</i> = 16.67 Hz, 1H), 2.94–3.05 (m, 2H), 3.32–3.40 (m, 1H), 4.68 (s, 2H), 6.38–6.43 (m, 1H), 6.46–6.54 (m, 2H), 6.57 (dd, <i>J</i> = 9.09, 5.05 Hz, 2H), 6.67 (t, <i>J</i> = 8.84 Hz, 2H), 7.01 (d, <i>J</i> = 16.17 Hz, 1H), 7.18 (d, <i>J</i> = 8.59 Hz, 2H), 7.43 (d, <i>J</i> = 8.08 Hz, 2H), 7.54 (d, <i>J</i> = 16.17 Hz, 1H).</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>E</i>)-3-(4-(6-Hydroxy-1-methyl-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>36</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 6-methoxy-2-phenyl-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>64</b>) (117 mg, 0.460 mmol) as described for <b>6</b>. Purified by FCC (1–30% EtOAc/heptanes) to obtain 1-(4-bromophenyl)-6-methoxy-1-methyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (158 mg, 28% yield) as a cream solid. LC/MS (ESI) <i>m</i>/<i>z</i> 409.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.28 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.69 (s, 3H), 2.93 (d, <i>J</i> = 16.3 Hz, 1H), 3.12 (s, 1H), 3.44 (d, <i>J</i> = 28.1 Hz, 2H), 3.79 (s, 3H), 6.53–6.81 (m, 5H), 6.97 (s, 1H), 7.09 (t, <i>J</i> = 7.7 Hz, 4H), 7.33 (d, <i>J</i> = 8.5 Hz, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-6-methoxy-1-methyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (158 mg, 0.387 mmol) as described for <b>7</b>. Purified by FCC (1–50% EtOAc/heptanes) to obtain (<i>E</i>)-methyl 3-(4-(6-methoxy-1-methyl-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (43 mg, 27% yield) as a white solid. LC/MS (ESI) <i>m</i>/<i>z</i> 414.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.71 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.75 (s, 3H), 2.91–3.03 (m, 1H), 3.19 (d, <i>J</i> = 5.56 Hz, 1H), 3.39–3.60 (m, 2H), 3.82 (s, 3H), 3.83 (s, 3H), 6.44 (d, <i>J</i> = 16.17 Hz, 1H), 6.64–6.74 (m, 4H), 6.77 (d, <i>J</i> = 8.59 Hz, 1H), 6.94–7.02 (m, 1H), 7.06–7.13 (m, 2H), 7.27–7.33 (m, 2H), 7.42 (d, <i>J</i> = 8.08 Hz, 2H), 7.70 (d, <i>J</i> = 16.17 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl 3-(4-(6-methoxy-1-methyl-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>18</b> to afford (<i>E</i>)-methyl 3-(4-(6-hydroxy-1-methyl-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate which was purified by HPLC (3% <i>n</i>-PrOH modifier, 30–100% CH<sub>3</sub>CN/H<sub>2</sub>O). LC/MS (ESI) <i>m</i>/<i>z</i> 400.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.50 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.63 (br s, 3H), 2.82 (d, <i>J</i> = 15.16 Hz, 1H), 2.98–3.11 (m, 1H), 3.28–3.44 (m, 2H), 3.72 (s, 3H), 4.87 (br s, 1H), 6.32 (d, <i>J</i> = 16.17 Hz, 1H), 6.48 (dd, <i>J</i> = 8.59, 2.53 Hz, 1H), 6.51–6.64 (m, 4H), 6.83–6.93 (m, 1H), 6.93–7.02 (m, 2H), 7.13–7.21 (m, 2H), 7.29 (d, <i>J</i> = 8.59 Hz, 2H), 7.58 (d, <i>J</i> = 15.66 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> To (<i>E</i>)-methyl 3-(4-(6-hydroxy-1-methyl-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (48 mg, 0.120 mmol) was added in 1,4-dioxanes (1 mL) and 1 M LiOH (2.52 mL, 2.52 mmol). The reaction was stirred at rt for 5 h and acidified to pH 1 with 1 M HCl. The reaction was partitioned between water and DCM. The organic layer was passed through a phase separator and concentrated in vacuo to afford <b>36</b> (42 mg, 88% yield) as a white solid. LC/MS (ESI) <i>m</i>/<i>z</i> 386.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.30 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.69 (s, 3H), 2.86–2.91 (m, 1H), 3.04–3.16 (m, 1H), 3.36–3.39 (m, 1H), 3.45–3.56 (m, 1H), 6.44 (d, <i>J</i> = 15.66 Hz, 1H), 6.47–6.52 (m, 1H), 6.57 (d, <i>J</i> = 2.53 Hz, 1H), 6.62 (d, <i>J</i> = 8.59 Hz, 1H), 6.64–6.69 (m, 2H), 6.87–6.95 (m, 1H), 6.98–7.06 (m, 2H), 7.27 (d, <i>J</i> = 8.59 Hz, 2H), 7.44 (d, <i>J</i> = 8.59 Hz, 2H), 7.64 (d, <i>J</i> = 15.66 Hz, 1H).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>E</i>)-3-(4-(2-(3-Fluorophenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>37</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(3-fluorophenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>65</b>) as described for <b>6</b>. Purified by FCC (1–30% EtOAc/heptanes) to obtain 1-(4-bromophenyl)-2-(3-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (483 mg, 50% yield) as a white solid. LC/MS (ESI) <i>m</i>/<i>z</i> 427.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.58 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.62 (s, 3H), 2.82–2.87 (m, 1H), 3.01–3.14 (m, 1H), 3.30–3.44 (m, 2H), 3.70 (s, 3H), 6.22–6.36 (m, 2H), 6.50–6.67 (m, 4H), 6.84–6.97 (m, 1H), 7.02–7.11 (m, 2H), 7.23–7.32 (m, 2H).</div><div class="NLM_p"><i>Step 2.</i> To 1-(4-bromophenyl)-2-(3-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (420 mg, 0.99 mmol) in DMF (25 mL) was added Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (104 mg, 0.15 mmol), TEA (0.687 mL, 4.93 mmol), and methyl acrylate (0.89 mL, 9.85 mmol). The reaction was stirred for 1 h at 120 °C. The crude material was purified directly by FCC (0–20% EtOAc/heptanes) to afford (<i>E</i>)-methyl 3-(4-(2-(3-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a white solid (322 mg, 76% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 432.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.52 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.76 (s, 3H), 2.96 (d, <i>J</i> = 16.17 Hz, 1H), 3.13–3.31 (m, 1H), 3.42–3.58 (m, 2H), 3.74–3.89 (m, 6H), 6.32–6.49 (m, 3H), 6.59–6.71 (m, 3H), 6.71–6.80 (m, 1H), 6.94–7.07 (m, 1H), 7.33 (d, <i>J</i> = 8.08 Hz, 2H), 7.43 (d, <i>J</i> = 8.59 Hz, 2H), 7.69 (d, <i>J</i> = 16.17 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl 3-(4-(2-(3-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b> to afford (<i>E</i>)-methyl 3-(4-(2-(3-fluorophenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate.</div><div class="NLM_p">LC/MS (ESI) <i>m</i>/<i>z</i> 418.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.59 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.65 (s, 3H), 2.82 (d, <i>J</i> = 16.17 Hz, 1H), 2.99–3.15 (m, 1H), 3.29–3.44 (m, 2H), 3.72 (s, 3H), 6.20–6.36 (m, 3H), 6.42–6.50 (m, 1H), 6.50–6.58 (m, 2H), 6.60 (d, <i>J</i> = 8.59 Hz, 1H), 6.89 (q, <i>J</i> = 8.08 Hz, 1H), 7.21 (d, <i>J</i> = 8.59 Hz, 2H), 7.32 (d, <i>J</i> = 8.59 Hz, 2H), 7.58 (d, <i>J</i> = 15.66 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> To (<i>E</i>)-methyl 3-(4-(2-(3-fluorophenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (90 mg, 0.22 mmol) in THF (4 mL), MeOH (2 mL), and H<sub>2</sub>O (2 mL) was added LiOH (25.8 mg, 1.08 mmol). The reaction was stirred for 60 min at rt. The reaction was concentrated in vacuo, diluted with H<sub>2</sub>O, and acidified with citric acid. The reaction was partitioned between the aqueous phase and DCM/MeOH. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–100% EtOAc/heptanes) to afford <b>37</b> as a pale yellow solid (72 mg, 83% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 404.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.15 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.63 (s, 3H), 2.75–2.80 (m, 1H), 3.03–3.05 (m, 1H), 3.31–3.49 (m, 2H), 6.25–6.27 (m, 1H), 6.30–6.43 (m, 3H), 6.43–6.59 (m, 3H), 6.87–6.93 (m, 1H), 7.25 (d, <i>J</i> = 8.08 Hz, 2H), 7.38 (d, <i>J</i> = 8.59 Hz, 2H), 7.55 (d, <i>J</i> = 16.17 Hz, 1H).</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>E</i>)-3-(4-(6-Hydroxy-2-(2-isopropylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>38</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(2-isopropylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>66</b>) as described for <b>6</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(2-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (300 mg, 37% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 450.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.57 min.</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(2-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford (<i>E</i>)-methyl 3-(4-(2-(2-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (40 mg, 56% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 456.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.42 min.</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl 3-(4-(2-(2-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford (<i>E</i>)-methyl 3-(4-(6-hydroxy-2-(2-isopropylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (10 mg, 51% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 442.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.18 min.</div><div class="NLM_p last"><i>Step 4.</i> To (<i>E</i>)-methyl 3-(4-(6-hydroxy-2-(2-isopropylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (10 mg, 22 μmol) in MeOH (2 mL) was added 2 M LiOH (0.219 mL, 0.439 mmol). The reaction was stirred at 60 °C for 2 h. The reaction was cooled to rt and concentrated <i>in vacuo.</i> The residue was acidified to pH 5 with saturated citric acid and partitioned with DCM. The organic layer was dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo.</i> The material was purified by HPLC (3% <i>n</i>-PrOH modifier, 1–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to <b>38</b> (5 mg, 25% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 428.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.49 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.23–1.28 (m, 6H), 1.56 (s, 3H), 2.34–2.39 (m, 1H), 2.82–2.90 (m, 2H), 3.18–3.23 (m, 1H), 3.87–3.91 (m, 1H), 6.45 (d, <i>J</i> = 16.2 Hz, 1H), 6.63–6.64 (m, 1H), 6.74–6.76 (m, 1H), 6.87–6.90 (m, 2H), 7.09–7.15 (m, 2H), 7.28–7.33 (m, 3H), 7.43–7.47 (m, 2H), 7.59 (d, <i>J</i> = 16.2 Hz, 1H).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>E</i>)-3-(4-(6-Hydroxy-2-(3-isopropylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>39</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(3-isopropylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>67</b>) as described for <b>6</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(3-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as a yellow solid (300 mg, 22% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 452.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.94 min.</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(3-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford (<i>E</i>)-methyl 3-(4-(2-(3-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a sticky solid (150 mg, 67% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 456.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.60 min.</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl 3-(4-(2-(3-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford (<i>E</i>)-methyl 3-(4-(6-hydroxy-2-(3-isopropylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a white solid (25 mg, 20% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 442.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.72 min.</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl 3-(4-(6-hydroxy-2-(3-isopropylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described in step 4 of <b>38</b>. Purified by HPLC (5 mM NH<sub>4</sub>OH modifier, 10–100% MeCN/H<sub>2</sub>O) to afford <b>39</b> as a white powder (6 mg, 35% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 428.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.26 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 0.97 (d, <i>J</i> = 7.07 Hz, 3H), 0.95 (d, <i>J</i> = 7.07 Hz, 3H), 1.67 (s, 3H), 2.39–2.66 (m, 1H), 2.76–2.97 (m, 1H), 3.02–3.24 (m, 1H), 3.34–3.38 (m, 1H), 3.40–3.65 (m, 1H), 6.29 (s, 1H), 6.36–6.52 (m, 2H), 6.53–6.63 (m, 2H), 6.64–6.72 (m, 1H), 6.78 (d, <i>J</i> = 7.58 Hz, 1H), 7.01 (t, <i>J</i> = 7.83 Hz, 1H), 7.24 (d, <i>J</i> = 8.59 Hz, 2H), 7.43 (d, <i>J</i> = 8.08 Hz, 2H), 7.59 (d, <i>J</i> = 16.17 Hz, 1H).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<i>E</i>)-3-(4-(6-Hydroxy-2-(4-isopropylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>40</b>)</h3><div class="NLM_p"><i>Step 1</i>. Prepared from 2-(4-isopropylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>58</b>) as described for <b>6</b>. Purified by FCC (0–60% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as a white solid (1.99 g, 65% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 450.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.80 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.21 (d, <i>J</i> = 7.1 Hz, 6H), 1.69 (s, 3H), 2.79–2.84 (m, 1H), 2.91–2.97 (m, 1H), 3.06–3.19 (m, 1H), 3.32–3.42 (m, 1H), 3.42–3.52 (m, 1H), 3.81 (s, 3H), 6.54–6.61 (m, 2H), 6.62–6.71 (m, 2H), 6.71–6.80 (m, 1H), 6.91–7.01 (m, 2H), 7.12 (d, <i>J</i> = 8.6 Hz, 2H), 7.35 (d, <i>J</i> = 8.6 Hz, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (0–70% EtOAc/heptanes) to afford (<i>E</i>)-methyl 3-(4-(2-(4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a pale yellow solid (1.18 g, 59% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 456.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.66 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.10 (dd, <i>J</i> = 6.8, 1.3 Hz, 6H), 1.63 (s, 3H), 2.68–2.75 (m, 1H), 2.83–2.89 (m, 1H), 2.99–3.14 (m, 1H), 3.25–3.45 (m, 2H), 3.71 (s, 3H), 3.73 (s, 3H), 6.33 (d, <i>J</i> = 16.2 Hz, 1H), 6.44–6.52 (m, 2H), 6.52–6.63 (m, 2H), 6.67 (d, <i>J</i> = 8.6 Hz, 1H), 6.78–6.91 (m, 2H), 7.20 (d, <i>J</i> = 7.1 Hz, 2H), 7.31 (d, <i>J</i> = 8.1 Hz, 2H), 7.60 (d, <i>J</i> = 16.2 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl 3-(4-(2-(4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (1–30% EtOAc/heptanes) to afford (<i>E</i>)-methyl 3-(4-(6-hydroxy-2-(4-isopropylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (1.8 g, 74% yield) as a white solid. LC/MS (ESI) <i>m</i>/<i>z</i> 442.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.35 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.19 (d, <i>J</i> = 7.1 Hz, 6H), 1.71 (s, 3H), 2.77–2.82 (m, 1H), 2.90–2.95 (m, 1H), 3.03–3.22 (m, 1H), 3.32–3.52 (m, 2H), 3.83 (s, 3H), 6.43 (d, <i>J</i> = 16.2 Hz, 1H), 6.58 (d, <i>J</i> = 8.6 Hz, 3H), 6.62–6.67 (m, 1H), 6.73 (d, <i>J</i> = 8.6 Hz, 1H), 6.94 (d, <i>J</i> = 8.6 Hz, 2H), 7.29 (d, <i>J</i> = 3.5 Hz, 2H), 7.40 (d, <i>J</i> = 8.1 Hz, 2H), 7.70 (d, <i>J</i> = 16.2 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl 3-(4-(6-hydroxy-2-(4-isopropylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described in step 4 of <b>37</b>. Purified by FCC (1–20% MeOH/DCM) to afford <b>40</b> as a white solid (1.68 g, 96% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 428.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.04 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.09 (dd, <i>J</i> = 7.1, 1.0 Hz, 6H), 1.62 (s, 3H), 2.69–2.72 (m, 1H), 2.76–2.92 (m, 1H), 2.92–3.10 (m, 1H), 3.21–3.48 (m, 2H), 6.33 (d, <i>J</i> = 16.2 Hz, 1H), 6.48 (d, <i>J</i> = 8.6 Hz, 3H), 6.54 (d, <i>J</i> = 2.5 Hz, 1H), 6.62 (d, <i>J</i> = 8.6 Hz, 1H), 6.84 (d, <i>J</i> = 8.6 Hz, 2H), 7.20 (d, <i>J</i> = 8.6 Hz, 2H), 7.33 (d, <i>J</i> = 8.6 Hz, 2H), 7.68 (d, <i>J</i> = 16.2 Hz, 1H). <sup>13</sup>C NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 22.57 (1C), 23.72 (1C), 23.87 (1C), 30.15 (1C), 32.44 (1C), 45.60 (1C), 63.93 (1C), 113.61 (1C), 113.81 (1C), 118.62 (1C), 124.06 (2C), 125.50 (2C), 127.58 (2C), 128.14 (2C), 129.57 (1C), 131.98 (1C), 134.22 (1C), 134.89 (1C), 141.95 (1C), 143.48 (1C), 147.77 (1C), 152.19 (1C), 154.74 (1C), 167.53 (1C).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<i>E</i>)-3-(4-(6-Hydroxy-1-methyl-2-(<i>p</i>-tolyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>41</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 6-methoxy-2-(<i>p</i>-tolyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>68</b>) as described for <b>6</b>. Purified by FCC (1–30% EtOAc/heptanes) to afford 1-(4-bromophenyl)-6-methoxy-1-methyl-2-(<i>p</i>-tolyl)-1,2,3,4-tetrahydroisoquinoline as an off white solid (750 mg, 89% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 423.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.67 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.68 (s, 3H), 2.26 (s, 3H), 2.87–3.03 (m, 1H), 3.07–3.21 (m, 1H), 3.29–3.41 (m, 1H), 3.41–3.52 (m, 1H), 3.81 (s, 3H), 6.48–6.60 (m, 2H), 6.62–6.77 (m, 3H), 6.86–6.98 (m, 2H), 7.05–7.15 (m, 2H), 7.30–7.45 (m, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-6-methoxy-1-methyl-2-(<i>p</i>-tolyl)-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (1–20% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(6-methoxy-1-methyl-2-(<i>p</i>-tolyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as an off white solid (428 mg, 56% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 428.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.50 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.58 (s, 3H), 2.10 (s, 3H), 2.81–2.86 (m, 1H), 2.93–3.12 (m, 1H), 3.24–3.28 (m, 1H), 3.34–3.38 (m, 1H), 3.66 (s, 3H), 3.68 (s, 3H), 6.39 (d, <i>J</i> = 16.17 Hz, 1H), 6.42–6.47 (m, 2H), 6.47–6.55 (m, 1H), 6.59 (d, <i>J</i> = 8.59 Hz, 2H), 6.70–6.78 (m, 2H), 7.14 (d, <i>J</i> = 8.59 Hz, 2H), 7.34 (d, <i>J</i> = 8.08 Hz, 2H), 7.56 (d, <i>J</i> = 16.17 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(6-methoxy-1-methyl-2-(<i>p</i>-tolyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Carried forward without purification to obtain (<i>E</i>)-methyl 3-(4-(6-hydroxy-1-methyl-2-(<i>p</i>-tolyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a white solid (380 mg, 98% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 414.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.65 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.70 (br s, 3H), 2.25 (s, 3H), 2.83–2.98 (m, 1H), 3.06–3.24 (m, 1H), 3.24–3.40 (m, 1H), 3.40–3.55 (m, 1H), 3.83 (s, 3H), 6.43 (d, <i>J</i> = 15.81 Hz, 1H), 6.48–6.63 (m, 3H), 6.63–6.78 (m, 2H), 6.89 (d, <i>J</i> = 8.03 Hz, 2H), 7.19–7.33 (m, 2H), 7.39 (d, <i>J</i> = 8.28 Hz, 2H), 7.69 (d, <i>J</i> = 16.06 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl 3-(4-(6-hydroxy-1-methyl-2-(<i>p</i>-tolyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described in step 4 of <b>37</b>. Purified by FCC (1–20% MeOH/DCM) to afford <b>41</b> as a white solid (290 mg, 79% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 400.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.24 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.71 (s, 3H), 2.26 (s, 3H), 2.91–2.95 (m, 1H), 3.07–3.21 (m, 1H), 3.31–3.42 (m, 1H), 3.42–3.54 (m, 1H), 6.44 (d, <i>J</i> = 15.66 Hz, 1H), 6.50–6.61 (m, 3H), 6.65 (d, <i>J</i> = 2.53 Hz, 1H), 6.71 (d, <i>J</i> = 8.59 Hz, 1H), 6.90 (d, <i>J</i> = 8.08 Hz, 2H), 7.26–7.32 (m, 2H), 7.43 (d, <i>J</i> = 8.08 Hz, 2H), 7.78 (d, <i>J</i> = 15.66 Hz, 1H).</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (<i>E</i>)-3-(4-(2-(3-Fluoro-4-methylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>42</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(3-fluoro-4-methylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>69</b>) as described for <b>6</b>. Purified by FCC (1–30% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(3-fluoro-4-methylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as a white solid (360 mg, 39% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 442.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.66 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.60 (s, 3H), 2.08 (d, <i>J</i> = 1.52 Hz, 3H), 2.82–2.87 (m, 1H), 3.00–3.16 (m, 1H), 3.23–3.43 (m, 2H), 3.71 (s, 3H), 6.18 (dd, <i>J</i> = 8.08, 2.02 Hz, 1H), 6.28 (dd, <i>J</i> = 12.13, 2.02 Hz, 1H), 6.50–6.66 (m, 3H), 6.77 (t, <i>J</i> = 8.84 Hz, 1H), 7.03–7.05 (m, 2H), 7.24–7.33 (m, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(3-fluoro-4-methylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (1–20% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(3-fluoro-4-methylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a white solid (237 mg, 73% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 446.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.56 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.73 (s, 3H), 2.16 (s, 3H), 2.85–3.06 (m, 1H), 3.21 (dd, <i>J</i> = 11.12, 5.05 Hz, 1H), 3.34–3.55 (m, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 6.28 (d, <i>J</i> = 8.08 Hz, 1H), 6.31–6.39 (m, 1H), 6.42 (d, <i>J</i> = 16.17 Hz, 1H), 6.60–6.71 (m, 2H), 6.71–6.77 (m, 1H), 6.84 (t, <i>J</i> = 8.59 Hz, 1H), 7.30 (d, <i>J</i> = 8.08 Hz, 2H), 7.42 (d, <i>J</i> = 8.59 Hz, 2H), 7.69 (d, <i>J</i> = 15.66 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(3-fluoro-4-methylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b> to obtain (<i>E</i>)-methyl 3-(4-(2-(3-fluoro-4-methylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a white solid (108 mg, 86% yield) that was carried forward without purification. LC/MS (ESI) <i>m</i>/<i>z</i> 432.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.63 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.69 (s, 3H), 2.11–2.17 (m, 3H), 2.86–2.92 (m, 1H), 3.10–3.17 (m, 1H), 3.30–3.51 (m, 2H), 3.80 (s, 3H), 6.21–6.37 (m, 2H), 6.40 (d, <i>J</i> = 15.66 Hz, 1H), 6.55 (dd, <i>J</i> = 8.5, 2.7 Hz, 1H), 6.61 (d, <i>J</i> = 2.6 Hz, 1H), 6.67 (d, <i>J</i> = 8.6 Hz, 1H), 6.81 (t, <i>J</i> = 8.7 Hz, 1H), 7.25–7.34 (m, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.67 (d, <i>J</i> = 16.0 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl 3-(4-(2-(3-fluoro-4-methylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described in step 4 of <b>37</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford <b>42</b> as an off white solid (68 mg, 78% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 418.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.19 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.59 (s, 3H), 2.01 (s, 3H), 2.75–2.80 (m, 1H), 2.95–3.11 (m, 1H), 3.26–3.32 (m, 1H), 3.32–3.43 (m, 1H), 6.19 (dd, <i>J</i> = 12.63, 2.02 Hz, 1H), 6.26 (dd, <i>J</i> = 8.08, 2.02 Hz, 1H), 6.30–6.43 (m, 2H), 6.43–6.56 (m, 2H), 6.76 (t, <i>J</i> = 8.84 Hz, 1H), 7.21 (d, <i>J</i> = 8.59 Hz, 2H), 7.38 (d, <i>J</i> = 8.08 Hz, 2H), 7.55 (d, <i>J</i> = 16.17 Hz, 1H).</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (<i>E</i>)-3-(4-(2-(4-(<i>tert</i>-butyl)phenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>43</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(4-(<i>tert</i>-butyl)phenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>70</b>) as described for <b>6</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(4-(<i>tert</i>-butyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as yellow solid (1.29 g, 86% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 466.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.61 min.</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(4-(<i>tert</i>-butyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described for <b>7</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(4-(<i>tert</i>-butyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a yellow solid (401 mg, 30% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 470.6 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.94 min.</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(4-(<i>tert</i>-butyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b> to obtain (<i>E</i>)-methyl 3-(4-(2-(4-(<i>tert-</i>butyl)phenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a yellow solid (385 mg, 99% yield) that was carried forward without purification. LC/MS (ESI) <i>m</i>/<i>z</i> 456.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.83 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.07 (s, 9H), 1.53 (s, 3H), 2.71–2.75 (m, 1H), 2.86–3.00 (m, 1H), 3.15–3.36 (m, 2H), 3.63 (s, 3H), 6.24 (d, <i>J</i> = 15.66 Hz, 1H), 6.35–6.48 (m, 4H), 6.54 (d, <i>J</i> = 8.59 Hz, 1H), 6.89 (d, <i>J</i> = 8.59 Hz, 2H), 7.07–7.15 (m, 2H), 7.22 (d, <i>J</i> = 8.59 Hz, 2H), 7.51 (d, <i>J</i> = 16.17 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl 3-(4-(2-(4-(<i>tert</i>-butyl)phenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described in step 4 of <b>37</b>. Purified by FCC (1–20% MeOH/DCM) to afford <b>43</b> as a white solid (180 mg, 48% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 442.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.32 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.16 (s, 9H), 1.62 (s, 3H), 2.80–2.84 (m, 1H), 2.94–3.13 (m, 1H), 3.24–3.45 (m, 2H), 6.34 (d, <i>J</i> = 16.17 Hz, 1H), 6.42–6.59 (m, 4H), 6.63 (d, <i>J</i> = 8.59 Hz, 1H), 6.94–7.04 (m, 2H), 7.19–7.27 (m, 2H), 7.29–7.39 (m, 2H), 7.68 (d, <i>J</i> = 16.17 Hz, 1H).</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (<i>E</i>)-3-(4-(6-Hydroxy-1-methyl-2-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>44</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 6-methoxy-2-(4-(trifluoromethyl)phenyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>71</b>) as described for <b>6</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford 1-(4-bromophenyl)-6-methoxy-1-methyl-2-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline (450 mg, 49% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 478.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.33 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.76 (s, 3H), 2.95 (d, <i>J</i> = 15.66 Hz, 1H), 3.12–3.28 (m, 1H), 3.56 (dd, <i>J</i> = 6.82, 4.29 Hz, 2H), 3.79 (s, 3H), 6.64–6.66 (m, 2H), 6.69–6.81 (m, 3H), 7.01–7.23 (m, 2H), 7.29–7.46 (m, 4H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-6-methoxy-1-methyl-2-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (0–70% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(6-methoxy-1-methyl-2-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a colorless sticky solid (100 mg, 50% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 482.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.20 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.79 (s, 3H), 2.88–3.03 (m, 1H), 3.12–3.21 (m, 1H), 3.56–3.60 (m, 2H), 3.78 (s, 3H), 3.80 (s, 3H), 6.40 (d, <i>J</i> = 16.0 Hz, 1H), 6.59–6.78 (m, 5H), 7.31 (dd, <i>J</i> = 19.1, 8.5 Hz, 4H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 7.66 (d, <i>J</i> = 16.0 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(6-methoxy-1-methyl-2-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–20% MeOH/DCM with 7 M NH<sub>3</sub> modifier) to afford (<i>E</i>)-methyl-3-(4-(6-hydroxy-1-methyl-2-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (60 mg, 62% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 468.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.55 min.</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl-3-(4-(6-hydroxy-1-methyl-2-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described in step 4 of <b>38</b>. Purified by HPLC (5 mM NH<sub>4</sub>OH modifier, 1–100% MeCN/H<sub>2</sub>O) to afford <b>44</b> white powder (20 mg, 35% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 454.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.39 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.82 (s, 3H), 2.88–2.92 (m, 1H), 3.16–3.19 (m, 1H), 3.49–3.76 (m, 2H), 6.39–6.52 (m, 2H), 6.57 (d, <i>J</i> = 2.5 Hz, 1H), 6.64 (d, <i>J</i> = 8.6 Hz, 1H), 6.79 (d, <i>J</i> = 8.6 Hz, 2H), 7.26 (d, <i>J</i> = 8.7 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.48 (d, <i>J</i> = 8.4 Hz, 2H), 7.58 (d, <i>J</i> = 16.0 Hz, 1H).</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (<i>E</i>)-3-(4-(2-(4-Butylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>45</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(4-butylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>72</b>) as described for <b>6</b>. Purified by FCC (1–20% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(4-butylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as a white solid (290 mg, 57% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 465.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.80 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.83 (t, <i>J</i> = 7.3 Hz, 3H), 1.22–1.27 (m, 2H), 1.43–1.49 (m, 2H), 1.59 (s, 3H), 2.34–2.49 (m, 2H), 2.77–2.91 (m, 1H), 2.96–3.10 (m, 1H), 3.21–3.31 (m, 1H), 3.31–3.41 (m, 1H), 3.72 (s, 3H), 6.42–6.51 (m, 2H), 6.53–6.61 (m, 2H), 6.61–6.70 (m, 1H), 6.67–6.86 (m, 2H), 7.01 (d, <i>J</i> = 9.1 Hz, 2H), 7.25 (d, <i>J</i> = 8.6 Hz, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(4-butylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (1–20% EtOAc/heptanes) to afford (<i>E</i>)<i>-</i>methyl 3-(4-(2-(4-butylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a yellow solid (130 mg, 44% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 470.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.71 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.77–0.89 (m, 3H), 1.17–1.30 (m, 2H), 1.41–1.49 (m, 2H), 1.62 (s, 3H), 2.36–2.47 (m, 2H), 2.86 (d, <i>J</i> = 16.2 Hz, 1H), 3.06 (s, 1H), 3.24–3.34 (m, 1H), 3.34–3.45 (m, 1H), 3.72 (s, 3H), 3.73 (s, 3H), 6.33 (d, <i>J</i> = 16.2 Hz, 1H), 6.42–6.51 (m, 2H), 6.52–6.62 (m, 2H), 6.66 (d, <i>J</i> = 8.6 Hz, 1H), 6.75–6.84 (m, 2H), 7.13–7.23 (m, 2H), 7.30 (d, <i>J</i> = 8.08 Hz, 2H), 7.60 (d, <i>J</i> = 16.2 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl 3-(4-(2-(4-butylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b> to obtain methyl (<i>E</i>)-3-(4-(2-(4-butylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a white solid (120 mg, 95% yield) which carried forward without purification. LC/MS (ESI) <i>m</i>/<i>z</i> 456.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.73 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.82 (t, <i>J</i> = 7.3 Hz, 3H), 1.21 (dd, <i>J</i> = 15.9, 8.3 Hz, 2H), 1.38–1.52 (m, 5H), 2.32–2.49 (m, 2H), 2.73–2.90 (m, 1H), 2.94–3.12 (m, 1H), 3.20–3.33 (m, 1H), 3.33–3.45 (m, 1H), 3.73 (s, 3H), 6.33 (d, <i>J</i> = 16.2 Hz, 1H), 6.39–6.53 (m, 3H), 6.55 (d, <i>J</i> = 2.5 Hz, 1H), 6.62 (d, <i>J</i> = 8.1 Hz, 1H), 6.79 (d, <i>J</i> = 8.6 Hz, 2H), 7.17 (d, <i>J</i> = 8.1 Hz, 2H), 7.30 (d, <i>J</i> = 8.6 Hz, 2H), 7.60 (d, <i>J</i> = 16.2 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from methyl (<i>E</i>)-3-(4-(2-(4-butylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described in step 4 of <b>37</b>. Purified by FCC (1–20% MeOH/DCM) to afford <b>45</b> as an off white solid (57 mg, 84% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 442.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.27 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.79–0.85 (m, 3H), 1.19–1.27 (m, 2H), 1.41–1.47 (m, 2H), 1.61 (s, 3H), 2.33–2.46 (m, 2H), 2.79–2.86 (m, 1H), 2.95–3.15 (m, 1H), 3.20–3.32 (m, 1H), 3.32–3.44 (m, 1H), 6.33 (d, <i>J</i> = 15.66 Hz, 1H), 6.40–6.52 (m, 3H), 6.54 (d, <i>J</i> = 2.53 Hz, 1H), 6.61 (d, <i>J</i> = 8.59 Hz, 1H), 6.79 (d, <i>J</i> = 8.59 Hz, 2H), 7.17–7.21 (m, 2H), 7.32 (d, <i>J</i> = 8.59 Hz, 2H), 7.67 (d, <i>J</i> = 16.17 Hz, 1H).</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (<i>E</i>)-3-(4-(6-Hydroxy-1-methyl-2-(4-pentylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>46</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 6-methoxy-2-(4-pentylphenyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>73</b>) as described for <b>6</b>. Purified by FCC (0–30% EtOAc/heptanes) to afford 1-(4-bromophenyl)-6-methoxy-1-methyl-2-(4-pentylphenyl)-1,2,3,4-tetrahydroisoquinoline as a yellow oil (553 mg, quantitative yield). LC/MS (ESI) <i>m</i>/<i>z</i> 479.8 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.84 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.76–0.86 (m, 3H), 1.22–1.26 (m, 4H), 1.40–1.53 (m, 2H), 1.59 (s, 3H), 2.36–2.46 (m, 2H), 2.79–2.92 (m, 1H), 2.98–3.10 (m, 1H), 3.22–3.32 (m, 1H), 3.32–3.41 (m, 1H), 3.71 (s, 3H), 6.45–6.48 (m, 2H), 6.53–6.62 (m, 2H), 6.62–6.68 (m, 1H), 6.80–6.83 (m, 2H), 7.00–7.02 (m, 2H), 7.22–7.27 (m, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-6-methoxy-1-methyl-2-(4-pentylphenyl)-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford methyl (<i>E</i>)-3-(4-(6-methoxy-1-methyl-2-(4-pentylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as an yellow oil (393 mg, 70% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 484.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.90 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.74–0.78 (m, 3H), 1.16–1.22 (m, 4H), 1.37–1.45 (m, 2H), 1.56 (s, 3H), 2.27–2.41 (m, 2H), 2.73–2.85 (m, 1H), 2.88–3.06 (m, 1H), 3.15–3.36 (m, 2H), 3.61 (s, 3H), 3.65 (s, 3H), 6.24–6.32 (m, 1H), 6.43 (d, <i>J</i> = 8.08 Hz, 2H), 6.46–6.52 (m, 1H), 6.54 (d, <i>J</i> = 2.53 Hz, 1H), 6.60 (d, <i>J</i> = 9.09 Hz, 1H), 6.74 (d, <i>J</i> = 8.59 Hz, 2H), 7.10–7.15 (m, 2H), 7.19–7.22 (m, 1H), 7.24 (s, 1H), 7.54 (d, <i>J</i> = 9.60 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from methyl (<i>E</i>)-3-(4-(6-methoxy-1-methyl-2-(4-pentylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford methyl (<i>E</i>)-3-(4-(6-hydroxy-1-methyl-2-(4-pentylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a red-orange solid (45 mg, 12% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 470.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.73 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.84–0.91 (m, 3H), 1.21–1.37 (m, 6H), 1.69 (br s, 3H), 2.49 (d, <i>J</i> = 7.58 Hz, 2H), 2.92 (br s, 1H), 3.08 (br s, 1H), 3.37 (br s, 1H), 3.43 (br s, 1H), 3.80 (s, 3H), 6.40 (d, <i>J</i> = 15.66 Hz, 1H), 6.53 (d, <i>J</i> = 7.58 Hz, 3H), 6.62 (br s, 1H), 6.69 (d, <i>J</i> = 7.07 Hz, 1H), 6.87 (d, <i>J</i> = 7.07 Hz, 2H), 7.24 (br s, 2H), 7.38 (d, <i>J</i> = 7.58 Hz, 2H), 7.67 (d, <i>J</i> = 16.17 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from methyl (<i>E</i>)-3-(4-(6-hydroxy-1-methyl-2-(4-pentylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>9</b> to afford <b>46</b> as a light gray solid (30 mg, 65% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 456.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.52 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.79 (t, <i>J</i> = 6.82 Hz, 3H), 1.17–1.25 (m, 4H), 1.42–1.50 (m, 2H), 1.64 (br s, 3H), 2.40 (t, <i>J</i> = 7.83 Hz, 2H), 2.74–2.93 (m, 1H), 3.01 (br s, 1H), 3.33 (d, <i>J</i> = 14.15 Hz, 2H), 6.33 (d, <i>J</i> = 15.66 Hz, 1H), 6.49 (dd, <i>J</i> = 8.34, 2.27 Hz, 3H), 6.53–6.57 (m, 1H), 6.59 (d, <i>J</i> = 8.59 Hz, 1H), 6.80 (d, <i>J</i> = 8.08 Hz, 2H), 7.11–7.21 (m, 2H), 7.31 (d, <i>J</i> = 8.59 Hz, 2H), 7.67 (d, <i>J</i> = 15.66 Hz, 1H).</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (<i>E</i>)-3-(4-(2-(4-Cyclopropylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>47</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(4-cyclopropylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>74</b>) as described for <b>6</b>. Purified by FCC (0–30% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(4-cyclopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as a clear oil (154 mg, 100% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 449.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.66 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.57–0.63 (m, 2H), 0.89–0.91 (m, 2H), 1.65 (s, 3H), 1.72–1.84 (m, 1H), 2.85–2.97 (m, 1H), 3.05–3.17 (m, 1H), 3.28–3.37 (m, 1H), 3.37–3.46 (m, 1H), 3.79 (s, 3H), 6.49–6.55 (m, 2H), 6.61–6.67 (m, 2H), 6.69–6.73 (m, 1H), 6.75–6.81 (m, 2H), 7.05–7.11 (m, 2H), 7.29–7.34 (m, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(4-cyclopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(4-cyclopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a yellow oil (118 mg, 76% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 454.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.59 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.58–0.65 (m, 2H), 0.87–0.97 (m, 2H), 1.71 (s, 3H), 1.76–1.83 (m, 1H), 2.92–2.98 (m, 1H), 3.07–3.23 (m, 1H), 3.32–3.43 (m, 1H), 3.43–3.53 (m, 1H), 3.80–3.82 (m, 3H), 3.82–3.86 (m, 3H), 6.43 (d, <i>J</i> = 16.17 Hz, 1H), 6.52–6.59 (m, 2H), 6.63–6.72 (m, 2H), 6.72–6.78 (m, 1H), 6.78–6.82 (m, 2H), 7.25–7.32 (m, 2H), 7.38–7.43 (m, 2H), 7.66–7.75 (m, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)<i>-</i>methyl-3-(4-(2-(4-cyclopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>18</b>. Purified by HPLC (5 mM NH<sub>4</sub>OH modifier, 45–70% MeCN/H<sub>2</sub>O) to afford (<i>E</i>)<i>-</i>methyl-3-(4-(2-(4-cyclopropylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a clear oil (12 mg, 21% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 440.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.70 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.51–0.62 (m, 2H), 0.82–0.92 (m, 2H), 1.67 (s, 3H), 1.70–1.81 (m, 1H), 2.83–2.94 (m, 1H), 3.01–3.15 (m, 1H), 3.25–3.37 (m, 1H), 3.35–3.42 (m, 1H), 3.80 (s, 3H), 6.40 (d, <i>J</i> = 16.0 Hz, 1H), 6.48–6.58 (m, 3H), 6.61 (d, <i>J</i> = 2.7 Hz, 1H), 6.68 (d, <i>J</i> = 8.5 Hz, 1H), 6.71–6.80 (m, 2H), 7.17–7.25 (m, 2H), 7.31–7.40 (m, 2H), 7.67 (d, <i>J</i> = 16.1 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(4-cyclopropylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>9</b> to obtain <b>47</b> as a cream solid (10.3 mg, 89% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 426.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 0.56 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 0.52–0.56 (m, 2H), 0.83–0.91 (m, 2H), 1.66 (s, 3H), 1.72–1.79 (m, 1H), 2.84–2.90 (m, 1H), 3.04–3.12 (m, 1H), 3.28–3.34 (m, 1H), 3.41–3.49 (m, 1H), 6.44 (d, <i>J</i> = 15.9 Hz, 1H), 6.47–6.64 (m, 5H), 6.75 (d, <i>J</i> = 8.5 Hz, 2H), 7.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.64 (d, <i>J</i> = 16.0 Hz, 1H).</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (<i>E</i>)-3-(4-(2-(4-Cyclobutylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>48</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(4-cyclobutylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>75</b>) as described for <b>6</b>. Purified by FCC (0–30% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(4-cyclobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as a yellow oil (580 mg, 96% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 464.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.49 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.67 (s, 3H), 1.75–1.86 (m, 1H), 1.90–2.15 (m, 3H), 2.20–2.37 (m, 2H), 2.80–3.00 (m, 1H), 3.04–3.22 (m, 1H), 3.26–3.40 (m, 1H), 3.41–3.57 (m, 2H), 3.80 (s, 3H), 6.38–6.62 (m, 2H), 6.62–6.70 (m, 2H), 6.71–6.83 (m, 1H), 6.94 (d, <i>J</i> = 8.59 Hz, 2H), 7.07–7.20 (m, 2H), 7.27–7.43 (m, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(4-cyclobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described for <b>7</b>. Purified by FCC (0–70% EtOAc/heptanes) to afford (<i>E</i>)<i>-</i>methyl-3-(4-(2-(4-cyclobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a light yellow solid (330 mg, 65% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 468.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.71 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.56 (s, 3H), 1.76–1.86 (m, 1H), 1.91–2.14 (m, 3H), 2.23–2.33 (m, 2H), 2.91–2.96 (m, 1H), 3.10–3.17 (m, 1H), 3.35–3.49 (m, 3H), 3.81 (s, 3H), 3.82 (s, 3H), 6.42 (d, <i>J</i> = 15.9 Hz, 1H), 6.55–6.60 (m, 2H), 6.64–6.71 (m, 2H), 6.76 (d, <i>J</i> = 8.6 Hz, 1H), 6.93 (d, <i>J</i> = 8.4 Hz, 2H), 7.26–7.31 (m, 2H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.69 (d, <i>J</i> = 16.0 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(4-cyclobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(4-cyclobutylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a white solid (36 mg, 74% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 454.6 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.62 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.56 (s, 3H), 1.76–1.86 (m, 1H), 1.90–2.14 (m, 3H), 2.23–2.33 (m, 2H), 2.88–2.93 (m, 1H), 3.06–3.12 (m, 1H), 3.33–3.50 (m, 3H), 3.82 (s, 3H), 6.42 (d, <i>J</i> = 15.9 Hz, 1H), 6.54–6.61 (m, 3H), 6.63 (d, <i>J</i> = 2.6 Hz, 1H), 6.72 (d, <i>J</i> = 8.5 Hz, 1H), 6.93 (d, <i>J</i> = 8.4 Hz, 2H), 7.25–7.29 (m, 2H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.69 (d, <i>J</i> = 16.0 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(4-cyclobutylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described in step 4 of <b>38</b>. Purified by HPLC (5 mM NH<sub>4</sub>OH modifier, 1–100% MeCN/H<sub>2</sub>O) to afford <b>48</b> as a white solid (6 mg, 17% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 440.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.40 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.67 (s, 3H), 1.72–1.86 (m, 1H), 1.90–2.18 (m, 3H), 2.19–2.37 (m, 1H), 2.67–2.96 (m, 1H), 3.01–3.20 (m, 2H), 3.39–3.55 (m, 3H), 6.34–6.53 (m, 2H), 6.55–6.71 (m, 4H), 6.90 (d, <i>J</i> = 8.59 Hz, 2H), 7.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.42 (d, <i>J</i> = 8.3 Hz, 2H), 7.56 (d, <i>J</i> = 16.2 Hz, 1H).</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (<i>E</i>)-3-(4-(6-Hydroxy-2-(4-isobutylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>49</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(4-isobutylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>76</b>) as described for <b>6</b>. Purified by FCC (0–30% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(4-isobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as a yellow oil (118 mg, 79% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 466.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.97 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.77 (d, <i>J</i> = 6.6 Hz, 6H), 1.58 (s, 3H), 1.68–1.73 (m, 1H), 2.27 (d, <i>J</i> = 7.1 Hz, 2H), 2.82–2.87 (m, 1H), 2.99–3.02 (m, 1H), 3.25–3.29 (m, 1H), 3.32–3.37 (m, 1H), 3.69 (s, 3H), 6.42–6.49 (m, 2H), 6.50–6.60 (m, 2H), 6.63 (d, <i>J</i> = 8.6 Hz, 1H), 6.74–6.80 (m, 2H), 6.95–7.03 (m, 2H), 7.20–7.26 (m, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(4-isobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(4-isobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a yellow oil (63 mg, 53% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 470.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.72 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.77 (d, <i>J</i> = 6.6 Hz, 6H), 1.61 (s, 3H), 1.66 (d, <i>J</i> = 6.7 Hz, 1H), 2.27 (d, <i>J</i> = 7.1 Hz, 2H), 2.84–2.89 (m, 1H), 3.04–3.06 (m, 1H), 3.21–3.41 (m, 2H), 3.70 (s, 3H), 3.71 (s, 3H), 6.32 (d, <i>J</i> = 16.0 Hz, 1H), 6.42–6.49 (m, 2H), 6.51–6.61 (m, 2H), 6.66 (d, <i>J</i> = 8.6 Hz, 1H), 6.71–6.79 (m, 2H), 7.16 (d, <i>J</i> = 8.2 Hz, 2H), 7.25–7.33 (m, 2H), 7.55–7.63 (m, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(4-isobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(6-hydroxy-2-(4-isobutylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a yellow oil (38 mg, 62% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 456.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.41 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.87 (d, <i>J</i> = 6.6 Hz, 6H), 1.71 (s, 3H), 1.75–1.82 (m, 1H), 2.37 (d, <i>J</i> = 7.2 Hz, 2H), 2.83–2.99 (m, 1H), 3.09–3.11 (m, 1H), 3.30–3.50 (m, 2H), 3.83 (s, 3H), 6.42 (d, <i>J</i> = 16.0 Hz, 1H), 6.51–6.62 (m, 3H), 6.65 (d, <i>J</i> = 2.6 Hz, 1H), 6.70 (d, <i>J</i> = 8.5 Hz, 1H), 6.83–6.90 (m, 2H), 7.23–7.28 (m, 2H), 7.35–7.43 (m, 2H), 7.69 (d, <i>J</i> = 16.0 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl-3-(4-(6-hydroxy-2-(4-isobutylphenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>9</b> to obtain <b>49</b> as a light yellow powder (26 mg, 71% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 442.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.40 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 0.83 (d, <i>J</i> = 6.6 Hz, 6H), 1.67 (s, 3H), 1.71–1.78 (m, 1H), 2.33 (d, <i>J</i> = 7.2 Hz, 2H), 2.81–2.91 (m, 1H), 3.04–3.11 (m, 1H), 3.34 (t, <i>J</i> = 5.2 Hz, 1H), 3.41–3.47 (m, 1H), 6.42 (d, <i>J</i> = 16.0 Hz, 1H), 6.49 (dd, <i>J</i> = 8.5, 2.7 Hz, 1H), 6.52–6.59 (m, 3H), 6.60 (d, <i>J</i> = 8.6 Hz, 1H), 6.76–6.87 (m, 2H), 7.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.34–7.44 (m, 2H), 7.63 (d, <i>J</i> = 16.0 Hz, 1H).</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (<i>E</i>)-3-(4-(2-(4-(cyclopropylmethyl)phenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>50</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(4-(cyclopropylmethyl)phenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>77</b>) as described for <b>6</b>. Purified by FCC (0–25% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(4-(cyclopropylmethyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (21 mg, 48% yield) as a clear oil. LC/MS (ESI) <i>m</i>/<i>z</i> 462.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.42 min.</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(4-(cyclopropylmethyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(4-(cyclopropylmethyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (10 mg, 23% yield) as a yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 468.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.23 min.</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(4-(cyclopropylmethyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>18</b> to obtain methyl (<i>E</i>)-3-(4-(2-(4-(cyclopropylmethyl)phenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a brown oil that was carried forward without purification. LC/MS (ESI) <i>m</i>/<i>z</i> 454.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.47 min.</div><div class="NLM_p last"><i>Step 4.</i> Prepared from methyl (<i>E</i>)-3-(4-(2-(4-(cyclopropylmethyl)phenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>9</b>. Purified by HPLC (0.1% TFA modifier, 25–50% MeCN/H<sub>2</sub>O) to afford <b>50</b> (4.6 mg, 20% yield over two steps) as a white solid and separation of side product. LC/MS (ESI) <i>m</i>/<i>z</i> 440.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.34 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 0.11 (q, <i>J</i> = 5.0 Hz, 2H), 0.34–0.47 (m, 2H), 0.87 (q, <i>J</i> = 7.6, 6.5 Hz, 1H), 1.62 (s, 3H), 2.35 (d, <i>J</i> = 7.0 Hz, 2H), 2.83 (s, 1H), 3.08 (s, 2H), 3.31 (s, 1H), 6.43–6.61 (m, 6H), 6.93 (d, <i>J</i> = 8.2 Hz, 2H), 7.29 (d, <i>J</i> = 8.1 Hz, 2H), 7.50–7.59 (m, 3H).</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>E</i>)-3-(4-(6-Hydroxy-1-methyl-2-(4-(2,2,2-trifluoroethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>51</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 6-methoxy-2-(4-(2,2,2-trifluoroethyl)phenyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>78</b>) as described for <b>6</b>. Purified by FCC (0–30% EtOAc/heptanes) to afford 1-(4-bromophenyl)-6-methoxy-1-methyl-2-(4-(2,2,2-trifluoroethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline as a yellow powder (150 mg, 50% yield over two steps). LC/MS (ESI) <i>m</i>/<i>z</i> 491.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.63 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.70 (s, 3H), 2.89–2.95 (m, 1H), 3.06–3.21 (m, 1H), 3.25 (q, <i>J</i> = 10.61 Hz, 2H), 3.35–3.59 (m, 2H), 3.79 (s, 3H), 6.46–6.70 (m, 4H), 6.70–6.80 (m, 1H), 7.01 (d, <i>J</i> = 8.59 Hz, 2H), 7.13 (d, <i>J</i> = 8.59 Hz, 2H), 7.31–7.41 (m, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-6-methoxy-1-methyl-2-(4-(2,2,2-trifluoroethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline as described for <b>7</b>. Purified by FCC (0–70% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(6-methoxy-1-methyl-2-(4-(2,2,2-trifluoroethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a light yellow solid (80 mg, 72% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 496.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.70 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.73 (s, 3H), 2.91–2.96 (m, 1H), 3.14–3.29 (m, 3H), 3.38–3.54 (m, 2H), 3.79 (s, 3H), 3.81 (s, 3H), 6.41 (d, <i>J</i> = 15.66 Hz, 1H), 6.52–6.69 (m, 4H), 6.75 (d, <i>J</i> = 8.59 Hz, 1H), 6.99 (d, <i>J</i> = 8.59 Hz, 2H), 7.29 (d, <i>J</i> = 8.59 Hz, 2H), 7.40 (d, <i>J</i> = 8.59 Hz, 2H), 7.68 (d, <i>J</i> = 16.17 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(6-methoxy-1-methyl-2-(4-(2,2,2-trifluoroethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(6-hydroxy-1-methyl-2-(4-(2,2,2-trifluoroethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a white powder (50 mg, 74% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 482.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 0.90 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.73 (s, 3H), 2.87–2.96 (m, 1H), 3.09–3.31 (m, 3H), 3.40–3.54 (m, 2H), 3.82 (s, 3H), 6.42 (d, <i>J</i> = 15.9 Hz, 1H), 6.55–6.66 (m, 4H), 6.72 (d, <i>J</i> = 8.6 Hz, 1H), 7.00 (d, <i>J</i> = 8.3 Hz, 2H), 7.30 (d, <i>J</i> = 8.4 Hz, 2H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 7.69 (d, <i>J</i> = 16.0 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl-3-(4-(6-hydroxy-1-methyl-2-(4-(2,2,2-trifluoroethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described in step 4 of <b>37</b>. Purified by reverse phase HPLC (5 mM NH<sub>4</sub>OH modifier, 1–100% MeCN/H<sub>2</sub>O) to afford <b>51</b> as a white powder (20 mg, 43% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 468.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.33 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.70 (s, 3H), 2.86–2.91 (m, 1H), 3.04–3.21 (m, 1H), 3.27–3.57 (m, 4H), 6.43–6.51 (m, 2H), 6.57–6.67 (m, 4H), 7.00 (d, <i>J</i> = 8.3 Hz, 2H), 7.28 (d, <i>J</i> = 8.3 Hz, 2H), 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 7.57 (d, <i>J</i> = 16.0 Hz, 1H).</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (<i>E</i>)-3-(4-(2-(4-(<i>sec</i>-Butyl)phenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>53</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(4-(<i>sec</i>-butyl)phenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>79</b>) as described for <b>6</b>. Purified by FCC (0-25% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(4-(sec-butyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (68 mg, 69% yield) as a light green oil. LC/MS (ESI) <i>m</i>/<i>z</i> 465.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.80 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.67–0.71 (m, 3H), 1.08 (d, <i>J</i> = 7.0 Hz, 3H), 1.41–1.46 (m, 2H), 1.55–1.63 (m, 3H), 2.37–2.42 (m, 1H), 2.82–2.87 (m, 1H), 2.99–3.02 (m, 1H), 3.23–3.41 (m, 2H), 3.69 (s, 3H), 6.43–6.50 (m, 2H), 6.52–6.59 (m, 2H), 6.64 (d, <i>J</i> = 8.4 Hz, 1H), 6.77–6.83 (m, 2H), 6.97–7.03 (m, 2H), 7.20–7.26 (m, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(4-(<i>sec</i>-butyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(4-(sec-butyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (38 mg, 55% yield) as a yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 470.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.51 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.67–0.71 (m, 3H), 1.08 (d, <i>J</i> = 6.9 Hz, 3H), 1.39–1.46 (m, 2H), 1.62 (s, 3H), 2.36–2.42 (m, 1H), 2.84–2.89 (m, 1H), 3.03–3.06 (m, 1H), 3.25–3.43 (m, 2H), 3.71 (d, <i>J</i> = 6.1 Hz, 6H), 6.32 (d, <i>J</i> = 16.0 Hz, 1H), 6.43–6.50 (m, 2H), 6.53–6.61 (m, 2H), 6.67 (d, <i>J</i> = 8.6 Hz, 1H), 6.75–6.82 (m, 2H), 7.13–7.21 (m, 2H), 7.28–7.33 (m, 2H), 7.59 (d, <i>J</i> = 16.0 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(4-(<i>sec</i>-butyl)phenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–30% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(4-(sec-butyl)phenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (20.6 mg, 56% yield) as a yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 456.6 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.64 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.77–0.81 (m, 3H), 1.18 (d, <i>J</i> = 6.9 Hz, 3H), 1.49–1.56 (m, 2H), 1.72 (s, 3H), 2.47–2.52 (m, 1H), 2.90–2.96 (m, 1H), 3.08–3.15 (m, 1H), 3.38–3.48 (m, 2H), 3.83 (s, 3H), 6.43 (d, <i>J</i> = 16.0 Hz, 1H), 6.52–6.62 (m, 3H), 6.65 (d, <i>J</i> = 2.7 Hz, 1H), 6.72 (d, <i>J</i> = 8.5 Hz, 1H), 6.89 (d, <i>J</i> = 8.1 Hz, 2H), 7.27 (d, <i>J</i> = 7.9 Hz, 2H), 7.36–7.43 (m, 2H), 7.70 (d, <i>J</i> = 16.0 Hz, 1H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(4-(<i>sec</i>-butyl)phenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>9</b> to afford <b>53</b> as a cream colored solid (12.8 mg, 68% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 442.6 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.41 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 0.76 (t, <i>J</i> = 7.4 Hz, 3H), 1.15 (dd, <i>J</i> = 7.0, 1.4 Hz, 3H), 1.46–1.57 (m, 2H), 1.68 (s, 3H), 2.43–2.48 (m, 1H), 2.85–2.92 (m, 1H), 3.02–3.14 (m, 1H), 3.33–3.39 (m, 1H), 3.42–3.51 (m, 1H), 6.44 (d, <i>J</i> = 16.0 Hz, 1H), 6.50 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 6.55–6.65 (m, 4H), 6.81–6.90 (m, 2H), 7.25 (d, <i>J</i> = 8.0 Hz, 2H), 7.38–7.47 (m, 2H), 7.64 (d, <i>J</i> = 16.1 Hz, 1H).</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>E</i>)-3-(4-(2-(3-Fluoro-4-isopropylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>54</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(3-fluoro-4-isopropylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2H)-one (<b>80</b>) as described for <b>6</b>. Purified by FCC (0–25% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(3-fluoro-4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as a clear oil (31.1 mg, 83% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 469.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.74 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.11 (d, <i>J</i> = 6.9 Hz, 6H), 1.61 (s, 3H), 2.80–2.86 (m, 1H), 3.00–3.10 (m, 2H), 3.26–3.40 (m, 2H), 3.70 (s, 3H), 6.18–6.31 (m, 2H), 6.56 (d, <i>J</i> = 8.3 Hz, 2H), 6.64 (d, <i>J</i> = 8.1 Hz, 1H), 6.82 (t, <i>J</i> = 8.6 Hz, 1H), 7.01–7.10 (m, 2H), 7.24–7.32 (m, 2H).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(3-fluoro-4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(3-fluoro-4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a yellow oil (29.6 mg, 94% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 474.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.49 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.19 (d, <i>J</i> = 6.9 Hz, 6H), 1.74 (s, 3H), 2.89–2.95 (m, 1H), 3.05–3.26 (m, 2H), 3.42–3.53 (m, 2H), 3.81 (d, <i>J</i> = 9.1 Hz, 6H), 6.28–6.38 (m, 2H), 6.43 (d, <i>J</i> = 16.0 Hz, 1H), 6.63–6.71 (m, 2H), 6.76 (d, <i>J</i> = 8.6 Hz, 1H), 6.86–6.94 (m, 1H), 7.31–7.36 (m, 2H), 7.40–7.46 (m, 2H), 7.70 (d, <i>J</i> = 16.0 Hz, 1H).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(3-fluoro-4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–30% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(3-fluoro-4-isopropylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as a yellow oil (14 mg, 49% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 460.6 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.65 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.20 (d, <i>J</i> = 6.9 Hz, 6H), 1.73 (s, 3H), 2.88–2.94 (m, 1H), 3.07–3.19 (m, 2H), 3.37–3.48 (m, 2H), 3.83 (s, 3H), 6.27–6.39 (m, 2H), 6.43 (d, <i>J</i> = 16.0 Hz, 1H), 6.58 (dd, <i>J</i> = 8.5, 2.7 Hz, 1H), 6.64 (d, <i>J</i> = 2.6 Hz, 1H), 6.71 (d, <i>J</i> = 8.6 Hz, 1H), 6.90 (t, <i>J</i> = 8.6 Hz, 1H), 7.32 (d, <i>J</i> = 8.1 Hz, 2H), 7.38–7.49 (m, 2H), 7.70 (d, <i>J</i> = 16.0 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −118.89 (1F).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(3-fluoro-4-isopropylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>9</b> to obtain <b>54</b> as a cream solid (11.6 mg, 85% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 446.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.49 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.16 (d, <i>J</i> = 6.9 Hz, 6H), 1.69 (s, 3H), 2.86 (dd, <i>J</i> = 15.9, 4.1 Hz, 1H), 3.00–3.19 (m, 2H), 3.36–3.41 (m, 1H), 3.42–3.51 (m, 1H), 6.28 (dd, <i>J</i> = 13.5, 2.3 Hz, 1H), 6.39–6.52 (m, 3H), 6.56 (d, <i>J</i> = 2.5 Hz, 1H), 6.61 (d, <i>J</i> = 8.6 Hz, 1H), 6.92 (t, <i>J</i> = 8.7 Hz, 1H), 7.26–7.39 (m, 2H), 7.48 (d, <i>J</i> = 8.3 Hz, 2H), 7.64 (d, <i>J</i> = 16.0 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD, δ) −121.21 (1F).</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (<i>E</i>)-3-(4-(2-(2-Fluoro-4-isopropylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic aAcid (<b>55</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from (2-(2-fluoro-4-isopropylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>81</b>) as described for <b>6</b>. Purified by FCC (0–25% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(2-fluoro-4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as a yellow oil (78 mg, 76% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 470.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.52 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.12 (dd, <i>J</i> = 7.0, 1.5 Hz, 6H), 1.66 (s, 3H), 2.70–2.79 (m, 1H), 2.84 (q, <i>J</i> = 14.4, 11.3 Hz, 2H), 3.14–3.38 (m, 2H), 3.74 (s, 3H), 6.36 (s, 1H), 6.52–6.67 (m, 3H), 6.74–6.81 (m, 2H), 6.99 (d, <i>J</i> = 8.1 Hz, 2H), 7.23 (d, <i>J</i> = 8.5 Hz, 2H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −118.17 (1F).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(2-fluoro-4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(2-fluoro-4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (55 mg, 70% yield) as a light yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 474.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.38 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.10 (dd, <i>J</i> = 6.9, 1.8 Hz, 6H), 1.67 (d, <i>J</i> = 1.8 Hz, 3H), 2.68–2.90 (m, 3H), 3.15–3.37 (m, 2H), 3.72 (d, <i>J</i> = 7.1 Hz, 6H), 6.25–6.39 (m, 2H), 6.53 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.62 (d, <i>J</i> = 8.6 Hz, 2H), 6.73–6.83 (m, 2H), 7.15 (t, <i>J</i> = 8.4 Hz, 2H), 7.29 (s, 2H), 7.58 (d, <i>J</i> = 16.0 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −118.20 (1F).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(2-fluoro-4-isopropylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–30% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(2-fluoro-4-isopropylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (41 mg, 77% yield) as a light brown oil. LC/MS (ESI) <i>m</i>/<i>z</i> 460.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.13 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.01 (dd, <i>J</i> = 6.8, 1.9 Hz, 6H), 1.57 (s, 3H), 2.59–2.76 (m, 3H), 3.04–3.26 (m, 2H), 3.63 (s, 3H), 6.18–6.30 (m, 2H), 6.40–6.51 (m, 3H), 6.61–6.72 (m, 2H), 7.04 (d, <i>J</i> = 7.9 Hz, 2H), 7.18 (d, <i>J</i> = 8.1 Hz, 2H), 7.49 (d, <i>J</i> = 16.0 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −118.23 (1F).</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(2-fluoro-4-isopropylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>9</b> to obtain <b>55</b> as a cream colored solid (27 mg, 64% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 446.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.51 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.16 (dd, <i>J</i> = 6.8, 1.9 Hz, 6H), 1.70 (d, <i>J</i> = 2.0 Hz, 3H), 2.69–2.88 (m, 3H), 3.26 (q, <i>J</i> = 6.2 Hz, 2H), 6.36–6.50 (m, 2H), 6.55–6.65 (m, 3H), 6.74 (d, <i>J</i> = 8.4 Hz, 1H), 6.86 (dd, <i>J</i> = 12.7, 2.0 Hz, 1H), 7.17–7.25 (m, 2H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.61 (d, <i>J</i> = 16.0 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD, δ) −119.38 (1F).</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> (<i>E</i>)-3-(4-(2-(2-Fluoro-4-isobutylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>56</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from 2-(2-fluoro-4-isobutylphenyl)-6-methoxy-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>82</b>) as described for <b>6</b>. Purified by FCC (0–25% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(2-fluoro-4-isobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (70 mg, 81% yield) as an orange oil. LC/MS (ESI) <i>m</i>/<i>z</i> 484.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.54 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.78–0.81 (m, 6H), 1.65 (d, <i>J</i> = 1.9 Hz, 3H), 1.67–1.75 (m, 1H), 2.29 (d, <i>J</i> = 7.1 Hz, 2H), 2.78–2.87 (m, 2H), 3.14–3.36 (m, 2H), 3.73 (s, 3H), 6.32 (t, <i>J</i> = 8.4 Hz, 1H), 6.49 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 6.62 (d, <i>J</i> = 8.3 Hz, 2H), 6.70 (dd, <i>J</i> = 12.5, 2.0 Hz, 1H), 6.77 (d, <i>J</i> = 8.3 Hz, 1H), 6.93–7.00 (m, 2H), 7.18–7.24 (m, 2H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −118.57 (1F).</div><div class="NLM_p"><i>Step 2.</i> Prepared from 1-(4-bromophenyl)-2-(2-fluoro-4-isobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline as described in step 2 of <b>37.</b> Purified by FCC (0–50% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(2-fluoro-4-isobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (23 mg, 33% yield) as a light yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 488.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.42 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.77–0.80 (m, 6H), 1.63–1.77 (m, 4H), 2.28 (d, <i>J</i> = 7.2 Hz, 2H), 2.82–2.88 (m, 2H), 3.18–3.27 (m, 1H), 3.27–3.37 (m, 1H), 3.72 (s, 3H), 3.74 (s, 3H), 6.26–6.36 (m, 2H), 6.46 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 6.63 (d, <i>J</i> = 7.5 Hz, 2H), 6.69 (dd, <i>J</i> = 12.5, 2.0 Hz, 1H), 6.77–6.80 (m, 1H), 7.08–7.16 (m, 2H), 7.24–7.30 (m, 2H), 7.58 (d, <i>J</i> = 16.0 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −118.65 (1F).</div><div class="NLM_p"><i>Step 3.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(2-fluoro-4-isobutylphenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–30% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(2-fluoro-4-isobutylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (21 mg, 94% yield) as a light yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 474.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.16 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.90 (dd, <i>J</i> = 11.4, 6.8 Hz, 6H), 1.72–1.89 (m, 4H), 2.38 (d, <i>J</i> = 7.5 Hz, 2H), 2.92 (d, <i>J</i> = 12.3 Hz, 2H), 3.37 (d, <i>J</i> = 25.1 Hz, 2H), 3.83 (d, <i>J</i> = 3.4 Hz, 3H), 6.34–6.50 (m, 2H), 6.56 (d, <i>J</i> = 8.4 Hz, 1H), 6.67 (q, <i>J</i> = 8.5, 7.9 Hz, 2H), 6.82 (dd, <i>J</i> = 17.3, 10.1 Hz, 2H), 7.19–7.32 (m, 2H), 7.37 (d, <i>J</i> = 8.0 Hz, 2H), 7.69 (dd, <i>J</i> = 16.2, 4.6 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −118.64.</div><div class="NLM_p last"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(2-fluoro-4-isobutylphenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>9</b> to obtain <b>56</b> as a cream solid (12.6 mg, 62% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 460.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.59 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 0.86 (d, <i>J</i> = 6.6 Hz, 6H), 1.66–1.74 (m, 3H), 1.77–1.80 (m, 1H), 2.36 (d, <i>J</i> = 7.2 Hz, 2H), 2.80–2.91 (m, 2H), 3.22–3.29 (m, 1H), 3.33–3.41 (m, 1H), 6.37–6.48 (m, 2H), 6.54–6.62 (m, 3H), 6.74 (d, <i>J</i> = 8.4 Hz, 1H), 6.79 (dd, <i>J</i> = 12.6, 2.0 Hz, 1H), 7.16–7.25 (m, 2H), 7.36–7.43 (m, 2H), 7.62 (d, <i>J</i> = 16.0 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD, δ) −119.93 (1F).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (<i>E</i>)-3-(4-(6-Hydroxy-2-(4-isopropylphenyl)-1-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>rac-59</b>)</h3><div class="NLM_p"><i>Step 1.</i> To 1-bromo-4-iodobenzene (575 mg, 2.03 mmol) in pentanes (5.34 mL) was added 2.5 M <i>n</i>-BuLi in hexanes (0.815 mL, 2.038 mmol); a white precipitate formed immediately. The reaction was stirred at rt for 1 h and was then cooled to −78 °C. A solution of <b>58</b> (200 mg, 0.68 mmol) in THF (3.81 mL) was added and the reaction was stirred at −78 °C for 1 h. The reaction was quenched with water (8 mL) and EtOAc (8 mL). Perchloric acid (70% in water, 0.25 mL, 2.91 mmol) was added, the reaction was stirred for 30 min at rt. The reaction was partitioned between DCM and water. The organic layer was passed through a phase separator and concentrated in vacuo. The crude iminium intermediate which was used directly in the next step. LC/MS (ESI) <i>m</i>/<i>z</i> 435.8 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.48 min.</div><div class="NLM_p"><i>Step 2.</i> To the iminium intermediate in DMF (4.39 mL) was added NaOAc (167 mg, 2.03 mmol) trimethyl(trifluoromethyl)silane (2.71 mL, 1.35 mmol) dropwise. The reaction was stirred at rt for 30 min. The reaction was partitioned between saturated NaHCO<sub>3</sub> and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–10% EtOAc/heptanes) to afford 1-(4-bromophenyl)-2-(4-isopropylphenyl)-6-methoxy-1-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline (243 mg, 71% yield) as a yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 506.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.53 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.12 (dd, <i>J</i> = 6.82, 1.26 Hz, 6H), 2.59–2.78 (m, 1H), 2.89–3.02 (m, 1H), 3.04–3.17 (m, 1H), 3.38–3.52 (m, 1H), 3.74 (s, 3H), 3.83–3.93 (m, 1H), 6.51–6.54 (m, 2H), 6.60 (dd, <i>J</i> = 9.09, 3.03 Hz, 1H), 6.68 (d, <i>J</i> = 2.53 Hz, 1H), 6.76–6.86 (m, 3H), 7.09 (d, <i>J</i> = 8.08 Hz, 2H), 7.24–7.31 (m, 2H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −62.10 (3F).</div><div class="NLM_p"><i>Step 3.</i> Prepared from 1-(4-bromophenyl)-2-(4-isopropylphenyl)-6-methoxy-1-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline as described for <b>7</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford (<i>E</i>)-methyl-3-(4-(2-(4-isopropylphenyl)-6-methoxy-1-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (162 mg, 66% yield) as a yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 510.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.72 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.99–1.07 (m, 6H), 2.62–2.66 (m, 1H), 2.88–2.93 (m, 1H), 3.01–3.14 (m, 1H), 3.37–3.48 (m, 1H), 3.66–3.72 (m, 6H), 3.76–3.89 (m, 1H), 6.32 (d, <i>J</i> = 16.17 Hz, 1H), 6.47 (d, <i>J</i> = 8.59 Hz, 2H), 6.54 (dd, <i>J</i> = 8.84, 2.78 Hz, 1H), 6.63 (d, <i>J</i> = 2.53 Hz, 1H), 6.75 (d, <i>J</i> = 8.59 Hz, 3H), 7.18–7.20 (m, 2H), 7.25–7.27 (m, 2H), 7.56 (d, <i>J</i> = 16.17 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −62.19 (3F).</div><div class="NLM_p"><i>Step 4.</i> Prepared from (<i>E</i>)-methyl-3-(4-(2-(4-isopropylphenyl)-6-methoxy-1-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described for <b>8</b>. Purified by FCC (0–100% EtOAc/heptanes) to afford (<i>E</i>)-methyl 3-(4-(6-hydroxy-2-(4-isopropylphenyl)-1-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (143 mg, 91% yield) as a yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 496.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.65 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.16 (dd, <i>J</i> = 6.82, 1.77 Hz, 6H), 2.74–2.80 (m, 1H), 2.94–3.06 (m, 1H), 3.11–3.22 (m, 1H), 3.47–3.58 (m, 1H), 3.85 (s, 3H), 3.89–4.03 (m, 1H), 6.45 (d, <i>J</i> = 15.66 Hz, 1H), 6.55–6.64 (m, 3H), 6.73 (d, <i>J</i> = 2.53 Hz, 1H), 6.76–6.84 (m, 1H), 6.84–6.91 (m, 2H), 7.30–7.33 (m, 2H), 7.37–7.39 (m, 2H), 7.69 (d, <i>J</i> = 16.17 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −62.22 (3F).</div><div class="NLM_p last"><i>Step 5.</i> Prepared from (<i>E</i>)-methyl 3-(4-(6-hydroxy-2-(4-isopropylphenyl)-1-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate as described in step 4 of <b>37</b> to obtain <b>rac-59</b> as a yellow solid (20 mg, 14% yield). LC/MS (ESI) <i>m</i>/<i>z</i> 482.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.50 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.06–1.16 (m, 6H), 2.68–2.75 (m, 1H), 2.93–2.99 (m, 1H), 3.06–3.18 (m, 1H), 3.44–3.55 (m, 1H), 3.80–3.90 (m, 1H), 6.46 (d, <i>J</i> = 16.17 Hz, 1H), 6.52 (dd, <i>J</i> = 9.09, 2.53 Hz, 1H), 6.60–6.62 (m, 2H), 6.65–6.72 (m, 2H), 6.82–6.83 (m, 2H), 7.27–7.28 (m, 2H), 7.41–7.44 (m, 2H), 7.63 (d, <i>J</i> = 16.17 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD, δ) −63.66 (3F).</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Ethyl 2-(1-(4-Bromophenyl)-2-(4-isopropylphenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)-2,2-difluoroacetate (<b>60</b>)</h3><div class="NLM_p"><i>Step 1.</i> To 1-bromo-4-iodobenzene (718 mg, 2.54 mmol) in pentanes (6.68 mL) was added 2.5 M <i>n</i>-BuLi in hexanes (1.019 mL, 2.55 mmol); a white precipitate formed immediately. The reaction was stirred at rt for 1 h and was then cooled to −78 °C. A solution of <b>58</b> (250 mg, 0.85 mmol) in THF (4.77 mL) was added. The reaction was stirred at −78 °C for 1 h. The reaction was quenched with H<sub>2</sub>O (10 mL) and EtOAc (10 mL). Perchloric acid (70% in water, 0.219 mL, 3.64 mmol) was added. The reaction was stirred for 30 min at rt. The reaction was partitioned between H<sub>2</sub>O and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The iminium intermediate was used directly in the next step. LC/MS (ESI) <i>m</i>/<i>z</i> 435.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.61 min.</div><div class="NLM_p last"><i>Step 2.</i> To the iminium intermediate in DMF (7 mL) was added KF (148 mg, 2.54 mmol). A solution of ethyl-2,2-difluoro-2-(trimethylsilyl)acetate (332 mg, 1.69 mmol) in DMF (4.5 mL) was added dropwise. The reaction was stirred at rt for 30 min. The reaction was partitioned between saturated NaHCO<sub>3</sub> and DCM. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–10% EtOAc/heptanes) to afford <b>60</b> (362 mg, 77% yield) as a yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 559.8 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.80 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.05 (t, <i>J</i> = 7.33 Hz, 3H), 1.09–1.18 (m, 6H), 2.69–2.87 (m, 2H), 2.93–3.01 (m, 1H), 3.14–3.27 (m, 1H), 3.40–3.51 (m, 1H), 3.76 (s, 3H), 4.00 (q, <i>J</i> = 7.07 Hz, 2H), 6.60–6.69 (m, 4H), 6.85 (d, <i>J</i> = 8.59 Hz, 2H), 6.90 (dd, <i>J</i> = 8.34, 3.79 Hz, 1H), 7.15 (d, <i>J</i> = 8.59 Hz, 2H), 7.27 (d, <i>J</i> = 8.59 Hz, 2H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −99.75 (d, <i>J</i> = 247.6 Hz, 1F), −97.56 (d, <i>J</i> = 247.3 Hz, 1F).</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 1-(4-Bromophenyl)-1-(difluoromethyl)-2-(4-isopropylphenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline (<b>61</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from <b>60</b> as described for <b>9</b> to obtain 2-(1-(4-bromophenyl)-2-(4-isopropylphenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)-2,2-difluoroacetic acid was obtained as a yellow solid (346 mg, quantitative yield) and carried forward without purification. LC/MS (ESI) <i>m</i>/<i>z</i> 530.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.61 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 0.98–1.08 (m, 6H), 2.61–2.74 (m, 1H), 2.74–2.85 (m, 1H), 3.04 (d, <i>J</i> = 8.08 Hz, 1H), 3.22–3.34 (m, 1H), 3.34–3.44 (m, 1H), 3.64–3.70 (m, 3H), 6.40 (d, <i>J</i> = 6.57 Hz, 2H), 6.54–6.66 (m, 2H), 6.81 (d, <i>J</i> = 8.59 Hz, 2H), 6.89 (dd, <i>J</i> = 8.59, 5.56 Hz, 2H), 7.21 (d, <i>J</i> = 8.08 Hz, 2H), 7.25–7.30 (m, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −107.48 (s, 1F), −97.18 (d, <i>J</i> = 271.9 Hz, 1F).</div><div class="NLM_p last"><i>Step 2.</i> To 2-(1-(4-bromophenyl)-2-(4-isopropylphenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)-2,2-difluoroacetic acid (100 mg, 0.189 mmol) in NMP (9.43 mL) and CsF (143 mg, 0.94 mmol). Under nitrogen, the reaction was stirred at 192 °C for 24 h. After cooling to rt, the reaction was partitioned between H<sub>2</sub>O and Et<sub>2</sub>O. The organic layer was passed through a phase separator and concentrated in vacuo. The crude material was purified by FCC (0–10% EtOAc/heptanes) to <b>61</b> (73 mg, 80% yield) as a yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 487.8 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.76 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.07–1.13 (m, 6H), 2.68–2.75 (m, 1H), 2.86–3.07 (m, 2H), 3.26–3.31 (m, 1H), 3.57–3.63 (m, 1H), 3.71 (s, 3H), 6.21 (s, 1H), 6.44–6.52 (m, 2H), 6.59 (dd, <i>J</i> = 8.84, 2.78 Hz, 1H), 6.65 (d, <i>J</i> = 2.53 Hz, 1H), 6.79–6.94 (m, 5H), 7.20–7.28 (m, 2H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −125.80 (d, <i>J</i> = 280.3 Hz, 1F), −120.82 (d, <i>J</i> = 280.2 Hz, 1F).</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (<i>E</i>)-Methyl-3-(4-(1-(difluoromethyl)-2-(4-isopropylphenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (<b>62</b>)</h3><div class="NLM_p last">Prepared from <b>61</b> (73 mg, 0.15 mmol) as described in step 2 of <b>37</b>. Purified by FCC (0–50% EtOAc/heptanes) to afford <b>62</b> (11 mg, 15% yield) as a yellow oil. LC/MS (ESI) <i>m</i>/<i>z</i> 492.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.72 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.17–1.21 (m, 6H), 2.78–2.84 (m, 1H), 3.00–3.18 (m, 2H), 3.35–3.48 (m, 1H), 3.66–3.78 (m, 1H), 3.81–3.86 (m, 6H), 6.34–6.53 (m, 2H), 6.56–6.66 (m, 2H), 6.70 (dd, <i>J</i> = 8.84, 2.78 Hz, 1H), 6.78 (d, <i>J</i> = 2.53 Hz, 1H), 6.90–7.00 (m, 3H), 7.17 (d, <i>J</i> = 8.08 Hz, 2H), 7.39 (d, <i>J</i> = 8.59 Hz, 2H), 7.69 (d, <i>J</i> = 16.17 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>, δ) −126.04 (d, <i>J</i> = 280.2 Hz, 1F), −120.82 (d, <i>J</i> = 280.3 Hz, 1F).</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (<i>E</i>)-3-(4-(1-(Difluoromethyl)-6-hydroxy-2-(4-isopropylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylic Acid (<b>rac-63</b>)</h3><div class="NLM_p"><i>Step 1.</i> Prepared from <b>62</b> (11 mg, 22 μmol) as described for <b>8</b>. (<i>E</i>)-Methyl-3-(4-(1-(difluoromethyl)-6-hydroxy-2-(4-isopropylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate was obtained as a yellow oil (9 mg, 84% yield) and carried forward without purification. LC/MS (ESI) <i>m</i>/<i>z</i> 478.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.62 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ) 1.04–1.12 (m, 6H), 2.67–2.74 (m, 1H), 2.91–3.03 (m, 2H), 3.27–3.30 (m, 1H), 3.50–3.69 (m, 1H), 3.73 (s, 3H), 6.20–6.43 (m, 2H), 6.48 (d, <i>J</i> = 8.59 Hz, 2H), 6.55 (dd, <i>J</i> = 8.59, 2.53 Hz, 1H), 6.66 (d, <i>J</i> = 2.53 Hz, 1H), 6.79 (dd, <i>J</i> = 8.59, 3.54 Hz, 1H), 6.84 (d, <i>J</i> = 8.59 Hz, 2H), 7.07 (d, <i>J</i> = 7.58 Hz, 2H), 7.29 (d, <i>J</i> = 8.59 Hz, 2H), 7.58 (d, <i>J</i> = 16.17 Hz, 1H).</div><div class="NLM_p last"><i>Step 2.</i> Prepared from (<i>E</i>)-methyl-3-(4-(1-(difluoromethyl)-6-hydroxy-2-(4-isopropylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl)acrylate (9 mg, 19 μmol) as described for <b>9</b>. Purified by HPLC (5 mM NH<sub>4</sub>OH modifier, 15–40% MeCN/H<sub>2</sub>O) to afford <b>rac-63</b> (3.8 mg, 44% yield) as a white solid. LC/MS (ESI) <i>m</i>/<i>z</i> 464.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.45 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, δ) 1.05 (dd, <i>J</i> = 6.82, 2.27 Hz, 6H), 2.63–2.70 (m, 1H), 2.82–2.97 (m, 2H), 3.30 (dd, <i>J</i> = 11.87, 5.31 Hz, 1H), 3.54 (d, <i>J</i> = 6.06 Hz, 1H), 6.31–6.67 (m, 7H), 6.82 (d, <i>J</i> = 8.59 Hz, 2H), 7.04 (d, <i>J</i> = 7.58 Hz, 2H), 7.28–7.37 (m, 2H), 7.47 (d, <i>J</i> = 15.66 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD, δ) −127.64 (d, <i>J</i> = 279.8 Hz, 1F), −122.32 (d, <i>J</i> = 279.9 Hz, 1F).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> ERα SPA Binding Assay</h3><div class="NLM_p last">The ligand binding domain (LBD) of the human estrogen receptor alpha (aa: 301–553) was expressed and purified from an internal lab containing a histidine tag on the N-terminus. Tritiated estradiol (PerkinElmer, catalog NET-515250UC) was used as the radioligand. Copper HIS-tag PVT beads (PerkinElmer, catalog RPNQ0095) were used as a method for detection. The assay was performed in a white clear bottom 384 well plate (Costar, catalog 3706) with a final assay volume of 50 μL. The assay buffer was purchased (ThermoFisher, catalog PV4540) and was supplemented with 5 mM DTT (Sigma, catalog D5545) and 0.1% Tween20 (Sigma, catalog P1379). Final concentrations of estrogen receptor α, <sup>3</sup>H-estradiol, and copper beads were 100 ng/mL, 0.5 nM and 100 μg/mL respectively. Fulvestrant (Sigma, catalog I4409) was used as the positive control (10 μM) as well as a reference with an observed IC<sub>50</sub> of 3.9 nM ± 2.5 nM (<i>n</i> = 27). The reaction was sealed and incubated at room temperature for 1 h. Plates were read on a PerkinElmer Microbeta Trilux reader, counted for 90 s per well. Compounds were tested as a concentration–response curve in 12 concentrations.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> MCF-7 ERE Reporter Gene Assay</h3><div class="NLM_p last">MCF-7 cells were maintained in Dulbecco’s modified Eagle medium (DMEM)/F12 supplemented with 8% fetal bovine serum (FBS). Cells were seeded in 96-well plates and transfected with an estrogen responsive reporter gene (7x-TK-ERE-Luc) and Renilla-luc (to monitor cellular toxicity) using Lipofectin reagent (Invitrogen), as described in the manufacturer’s instructions. After overnight incubation, cells were treated with hormone for 24 h. Cells were then lysed and quantified for luciferase activity using dual luciferase reagent.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> In-Cell Western To Detect ER Protein Levels</h3><div class="NLM_p">MCF-7 cells were cultured in CDT growth medium (DMEM/F12-phenol red-free media (Gibco, catalog no. 21041) supplemented with 10% charcoal dextran-stripped serum (Gemini Bio-Products, catalog no. 100-119) 72 h prior to plating of cells. The cells were seeded in 100 μL CDT growth medium at a density of 30 000 cells/well in a Greiner black, clear-bottom 96-well assay plate (Greiner, catalog no. 655090) and incubated for 24–36 h at 37 °C with 5% CO<sub>2</sub>.</div><div class="NLM_p">For THIQ <b>40</b>, 4-hydroxytamoxifen, and fulvestrant compound treatment, 11 μL of 10× compound was added to each well in a 7-point, 1:10 dilution series (CDT growth media; normalized for a final assay concentration of 0.1% DMSO), starting at 10 μM, and incubated for 18–24 h at 37 °C with 5% CO<sub>2</sub>. DMSO and fulvestrant were used to determine the baseline for maximal response and ERα degradation, respectively.</div><div class="NLM_p">To fix cells, medium was first decanted by inversion, followed immediately by the addition of 100 μL/well of 3.7% formaldehyde (Sigma, catalog no. F8775) in PBS (Gibco, catalog no. 20012) and incubated for 20 min at room temperature. Cells were then blocked with 50 μL/well of blocking buffer (PBS pH7.4, 3% goat serum (Life Technologies, catalog no. 16210072), 1% BSA (Sigma, catalog no. A7906), 0.1% cold fish skin gelatin (Sigma, catalog no. G7041), 0.1% TritonX100 (OmniPur, catalog no. 9410)) for 2 h with shaking at room temperature or at 4 °C overnight. Blocking buffer was then decanted and 40 μL of ERα primary antibody (Santa Cruz, catalog no. SC543) at 1:3000 in blocking buffer diluted 1:3 with PBS was added to each well, excluding negative control wells used for background subtraction, sealed with film, and incubated at 4 °C overnight. To remove primary antibody, cells were washed 3 times with 100 μL/well PBS + 0.1% Tween (AMRESCO, catalog no. 0777) (PBST) for 5 min each. 40 μL of polyclonal anti-rabbit IgG (H+L) CF770 antibody (Biotium, catalog no. 20078) at 1:2000 and DRAQ5 DNA stain (Thermo Scientific, catalog no. 62251) at 1:10,000 in blocking buffer diluted 1:3 with PBS was then added to each well and incubated at room temperature with shaking for 2 h. To remove secondary antibody, cells were washed 3 times with 100 μL/well of PBST for 5 min each. To minimize tween autofluorescence signaling, the cells were washed once with 100 μL/well of PBS. To prevent drying during detection, 100 μL/well PBS was then added to each well.</div><div class="NLM_p last">For detection, the integrated intensities of ERα (700 channel) and DNA stain (800 channel) were measured using a Licor Odyssey (Li-Cor Biosciences, Lincoln, NE). Data were then normalized by dividing the integrated intensities of the 700 channel (ER) by the integrated intensities of the 800 channel (DNA). Background subtraction was carried out by subtracting the average of the normalized negative control wells (no primary antibody) from all normalized experimental values. Percent response of normalized/background subtracted data was then calculated by dividing each experimental value by the average of the DMSO control values (% response = (value experimental/value DMSO control) × 100). Dose–response curves, IC<sub>50</sub> and percent ERα remaining values were generated using GraphPad Prism version 6.02 software (GraphPad, San Diego, CA).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> MCF-7 Insulin-Driven Proliferation Assay</h3><div class="NLM_p last">MCF-7 cells were routinely cultured in Dulbecco’s modified Eagle medium (DMEM) plus 8% fetal bovine serum (FBS). For the insulin-driven proliferation assay, cells were trypsinized and resuspended in DMEM (without phenol red) plus 8% charcoal dextran-stripped serum and plated at a density of 3,000 cells/well in 96-well plates (Corning). Cells were treated with insulin (20 nM) and test compound (10 pM to 10 μM final concentration made by serial dilution from a 10 mM compound DMSO stock solution for a 7-point dose–response curve). Plates were incubated for 6 d after the addition of test compound at 37 °C in a humidified incubator with 5% CO<sub>2.</sub> Cellular proliferation was quantified by measuring DNA content. 96-well plates were inverted and blotted onto paper towels to remove media. Plates were frozen at −80 °C overnight. Plates were thawed to room temperature and 100 μL of water was added to each well and incubated at 37 °C for 1 h. Plates were placed at −80 °C until frozen, then thawed to room temperature. An amount of 100 μL of aqueous Hoechst dye 33258 in TNE (10 mM Tris Ph8.0, 1 mM EDTA, 100 mM NaCl) buffer was added and fluorescence measured at 460 nM emission. IC<sub>50</sub> values were determined using GraphPad Prism software. The IC<sub>50</sub> values reported in this manuscript are defined as inflection point of the fitted inhibition curves.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> In Vivo Efficacy and ER Degradation in the MCF-7 Breast Cancer Xenograft Model in Mice</h3><div class="NLM_p last">Mice were handled in accordance with Novartis IACUC regulations and guidelines. Female athymic nude mice were used for tumor xenograft studies. Time released 17-β estradiol pellets (0.36 mg E2, 90-day release; Innovative Research of America) were subcutaneously implanted into mice 2 days prior to tumor implantation. MCF-7 cells were grown in EMEM growth medium supplemented with 10% FBS and human insulin (Sigma-Aldrich catalog no. I9278) at 5% CO<sub>2</sub>, 37 °C. Trypsinized cells were pelleted and resuspended in 50% HBSS and 50% Matrigel at 10 million cells/mL. MCF-7 cells were subcutaneously injected (200 μL/animal) on the right axillary mammary fat pad area. Tumor volume (width<sup>2</sup> × length × <sup>π</sup>/<sub>6</sub>) and body weights were measured twice weekly. When tumors reached an average volume of ∼230 mm<sup>3</sup>, mice were randomized into groups and treatment began. Animals were orally administered vehicle alone or 20 mg/kg THIQ <b>40</b> daily or tamoxifen 60 mg/kg 5 days per week. Fulvestrant was administered subcutaneously at 250 mg/kg once weekly, providing a slow release from the depot in the subcutis. The formulations of these three reagents are the following: 10% ethanol and 90% peanut oil for fulvestrant; 0.5% hydroxypropyl cellulose for tamoxifen; and 10% PEG300, 25% of 20% solutol, 65% PBS for THIQ <b>40</b>.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> In Vivo ER Degradation</h3><div class="NLM_p">At the end of the efficacy study on day 108 postimplantation, MCF-7 tumors (<i>n</i> = 3–8) were collected 7 and 24 h after last oral dose of THIQ <b>40</b> or 24 h after last subcutaneous dose of fulvestrant.</div><div class="NLM_p last">Tumors from snap frozen tube were pulverized into powder and transferred to Lysing Matrix Tubes (MP Biomedicals catalog no. 6913-500) mixed with cold lysis buffer (1× cell lysis buffer; Cell Signaling, catalog no. 9803S) containing Complete Mini (1 tablet to 10 mL), PhosStop (1 tablet to 10 mL and 1 M urea) homogenized by a Fast Prep 24 tissue lyser (MP Biomedicals). Lysates were centrifuged at 14 000 rpm for 20 min at 4 °C. Supernatant was collected and total protein concentration was tested by BCA assay (Pierce BCA protein assay lit, product no. 23225, Thermo Scientific) according to the manufacturer’s instructions. ERα protein levels were analyzed from tumor lysates by ELISA (DuoSet, R&D System, catalog no. DYC5715-5) according to the manufacturer’s instructions. High binding 384-well plates were coated overnight at room temperature with capture antibody (1 μg/mL), washed three times in the manufacturer’s wash buffer, blocked with blocking buffer for 2 h, and washed again. The prepared plates were incubated with 30 μL per well of diluted ERα standard (1000–15.78 pg/mL) and the prepared cell lysate (10–20 μg/well) for 2 h, washed, incubated with biotinylated detection antibody for 2 h, and washed again. After a 20 min incubation with streptavidin–horseradish peroxidase, the plates were washed and incubated with substrate solution for 15 min. The reaction was stopped with stop solution, and the plates were analyzed on Spectra Max M5 (Molecular Devices) microplate reader (OD450) to determine ERα levels based on standard curve. The percent of ERα remaining was determined by comparing tumors from the treated mice versus those from the vehicle control group.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Statistical Analyses for in Vivo Studies</h3><div class="NLM_p last">Statistical analyses of data were generated using GraphPad Prism (San Diego, CA, USA). Tests used are listed in the figure legends.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01468">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01468" class="ext-link">10.1021/acs.jmedchem.6b01468</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthesis of <b>52</b>, <b>66</b>, <b>69</b>–<b>82</b>, 1-methyl-4-vinyl-1<i>H</i>-imidazole, and 1-methyl-5-vinyl-1<i>H</i>-imidazole in addition to the chiral separation of <b>rac-10</b>, <b>rac-40</b>, <b>rac-59</b>, and <b>rac-63</b>, solution and plasma stability of <b>(<i>R</i>)-</b> and <b>(<i>S</i>)-40</b>, crystallographic parameters, pharmacokinetic studies, and methods for solubility and permeability determination (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01468/suppl_file/jm6b01468_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01468/suppl_file/jm6b01468_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01468/suppl_file/jm6b01468_si_001.pdf">jm6b01468_si_001.pdf (1.67 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01468/suppl_file/jm6b01468_si_002.csv">jm6b01468_si_002.csv (6.52 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB code for compound <b>9</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T92">5T92</a> and for <b>40</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T97">5T97</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b01468" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56864" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56864" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heather E. Burks</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9115-9970" title="Orcid link">http://orcid.org/0000-0001-9115-9970</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d1b9b4b0a5b9b4a3ffb3a4a3baa291bfbea7b0a3a5b8a2ffb2bebc"><span class="__cf_email__" data-cfemail="31595450455954431f5344435a42715f5e4750434558421f525e5c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tinya Abrams</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christina A. Kirby</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Baird</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander Fekete</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lawrence G. Hamann</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sunkyu Kim</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Franco Lombardo</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alice Loo</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danuta Lubicka</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kaitlin Macchi</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donald P. McDonnell</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina 27710, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuji Mishina</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John D. Norris</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina 27710, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jill Nunez</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chitra Saran</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingchuan Sun</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noel M. Thomsen</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunrong Wang</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianling Wang</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Peukert</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes
for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. These authors have contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d88e10269-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23065" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23065" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Use of the IMCA-CAT beamline 17-ID at the Advanced Photon Source was supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract DE-AC02-06CH11357. The research performed in the McDonnell laboratory was supported by Novartis.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i84" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i84"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i85" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i85"> Abbreviations Used</h2><tr><td class="NLM_term">BAV</td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle medium</p></td></tr><tr><td class="NLM_term">dn</td><td class="NLM_def"><p class="first last">dose normalized</p></td></tr><tr><td class="NLM_term">FCC</td><td class="NLM_def"><p class="first last">flash column chromatography</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>N</i>-[(dimethylamino)-1<i>H</i>-1,2,3-triazolo-[4,5-<i>b</i>]pyridin-1-ylmethylene]-<i>N</i>-methylmethanaminium hexafluorophosphate <i>N</i>-oxide</p></td></tr><tr><td class="NLM_term">nd</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>R</sub></td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">2-(trimethylsilyl)ethoxymethyl</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">trimethylamine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 31 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fedele, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlando, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiavone, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caliolo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaranta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cinieri, S.</span><span> </span><span class="NLM_article-title">Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1016/j.critrevonc.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.critrevonc.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=25624176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A280%3ADC%252BC2MvpvVeisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2015&pages=291-301&author=P.+Fedeleauthor=L.+Orlandoauthor=P.+Schiavoneauthor=N.+Calvaniauthor=C.+Calioloauthor=A.+Quarantaauthor=A.+Nacciauthor=S.+Cinieri&title=Recent+advances+in+the+treatment+of+hormone+receptor+positive+HER2+negative+metastatic+breast+cancer&doi=10.1016%2Fj.critrevonc.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer</span></div><div class="casAuthors">Fedele Palma; Orlando Laura; Schiavone Paola; Calvani Nicola; Caliolo Chiara; Quaranta Annamaria; Nacci Angelo; Cinieri Saverio</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-301</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Endocrine therapy is the recommended systemic therapy for hormone receptor (HR) positive metastatic breast cancer (MBC).  However so far the limited number of endocrine agents and the onset of endocrine resistance have severely limited the therapeutic options for this patients.  In the last years many targeted agents have been investigated to prevent or overcome endocrine resistance; only a few of them have been found effective in HR positive MBC, such as everolimus, CK4/6 inhibitors and HDAC inhibitors.  Furthermore, translational medicine studies using next generation sequencing technologies have evaluated genetic variations of a broad panel of cancer-related genes and explored their correlations with targeted agents benefit.  In some studies predictive biomarkers have been identified and many ongoing studies are evaluating the efficacy of targeted drugs in HR positive MBC patients selected for biomarkers or stratified by pathways amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZOhFUzosBFP6xYuD7tu2XfW6udTcc2ea8P2usRLBRELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvpvVeisA%253D%253D&md5=28a33613eeb8f3c3ee1b60e3043c64bf</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DFedele%26aufirst%3DP.%26aulast%3DOrlando%26aufirst%3DL.%26aulast%3DSchiavone%26aufirst%3DP.%26aulast%3DCalvani%26aufirst%3DN.%26aulast%3DCaliolo%26aufirst%3DC.%26aulast%3DQuaranta%26aufirst%3DA.%26aulast%3DNacci%26aufirst%3DA.%26aulast%3DCinieri%26aufirst%3DS.%26atitle%3DRecent%2520advances%2520in%2520the%2520treatment%2520of%2520hormone%2520receptor%2520positive%2520HER2%2520negative%2520metastatic%2520breast%2520cancer%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2015%26volume%3D94%26spage%3D291%26epage%3D301%26doi%3D10.1016%2Fj.critrevonc.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ryerson, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eheman, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altekruse, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holtzman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lake, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noone, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penberthy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohler, B. A.</span><span> </span><span class="NLM_article-title">Annual report to the nation on the status of cancer 1975–2012, featuring the increasing incidence of liver cancer</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1312</span><span class="NLM_x">–</span> <span class="NLM_lpage">1337</span><span class="refDoi"> DOI: 10.1002/cncr.29936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1002%2Fcncr.29936" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2016&pages=1312-1337&author=A.+B.+Ryersonauthor=C.+R.+Ehemanauthor=S.+F.+Altekruseauthor=J.+W.+Wardauthor=A.+Jemalauthor=R.+L.+Shermanauthor=S.+J.+Henleyauthor=D.+Holtzmanauthor=A.+Lakeauthor=A.-M.+Nooneauthor=R.+N.+Andersonauthor=J.+Maauthor=K.+N.+Lyauthor=K.+A.+Croninauthor=L.+Penberthyauthor=B.+A.+Kohler&title=Annual+report+to+the+nation+on+the+status+of+cancer+1975%E2%80%932012%2C+featuring+the+increasing+incidence+of+liver+cancer&doi=10.1002%2Fcncr.29936"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29936%26sid%3Dliteratum%253Aachs%26aulast%3DRyerson%26aufirst%3DA.%2BB.%26aulast%3DEheman%26aufirst%3DC.%2BR.%26aulast%3DAltekruse%26aufirst%3DS.%2BF.%26aulast%3DWard%26aufirst%3DJ.%2BW.%26aulast%3DJemal%26aufirst%3DA.%26aulast%3DSherman%26aufirst%3DR.%2BL.%26aulast%3DHenley%26aufirst%3DS.%2BJ.%26aulast%3DHoltzman%26aufirst%3DD.%26aulast%3DLake%26aufirst%3DA.%26aulast%3DNoone%26aufirst%3DA.-M.%26aulast%3DAnderson%26aufirst%3DR.%2BN.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLy%26aufirst%3DK.%2BN.%26aulast%3DCronin%26aufirst%3DK.%2BA.%26aulast%3DPenberthy%26aufirst%3DL.%26aulast%3DKohler%26aufirst%3DB.%2BA.%26atitle%3DAnnual%2520report%2520to%2520the%2520nation%2520on%2520the%2520status%2520of%2520cancer%25201975%25E2%2580%25932012%252C%2520featuring%2520the%2520increasing%2520incidence%2520of%2520liver%2520cancer%26jtitle%3DCancer%26date%3D2016%26volume%3D122%26spage%3D1312%26epage%3D1337%26doi%3D10.1002%2Fcncr.29936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">R235</span><span class="NLM_x">–</span> <span class="NLM_lpage">R246</span><span class="refDoi"> DOI: 10.1530/ERC-14-0092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1530%2FERC-14-0092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=24659478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlOmsbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=R235-R246&author=V.+C.+Jordan&title=Tamoxifen+as+the+first+targeted+long-term+adjuvant+therapy+for+breast+cancer&doi=10.1530%2FERC-14-0092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer</span></div><div class="casAuthors">Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">R235-R246</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">A review.  Tamoxifen is an unlikely pioneering medicine in medical oncol.  Nevertheless, the medicine has continued to surprise us, perform, and save lives for the past 40 years.  Unlike any other medicine in oncol., it is used to treat all stages of breast cancer, ductal carcinoma in situ, and male breast cancer and pioneered the use of chemoprevention by reducing the incidence of breast cancer in women at high risk and induces ovulation in subfertile women!  The impact of tamoxifen is ubiquitous.  However, the power to save lives from this unlikely success story came from the first lab. studies which defined that 'longer was going to be better' when tamoxifen was being considered as an adjuvant therapy.  This is that success story, with a focus on the interdependent components of: excellence in drug discovery, investment in self-selecting young investigators, a conversation with Nature, a conversation between the lab. and the clinic, and the creation of the Oxford Overview Anal.  Each of these factors was essential to propel the progress of tamoxifen to evolve as an essential part of the fabric of society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDHcUccrokKrVg90H21EOLACvtfcHk0lhTVHTrD5prVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlOmsbrI&md5=1ce0dc42b512c264d8a20278e582ef59</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1530%2FERC-14-0092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-14-0092%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DTamoxifen%2520as%2520the%2520first%2520targeted%2520long-term%2520adjuvant%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2014%26volume%3D21%26spage%3DR235%26epage%3DR246%26doi%3D10.1530%2FERC-14-0092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Osborne, C. K.</span><span> </span><span class="NLM_article-title">Tamoxifen in the treatment of breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">1609</span><span class="NLM_x">–</span> <span class="NLM_lpage">1618</span><span class="refDoi"> DOI: 10.1056/NEJM199811263392207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1056%2FNEJM199811263392207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=9828250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFOitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=1998&pages=1609-1618&author=C.+K.+Osborne&title=Tamoxifen+in+the+treatment+of+breast+cancer&doi=10.1056%2FNEJM199811263392207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen in the treatment of breast cancer</span></div><div class="casAuthors">Osborne, C. Kent</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1609-1618</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review with 111 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXdjwzJ2N3sLVg90H21EOLACvtfcHk0lhTVHTrD5prVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFOitLs%253D&md5=04c33aef97d8087d0afaa1d868019925</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1056%2FNEJM199811263392207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199811263392207%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26atitle%3DTamoxifen%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1998%26volume%3D339%26spage%3D1609%26epage%3D1618%26doi%3D10.1056%2FNEJM199811263392207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Clarke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyson, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, J. M.</span><span> </span><span class="NLM_article-title">Endrocrine resistance in breast cancer – an overview and update</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">418</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.mce.2015.09.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.mce.2015.09.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=26455641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1KisbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=2015&pages=220-234&author=R.+Clarkeauthor=J.+J.+Tysonauthor=J.+M.+Dixon&title=Endrocrine+resistance+in+breast+cancer+%E2%80%93+an+overview+and+update&doi=10.1016%2Fj.mce.2015.09.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine resistance in breast cancer - An overview and update</span></div><div class="casAuthors">Clarke, Robert; Tyson, John J.; Dixon, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue">Part_3</span>),
    <span class="NLM_cas:pages">220-234</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Tumors that express detectable levels of the product of the ESR1 gene (estrogen receptor-α; ERα) represent the single largest mol. subtype of breast cancer.  More women eventually die from ERα+ breast cancer than from either HER2+ disease (almost half of which also express ERα) and/or from triple neg. breast cancer (ERα-neg., progesterone receptor-neg., and HER2-neg.).  Antiestrogens and aromatase inhibitors are largely indistinguishable from each other in their abilities to improve overall survival and almost 50% of ERα+ breast cancers will eventually fail one or more of these endocrine interventions.  The precise reasons why these therapies fail in ERα+ breast cancer remain largely unknown.  Pharmacogenetic explanations for Tamoxifen resistance are controversial.  The role of ERα mutations in endocrine resistance remains unclear.  Targeting the growth factors and oncogenes most strongly correlated with endocrine resistance has proven mostly disappointing in their abilities to improve overall survival substantially, particularly in the metastatic setting.  Nonetheless, there are new concepts in endocrine resistance that integrate mol. signaling, cellular metab., and stress responses including endoplasmic reticulum stress and the unfolded protein response (UPR) that provide novel insights and suggest innovative therapeutic targets.  Encouraging evidence that drug combinations with CDK4/CDK6 inhibitors can extend recurrence free survival may yet translate to improvements in overall survival.  Whether the improvements seen with immunotherapy in other cancers can be achieved in breast cancer remains to be detd., particularly for ERα+ breast cancers.  This review explores the basic mechanisms of resistance to endocrine therapies, concluding with some new insights from systems biol. approaches further implicating autophagy and the UPR in detail, and a brief discussion of exciting new avenues and future prospects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHhMBDWyJnLLVg90H21EOLACvtfcHk0lgsl6vUnojpxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1KisbzO&md5=dc6a3084f11f5c7d0fbe04968752bc27</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2015.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2015.09.035%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DR.%26aulast%3DTyson%26aufirst%3DJ.%2BJ.%26aulast%3DDixon%26aufirst%3DJ.%2BM.%26atitle%3DEndrocrine%2520resistance%2520in%2520breast%2520cancer%2520%25E2%2580%2593%2520an%2520overview%2520and%2520update%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2015%26volume%3D418%26spage%3D220%26epage%3D234%26doi%3D10.1016%2Fj.mce.2015.09.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Goss, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingle, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muss, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccart, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castiglione, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livingston, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therasse, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pater, J. L.</span><span> </span><span class="NLM_article-title">A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">1793</span><span class="NLM_x">–</span> <span class="NLM_lpage">1802</span><span class="refDoi"> DOI: 10.1056/NEJMoa032312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1056%2FNEJMoa032312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=14551341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosl2gtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=1793-1802&author=P.+E.+Gossauthor=J.+N.+Ingleauthor=S.+Martinoauthor=N.+J.+Robertauthor=H.+B.+Mussauthor=M.+J.+Piccartauthor=M.+Castiglioneauthor=D.+Tuauthor=L.+E.+Shepherdauthor=K.+I.+Pritchardauthor=R.+B.+Livingstonauthor=N.+E.+Davidsonauthor=L.+Nortonauthor=E.+A.+Perezauthor=J.+S.+Abramsauthor=P.+Therasseauthor=M.+J.+Palmerauthor=J.+L.+Pater&title=A+randomized+trial+of+letrozole+in+postmenopausal+women+after+five+years+of+tamoxifen+therapy+for+early-stage+breast+cancer&doi=10.1056%2FNEJMoa032312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer</span></div><div class="casAuthors">Goss, Paul E.; Ingle, James N.; Martino, Silvana; Robert, Nicholas J.; Muss, Hyman B.; Piccart, Martine J.; Castiglione, Monica; Tu, Dongsheng; Shepherd, Lois E.; Pritchard, Kathleen I.; Livingston, Robert B.; Davidson, Nancy E.; Norton, Larry; Perez, Edith A.; Abrams, Jeffrey S.; Therasse, Patrick; Palmer, Michael J.; Pater, Joseph L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy - but not tamoxifen therapy of longer duration - prolongs disease-free and overall survival.  The aromatase inhibitor letrozole, by suppressing estrogen prodn., might improve the outcome after the discontinuation of tamoxifen therapy.  Methods: We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy.  The primary end point was disease-free survival.  Results: A total of 5187 women were enrolled (median follow-up, 2.4 yr).  At the first interim anal., there were 207 local or metastatic recurrences of breast cancer or new primary cancers in the contralateral breast - 75 in the letrozole group and 132 in the placebo group - with estd. four-year disease-free survival rates of 93% and 87%, resp., in the two groups (p ≤ 0.001 for the comparison of disease-free survival).  A total of 42 women in the placebo group and 31 women in the letrozole group died (P = 0.25 for the comparison of overall survival).  Low-grade hot flashes, arthritis, arthralgia, and myalgia were more frequent in the letrozole group, but vaginal bleeding was less frequent.  There were new diagnoses of osteoporosis in 5.8% of the women in the letrozole group and 4.5% of the women in the placebo group (P = 0.07); the rates of fracture were similar.  After the first interim anal., the independent data and safety monitoring committee recommended termination of the trial and prompt communication of the results to the participants.  Conclusions: As compared with placebo, letrozole therapy after the completion of std. tamoxifen treatment significantly improves disease-free survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn8Yeh_0VFRbVg90H21EOLACvtfcHk0lgsl6vUnojpxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosl2gtbc%253D&md5=b7ccc0fb80f769bc70d2768567a4c31f</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032312%26sid%3Dliteratum%253Aachs%26aulast%3DGoss%26aufirst%3DP.%2BE.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DMartino%26aufirst%3DS.%26aulast%3DRobert%26aufirst%3DN.%2BJ.%26aulast%3DMuss%26aufirst%3DH.%2BB.%26aulast%3DPiccart%26aufirst%3DM.%2BJ.%26aulast%3DCastiglione%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DShepherd%26aufirst%3DL.%2BE.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DLivingston%26aufirst%3DR.%2BB.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DAbrams%26aufirst%3DJ.%2BS.%26aulast%3DTherasse%26aufirst%3DP.%26aulast%3DPalmer%26aufirst%3DM.%2BJ.%26aulast%3DPater%26aufirst%3DJ.%2BL.%26atitle%3DA%2520randomized%2520trial%2520of%2520letrozole%2520in%2520postmenopausal%2520women%2520after%2520five%2520years%2520of%2520tamoxifen%2520therapy%2520for%2520early-stage%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D1793%26epage%3D1802%26doi%3D10.1056%2FNEJMoa032312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paridaens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolé, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildiers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiche, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clément, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köberle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldhirsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thürlimann, B.</span><span> </span><span class="NLM_article-title">Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss group for clinical cancer research trial (SAKK 21/00)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">64</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span><span class="refDoi"> DOI: 10.1093/annonc/mdl341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1093%2Fannonc%2Fmdl341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=17030543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FisVWntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=64-69&author=L.+Pereyauthor=R.+Paridaensauthor=H.+Hawleauthor=K.+Zamanauthor=F.+Nol%C3%A9author=H.+Wildiersauthor=M.+Ficheauthor=D.+Dietrichauthor=P.+Cl%C3%A9mentauthor=D.+K%C3%B6berleauthor=A.+Goldhirschauthor=B.+Th%C3%BCrlimann&title=Clinical+benefit+of+fulvestrant+in+postmenopausal+women+with+advanced+breast+cancer+and+primary+or+acquired+resistance+to+aromatase+inhibitors%3A+final+results+of+phase+II+Swiss+group+for+clinical+cancer+research+trial+%28SAKK+21%2F00%29&doi=10.1093%2Fannonc%2Fmdl341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)</span></div><div class="casAuthors">Perey L; Hawle H; Fiche M; Dietrich D; Koberle D; Thurlimann B; Paridaens R; Wildiers H; Clement P; Zaman K; Nole F; Goldhirsch A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-69</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment.  PATIENTS AND METHODS:  This is a phase II, open, multicenter, noncomparative study.  Two patient groups were prospectively considered: group A (n=70) with AI-responsive disease and group B (n=20) with AI-resistant disease.  Fulvestrant 250 mg was administered as intramuscular injection every 28 (+/-3) days.  RESULTS:  All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases.  Fulvestrant administration was well tolerated and yielded a clinical benefit (CB; defined as objective response or stable disease [SD] for >or=24 weeks) in 28% (90% confidence interval [CI] 19% to 39%) of patients in group A and 37% (90% CI 19% to 58%) of patients in group B.  Median time to progression (TTP) was 3.6 (95% CI 3.0 to 4.8) months in group A and 3.4 (95% CI 2.5 to 6.7) months in group B.  CONCLUSIONS:  Overall, 30% of patients who had progressed following prior AI treatment gained CB with fulvestrant, thereby delaying indication to start chemotherapy.  Prior response to an AI did not appear to be predictive for benefit with fulvestrant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgdgcuVoVvhr7NkxioyDXTfW6udTcc2easLEhOHqT74rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FisVWntQ%253D%253D&md5=33f52d40ebeba134195a6311c0e8d854</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdl341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdl341%26sid%3Dliteratum%253Aachs%26aulast%3DPerey%26aufirst%3DL.%26aulast%3DParidaens%26aufirst%3DR.%26aulast%3DHawle%26aufirst%3DH.%26aulast%3DZaman%26aufirst%3DK.%26aulast%3DNol%25C3%25A9%26aufirst%3DF.%26aulast%3DWildiers%26aufirst%3DH.%26aulast%3DFiche%26aufirst%3DM.%26aulast%3DDietrich%26aufirst%3DD.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DP.%26aulast%3DK%25C3%25B6berle%26aufirst%3DD.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DTh%25C3%25BCrlimann%26aufirst%3DB.%26atitle%3DClinical%2520benefit%2520of%2520fulvestrant%2520in%2520postmenopausal%2520women%2520with%2520advanced%2520breast%2520cancer%2520and%2520primary%2520or%2520acquired%2520resistance%2520to%2520aromatase%2520inhibitors%253A%2520final%2520results%2520of%2520phase%2520II%2520Swiss%2520group%2520for%2520clinical%2520cancer%2520research%2520trial%2520%2528SAKK%252021%252F00%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2007%26volume%3D18%26spage%3D64%26epage%3D69%26doi%3D10.1093%2Fannonc%2Fmdl341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Deshmane, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melemed, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzdar, A. U.</span><span> </span><span class="NLM_article-title">Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">4967</span><span class="NLM_x">–</span> <span class="NLM_lpage">4973</span><span class="refDoi"> DOI: 10.1200/JCO.2006.09.5992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1200%2FJCO.2006.09.5992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=17971595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOhtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=4967-4973&author=V.+Deshmaneauthor=S.+Krishnamurthyauthor=A.+S.+Melemedauthor=P.+Petersonauthor=A.+U.+Buzdar&title=Phase+III+double-blind+trial+of+arzoxifene+compared+with+tamoxifen+for+locally+advanced+or+metastic+breast+cancer&doi=10.1200%2FJCO.2006.09.5992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer</span></div><div class="casAuthors">Deshmane, VijayaLaxmi; Krishnamurthy, S.; Melemed, Allen S.; Peterson, Patrick; Buzdar, Aman U.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">4967-4973</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To compare the efficacy of arzoxifene with tamoxifen for the treatment of locally advanced or metastatic breast cancer.  Patients and Methods: Women with estrogen- or progesterone-receptor-pos. breast cancer who had not received prior systemic therapy, or who had relapsed more than 12 mo after stopping adjuvant hormonal therapy, were randomly assigned to receive 20 mg arzoxifene or 20 mg tamoxifen daily.  Each treatment arm was to have 240 patients enrolled.  The primary end point was progression-free survival.  Secondary end points included other measures of tumor response, overall survival, and safety.  Results: Enrollment was stopped when a planned interim anal. of the first 200 patients suggested arzoxifene to be significantly inferior to tamoxifen.  The median progression-free survival for the 352 patients who had been randomly assigned when enrollment was stopped was 4.0 mo (95% CI, 3.4 to 5.6 mo) for the arzoxifene group and 7.5 mo (95% CI, 5.9 to 8.8 mo) for the tamoxifen group.  On-study progression-free survival (P = .011) and time to treatment failure (P = .029) also favored tamoxifen.  Overall tumor response rate and median response duration were comparable between the groups.  Adverse events were similar between the treatments, except for nausea (more frequent with arzoxifene) and vaginal discharge (more frequent with tamoxifen).  Conclusion: Tamoxifen produced significantly longer progression-free survival and time to treatment failure compared with arzoxifene in the treatment of locally advanced and metastatic breast cancer.  There were no significant differences between tumor response rate, clin. benefit rate, or median response duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0TBBdzHZWMbVg90H21EOLACvtfcHk0ljWpHwMms0hpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOhtbfK&md5=464ad5ce1273cc4210417b6e85f763e7</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.09.5992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.09.5992%26sid%3Dliteratum%253Aachs%26aulast%3DDeshmane%26aufirst%3DV.%26aulast%3DKrishnamurthy%26aufirst%3DS.%26aulast%3DMelemed%26aufirst%3DA.%2BS.%26aulast%3DPeterson%26aufirst%3DP.%26aulast%3DBuzdar%26aufirst%3DA.%2BU.%26atitle%3DPhase%2520III%2520double-blind%2520trial%2520of%2520arzoxifene%2520compared%2520with%2520tamoxifen%2520for%2520locally%2520advanced%2520or%2520metastic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D4967%26epage%3D4973%26doi%3D10.1200%2FJCO.2006.09.5992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Johnston, S. R. D.</span><span> </span><span class="NLM_article-title">Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">4376s</span><span class="NLM_x">–</span> <span class="NLM_lpage">4387s</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=11916228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD38Xltlyjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=4376s-4387s&author=S.+R.+D.+Johnston&title=Endocrine+manipulation+in+advanced+breast+cancer%3A+recent+advances+with+SERM+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine manipulation in advanced breast cancer: Recent advances with SERM therapies</span></div><div class="casAuthors">Johnston, Stephen R. D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12, Suppl.</span>),
    <span class="NLM_cas:pages">4376S-4387S</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Tamoxifen is one of the most effective treatments for breast cancer through its ability to antagonize estrogen-dependent growth by binding estrogen receptors (ERs) and inhibiting breast epithelial cell proliferation.  However, tamoxifen has estrogenic agonist effects in other tissues such as bone and endometrium because of liganded ER-activating target genes in these different cell types.  Several novel antiestrogen compds. have been developed that are also selective ER modulators (SERMs) but that have a reduced agonist profile on breast and gynecol. tissues.  These SERMs offer the potential for enhanced efficacy and reduced toxicity compared with tamoxifen.  In advanced breast cancer clin. data exist for three first-generation SERMs (toremifene, droloxifene, idoxifene), which are related to the triphenylethylene structure of tamoxifen.  In Phase II trials in a total of 263 patients resistant to tamoxifen, the median objective response rate to these SERMs way only 5% (range, 0-15%), with stable disease for 6 mo in an addnl. 18% (range, 9-23%).  As first-line therapy for advanced breast cancer, the median response rate was 31% (range, 20-68%) with a median time to progression of 7 mo.  Randomized Phase III trials for toremifene and idoxifene in more than 1500 patients showed no significant difference compared with tamoxifen.  Fewer clin. data exist for the structurally distinct second- and third-generation SERMs (raloxifene, arzoxifene, EM-800, and ERA-923), although a similarly low median response rate of 6% (range, 0-14%) was seen in Phase II trials in tamoxifen-resistant patients.  It remains unclear whether any clin. advantage exists for second- and third-generation SERMs over tamoxifen as first-line therapy.  With the emergence of potent aromatase inhibitors (AIs) that are superior to tamoxifen, the clin. questions in advanced disease have shifted to which antiestrogen (including SERMs) may be effective following failure of AIs, and whether any merit exists for combined AI/SERM therapy.  The main advantage for SERM therapy probably remains in early stage-disease (adjuvant therapy or prevention), in which the estrogenic effects on bone and reduced gynecol. side effects may prove more beneficial than either tamoxifen or AI.  The issue is whether the current clin. data for SERMs in advanced breast cancer are sufficiently strong to encourage that further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpF6hXEfwfYLVg90H21EOLACvtfcHk0ljWpHwMms0hpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xltlyjug%253D%253D&md5=e8213625c91f3c25c9fbdcccab013aa2</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26atitle%3DEndocrine%2520manipulation%2520in%2520advanced%2520breast%2520cancer%253A%2520recent%2520advances%2520with%2520SERM%2520therapies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D4376s%26epage%3D4387s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradishar, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauriac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bines, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amant, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romieu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzdar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brufsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possinger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapunar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccart, M.</span><span> </span><span class="NLM_article-title">Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1664</span><span class="NLM_x">–</span> <span class="NLM_lpage">1670</span><span class="refDoi"> DOI: 10.1200/JCO.2007.13.5822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1200%2FJCO.2007.13.5822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=18316794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWhsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1664-1670&author=S.+Chiaauthor=W.+Gradisharauthor=L.+Mauriacauthor=J.+Binesauthor=F.+Amantauthor=M.+Federicoauthor=L.+Feinauthor=G.+Romieuauthor=A.+Buzdarauthor=J.+F.+R.+Robertsonauthor=A.+Brufskyauthor=K.+Possingerauthor=P.+Rennieauthor=F.+Sapunarauthor=E.+Loweauthor=M.+Piccart&title=Double-blind%2C+randomized+placebo+controlled+trial+of+fulvestrant+compared+with+exemestane+after+prior+nonsteroidal+aromatase+inhibitor+therapy+in+postmenopausal+women+with+hormone+receptor-positive%2C+advanced+breast+cancer%3A+results+from+EFECT&doi=10.1200%2FJCO.2007.13.5822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from Effect</span></div><div class="casAuthors">Chia, Stephen; Gradishar, William; Mauriac, Louis; Bines, Jose; Amant, Frederic; Federico, Miriam; Fein, Luis; Romieu, Gilles; Buzdar, Aman; Robertson, John F. R.; Brufsky, Adam; Possinger, Kurt; Rennie, Pamela; Sapunar, Francisco; Lowe, Elizabeth; Piccart, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1664-1670</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The third-generation nonsteroidal aromatase inhibitors (AIs) are increasingly used as adjuvant and first-line advanced therapy for postmenopausal, hormone receptor-pos. (HR+) breast cancer.  Because many patients subsequently experience progression or relapse, it is important to identify agents with efficacy after Al failure.  Materials and Methods: Evaluation of Faslodex vs. Exemestane Clin. Trial (Effect) is a randomized, double-blind, placebo controlled, multicenter phase III trial of fulvestrant vs. exemestane in postmenopausal women with HR+ advanced breast cancer (ABC) progressing or recurring after nonsteroidal AI.  The primary end point was time to progression (TTP).  A fulvestrant loading-dose (LD) regimen was used: 500 mg i.m. on day 0, 250 mg on days 14, 28, and 250 mg every 28 days thereafter.  Exemestane 25 mg orally was administered once daily.  Results: A total of 693 women were randomly assigned to fulvestrant (n = 351) or exemestane (n = 342).  Approx. 60% of patients had received at least two prior endocrine therapies.  Median TTP was 3.7 mo in both groups (hazard ratio = 0.963; 95% CI, 0.819 to 1.133; P = .6531).  The overall response rate (7.4% v 6.7%; P = .736) and clin. benefit rate (32.2% v 31.5%; P = .853) were similar between fulvestrant and exemestane resp.  Median duration of clin. benefit was 9.3 and 8.3 mo, resp.  Both treatments were well tolerated, with no significant differences in the incidence of adverse events or quality of life.  Pharmacokinetic data confirm that steady-state was reached within 1 mo with the LD schedule of fulvestrant.  Conclusion: Fulvestrant LD and exemestane are equally active and well-tolerated in a meaningful proportion of postmenopausal women with ABC who have experienced progression or recurrence during treatment with a nonsteroidal AI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWaXOCyTBWnrVg90H21EOLACvtfcHk0ljWpHwMms0hpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWhsrg%253D&md5=6c92d61eb60518a1fee2a82e8f9b892c</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.5822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.5822%26sid%3Dliteratum%253Aachs%26aulast%3DChia%26aufirst%3DS.%26aulast%3DGradishar%26aufirst%3DW.%26aulast%3DMauriac%26aufirst%3DL.%26aulast%3DBines%26aufirst%3DJ.%26aulast%3DAmant%26aufirst%3DF.%26aulast%3DFederico%26aufirst%3DM.%26aulast%3DFein%26aufirst%3DL.%26aulast%3DRomieu%26aufirst%3DG.%26aulast%3DBuzdar%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DBrufsky%26aufirst%3DA.%26aulast%3DPossinger%26aufirst%3DK.%26aulast%3DRennie%26aufirst%3DP.%26aulast%3DSapunar%26aufirst%3DF.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DPiccart%26aufirst%3DM.%26atitle%3DDouble-blind%252C%2520randomized%2520placebo%2520controlled%2520trial%2520of%2520fulvestrant%2520compared%2520with%2520exemestane%2520after%2520prior%2520nonsteroidal%2520aromatase%2520inhibitor%2520therapy%2520in%2520postmenopausal%2520women%2520with%2520hormone%2520receptor-positive%252C%2520advanced%2520breast%2520cancer%253A%2520results%2520from%2520EFECT%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D1664%26epage%3D1670%26doi%3D10.1200%2FJCO.2007.13.5822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wittmann, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9549</span><span class="NLM_x">–</span> <span class="NLM_lpage">9560</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1158%2F0008-5472.CAN-07-1590" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9549-9560&author=B.+M.+Wittmannauthor=A.+Sherkauthor=D.+P.+McDonnell&title=Definition+of+functionally+important+mechanistic+differences+among+selective+estrogen+receptor+down-regulators&doi=10.1158%2F0008-5472.CAN-07-1590"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1590%26sid%3Dliteratum%253Aachs%26aulast%3DWittmann%26aufirst%3DB.%2BM.%26aulast%3DSherk%26aufirst%3DA.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DDefinition%2520of%2520functionally%2520important%2520mechanistic%2520differences%2520among%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9549%26epage%3D9560%26doi%3D10.1158%2F0008-5472.CAN-07-1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Howell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapunar, F.</span><span> </span><span class="NLM_article-title">Fulvestrant revisited: efficacy and safety of the 500-mg dose</span> <span class="citation_source-journal">Clin. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">204</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1016/j.clbc.2011.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.clbc.2011.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=21729658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKisr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=204-210&author=A.+Howellauthor=F.+Sapunar&title=Fulvestrant+revisited%3A+efficacy+and+safety+of+the+500-mg+dose&doi=10.1016%2Fj.clbc.2011.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant revisited: efficacy and safety of the 500-mg dose</span></div><div class="casAuthors">Howell, Anthony; Sapunar, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">204-210</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Postmenopausal women with hormone receptor-pos. advanced breast cancer are candidates for endocrine therapy.  As the disease will eventually progress in most patients, it is important to investigate agents with novel modes of action to reduce the likelihood of treatment cross-resistance.  Fulvestrant is an estrogen receptor antagonist with no known agonist effects that has been shown to be as effective as anastrozole following failure on tamoxifen, at the approved dose of 250 mg/mo.  However, pharmacokinetic modeling and evidence of clin. efficacy in early trials, together with the favorable tolerability profile of fulvestrant 250 mg, led to suggestions that increasing the fulvestrant dose would lead to an improved benefit-risk profile.  This review describes the rationale behind the development of a 500 mg/mo higher dose of fulvestrant and details relevant clin. trials, including the pivotal phase III COmparisoN of Faslodex In Recurrent or Metastatic breast cancer (CONFIRM) study.  CONFIRM demonstrated a significant improvement in progression-free survival for fulvestrant 500 mg vs. 250 mg in postmenopausal patients who had progressed on previous endocrine therapy.  Here, we present and discuss a pooled safety anal. of CONFIRM and three further clin. studies demonstrating fulvestrant 500 mg to be well-tolerated with no evidence of dose-related adverse events.  Overall, these data indicate an improved benefit-risk profile for fulvestrant 500 mg vs. 250 mg following failure on prior endocrine therapy, and suggest that fulvestrant 500 mg may be considered in future as initial endocrine treatment for advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4U1d7Q6edlbVg90H21EOLACvtfcHk0lh-7HFQVZUseg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKisr7E&md5=0d1063c9546320294193e92d3f2097dd</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2011.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2011.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DHowell%26aufirst%3DA.%26aulast%3DSapunar%26aufirst%3DF.%26atitle%3DFulvestrant%2520revisited%253A%2520efficacy%2520and%2520safety%2520of%2520the%2520500-mg%2520dose%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D204%26epage%3D210%26doi%3D10.1016%2Fj.clbc.2011.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">van Kruchten</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaudemans, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Lanschot, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Faassen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kema, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schröder, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hospers, G. A.</span><span> </span><span class="NLM_article-title">Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1158%2F2159-8290.CD-14-0697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=25380844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-81&author=+van+Kruchtenauthor=E.+G.+de+Vriesauthor=A.+W.+Glaudemansauthor=M.+C.+van+Lanschotauthor=M.+van+Faassenauthor=I.+P.+Kemaauthor=M.+Brownauthor=C.+P.+Schr%C3%B6derauthor=E.+F.+de+Vriesauthor=G.+A.+Hospers&title=Measuring+residual+estrogen+receptor+availability+during+fulvestrant+therapy+in+patients+with+metastatic+breast+cancer&doi=10.1158%2F2159-8290.CD-14-0697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">van Kruchten, Michel; de Vries, Elisabeth G.; Glaudemans, Andor W.; van Lanschot, Meta C.; van Faassen, Martijn; Kema, Ido P.; Brown, Myles; Schroeder, Carolien P.; de Vries, Erik F.; Hospers, Geke A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-81</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Decreased [18F]fluoroestradiol uptake visualized by PET/CT provides a measure of tumor ER availability and correlates with fulvestrant treatment outcome in patients with metastatic breast cancer.  It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer.  We performed a feasibility study to assess ER availability before and during fulvestrant.  Sixteen patients with ER-pos. metastatic breast cancer underwent positron emission tomog./computed tomog. (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18F]fluoroestradiol (FES) uptake.  Incomplete redn. in ER availability was predefined as <75% decrease in median tumor FES uptake and a residual standardized uptake value (SUVmax) of ≥1.5.  In total, 131 FES-pos. lesions were identified (median SUVmax of 2.9; range, 1.7-6.5).  The median change in patients during fulvestrant treatment was -85% at scan 2, but varied widely (-99% to +60%).  Fulvestrant reduced tumor FES uptake incompletely at scan 2 in 6 (38%) of the 16 patients, which was assocd. with early progression.  Significance: Serial imaging of tumor estrogen uptake by FES-PET can give insight into the dose needed for ER antagonists to completely abolish ER.  FES-PET showed significant residual ER availability in tumors during fulvestrant therapy in 38% of patients, which was assocd. with early progression.  Cancer Discov; 5(1); 72-81. ©2014 AACR.  This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAIvv5LaIyrVg90H21EOLACvtfcHk0lh-7HFQVZUseg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D&md5=c5e8291be59caa5bf772cb6da80d52fb</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0697%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BKruchten%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3DGlaudemans%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLanschot%26aufirst%3DM.%2BC.%26aulast%3Dvan%2BFaassen%26aufirst%3DM.%26aulast%3DKema%26aufirst%3DI.%2BP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DC.%2BP.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DHospers%26aufirst%3DG.%2BA.%26atitle%3DMeasuring%2520residual%2520estrogen%2520receptor%2520availability%2520during%2520fulvestrant%2520therapy%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D72%26epage%3D81%26doi%3D10.1158%2F2159-8290.CD-14-0697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Robertson, J. F. R.</span><span> </span><span class="NLM_article-title">Fulvestrant (Faslodex)- how to make a good drug better</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">774</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span><span class="refDoi"> DOI: 10.1634/theoncologist.12-7-774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1634%2Ftheoncologist.12-7-774" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=774-784&author=J.+F.+R.+Robertson&title=Fulvestrant+%28Faslodex%29-+how+to+make+a+good+drug+better&doi=10.1634%2Ftheoncologist.12-7-774"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-7-774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-7-774%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%2BR.%26atitle%3DFulvestrant%2520%2528Faslodex%2529-%2520how%2520to%2520make%2520a%2520good%2520drug%2520better%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D774%26epage%3D784%26doi%3D10.1634%2Ftheoncologist.12-7-774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ma, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielewska, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M. J.</span><span> </span><span class="NLM_article-title">Mechanisms of aromatase inhibitor resistance</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1038/nrc3920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1038%2Fnrc3920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=25907219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wrur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=261-275&author=C.+X.+Maauthor=T.+Reinertauthor=I.+Chmielewskaauthor=M.+J.+Ellis&title=Mechanisms+of+aromatase+inhibitor+resistance&doi=10.1038%2Fnrc3920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of aromatase inhibitor resistance</span></div><div class="casAuthors">Ma, Cynthia X.; Reinert, Tomas; Chmielewska, Izabela; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">261-275</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Estrogen receptor-pos. (ER+) breast cancer is a major cause of cancer death in women.  Although aromatase inhibitors suppress the function of ER and reduce the risk of recurrence, therapeutic resistance is common and essentially inevitable in advanced disease.  This Review considers both genomic and cell biol. explanations as to why ER+ breast cancer cells persist, progress and cause an incurable, lethal, systemic disease.  The design and outcomes of clin. trials are considered with the perspective that resistance mechanisms are heterogeneous, and therefore biomarker and somatic mutation-based stratification and eligibility will be essential for improvements in patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFQZc2ZDe2yrVg90H21EOLACvtfcHk0li4efG0hUMv1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wrur3F&md5=8873908dbbf917eece0cdc51d19efea1</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1038%2Fnrc3920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3920%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%2BX.%26aulast%3DReinert%26aufirst%3DT.%26aulast%3DChmielewska%26aufirst%3DI.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DMechanisms%2520of%2520aromatase%2520inhibitor%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D261%26epage%3D275%26doi%3D10.1038%2Fnrc3920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Masamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitjan, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santen, R. J.</span><span> </span><span class="NLM_article-title">Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">2918</span><span class="NLM_x">–</span> <span class="NLM_lpage">2925</span><span class="refDoi"> DOI: 10.1210/jcem.80.10.7559875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1210%2Fjcem.80.10.7559875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=7559875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK2MXoslCns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=2918-2925&author=S.+Masamuraauthor=S.+J.+Santnerauthor=D.+F.+Heitjanauthor=R.+J.+Santen&title=Estrogen+deprivation+causes+estradiol+hypersensitivity+in+human+breast+cancer+cells&doi=10.1210%2Fjcem.80.10.7559875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells</span></div><div class="casAuthors">Masamura, Shigeru; Santner, Steven J.; Heitjan, Daniel F.; Santen, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2918-25</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Genetic and environmental factors can modulate the level of sensitivity to various hormones, including estrogens.  Enhanced sensitivity to estradiol (E2) has been demonstrated in several biol. conditions, such as in sheep during the nonbreeding season, in untreated patients with Turner's syndrome, and in the prepubertal state in normal girls.  The authors postulated that secondary responses to hormonal therapy in patients with breast cancer could also result from enhanced E2 sensitivity, developing as an adaptive mechanism to E2 deprivation.  The present study used the MCF-7 human breast cancer cell line as a model system to test the concept that enhanced sensitivity to E2 may occur as a result of adaptation to low E2 levels.  After depriving MCF-7 cells of estrogens in tissue culture medium for periods of 1-6 mo, the authors established conditions under which replication could be stimulated maximally by 10-14-10-15M E2.  In contrast, wild-type cells not exposed to estrogen deprivation required 10-10M E2 to grow at the same rate.  Further, the concn. of the antiestrogen, ICI 164384, needed to inhibit growth by 50% in estrogen-deprived cells was much lower than that required in wild-type cells (i.e. 10-15 vs. 10-9M).  Nude mice implanted with these estrogen-deprived cells demonstrated an earlier appearance of palpable tumors in response to E2 than animals bearing wild-type cells.  Reexposure to 10-10-10-9M E2, either in vivo or in vitro, returned these cells to the level of estrogen sensitivity obsd. in wild-type cells.  Apparently, breast cancer cells can adapt to low levels of estrogens by enhancing their sensitivity to E2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcOoAZDaWphbVg90H21EOLACvtfcHk0li4efG0hUMv1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslCns7Y%253D&md5=e61b1298d67a65bc5854b1afc3376af3</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1210%2Fjcem.80.10.7559875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.80.10.7559875%26sid%3Dliteratum%253Aachs%26aulast%3DMasamura%26aufirst%3DS.%26aulast%3DSantner%26aufirst%3DS.%2BJ.%26aulast%3DHeitjan%26aufirst%3DD.%2BF.%26aulast%3DSanten%26aufirst%3DR.%2BJ.%26atitle%3DEstrogen%2520deprivation%2520causes%2520estradiol%2520hypersensitivity%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1995%26volume%3D80%26spage%3D2918%26epage%3D2925%26doi%3D10.1210%2Fjcem.80.10.7559875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Jeselsohn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwalter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, R.</span><span> </span><span class="NLM_article-title"><i>ESR1</i> mutations—a mechanism for acquired endocrine resistance in breast cancer. <i>Nat. Rev</i></span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2015.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1038%2Fnrclinonc.2015.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=26122181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOju77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=573-583&author=R.+Jeselsohnauthor=G.+Buchwalterauthor=C.+De+Angelisauthor=M.+Brownauthor=R.+Schiff&title=ESR1+mutations%E2%80%94a+mechanism+for+acquired+endocrine+resistance+in+breast+cancer.+Nat.+Rev&doi=10.1038%2Fnrclinonc.2015.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer</span></div><div class="casAuthors">Jeselsohn, Rinath; Buchwalter, Gilles; De Angelis, Carmine; Brown, Myles; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">573-583</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Approx. 70% of breast cancers are estrogen receptor α (ER) pos., and are, therefore, treated with endocrine therapies.  However, about 25% of patients with primary disease and almost all patients with metastases will present with or eventually develop endocrine resistance.  Despite the magnitude of this clin. challenge, the mechanisms underlying the development of resistance remain largely unknown.  In the past 2 years, several studies unveiled gain-of-function mutations in ESR1, the gene encoding the ER, in approx. 20% of patients with metastatic ER-pos. disease who received endocrine therapies, such as tamoxifen and aromatase inhibitors.  These mutations are clustered in a 'hotspot' within the ligand-binding domain (LBD) of the ER and lead to ligand-independent ER activity that promotes tumor growth, partial resistance to endocrine therapy, and potentially enhanced metastatic capacity; thus, ER LBD mutations might account for a mechanism of acquired endocrine resistance in a substantial fraction of patients with metastatic disease.  In general, the absence of detectable ESR1 mutations in patients with treatment-naive disease, and the correlation between the frequency of patients with tumors harbouring these mutations and the no. of endocrine treatments received suggest that, under selective treatment pressure, clonal expansion of rare mutant clones occurs, leading to resistance.  Preclin. and clin. development of rationale-based novel therapeutic strategies that inhibit these ER mutants has the potential to substantially improve treatment outcomes.  We discuss the contribution of ESR1 mutations to the development of acquired resistance to endocrine therapy, and evaluate how mutated ER can be detected and targeted to overcome resistance and improve patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIrcfX3mOHgLVg90H21EOLACvtfcHk0li4efG0hUMv1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOju77E&md5=76da7da110c253410b40853bbf3b1be6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.117%26sid%3Dliteratum%253Aachs%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DBuchwalter%26aufirst%3DG.%26aulast%3DDe%2BAngelis%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DESR1%2520mutations%25E2%2580%2594a%2520mechanism%2520for%2520acquired%2520endocrine%2520resistance%2520in%2520breast%2520cancer.%2520Nat.%2520Rev%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26spage%3D573%26epage%3D583%26doi%3D10.1038%2Fnrclinonc.2015.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">McDonnell, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span> </span><span class="NLM_article-title">Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4883</span><span class="NLM_x">–</span> <span class="NLM_lpage">4887</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4883-4887&author=D.+P.+McDonnellauthor=S.+E.+Wardellauthor=J.+D.+Norris&title=Oral+selective+estrogen+receptor+downregulators+%28SERDs%29%2C+a+breakthrough+endocrine+therapy+for+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.; Norris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4883-4887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drugs that inhibit estrogen receptor alpha (ERα) or that block the prodn. of estrogens remain frontline interventions in the treatment and management of breast cancer at all stages.  However, resistance to endocrine therapies, esp. in the setting of advanced disease, remains an impediment to durable clin. responses.  Although the mechanisms underlying resistance to existing agents are complex, preclin. studies suggest that selective estrogen receptor downregulators (SERDs), mols. which eliminate ERα expression, may have particular utility in the treatment of breast cancers that have progressed on tamoxifen and/or aromatase inhibitors.  The discovery and development of orally bioavailable SERDs provide the opportunity to evaluate the utility of eliminating ERα expression in advanced metastatic breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQkRKbmjeJdLVg90H21EOLACvtfcHk0ljS2taHrvmNzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D&md5=127869f40034451832a82fb2d7816528</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00760%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26atitle%3DOral%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%252C%2520a%2520breakthrough%2520endocrine%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4883%26epage%3D4887%26doi%3D10.1021%2Facs.jmedchem.5b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Wu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span> </span><span class="NLM_article-title">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.molcel.2005.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=15893725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=413-424&author=Y.-L.+Wuauthor=X.+Yangauthor=Z.+Renauthor=D.+P.+McDonnellauthor=J.+D.+Norrisauthor=T.+M.+Willsonauthor=G.+L.+Greene&title=Structural+basis+for+an+unexpected+mode+of+SERM-mediated+ER+antagonism&doi=10.1016%2Fj.molcel.2005.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span></div><div class="casAuthors">Wu, Ya-Ling; Yang, Xiaojing; Ren, Zhong; McDonnell, Donald P.; Norris, John D.; Willson, Timothy M.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-424</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tamoxifen is effective for the prevention and treatment of estrogen-dependent breast cancers, but is assocd. with an increased incidence of endometrial tumors.  The authors report the crystal structure of the estrogen receptor α (ERα) ligand binding domain (LBD) bound to the structurally similar compd. GW5638, which has therapeutic potential and does not stimulate the uterus.  Like tamoxifen, GW5638 relocates the carboxy-terminal helix (H12) to the known coactivator-docking site in the ERα LBD.  However, GW5638 repositions residues in H12 through specific contacts with the N terminus of this helix.  In contrast to tamoxifen, the resulting increase in exposed hydrophobic surface of ERα LBD correlates with a significant destabilization of ERα in MCF-7 cells.  Thus, the GW5638-ERα LBD structure reveals an unexpected mode of SERM-mediated ER antagonism, in which the stability of ERα is decreased through an altered position of H12.  This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBuyhLNSdbQbVg90H21EOLACvtfcHk0ljS2taHrvmNzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D&md5=c60e01b31b57c07b934da01a34efb255</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DStructural%2520basis%2520for%2520an%2520unexpected%2520mode%2520of%2520SERM-mediated%2520ER%2520antagonism%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26spage%3D413%26epage%3D424%26doi%3D10.1016%2Fj.molcel.2005.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henke, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Momtahen, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charifson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batchelor, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubahn, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauls, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Triantafillou, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, P. G.</span><span> </span><span class="NLM_article-title">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1550</span><span class="NLM_x">–</span> <span class="NLM_lpage">1552</span><span class="refDoi"> DOI: 10.1021/jm00037a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00037a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1550-1552&author=T.+M.+Willsonauthor=B.+R.+Henkeauthor=T.+M.+Momtahenauthor=P.+S.+Charifsonauthor=K.+W.+Batchelorauthor=D.+B.+Lubahnauthor=L.+B.+Mooreauthor=B.+B.+Oliverauthor=H.+R.+Saulsauthor=J.+A.+Triantafillouauthor=S.+G.+Wolfeauthor=P.+G.+Baer&title=3-%5B4-%281%2C2-Diphenylbut-1-enyl%29phenyl%5Dacrylic+acid%3A+a+non-steroidal+estrogen+with+functional+selectivity+for+bone+over+uterus+in+rats&doi=10.1021%2Fjm00037a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats</span></div><div class="casAuthors">Willson, Timothy M.; Henke, Brad R.; Momtahen, Tanya M.; Charifson, Paul S.; Batchelor, Kenneth W.; Lubahn, Dennis B.; Moore, Linda B.; Oliver, Beverly B.; Sauls, Howard R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1550-2</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Exploiting knowledge of the mol. biol. of the estrogen receptor and the existence of two independent transcription activation domains, a series of tissue-selective non-steroidal estrogens was designed.  The ethanolamine side-chain of tamoxifen was targeted for modification, resulting in the identification of a series of α,β-unsatd. acid and amide analogs I [R = OH, NEt2, morpholino, NH(CH2)3OMe, dicyclohexylamino, NEtCH2CH2NMe2, NH(CH2)3OH, N-methyloctylamino, NHEt,NH2].  I [R = OH] profiled as an estrogen with full agonist activity in bone while maintaining antagonist activity in the uterus of rats.  The demonstration that different parts of the triphenylethylene structure control expression of estrogenic activity in bone and uterus has implications in the design of tissue selective ligands for other members of the steroid/retinoid family of intracellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4iuXq4R8fm7Vg90H21EOLACvtfcHk0lgDOZUzAgBcgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D&md5=721906b3513f7e8cdc9ae08ecd99a93b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm00037a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00037a002%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DHenke%26aufirst%3DB.%2BR.%26aulast%3DMomtahen%26aufirst%3DT.%2BM.%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26aulast%3DBatchelor%26aufirst%3DK.%2BW.%26aulast%3DLubahn%26aufirst%3DD.%2BB.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26aulast%3DTriantafillou%26aufirst%3DJ.%2BA.%26aulast%3DWolfe%26aufirst%3DS.%2BG.%26aulast%3DBaer%26aufirst%3DP.%2BG.%26atitle%3D3-%255B4-%25281%252C2-Diphenylbut-1-enyl%2529phenyl%255Dacrylic%2520acid%253A%2520a%2520non-steroidal%2520estrogen%2520with%2520functional%2520selectivity%2520for%2520bone%2520over%2520uterus%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1550%26epage%3D1552%26doi%3D10.1021%2Fjm00037a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asplin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauls, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Dissection of the molecular mechanism of action of GW5368, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">3901</span><span class="NLM_x">–</span> <span class="NLM_lpage">3911</span><span class="refDoi"> DOI: 10.1210/endo.138.9.5358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1210%2Fendo.138.9.5358" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1997&pages=3901-3911&author=T.+M.+Willsonauthor=J.+D.+Norrisauthor=B.+L.+Wagnerauthor=I.+Asplinauthor=P.+Baerauthor=H.+R.+Brownauthor=S.+A.+Jonesauthor=B.+Henkeauthor=H.+Saulsauthor=S.+Wolfeauthor=D.+C.+Morrisauthor=D.+P.+McDonnell&title=Dissection+of+the+molecular+mechanism+of+action+of+GW5368%2C+a+novel+estrogen+receptor+ligand%2C+provides+insights+into+the+role+of+estrogen+receptor&doi=10.1210%2Fendo.138.9.5358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1210%2Fendo.138.9.5358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.138.9.5358%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWagner%26aufirst%3DB.%2BL.%26aulast%3DAsplin%26aufirst%3DI.%26aulast%3DBaer%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DH.%2BR.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DHenke%26aufirst%3DB.%26aulast%3DSauls%26aufirst%3DH.%26aulast%3DWolfe%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DD.%2BC.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DDissection%2520of%2520the%2520molecular%2520mechanism%2520of%2520action%2520of%2520GW5368%252C%2520a%2520novel%2520estrogen%2520receptor%2520ligand%252C%2520provides%2520insights%2520into%2520the%2520role%2520of%2520estrogen%2520receptor%26jtitle%3DEndocrinology%26date%3D1997%26volume%3D138%26spage%3D3901%26epage%3D3911%26doi%3D10.1210%2Fendo.138.9.5358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowler, J.</span><span> </span><span class="NLM_article-title">Novel antioestrogens without partial agonist activity</span> <span class="citation_source-journal">J. Steroid Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">653</span><span class="refDoi"> DOI: 10.1016/0022-4731(88)90014-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2F0022-4731%2888%2990014-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=3199810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=645-653&author=A.+E.+Wakelingauthor=J.+Bowler&title=Novel+antioestrogens+without+partial+agonist+activity&doi=10.1016%2F0022-4731%2888%2990014-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antiestrogens without partial agonist activity</span></div><div class="casAuthors">Wakeling, A. E.; Bowler, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4B</span>),
    <span class="NLM_cas:pages">645-53</span>CODEN:
                <span class="NLM_cas:coden">JSTBBK</span>;
        ISSN:<span class="NLM_cas:issn">0022-4731</span>.
    </div><div class="casAbstract">The estrogenic and antiestrogenic properties of some novel 7α-alkyl amide derivs. of 17β-estradiol have been measured in rats and mice.  The compd. ICI 164384 (I) was devoid of estrogenic activity in the uterus and vagina of both species and on the hypothalamic-pituitary axis of the rat.  ICI 164384 blocked completely the uterotrophic action of exogenous and endogenous estradiol and of the partial agonist antiestrogens typified by tamoxifen.  Unlike tamoxifen, ICI 164384 did not promote premature vaginal opening in neonatal rats.  The affinity of ICI 164384 for the rat uterus estrogen receptor was substantially greater than that of tamoxifen.  In MCF-7 and ZR-75-1 breast cancer cells in tissue culture, ICI 164384 was a more potent inhibitor of cell growth than was tamoxifen and growth inhibition was reversed by estradiol.  The properties of ICI 164384 satisfy many of the criteria which define pure antiestrogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSFknFn53ejrVg90H21EOLACvtfcHk0lgDOZUzAgBcgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCjtw%253D%253D&md5=038d59b06202ab394d535e1bf20a8577</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2F0022-4731%2888%2990014-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-4731%252888%252990014-3%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DNovel%2520antioestrogens%2520without%2520partial%2520agonist%2520activity%26jtitle%3DJ.%2520Steroid%2520Biochem.%26date%3D1988%26volume%3D31%26spage%3D645%26epage%3D653%26doi%3D10.1016%2F0022-4731%2888%2990014-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pike, A. C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brzozowski, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsell, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafsson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlquist, M.</span><span> </span><span class="NLM_article-title">Structural insights into the mode of action of a pure antiestrogen</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.1016/S0969-2126(01)00568-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2FS0969-2126%2801%2900568-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=11250199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslKgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2001&pages=145-153&author=A.+C.+W.+Pikeauthor=A.+M.+Brzozowskiauthor=J.+Waltonauthor=R.+E.+Hubbardauthor=A.+G.+Thorsellauthor=Y.+L.+Liauthor=J.+A.+Gustafssonauthor=M.+Carlquist&title=Structural+insights+into+the+mode+of+action+of+a+pure+antiestrogen&doi=10.1016%2FS0969-2126%2801%2900568-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the mode of action of a pure antiestrogen</span></div><div class="casAuthors">Pike, Ashley C. W.; Brzozowski, A. Marek; Walton, Julia; Hubbard, Roderick E.; Thorsell, Ann-Gerd; Li, Yi-Lin; Gustafsson, Jan-Ake; Carlquist, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-153</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Background: Estrogens exert their effects on target tissues by binding to a nuclear transcription factor termed the estrogen receptor (ER).  Previous structural studies have demonstrated that each class of ER ligand (agonist, partial agonist, and SERM antagonist) induces distinctive orientations in the receptor's carboxy-terminal transactivation helix.  The conformation of this portion of the receptor dets. whether ER can recruit and interact with the components of the transcriptional machinery, thereby facilitating target gene expression.  Results: We have detd. the structure of rat ERβ ligand binding domain (LBD) in complex with the pure antiestrogen ICI 164,384 at 2.3 Å resoln.  The binding of this compd. to the receptor completely abolishes the assocn. between the transactivation helix (H12) and the rest of the LBD.  The structure reveals that the terminal portion of ICI's bulky side chain substituent protrudes from the hormone binding pocket, binds along the coactivator recruitment site, and phys. prevents H12 from adopting either its characteristic agonist or AF2 antagonist orientation.  Conclusions: The binding mode adopted by the pure antiestrogen is similar to that seen for other ER antagonists.  However, the size and resultant positioning of the ligand's side chain substituent produces a receptor conformation that is distinct from that adopted in the presence of other classes of ER ligands.  The novel observation that binding of ICI results in the complete destabilization of H12 provides some indications as to a possible mechanism for pure receptor antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_dBAqpVZPtrVg90H21EOLACvtfcHk0lgDOZUzAgBcgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslKgsrg%253D&md5=ac139f6c39a2605e15314176397f11d4</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2801%2900568-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252801%252900568-8%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DA.%2BC.%2BW.%26aulast%3DBrzozowski%26aufirst%3DA.%2BM.%26aulast%3DWalton%26aufirst%3DJ.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DThorsell%26aufirst%3DA.%2BG.%26aulast%3DLi%26aufirst%3DY.%2BL.%26aulast%3DGustafsson%26aufirst%3DJ.%2BA.%26aulast%3DCarlquist%26aufirst%3DM.%26atitle%3DStructural%2520insights%2520into%2520the%2520mode%2520of%2520action%2520of%2520a%2520pure%2520antiestrogen%26jtitle%3DStructure%26date%3D2001%26volume%3D9%26spage%3D145%26epage%3D153%26doi%3D10.1016%2FS0969-2126%2801%2900568-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Shiau, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barstad, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loria, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agard, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span> </span><span class="NLM_article-title">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">927</span><span class="NLM_x">–</span> <span class="NLM_lpage">937</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81717-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2FS0092-8674%2800%2981717-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=9875847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=927-937&author=A.+K.+Shiauauthor=D.+Barstadauthor=P.+M.+Loriaauthor=L.+Chengauthor=P.+J.+Kushnerauthor=D.+A.+Agardauthor=G.+L.+Greene&title=The+structural+basis+of+estrogen+receptor%2Fcoactivator+recognition+and+the+antagonism+of+this+interaction+by+tamoxifen&doi=10.1016%2FS0092-8674%2800%2981717-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</span></div><div class="casAuthors">Shiau, Andrew K.; Barstad, Danielle; Loria, Paula M.; Cheng, Lin; Kushner, Peter J.; Agard, David A.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">927-937</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by interactions with coactivators.  Receptor agonists promote coactivator binding, and antagonists block coactivator binding.  Here we report the crystal structure of the human estrogen receptor α (hERα) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hERα LBD bound to the selective antagonist 4-hydroxytamoxifen (OHT).  In the DES-LBD-peptide complex, the peptide binds as a short α helix to a hydrophobic groove on the surface of the LBD.  In the OHT-LBD complex, helix 12 occludes the coactivator recognition groove by mimicking the interactions of the NR box peptide with the LBD.  These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrjqf40oHhE7Vg90H21EOLACvtfcHk0liMHQoIQMs1vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D&md5=074d616cf353f0d98cea5b26c4595c10</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981717-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981717-1%26sid%3Dliteratum%253Aachs%26aulast%3DShiau%26aufirst%3DA.%2BK.%26aulast%3DBarstad%26aufirst%3DD.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DThe%2520structural%2520basis%2520of%2520estrogen%2520receptor%252Fcoactivator%2520recognition%2520and%2520the%2520antagonism%2520of%2520this%2520interaction%2520by%2520tamoxifen%26jtitle%3DCell%26date%3D1998%26volume%3D95%26spage%3D927%26epage%3D937%26doi%3D10.1016%2FS0092-8674%2800%2981717-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Renaud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floersheim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halleux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaeppi, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, W.</span><span> </span><span class="NLM_article-title">Estrogen receptor modulators: identification and structure-activity relationships of potent ERα-selective tetrahydroisoquinoline ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2945</span><span class="NLM_x">–</span> <span class="NLM_lpage">2957</span><span class="refDoi"> DOI: 10.1021/jm030086h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030086h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2945-2957&author=J.+Renaudauthor=S.+F.+Bischoffauthor=T.+Buhlauthor=P.+Floersheimauthor=B.+Fournierauthor=C.+Halleuxauthor=J.+Kallenauthor=H.+Kellerauthor=J.-M.+Schlaeppiauthor=W.+Stark&title=Estrogen+receptor+modulators%3A+identification+and+structure-activity+relationships+of+potent+ER%CE%B1-selective+tetrahydroisoquinoline+ligands&doi=10.1021%2Fjm030086h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm030086h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030086h%26sid%3Dliteratum%253Aachs%26aulast%3DRenaud%26aufirst%3DJ.%26aulast%3DBischoff%26aufirst%3DS.%2BF.%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DFloersheim%26aufirst%3DP.%26aulast%3DFournier%26aufirst%3DB.%26aulast%3DHalleux%26aufirst%3DC.%26aulast%3DKallen%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DH.%26aulast%3DSchlaeppi%26aufirst%3DJ.-M.%26aulast%3DStark%26aufirst%3DW.%26atitle%3DEstrogen%2520receptor%2520modulators%253A%2520identification%2520and%2520structure-activity%2520relationships%2520of%2520potent%2520ER%25CE%25B1-selective%2520tetrahydroisoquinoline%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2945%26epage%3D2957%26doi%3D10.1021%2Fjm030086h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Renaud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floersheim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geiser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halleux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramage, P.</span><span> </span><span class="NLM_article-title">Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERα-Selective tetrahydroisoquinoline ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">364</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span><span class="refDoi"> DOI: 10.1021/jm040858p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040858p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=364-379&author=J.+Renaudauthor=S.+F.+Bischoffauthor=T.+Buhlauthor=P.+Floersheimauthor=B.+Fournierauthor=M.+Geiserauthor=C.+Halleuxauthor=J.+Kallenauthor=H.+Kellerauthor=P.+Ramage&title=Selective+estrogen+receptor+modulators+with+conformationally+restricted+side+chains.+Synthesis+and+structure-activity+relationship+of+ER%CE%B1-Selective+tetrahydroisoquinoline+ligands&doi=10.1021%2Fjm040858p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm040858p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040858p%26sid%3Dliteratum%253Aachs%26aulast%3DRenaud%26aufirst%3DJ.%26aulast%3DBischoff%26aufirst%3DS.%2BF.%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DFloersheim%26aufirst%3DP.%26aulast%3DFournier%26aufirst%3DB.%26aulast%3DGeiser%26aufirst%3DM.%26aulast%3DHalleux%26aufirst%3DC.%26aulast%3DKallen%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DH.%26aulast%3DRamage%26aufirst%3DP.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulators%2520with%2520conformationally%2520restricted%2520side%2520chains.%2520Synthesis%2520and%2520structure-activity%2520relationship%2520of%2520ER%25CE%25B1-Selective%2520tetrahydroisoquinoline%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D364%26epage%3D379%26doi%3D10.1021%2Fjm040858p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Govek, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasawa, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnefous, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darimont, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillot, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudente, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hager, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. D.</span><span> </span><span class="NLM_article-title">Optimization of an indazole series of selective estrogen receptor degraders: tumor regression in a tamoxifen-resistent breast cancer xenograft</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5163</span><span class="NLM_x">–</span> <span class="NLM_lpage">5167</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.bmcl.2015.09.074" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5163-5167&author=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=K.+L.+Douglasauthor=A.+G.+Laiauthor=M.+Kahramanauthor=C.+Bonnefousauthor=A.+M.+Aparicioauthor=B.+D.+Darimontauthor=K.+L.+Grillotauthor=J.+D.+Josephauthor=J.+A.+Kaufmanauthor=K.-J.+Leeauthor=N.+Luauthor=M.+J.+Moonauthor=R.+Y.+Prudenteauthor=J.+Sensintaffarauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Optimization+of+an+indazole+series+of+selective+estrogen+receptor+degraders%3A+tumor+regression+in+a+tamoxifen-resistent+breast+cancer+xenograft&doi=10.1016%2Fj.bmcl.2015.09.074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DAparicio%26aufirst%3DA.%2BM.%26aulast%3DDarimont%26aufirst%3DB.%2BD.%26aulast%3DGrillot%26aufirst%3DK.%2BL.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DKaufman%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DPrudente%26aufirst%3DR.%2BY.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DOptimization%2520of%2520an%2520indazole%2520series%2520of%2520selective%2520estrogen%2520receptor%2520degraders%253A%2520tumor%2520regression%2520in%2520a%2520tamoxifen-resistent%2520breast%2520cancer%2520xenograft%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5163%26epage%3D5167%26doi%3D10.1016%2Fj.bmcl.2015.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Savi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Almeida, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callis, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donald, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feron, L. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayter, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karoutchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, Z.</span><span> </span><span class="NLM_article-title">Optimization of a novel binding motif to (<i>E</i>)-3-(3,5-difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8128</span><span class="NLM_x">–</span> <span class="NLM_lpage">8140</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&author=C.+De+Saviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+L.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+novel+binding+motif+to+%28E%29-3-%283%2C5-difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C3%2C4%2C9-tetrahydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+acid+%28AZD9496%29%2C+a+potent+and+orally+bioavailable+selective+estrogen+receptor+downregulator+and+antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span></div><div class="casAuthors">De Savi, Chris; Bradbury, Robert H.; Rabow, Alfred A.; Norman, Richard A.; de Almeida, Camila; Andrews, David M.; Ballard, Peter; Buttar, David; Callis, Rowena J.; Currie, Gordon S.; Curwen, Jon O.; Davies, Chris D.; Donald, Craig S.; Feron, Lyman J. L.; Gingell, Helen; Glossop, Steven C.; Hayter, Barry R.; Hussain, Syeed; Karoutchi, Galith; Lamont, Scott G.; MacFaul, Philip; Moss, Thomas A.; Pearson, Stuart E.; Tonge, Michael; Walker, Graeme E.; Weir, Hazel M.; Wilson, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8128-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equiv. potency and preclin. pharmacol. to the i.m. SERD fulvestrant is described.  A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand.  Aided by crystal structures of novel ligands bound to an ER construct, medicinal chem. iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clin. candidate with high oral bioavailability across preclin. species that is currently being evaluated in phase I clin. trials for the treatment of advanced estrogen receptor (ER) pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP-ZYYxmMtg7Vg90H21EOLACvtfcHk0lj1xFib8vgNxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK&md5=df7eee70ca783a2933cd494b53f71488</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%2BL.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520novel%2520binding%2520motif%2520to%2520%2528E%2529-3-%25283%252C5-difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C3%252C4%252C9-tetrahydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520acid%2520%2528AZD9496%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520and%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasawa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnefous, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudente, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darimont, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillot, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hager, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. D.</span><span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4888</span><span class="NLM_x">–</span> <span class="NLM_lpage">4904</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&author=A.+Laiauthor=M.+Kahramanauthor=G.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.-J.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0lj1xFib8vgNxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DG.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Scott, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, R. D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degorce, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">Tetrahydroisoquinoline phenols: selective estrogen receptor downregulator antagonists with oral bioavailability in rat</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=94-99&author=J.+S.+Scottauthor=A.+Baileyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=P.+A.+MacFaulauthor=H.+Gingellauthor=T.+Mossauthor=R.+A.+Normanauthor=J.+H.+Pinkauthor=A.+A.+Rabowauthor=B.+Robertsauthor=P.+D.+Smith&title=Tetrahydroisoquinoline+phenols%3A+selective+estrogen+receptor+downregulator+antagonists+with+oral+bioavailability+in+rat&doi=10.1021%2Facsmedchemlett.5b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18dR"><div class="casContent"><span class="casTitleNuber">18d</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Davies, Robert D. M.; Degorce, Sebastien L.; MacFaul, Philip A.; Gingell, Helen; Moss, Thomas; Norman, Richard A.; Pink, Jennifer H.; Rabow, Alfred A.; Roberts, Bryan; Smith, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile.  Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compds. I [R = Ph, PhCH2, i-Bu, etc.] with subnanomolar levels of potency.  The phenol functionality was shown to be required to achieve highly potent compds., but unusually this was compatible with obtaining high oral bioavailabilities in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXOiEPK5ofVLVg90H21EOLACvtfcHk0li7ahTqqB5A-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK&md5=8c573b4e96e70cf61d40f349a7c19967</span></div><a href="/servlet/linkout?suffix=cit18d&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00413%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DTetrahydroisoquinoline%2520phenols%253A%2520selective%2520estrogen%2520receptor%2520downregulator%2520antagonists%2520with%2520oral%2520bioavailability%2520in%2520rat%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D94%26epage%3D99%26doi%3D10.1021%2Facsmedchemlett.5b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Wardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">–</span> <span class="NLM_lpage">724</span><span class="refDoi"> DOI: 10.1530/ERC-15-0287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1530%2FERC-15-0287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=26162914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=713-724&author=S.+E.+Wardellauthor=E.+R.+Nelsonauthor=C.+A.+Chaoauthor=H.+M.+Alleyauthor=D.+P.+McDonnell&title=Evaluation+of+the+pharmacological+activities+of+RAD1901%2C+a+selective+estrogen+receptor+degrader&doi=10.1530%2FERC-15-0287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18eR"><div class="casContent"><span class="casTitleNuber">18e</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader</span></div><div class="casAuthors">Wardell, Suzanne E.; Nelson, Erik R.; Chao, Christina A.; Alley, Holly M.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">713-724</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains a first-line treatment for estrogen receptor 1 (ESR1) pos. breast cancer.  However, tumor resistance limits the duration of response.  The clin. efficacy of fulvestrant, a selective ER degrader (SERD) that triggers receptor degrdn., has confirmed that ESR1 often remains engaged in endocrine therapy resistant cancers.  Recently developed, selective ER modulators (SERMs)/SERD hybrids (SSHs) that facilitate ESR1 degrdn. in breast cancer cells and reproductive tissues have been advanced as an alternative treatment for advanced breast cancer, particularly in the metastatic setting.  RAD1901 is one SSH currently being evaluated clin. that is unique among ESR1 modulators in that it readily enters the brain, a common site of breast cancer metastasis.  In this study, RAD1901 inhibited estrogen activation of ESR1 in vitro and in vivo, inhibited estrogen-dependent breast cancer cell proliferation and xenograft tumor growth, and mediated dose-dependent downregulation of ESR1 protein.  However, doses of RAD1901 insufficient to induce ESR1 degrdn. were shown to result in the activation of ESR1 target genes and in the stimulation of xenograft tumor growth.  RAD1901 is an SSH that exhibits complex pharmacol. in breast cancer models, having dose-dependent agonist/antagonist activity displayed in a tissue-selective manner.  It remains unclear how this unique pharmacol. will impact the utility of RAD1901 for breast cancer treatment.  However, being the only SERD currently known to access the brain, RAD1901 merits evaluation as a targeted therapy for the treatment of breast cancer brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZozvILn25g7Vg90H21EOLACvtfcHk0li7ahTqqB5A-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D&md5=0749b230c2a16355345c884438681d47</span></div><a href="/servlet/linkout?suffix=cit18e&amp;dbid=16384&amp;doi=10.1530%2FERC-15-0287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-15-0287%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNelson%26aufirst%3DE.%2BR.%26aulast%3DChao%26aufirst%3DC.%2BA.%26aulast%3DAlley%26aufirst%3DH.%2BM.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520pharmacological%2520activities%2520of%2520RAD1901%252C%2520a%2520selective%2520estrogen%2520receptor%2520degrader%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2015%26volume%3D22%26spage%3D713%26epage%3D724%26doi%3D10.1530%2FERC-15-0287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Wander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hausoul, P. J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliedregt, L. A. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Steen, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Koten, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein Gebbink, R. J. M. K.</span><span> </span><span class="NLM_article-title">Synthesis of polyaryl rigid-core carbosilane dendrimers for supported organic synthesis</span> <span class="citation_source-journal">Organometallics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4415</span><span class="refDoi"> DOI: 10.1021/om900265v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/om900265v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFCmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=4406-4415&author=M.+Wanderauthor=P.+J.+C.+Hausoulauthor=L.+A.+J.+M.+Sliedregtauthor=B.+J.+van+Steenauthor=G.+van+Kotenauthor=R.+J.+M.+K.+Klein+Gebbink&title=Synthesis+of+polyaryl+rigid-core+carbosilane+dendrimers+for+supported+organic+synthesis&doi=10.1021%2Fom900265v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Polyaryl Rigid-Core Carbosilane Dendrimers for Supported Organic Synthesis</span></div><div class="casAuthors">Wander, Maaike; Hausoul, Peter J. C.; Sliedregt, Leo A. J. M.; van Steen, Bart J.; van Koten, Gerard; Klein Gebbink, Robertus J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Organometallics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4415</span>CODEN:
                <span class="NLM_cas:coden">ORGND7</span>;
        ISSN:<span class="NLM_cas:issn">0276-7333</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carbosilane dendrimers can be used as sol. supports for org. synthesis, since their structure allows sepn. of excess reagents from the supported products, eventually yielding products of high purity and in high yield, as in solid-phase org. synthesis (SPOS).  In previous studies often loss of dendritic material during filtration was obsd., due to the rather flexible structure of the conventional dendrimers.  In order to improve the diafiltration retention of the carbosilane dendrimers, the synthesis of carbosilane dendrimers based on more rigid-core mols. was investigated.  Both 1,3,5-tris(4-bromophenyl)benzene 1 and tetrakis(4-bromophenyl)silane 2 were selected on the basis of their rigid structure and suitable functional groups for further functionalization using organolithium chem.  An optimized halogen lithium exchange (HLE) protocol was developed for the synthesis of 2 via 1-bromo-4-lithiobenzene.  This protocol involves reaction of an aryl bromide with n-BuLi at room temp., followed by partial removal of the solvent by evapn. (∼70%, vol./vol.), addn. of pentane to promote pptn. of the aryl lithium compd., and centrifugation and removal of the solvent to obtain, after repeating the last two steps once, the wet aryl lithium compd. in pure form.  This HLE protocol was proven to be effective for mono- and dilithiation, as well as for polylithiation reactions of aryl bromides.  Furthermore, the rigid tris(4-bromophenyl)chlorosilane wedge 3 was synthesized to add a rigid generation to the prepd. core mols., and bromotriallylsilane 4 was synthesized for the introduction of triallylsilyl moieties on the periphery of the core mols.  With these four building blocks several rigid-core carbosilane dendrimers were synthesized, which can be applied as better retainable sol. supports for org. synthesis in a diafiltration setup.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ABOwsTdgL7Vg90H21EOLACvtfcHk0li7ahTqqB5A-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFCmu7c%253D&md5=d1f0861282cb40a1a2e3f55fcfa9f358</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fom900265v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fom900265v%26sid%3Dliteratum%253Aachs%26aulast%3DWander%26aufirst%3DM.%26aulast%3DHausoul%26aufirst%3DP.%2BJ.%2BC.%26aulast%3DSliedregt%26aufirst%3DL.%2BA.%2BJ.%2BM.%26aulast%3Dvan%2BSteen%26aufirst%3DB.%2BJ.%26aulast%3Dvan%2BKoten%26aufirst%3DG.%26aulast%3DKlein%2BGebbink%26aufirst%3DR.%2BJ.%2BM.%2BK.%26atitle%3DSynthesis%2520of%2520polyaryl%2520rigid-core%2520carbosilane%2520dendrimers%2520for%2520supported%2520organic%2520synthesis%26jtitle%3DOrganometallics%26date%3D2009%26volume%3D28%26spage%3D4406%26epage%3D4415%26doi%3D10.1021%2Fom900265v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wittenberger, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donner, B. G.</span><span> </span><span class="NLM_article-title">Dialkyltin oxide mediated addition of trimethylsilyl azide to nitriles. A novel preparation of 5-substituted tetrazols</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4139</span><span class="NLM_x">–</span> <span class="NLM_lpage">4141</span><span class="refDoi"> DOI: 10.1021/jo00067a058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00067a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK3sXkvFGnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1993&pages=4139-4141&author=S.+J.+Wittenbergerauthor=B.+G.+Donner&title=Dialkyltin+oxide+mediated+addition+of+trimethylsilyl+azide+to+nitriles.+A+novel+preparation+of+5-substituted+tetrazols&doi=10.1021%2Fjo00067a058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dialkyltin oxide mediated addition of trimethylsilyl azide to nitriles.  A novel preparation of 5-substituted tetrazols</span></div><div class="casAuthors">Wittenberger, Steven J.; Donner, B. Gregory</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4139-41</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">A new method for the conversion of nitriles into 5-substituted tetrazoles is presented.  Aryl and aliph. nitriles, R2CN (R2 = Ph, 2-, 3-BrC6H4, Bu, 4'methyl-1,1'-biphenyl-2-yl, etc.), were treated with trimethylsilyl azide in the presence of catalytic dialkyltin oxide, R12SnO (R1 = Me, n-Bu) in toluene at 93-110° to produce the tetrazoles I.  A tetracoordinate dialkyl(O-trimethylsilyl) azidostannylhydrin, Me3SiOSn(N3)R12, was implicated as the reactive intermediate.  The 5-substituted tetrazoles were isolated in good to excellent yield.  The procedure is esp. useful for the prepn. of 5-[4'-methyl-1,1'-biphenyl-2-yl]-1H-tetrazole, a subunit that has become ubiquitous in the most potent and bioavailable angiotensin II antagonists disclosed to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphNY7eA5hllLVg90H21EOLACvtfcHk0ljBmcSCEizzEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkvFGnsb8%253D&md5=1ca082880c6a390baae06845f6312431</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjo00067a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00067a058%26sid%3Dliteratum%253Aachs%26aulast%3DWittenberger%26aufirst%3DS.%2BJ.%26aulast%3DDonner%26aufirst%3DB.%2BG.%26atitle%3DDialkyltin%2520oxide%2520mediated%2520addition%2520of%2520trimethylsilyl%2520azide%2520to%2520nitriles.%2520A%2520novel%2520preparation%2520of%25205-substituted%2520tetrazols%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1993%26volume%3D58%26spage%3D4139%26epage%3D4141%26doi%3D10.1021%2Fjo00067a058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Milinkevich, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparks, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorsbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurth, M. J.</span><span> </span><span class="NLM_article-title">Synthesis and biological activity of 2-(4,5-dihydroisoxazol-5-yl)-1,3,4-oxadiazoles</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5796</span><span class="NLM_x">–</span> <span class="NLM_lpage">5798</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.07.139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.bmcl.2009.07.139" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5796-5798&author=K.+A.+Milinkevichauthor=C.+L.+Yooauthor=T.+C.+Sparksauthor=B.+A.+Lorsbachauthor=M.+J.+Kurth&title=Synthesis+and+biological+activity+of+2-%284%2C5-dihydroisoxazol-5-yl%29-1%2C3%2C4-oxadiazoles&doi=10.1016%2Fj.bmcl.2009.07.139"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.139%26sid%3Dliteratum%253Aachs%26aulast%3DMilinkevich%26aufirst%3DK.%2BA.%26aulast%3DYoo%26aufirst%3DC.%2BL.%26aulast%3DSparks%26aufirst%3DT.%2BC.%26aulast%3DLorsbach%26aufirst%3DB.%2BA.%26aulast%3DKurth%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%25202-%25284%252C5-dihydroisoxazol-5-yl%2529-1%252C3%252C4-oxadiazoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5796%26epage%3D5798%26doi%3D10.1016%2Fj.bmcl.2009.07.139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Brzozowski, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauter, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engström, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Öhman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafsson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlquist, M.</span><span> </span><span class="NLM_article-title">Molecular basis of agonism and antagonism in the oestrogen receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">389</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">758</span><span class="refDoi"> DOI: 10.1038/39645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1038%2F39645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=9338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=753-758&author=A.+M.+Brzozowskiauthor=A.+C.+Pikeauthor=Z.+Dauterauthor=R.+E.+Hubbardauthor=T.+Bonnauthor=O.+Engstr%C3%B6mauthor=L.+%C3%96hmanauthor=G.+L.+Greeneauthor=J.+A.+Gustafssonauthor=M.+Carlquist&title=Molecular+basis+of+agonism+and+antagonism+in+the+oestrogen+receptor&doi=10.1038%2F39645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of agonism and antagonism in the estrogen receptor</span></div><div class="casAuthors">Brzozowski, Andrzej M.; Pike, Ashley C. W.; Dauter, Zbigniew; Hubbard, Roderick E.; Bonn, Tomas; Engstrom, Owe; Ohman, Lars; Greene, Geoffrey L.; Gustafsson, Jan-Ake; Carlquist, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6652</span>),
    <span class="NLM_cas:pages">753-758</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Estrogens are involved in the growth, development and homeostasis of a no. of tissues.  The physiol. effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the estrogen receptor (ER).  Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of mol. events culminating in the activation or repression of target genes.  Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery.  Here we report the crystal structures of the LBD of ER in complex with the endogenous estrogen, 17β-estradiol, and the selective antagonist raloxifene, at resolns. of 3.1 and 2.6Å, resp.  The structures provide a mol. basis for the distinctive pharmacophore of the ER and its catholic binding properties.  Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes.  In addn., each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAXbSo66V1LrVg90H21EOLACvtfcHk0ljBmcSCEizzEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D&md5=2a63951b881b329ff142c9fbc82a13e3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2F39645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F39645%26sid%3Dliteratum%253Aachs%26aulast%3DBrzozowski%26aufirst%3DA.%2BM.%26aulast%3DPike%26aufirst%3DA.%2BC.%26aulast%3DDauter%26aufirst%3DZ.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DBonn%26aufirst%3DT.%26aulast%3DEngstr%25C3%25B6m%26aufirst%3DO.%26aulast%3D%25C3%2596hman%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DGustafsson%26aufirst%3DJ.%2BA.%26aulast%3DCarlquist%26aufirst%3DM.%26atitle%3DMolecular%2520basis%2520of%2520agonism%2520and%2520antagonism%2520in%2520the%2520oestrogen%2520receptor%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D753%26epage%3D758%26doi%3D10.1038%2F39645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Shiau, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barstad, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loria, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agard, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span> </span><span class="NLM_article-title">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">927</span><span class="NLM_x">–</span> <span class="NLM_lpage">937</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81717-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2FS0092-8674%2800%2981717-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=9875847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=927-937&author=A.+K.+Shiauauthor=D.+Barstadauthor=P.+M.+Loriaauthor=L.+Chengauthor=P.+J.+Kushnerauthor=D.+A.+Agardauthor=G.+L.+Greene&title=The+structural+basis+of+estrogen+receptor%2Fcoactivator+recognition+and+the+antagonism+of+this+interaction+by+tamoxifen&doi=10.1016%2FS0092-8674%2800%2981717-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</span></div><div class="casAuthors">Shiau, Andrew K.; Barstad, Danielle; Loria, Paula M.; Cheng, Lin; Kushner, Peter J.; Agard, David A.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">927-937</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by interactions with coactivators.  Receptor agonists promote coactivator binding, and antagonists block coactivator binding.  Here we report the crystal structure of the human estrogen receptor α (hERα) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hERα LBD bound to the selective antagonist 4-hydroxytamoxifen (OHT).  In the DES-LBD-peptide complex, the peptide binds as a short α helix to a hydrophobic groove on the surface of the LBD.  In the OHT-LBD complex, helix 12 occludes the coactivator recognition groove by mimicking the interactions of the NR box peptide with the LBD.  These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrjqf40oHhE7Vg90H21EOLACvtfcHk0ljBmcSCEizzEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D&md5=074d616cf353f0d98cea5b26c4595c10</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981717-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981717-1%26sid%3Dliteratum%253Aachs%26aulast%3DShiau%26aufirst%3DA.%2BK.%26aulast%3DBarstad%26aufirst%3DD.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DThe%2520structural%2520basis%2520of%2520estrogen%2520receptor%252Fcoactivator%2520recognition%2520and%2520the%2520antagonism%2520of%2520this%2520interaction%2520by%2520tamoxifen%26jtitle%3DCell%26date%3D1998%26volume%3D95%26spage%3D927%26epage%3D937%26doi%3D10.1016%2FS0092-8674%2800%2981717-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span>Department of Health and Human Services, Food and Drug Administration: FDA’s Policy Statement for the Development of New Stereoisomeric Drugs, Washington, DC,<span class="NLM_x"> </span><span class="NLM_year">1992</span>. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122883.htm" class="extLink">http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122883.htm</a> (accessed September 30, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Department+of+Health+and+Human+Services%2C+Food+and+Drug+Administration%3A+FDA%E2%80%99s+Policy+Statement+for+the+Development+of+New+Stereoisomeric+Drugs%2C+Washington%2C+DC%2C+1992.+http%3A%2F%2Fwww.fda.gov%2FDrugs%2FGuidanceComplianceRegulatoryInformation%2FGuidances%2Fucm122883.htm+%28accessed+September+30%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span>Configuration of enantiomers was randomly assigned.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Configuration+of+enantiomers+was+randomly+assigned."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J.</span><span> </span><span class="NLM_article-title">Nucleophilic difluoromethylation of C═N bonds in heterocycles with difluoromethyl silane reagents</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">5137</span><span class="NLM_x">–</span> <span class="NLM_lpage">5144</span><span class="refDoi"> DOI: 10.1016/j.tet.2012.04.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.tet.2012.04.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=5137-5144&author=W.+Huangauthor=C.+Niauthor=Y.+Zhaoauthor=W.+Zhangauthor=A.+D.+Dilmanauthor=J.+Hu&title=Nucleophilic+difluoromethylation+of+C%E2%95%90N+bonds+in+heterocycles+with+difluoromethyl+silane+reagents&doi=10.1016%2Fj.tet.2012.04.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2012.04.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2012.04.039%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DNi%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDilman%26aufirst%3DA.%2BD.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DNucleophilic%2520difluoromethylation%2520of%2520C%25E2%2595%2590N%2520bonds%2520in%2520heterocycles%2520with%2520difluoromethyl%2520silane%2520reagents%26jtitle%3DTetrahedron%26date%3D2012%26volume%3D68%26spage%3D5137%26epage%3D5144%26doi%3D10.1016%2Fj.tet.2012.04.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Fujikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amii, H.</span><span> </span><span class="NLM_article-title">A new method for aromatic difluoromethylation: copper-catalyzed cross-coupling and decarboxylation sequence from aryl iodides</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">5560</span><span class="NLM_x">–</span> <span class="NLM_lpage">5563</span><span class="refDoi"> DOI: 10.1021/ol202289z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol202289z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ClsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=5560-5563&author=K.+Fujikawaauthor=Y.+Fujiokaauthor=A.+Kobayashiauthor=H.+Amii&title=A+new+method+for+aromatic+difluoromethylation%3A+copper-catalyzed+cross-coupling+and+decarboxylation+sequence+from+aryl+iodides&doi=10.1021%2Fol202289z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A new method for aromatic difluoromethylation: copper-catalyzed cross-coupling and decarboxylation sequence from aryl iodides</span></div><div class="casAuthors">Fujikawa, Kenichi; Fujioka, Yasutaka; Kobayashi, Akira; Amii, Hideki</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5560-5563</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new methodol. for arom. difluoromethylation is described.  Aryl iodides reacted with α-silyldifluoroacetates upon treatment with copper catalyst in DMSO or DME to give the corresponding aryldifluoroacetates in moderate to good yields.  The subsequent hydrolysis of aryldifluoroacetates and KF-promoted decarboxylation afforded a variety of difluoromethyl aroms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGUe51qOd-PrVg90H21EOLACvtfcHk0liAaYTZXSiB4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ClsLjP&md5=c9f174dfbb2fc3a39e18968e5b2d678a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fol202289z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol202289z%26sid%3Dliteratum%253Aachs%26aulast%3DFujikawa%26aufirst%3DK.%26aulast%3DFujioka%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DA.%26aulast%3DAmii%26aufirst%3DH.%26atitle%3DA%2520new%2520method%2520for%2520aromatic%2520difluoromethylation%253A%2520copper-catalyzed%2520cross-coupling%2520and%2520decarboxylation%2520sequence%2520from%2520aryl%2520iodides%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D5560%26epage%3D5563%26doi%3D10.1021%2Fol202289z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Connor, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadwater, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewhirst, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2917</span><span class="NLM_x">–</span> <span class="NLM_lpage">2922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=11306468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2917-2922&author=C.+E.+Connorauthor=J.+D.+Norrisauthor=G.+Broadwaterauthor=T.+M.+Willsonauthor=M.+M.+Gottardisauthor=M.+W.+Dewhirstauthor=D.+P.+McDonnell&title=Circumventing+tamoxifen+resistance+in+breast+cancers+using+antiestrogens+that+induce+unique+conformational+changes+in+the+estrogen+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span></div><div class="casAuthors">Connor, Caroline E.; Norris, John D.; Broadwater, Gloria; Willson, Timothy M.; Gottardis, Marco M.; Dewhirst, Mark W.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2917-2922</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tamoxifen inhibits estrogen receptor (ER) transcriptional activity by competitively inhibiting estradiol binding and inducing conformational changes in the receptor that may prevent its interaction with coactivators.  In bone, the cardiovascular system, and some breast tumors, however, tamoxifen exhibits agonist activity, suggesting that the tamoxifen-ER complex is not recognized identically in all cells.  We used phage display to demonstrate that the antiestrogen GW5638 induces a unique structural change in the ER.  The biol. significance of this conformational change was revealed in studies that demonstrated that tamoxifen-resistant breast tumor explants are not cross-resistant to GW5638.  Because of these properties, this drug is currently being developed as a potential therapeutic for tamoxifen-resistant breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2YSN94iysMbVg90H21EOLACvtfcHk0liAaYTZXSiB4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D&md5=d7ecae7d445901e2f2c4f133ebbacdc5</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DC.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DBroadwater%26aufirst%3DG.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DCircumventing%2520tamoxifen%2520resistance%2520in%2520breast%2520cancers%2520using%2520antiestrogens%2520that%2520induce%2520unique%2520conformational%2520changes%2520in%2520the%2520estrogen%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2917%26epage%3D2922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiRenzo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span> </span><span class="NLM_article-title">Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">843</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)00188-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2FS0092-8674%2800%2900188-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=11136970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFCjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=843-852&author=Y.+Shangauthor=X.+Huauthor=J.+DiRenzoauthor=M.+A.+Lazarauthor=M.+Brown&title=Cofactor+dynamics+and+sufficiency+in+estrogen+receptor-regulated+transcription&doi=10.1016%2FS0092-8674%2800%2900188-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription</span></div><div class="casAuthors">Shang, Yongfeng; Hu, Xiao; DiRenzo, James; Lazar, Mitchell A.; Brown, Myles</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">843-852</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Many cofactors bind the hormone-activated estrogen receptor (ER), yet the specific regulators of endogenous ER-mediated gene transcription are unknown.  Using chromatin immunopptn. (ChIP), we find that ER and a no. of coactivators rapidly assoc. with estrogen responsive promoters following estrogen treatment in a cyclic fashion that is not predicted by current models of hormone activation.  Cycles of ER complex assembly are followed by transcription.  In contrast, the anti-estrogen tamoxifen (TAM) recruits corepressors but not coactivators.  Using a genetic approach, we show that recruitment of the p160 class of coactivators is sufficient for gene activation and for the growth stimulatory actions of estrogen in breast cancer supporting a model in which ER cofactors play unique roles in estrogen signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6m5Mq-rPwB7Vg90H21EOLACvtfcHk0lh5zbhxY1rk0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFCjt7s%253D&md5=6f5af3762620dfd880758ba9fafcba25</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900188-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900188-4%26sid%3Dliteratum%253Aachs%26aulast%3DShang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDiRenzo%26aufirst%3DJ.%26aulast%3DLazar%26aufirst%3DM.%2BA.%26aulast%3DBrown%26aufirst%3DM.%26atitle%3DCofactor%2520dynamics%2520and%2520sufficiency%2520in%2520estrogen%2520receptor-regulated%2520transcription%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D843%26epage%3D852%26doi%3D10.1016%2FS0092-8674%2800%2900188-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Wardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">122</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span><span class="refDoi"> DOI: 10.1016/j.bcp.2011.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.bcp.2011.03.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=122-130&author=S.+E.+Wardellauthor=J.+R.+Marksauthor=D.+P.+McDonnell&title=The+turnover+of+estrogen+receptor+%CE%B1+by+the+selective+estrogen+receptor+degrader+%28SERD%29+fulvestrant+is+a+saturable+process+that+is+not+required+for+antagonist+efficacy&doi=10.1016%2Fj.bcp.2011.03.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DMarks%26aufirst%3DJ.%2BR.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DThe%2520turnover%2520of%2520estrogen%2520receptor%2520%25CE%25B1%2520by%2520the%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520fulvestrant%2520is%2520a%2520saturable%2520process%2520that%2520is%2520not%2520required%2520for%2520antagonist%2520efficacy%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D122%26epage%3D130%26doi%3D10.1016%2Fj.bcp.2011.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Johnston, S. R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowsett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benz, C. C.</span><span> </span><span class="NLM_article-title">Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3723</span><span class="NLM_x">–</span> <span class="NLM_lpage">3727</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3723-3727&author=S.+R.+D.+Johnstonauthor=B.+Luauthor=M.+Dowsettauthor=X.+Liangauthor=M.+Kaufmannauthor=G.+K.+Scottauthor=C.+K.+Osborneauthor=C.+C.+Benz&title=Comparison+of+estrogen+receptor+DNA+binding+in+untreated+and+acquired+antiestrogen-resistant+human+breast+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DKaufmann%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DG.%2BK.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DBenz%26aufirst%3DC.%2BC.%26atitle%3DComparison%2520of%2520estrogen%2520receptor%2520DNA%2520binding%2520in%2520untreated%2520and%2520acquired%2520antiestrogen-resistant%2520human%2520breast%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3723%26epage%3D3727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Campbell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat-Nakshatri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinidou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakshatri, H.</span><span> </span><span class="NLM_article-title">Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">9817</span><span class="NLM_x">–</span> <span class="NLM_lpage">9824</span><span class="refDoi"> DOI: 10.1074/jbc.M010840200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1074%2Fjbc.M010840200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=9817-9824&author=R.+A.+Campbellauthor=P.+Bhat-Nakshatriauthor=N.+M.+Patelauthor=D.+Constantinidouauthor=S.+Aliauthor=H.+Nakshatri&title=Phosphatidylinositol+3-kinase%2FAKT-mediated+activation+of+estrogen+receptor+%CE%B1&doi=10.1074%2Fjbc.M010840200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010840200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010840200%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DR.%2BA.%26aulast%3DBhat-Nakshatri%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DN.%2BM.%26aulast%3DConstantinidou%26aufirst%3DD.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DNakshatri%26aufirst%3DH.%26atitle%3DPhosphatidylinositol%25203-kinase%252FAKT-mediated%2520activation%2520of%2520estrogen%2520receptor%2520%25CE%25B1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D9817%26epage%3D9824%26doi%3D10.1074%2Fjbc.M010840200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Regan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cisneros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacGregor, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muenzner, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assikis, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilimoria, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piette, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragan, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitot, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">1552</span><span class="NLM_x">–</span> <span class="NLM_lpage">1558</span><span class="refDoi"> DOI: 10.1093/jnci/90.20.1552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1093%2Fjnci%2F90.20.1552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=9790548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK1cXntVKru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1998&pages=1552-1558&author=R.+M.+O%E2%80%99Reganauthor=A.+Cisnerosauthor=G.+M.+Englandauthor=J.+I.+MacGregorauthor=H.+D.+Muenznerauthor=V.+J.+Assikisauthor=M.+M.+Bilimoriaauthor=M.+Pietteauthor=Y.+P.+Draganauthor=H.+C.+Pitotauthor=R.+Chattertonauthor=V.+C.+Jordan&title=Effects+of+the+antiestrogens+tamoxifen%2C+toremifene%2C+and+ICI+182%2C780+on+endometrial+cancer+growth&doi=10.1093%2Fjnci%2F90.20.1552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth</span></div><div class="casAuthors">O'Regan, Ruth M.; Cisneros, Angela; England, Gale M.; MacGregor, Jennifer I.; Muenzner, Henry D.; Assikis, Vasikios J.; Bilimoria, Malcolm M.; Piette, Michael; Dragan, Yvonne P.; Pitot, Henry C.; Chatterton, Robert; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Tamoxifen has been shown to promote the growth of human endometrial tumors implanted in athymic mice, and it has been assocd. with a twofold to threefold increase in endometrial cancer.  Toremifene, a chlorinated deriv. of tamoxifen, and ICI 182,780, a pure antiestrogen, are two new antiestrogens being developed for the treatment of breast cancer.  The effects of these drugs on endometrial cancer are currently unknown.  Our objective was to evaluate the effects of toremifene and ICI 182,780 on the growth of human endometrial cancer in athymic mice.  The effects of tamoxifen and toremifene on the growth of either tamoxifen-stimulated or tamoxifen-naive endometrial tumors in athymic mice were not substantially different.  ICI 182,780 inhibited the growth of tamoxifen-stimulated endometrial cancer, in both the presence and the absence of estrogen.  Conclusions: Toremifene and tamoxifen produce identical effects in our endometrial cancer models.  Therefore, it is possible that toremifene, like tamoxifen, may be assocd. with an increased incidence of endometrial cancer.  In contrast, ICI 182,780 inhibited tamoxifen-stimulated endometrial cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF1twx_YIjK7Vg90H21EOLACvtfcHk0lhd6kSQ5l4gtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntVKru7c%253D&md5=a9f77649d62eee3db3ae1480ba6980d4</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F90.20.1552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F90.20.1552%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DR.%2BM.%26aulast%3DCisneros%26aufirst%3DA.%26aulast%3DEngland%26aufirst%3DG.%2BM.%26aulast%3DMacGregor%26aufirst%3DJ.%2BI.%26aulast%3DMuenzner%26aufirst%3DH.%2BD.%26aulast%3DAssikis%26aufirst%3DV.%2BJ.%26aulast%3DBilimoria%26aufirst%3DM.%2BM.%26aulast%3DPiette%26aufirst%3DM.%26aulast%3DDragan%26aufirst%3DY.%2BP.%26aulast%3DPitot%26aufirst%3DH.%2BC.%26aulast%3DChatterton%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DEffects%2520of%2520the%2520antiestrogens%2520tamoxifen%252C%2520toremifene%252C%2520and%2520ICI%2520182%252C780%2520on%2520endometrial%2520cancer%2520growth%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1998%26volume%3D90%26spage%3D1552%26epage%3D1558%26doi%3D10.1093%2Fjnci%2F90.20.1552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowler, J.</span><span> </span><span class="NLM_article-title">A potent specific pure antiestrogen with clinical potential</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3867</span><span class="NLM_x">–</span> <span class="NLM_lpage">3873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1855205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=3867-3873&author=A.+E.+Wakelingauthor=M.+Dukesauthor=J.+Bowler&title=A+potent+specific+pure+antiestrogen+with+clinical+potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">A potent specific pure antiestrogen with clinical potential</span></div><div class="casAuthors">Wakeling, Alan E.; Dukes, Michael; Bowler, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3867-73</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Previous studies from this lab. have described a series of 7α-alkylamide analogs of estradiol with pure antiestrogenic activity, exemplified by ICI 164,384.  A new compd., 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol (ICI 182,780) has now been identified which has significantly increased antiestrogenic potency and retains pure estrogen antagonist activity.  The antiuterotropic potency of ICI 182,780 in the immature rat was more than 10-fold greater than that of ICI 164,384 (50% EDs of 0.06 and 0.9 mg/kg, resp.).  This order of magnitude increase of in vivo potency was also reflected, in part, by intrinsic activity at the estrogen receptor.  The relative binding affinities of ICI 182,780 and ICI 164,384 were 0.89 and 0.19, resp., compared with that of estradiol (1.0).  Similarly, the in vitro growth-inhibitory potency of ICI 182,780 exceeded that of ICI 164,384 in MCF-7 human breast cancer cells, where 50% inhibitory concns. of 0.29 and 1.3 nM, resp., were recorded.  ICI 182,780 was a more effective inhibitor of MCF-7 growth than 4'-hydroxytamoxifen, producing an 80% redn. of cell no. under conditions where 4'-hydroxytamoxifen achieved a max. of 50% inhibition.  This increased efficacy was reflected by a greater redn. of the proportion of cells engaged in DNA synthesis in ICI 182,780-treated cell cultures compared with tamoxifen-treated cells.  Sustained antiestrogenic effects, following a single parental dose of ICI 182,780 in oil suspension, were apparent in both rats and pigtail monkeys.  In vivo, antitumor activity of ICI 182,780 was demonstrated with xenografts of MCF-7 and Br10 human breast cancers in nude mice.  A single injection of ICI 182,780 provided antitumor efficacy equiv. to that of daily tamoxifen treatment for at least 4 wk.  The properties of ICI 182,780 identify this pure antiestrogen as a prime candidate with which to evaluate the potential therapeutic benefits of complete estrogen withdrawal in endocrine-responsive human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsBbUoU0rp-LVg90H21EOLACvtfcHk0lhd6kSQ5l4gtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D&md5=f73c3ea7810ce4780789bc69096f43ea</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DA%2520potent%2520specific%2520pure%2520antiestrogen%2520with%2520clinical%2520potential%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26spage%3D3867%26epage%3D3873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b'],'ref6':['cit6a','cit6b'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b','cit18c','cit18d','cit18e'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28a','cit28b'],'ref29':['cit29'],'ref30':['cit30a','cit30b'],'ref31':['cit31a','cit31b']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 21 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yunlong Lu, <span class="NLM_string-name hlFld-ContribAuthor">Wukun Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15094-15114. <a href="https://doi.org/10.1021/acs.jmedchem.0c00913" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00913</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00913%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%25253A%252BA%252BPromising%252BStrategy%252Bfor%252BEstrogen%252BReceptor%252BPositive%252BEndocrine-Resistant%252BBreast%252BCancer%26aulast%3DLu%26aufirst%3DYunlong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29052020%26date%3D02112020%26volume%3D63%26issue%3D24%26spage%3D15094%26epage%3D15114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13291-13315. <a href="https://doi.org/10.1021/acs.jmedchem.0c00829" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00829</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00829%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOpportunities%252Bfor%252BTapping%252Binto%252BThree-Dimensional%252BChemical%252BSpace%252Bthrough%252Ba%252BQuaternary%252BCarbon%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15052020%26date%3D31082020%26date%3D17082020%26volume%3D63%26issue%3D22%26spage%3D13291%26epage%3D13315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Emily J. Hanan, Jun Liang, Xiaojing Wang, Robert A. Blake, Nicole Blaquiere, <span class="NLM_string-name hlFld-ContribAuthor">Steven T. Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Monomeric Targeted Protein Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11330-11361. <a href="https://doi.org/10.1021/acs.jmedchem.0c00093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMonomeric%252BTargeted%252BProtein%252BDegraders%26aulast%3DHanan%26aufirst%3DEmily%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17012020%26date%3D15062020%26date%3D30042020%26volume%3D63%26issue%3D20%26spage%3D11330%26epage%3D11361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jun Liang, Robert Blake, Jae Chang, Lori S. Friedman, Simon Goodacre, Steven Hartman, Ellen Rei Ingalla, James R. Kiefer, Tracy Kleinheinz, Sharada Labadie, Jun Li, Kwong Wah Lai, Jiangpeng Liao, Vidhi Mody, Neville McLean, Ciara Metcalfe, Michelle Nannini, Daniel Otwine, Yingqing Ran, Nick Ray, Fabien Roussel, Amy Sambrone, Deepak Sampath, Maia Vinogradova, John Wai, Tao Wang, Kuen Yeap, Amy Young, Jason Zbieg, Birong Zhang, Xiaoping Zheng, Yu Zhong, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojing Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1342-1347. <a href="https://doi.org/10.1021/acsmedchemlett.0c00224" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00224%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BGNE-149%252Bas%252Ba%252BFull%252BAntagonist%252Band%252BEfficient%252BDegrader%252Bof%252BEstrogen%252BReceptor%252Balpha%252Bfor%252BER%25252B%252BBreast%252BCancer%26aulast%3DLiang%26aufirst%3DJun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28042020%26date%3D26052020%26date%3D29052020%26date%3D26052020%26volume%3D11%26issue%3D6%26spage%3D1342%26epage%3D1347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Jason Breed, Rodrigo J. Carbajo, Paul R. Davey, Ryan Greenwood, Hoan K. Huynh, Teresa Klinowska, Christopher J. Morrow, Thomas A. Moss, Radoslaw Polanski, J. Willem M. Nissink, Jeffrey Varnes, <span class="NLM_string-name hlFld-ContribAuthor">Bin Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     , 1492-1497. <a href="https://doi.org/10.1021/acsmedchemlett.9b00370" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00370%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBuilding%252BBridges%252Bin%252Ba%252BSeries%252Bof%252BEstrogen%252BReceptor%252BDegraders%25253A%252BAn%252BApplication%252Bof%252BMetathesis%252Bin%252BMedicinal%252BChemistry%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08082019%26date%3D23092019%26date%3D25092019%26date%3D23092019%26volume%3D10%26issue%3D10%26spage%3D1492%26epage%3D1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Andrew Bailey, David Buttar, Rodrigo J. Carbajo, Jon Curwen, Paul R. J. Davey, Robert D. M. Davies, Sébastien L. Degorce, Craig Donald, Eric Gangl, Ryan Greenwood, Sam D. Groombridge, Tony Johnson, Scott Lamont, Mandy Lawson, Andrew Lister, Christopher J. Morrow, Thomas A. Moss, Jennifer H. Pink, <span class="NLM_string-name hlFld-ContribAuthor">Radoslaw Polanski</span>. </span><span class="cited-content_cbyCitation_article-title">Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (3)
                                     , 1593-1608. <a href="https://doi.org/10.1021/acs.jmedchem.8b01837" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01837%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTricyclic%252BIndazoles%2525E2%252580%252594A%252BNovel%252BClass%252Bof%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252BAntagonists%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D23112018%26date%3D30012019%26date%3D14012019%26volume%3D62%26issue%3D3%26spage%3D1593%26epage%3D1608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">George S. Tria, Tinya Abrams, Jason Baird, Heather E. Burks, Brant Firestone, L. Alex Gaither, Lawrence G. Hamann, Guo He, Christina A. Kirby, Sunkyu Kim, Franco Lombardo, Kaitlin J. Macchi, Donald P. McDonnell, Yuji Mishina, John D. Norris, Jill Nunez, Clayton Springer, Yingchuan Sun, Noel M. Thomsen, Chunrong Wang, Jianling Wang, Bing Yu, Choi-Lai Tiong-Yip, <span class="NLM_string-name hlFld-ContribAuthor">Stefan Peukert</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 2837-2864. <a href="https://doi.org/10.1021/acs.jmedchem.7b01682" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01682</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01682%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BLSZ102%25252C%252Ba%252BPotent%25252C%252BOrally%252BBioavailable%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252B%252528SERD%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BEstrogen%252BReceptor%252BPositive%252BBreast%252BCancer%26aulast%3DTria%26aufirst%3DGeorge%2BS.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D14112017%26date%3D22032018%26volume%3D61%26issue%3D7%26spage%3D2837%26epage%3D2864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vankudoth  Jayaram</span>, <span class="hlFld-ContribAuthor ">Tailor  Sridhar</span>, <span class="hlFld-ContribAuthor ">Gangavaram V. M.  Sharma</span>, <span class="hlFld-ContribAuthor ">Fabienne  Berrée</span>, and <span class="hlFld-ContribAuthor ">Bertrand  Carboni</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Polysubstituted Isoquinolines and Related Fused Pyridines from Alkenyl Boronic Esters via a Copper-Catalyzed Azidation/Aza-Wittig Condensation Sequence. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (2)
                                     , 843-853. <a href="https://doi.org/10.1021/acs.joc.7b02831" title="DOI URL">https://doi.org/10.1021/acs.joc.7b02831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b02831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b02831%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BPolysubstituted%252BIsoquinolines%252Band%252BRelated%252BFused%252BPyridines%252Bfrom%252BAlkenyl%252BBoronic%252BEsters%252Bvia%252Ba%252BCopper-Catalyzed%252BAzidation%25252FAza-Wittig%252BCondensation%252BSequence%26aulast%3DJayaram%26aufirst%3DVankudoth%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D08112017%26date%3D05012018%26date%3D19012018%26date%3D18122017%26volume%3D83%26issue%3D2%26spage%3D843%26epage%3D853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Faheem</span>, <span class="hlFld-ContribAuthor ">Banoth  Karan Kumar</span>, <span class="hlFld-ContribAuthor ">Kondapalli  Venkata Gowri Chandra Sekhar</span>, <span class="hlFld-ContribAuthor ">Subhash  Chander</span>, <span class="hlFld-ContribAuthor ">Selvaraj  Kunjiappan</span>, <span class="hlFld-ContribAuthor ">Sankaranarayanan  Murugesan</span>. </span><span class="cited-content_cbyCitation_article-title">1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>5 </em>, 1-30. <a href="https://doi.org/10.1080/17460441.2021.1916464" title="DOI URL">https://doi.org/10.1080/17460441.2021.1916464</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1916464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1916464%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3D1%25252C2%25252C3%25252C4-Tetrahydroisoquinoline%252B%252528THIQ%252529%252Bas%252Bprivileged%252Bscaffold%252Bfor%252Banticancer%252Bde%252Bnovo%252Bdrug%252Bdesign%26aulast%3DFaheem%26date%3D2021%26date%3D2021%26volume%3D5%26spage%3D1%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carlo I.  Rosales</span>, <span class="hlFld-ContribAuthor ">Lauren M.  Gutgesell</span>, <span class="hlFld-ContribAuthor ">Kiira M.  Ratia</span>, <span class="hlFld-ContribAuthor ">Gregory R.J.  Thatcher</span>. </span><span class="cited-content_cbyCitation_article-title">Estrogen Receptor Modulators. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-74. <a href="https://doi.org/10.1002/0471266949.bmc054.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc054.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc054.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc054.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DEstrogen%252BReceptor%252BModulators%26aulast%3DRosales%26aufirst%3DCarlo%2BI.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D74%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kyu  Terashima</span>, <span class="hlFld-ContribAuthor ">Tomoko  Kawasaki-Takasuka</span>, <span class="hlFld-ContribAuthor ">Takashi  Yamazaki</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of fully substituted carbon centers containing a heteroatom and a CF
              3
              group
              via in situ
              generated
              p
              -quinone methides. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (6)
                                     , 1305-1314. <a href="https://doi.org/10.1039/D0OB02469D" title="DOI URL">https://doi.org/10.1039/D0OB02469D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB02469D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB02469D%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DConstruction%252Bof%252Bfully%252Bsubstituted%252Bcarbon%252Bcenters%252Bcontaining%252Ba%252Bheteroatom%252Band%252Ba%252BCF%252B3%252Bgroup%252Bvia%252Bin%252Bsitu%252Bgenerated%252Bp%252B-quinone%252Bmethides%26aulast%3DTerashima%26aufirst%3DKyu%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D6%26spage%3D1305%26epage%3D1314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Davide  Cirillo</span>, <span class="hlFld-ContribAuthor ">Francesco  Angelucci</span>, <span class="hlFld-ContribAuthor ">Hans‐René  Bjørsvik</span>. </span><span class="cited-content_cbyCitation_article-title">Functionalization of the Imidazole Backbone by Means of a Tailored and Optimized Oxidative Heck Cross‐Coupling. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (22)
                                     , 5079-5092. <a href="https://doi.org/10.1002/adsc.202000909" title="DOI URL">https://doi.org/10.1002/adsc.202000909</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202000909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202000909%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DFunctionalization%252Bof%252Bthe%252BImidazole%252BBackbone%252Bby%252BMeans%252Bof%252Ba%252BTailored%252Band%252BOptimized%252BOxidative%252BHeck%252BCross%2525E2%252580%252590Coupling%26aulast%3DCirillo%26aufirst%3DDavide%26date%3D2020%26date%3D2020%26volume%3D362%26issue%3D22%26spage%3D5079%26epage%3D5092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Wang</span>, <span class="hlFld-ContribAuthor ">Abhishek  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs). </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (22)
                                     , 2072-2097. <a href="https://doi.org/10.1002/cmdc.202000473" title="DOI URL">https://doi.org/10.1002/cmdc.202000473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000473%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DThe%252BQuest%252Bfor%252BOrally%252BAvailable%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%26aulast%3DWang%26aufirst%3DLucia%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D22%26spage%3D2072%26epage%3D2097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiuyu  Meng</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Ma</span>, <span class="hlFld-ContribAuthor ">Baohua  Xie</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Deng</span>, <span class="hlFld-ContribAuthor ">Jian  Huang</span>, <span class="hlFld-ContribAuthor ">Hai-Bing  Zhou</span>, <span class="hlFld-ContribAuthor ">Chune  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Establishment of evaluation criteria for the development of high quality ERα-targeted fluorescent probes. </span><span class="cited-content_cbyCitation_journal-name">The Analyst</span><span> <strong>2020,</strong> <em>145 </em>
                                    (18)
                                     , 5989-5995. <a href="https://doi.org/10.1039/D0AN01172J" title="DOI URL">https://doi.org/10.1039/D0AN01172J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0AN01172J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0AN01172J%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Analyst%26atitle%3DEstablishment%252Bof%252Bevaluation%252Bcriteria%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bhigh%252Bquality%252BER%2525CE%2525B1-targeted%252Bfluorescent%252Bprobes%26aulast%3DMeng%26aufirst%3DQiuyu%26date%3D2020%26date%3D2020%26volume%3D145%26issue%3D18%26spage%3D5989%26epage%3D5995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shagufta</span>, <span class="hlFld-ContribAuthor ">Irshad  Ahmad</span>, <span class="hlFld-ContribAuthor ">Shimy  Mathew</span>, <span class="hlFld-ContribAuthor ">Sofia  Rahman</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (4)
                                     , 438-454. <a href="https://doi.org/10.1039/C9MD00570F" title="DOI URL">https://doi.org/10.1039/C9MD00570F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00570F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00570F%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bselective%252Bestrogen%252Breceptor%252Bdownregulators%252B%252528SERDs%252529%252Bfor%252Bthe%252Btreatment%252Bof%252Bbreast%252Bcancer%26aulast%3DShagufta%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D4%26spage%3D438%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhong‐Hua  Gao</span>, <span class="hlFld-ContribAuthor ">Zi‐Hao  Xia</span>, <span class="hlFld-ContribAuthor ">Lei  Dai</span>, <span class="hlFld-ContribAuthor ">Song  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">N‐Heterocyclic Carbene Catalyzed Photooxidation: Intramolecular Cross Dehydrogenative Coupling of Tetrahydroisoquinoline‐Tethered Aldehydes. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (9)
                                     , 1819-1824. <a href="https://doi.org/10.1002/adsc.202000164" title="DOI URL">https://doi.org/10.1002/adsc.202000164</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202000164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202000164%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DN%2525E2%252580%252590Heterocyclic%252BCarbene%252BCatalyzed%252BPhotooxidation%25253A%252BIntramolecular%252BCross%252BDehydrogenative%252BCoupling%252Bof%252BTetrahydroisoquinoline%2525E2%252580%252590Tethered%252BAldehydes%26aulast%3DGao%26aufirst%3DZhong%25E2%2580%2590Hua%26date%3D2020%26date%3D2020%26volume%3D362%26issue%3D9%26spage%3D1819%26epage%3D1824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cuihua  Zhang</span>, <span class="hlFld-ContribAuthor ">Qunlin  Li</span>, <span class="hlFld-ContribAuthor ">Yujie  Ren</span>, <span class="hlFld-ContribAuthor ">Fei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular modeling studies of benzothiophene-containing derivatives as promising selective estrogen receptor downregulators: a combination of 3D-QSAR, molecular docking and molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em> </em>, 1-22. <a href="https://doi.org/10.1080/07391102.2020.1751717" title="DOI URL">https://doi.org/10.1080/07391102.2020.1751717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1751717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1751717%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DMolecular%252Bmodeling%252Bstudies%252Bof%252Bbenzothiophene-containing%252Bderivatives%252Bas%252Bpromising%252Bselective%252Bestrogen%252Breceptor%252Bdownregulators%25253A%252Ba%252Bcombination%252Bof%252B3D-QSAR%25252C%252Bmolecular%252Bdocking%252Band%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DZhang%26aufirst%3DCuihua%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suzanne E.  Wardell</span>, <span class="hlFld-ContribAuthor ">Alexander P.  Yllanes</span>, <span class="hlFld-ContribAuthor ">Christina A.  Chao</span>, <span class="hlFld-ContribAuthor ">Yeeun  Bae</span>, <span class="hlFld-ContribAuthor ">Kaitlyn J.  Andreano</span>, <span class="hlFld-ContribAuthor ">Taylor K.  Desautels</span>, <span class="hlFld-ContribAuthor ">Kendall A.  Heetderks</span>, <span class="hlFld-ContribAuthor ">Jeremy T.  Blitzer</span>, <span class="hlFld-ContribAuthor ">John D.  Norris</span>, <span class="hlFld-ContribAuthor ">Donald P.  McDonnell</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2020,</strong> <em>179 </em>
                                    (1)
                                     , 67-77. <a href="https://doi.org/10.1007/s10549-019-05454-y" title="DOI URL">https://doi.org/10.1007/s10549-019-05454-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-019-05454-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-019-05454-y%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DPharmacokinetic%252Band%252Bpharmacodynamic%252Banalysis%252Bof%252Bfulvestrant%252Bin%252Bpreclinical%252Bmodels%252Bof%252Bbreast%252Bcancer%252Bto%252Bassess%252Bthe%252Bimportance%252Bof%252Bits%252Bestrogen%252Breceptor-%2525CE%2525B1%252Bdegrader%252Bactivity%252Bin%252Bantitumor%252Befficacy%26aulast%3DWardell%26aufirst%3DSuzanne%2BE.%26date%3D2020%26date%3D2019%26volume%3D179%26issue%3D1%26spage%3D67%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Omodele  Ibraheem</span>, <span class="hlFld-ContribAuthor ">Toluwase Hezekiah  Fatoki</span>, <span class="hlFld-ContribAuthor ">Jesupemi Mercy  Enibukun</span>, <span class="hlFld-ContribAuthor ">Bolanle Christianah  Faleye</span>, <span class="hlFld-ContribAuthor ">Daniel Uwaremhevho  Momodu</span>. </span><span class="cited-content_cbyCitation_article-title">In silico toxicological analyzes of selected toxic compounds from dumpsite or contaminated soils on human health. </span><span class="cited-content_cbyCitation_journal-name">Nova Biotechnologica et Chimica</span><span> <strong>2019,</strong> <em>18 </em>
                                    (2)
                                     , 144-153. <a href="https://doi.org/10.2478/nbec-2019-0017" title="DOI URL">https://doi.org/10.2478/nbec-2019-0017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2478/nbec-2019-0017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2478%2Fnbec-2019-0017%26sid%3Dliteratum%253Aachs%26jtitle%3DNova%2520Biotechnologica%2520et%2520Chimica%26atitle%3DIn%252Bsilico%252Btoxicological%252Banalyzes%252Bof%252Bselected%252Btoxic%252Bcompounds%252Bfrom%252Bdumpsite%252Bor%252Bcontaminated%252Bsoils%252Bon%252Bhuman%252Bhealth%26aulast%3DIbraheem%26aufirst%3DOmodele%26date%3D2019%26volume%3D18%26issue%3D2%26spage%3D144%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Li</span>, <span class="hlFld-ContribAuthor ">Silong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhiye  Hu</span>, <span class="hlFld-ContribAuthor ">Yuan  Xiao</span>, <span class="hlFld-ContribAuthor ">Jian  Huang</span>, <span class="hlFld-ContribAuthor ">Chune  Dong</span>, <span class="hlFld-ContribAuthor ">Shengtang  Huang</span>, <span class="hlFld-ContribAuthor ">Hai-Bing  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>172 </em>, 48-61. <a href="https://doi.org/10.1016/j.ejmech.2019.03.058" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.058%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploring%252Bthe%252BPROTAC%252Bdegron%252Bcandidates%25253A%252BOBHSA%252Bwith%252Bdifferent%252Bside%252Bchains%252Bas%252Bnovel%252Bselective%252Bestrogen%252Breceptor%252Bdegraders%252B%252528SERDs%252529%26aulast%3DLi%26aufirst%3DYuanyuan%26date%3D2019%26volume%3D172%26spage%3D48%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.  Velmurugan</span>, <span class="hlFld-ContribAuthor ">N. H. V.  Kutumbarao</span>, <span class="hlFld-ContribAuthor ">V.  Viswanathan</span>, <span class="hlFld-ContribAuthor ">Atanu  Bhattacharjee</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Drug Design with a Special Emphasis on Herbal Extracts. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 271-305. <a href="https://doi.org/10.1007/978-3-030-05282-9_9" title="DOI URL">https://doi.org/10.1007/978-3-030-05282-9_9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-05282-9_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-05282-9_9%26sid%3Dliteratum%253Aachs%26atitle%3DStructure-Based%252BDrug%252BDesign%252Bwith%252Ba%252BSpecial%252BEmphasis%252Bon%252BHerbal%252BExtracts%26aulast%3DVelmurugan%26aufirst%3DD.%26date%3D2019%26date%3D2019%26spage%3D271%26epage%3D305%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DStructural%252BBioinformatics%25253A%252BApplications%252Bin%252BPreclinical%252BDrug%252BDiscovery%252BProcess%26aulast%3DMohan%26aufirst%3DC.%2BGopi%26date%3D2019%26volume%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0001.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Clinically approved SERMs, SERDs, and AIs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Triphenyl-based and THIQ-based SERMs and SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) (i) 1-bromo-4-iodobenzene (3 equiv), 2.5 M <i>n</i>-BuLi in hexanes (3.01 equiv), pentanes (0.12 M), 1 h, rt; (ii) <b>5</b> in THF (0.2 M), −78 °C, 1 h; (iii) HClO<sub>4</sub>, 1 h; (b) 1.4 M MeMgBr (3 equiv) in THF, 16 h, rt, 95% yield; (c) methyl acrylate (10 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (15 mol %), Et<sub>3</sub>N (5 equiv), DMF (0.15 M), 120 °C, 1 h, 63% yield; (d) AlCl<sub>3</sub> (4 equiv), EtSH (10 equiv), DCM (0.1 M), 0 °C, 1 h, 52% yield; (e) LiOH (16 equiv), dioxanes, H<sub>2</sub>O, 50 °C, 2 h, quantitative yield.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) 2 M LiOH, THF (0.1 M), 60 °C, 30 min, quantitative; (b) CoCl<sub>2</sub>·6H<sub>2</sub>O (0.02 equiv)/NaBH<sub>4</sub> (2 equiv), EtOH (0.1 M), 90% yield; (c) AlCl<sub>3</sub> (7 equiv), EtSH (18 equiv), DCM (0.04 M), 0 °C, 37% yield; (d) HATU (1.5 equiv), 2,2-difluoroethanamine (2 equiv), Et<sub>3</sub>N (2 equiv), DCM (0.05 M), 90% yield; (e) 1 M BBr<sub>3</sub> in DCM (0.4 equiv), DCM (0.1 M), 0 °C, 30 min, 38% yield.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) <b>15</b>, 1-((2-(trimethylsilyl)ethoxy)methyl)-4-vinyl-1<i>H</i>-imidazole and 1-((2-(trimethylsilyl)ethoxy)methyl)-5-vinyl-1<i>H</i>-imidazole (15.7 equiv), Et<sub>3</sub>N (236 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (0.78 equiv), DMF (0.01 M), 80 °C, 16 h, 35% yield; (b) 1 M BBr<sub>3</sub> in DCM (4 equiv), DCM (0.035 M), −78 to 0 °C, 30 min, 46% yield; (c) <b>16</b>, 1-methyl-4-vinylimidazole and 1-methyl-5-vinylimidazole (3.3 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (15 mol %), Et<sub>3</sub>N (5 equiv), DMF (0.15 M), 120 °C, 1 h, 5% yield; (d) <b>6</b>, acrylonitrile (10 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (15 mol %), Et<sub>3</sub>N (5 equiv), DMF (0.15 M), microwave, 150 °C, 1 h, 46% yield; (e) Bu<sub>2</sub>SnO (0.1 equiv), TMSN<sub>3</sub> (6 equiv), DME (0.1 M), microwave, 2 h, 180 °C, quant; (f) AlCl<sub>3</sub> (4 equiv), EtSH (10 equiv), DCM (0.1 M) 0 °C, 1 h, 21% yield; (g) MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, 29% yield; (h) AlCl<sub>3</sub> (4 equiv), EtSH (10 equiv), DCM (0.1 M) 0 °C, 1 h, 49% yield.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) HATU (1.2 equiv), NMM (5 equiv), DMF (0.1 M), 76–88% yield; (b) PPh<sub>3</sub> (1.8 equiv), EtN-<i>i</i>-Pr<sub>2</sub> (5.75 equiv), Cl<sub>3</sub>CCCl<sub>3</sub> (1.3 equiv), MeCN (0.05 M), 82–87%; (c) AlCl<sub>3</sub> (4 equiv), EtSH (10 equiv), DCM (0.1 M), 38–49% yield.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) Cu(I)I, ArX, base, Δ; (b) LiC<sub>6</sub>H<sub>4</sub>Br; HClO<sub>4</sub>; (c) MeMgBr; (d) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (cat.), Et<sub>3</sub>N, methyl acrylate, Δ; (e) BBr<sub>3</sub> or AlCl<sub>3</sub>/EtSH; (f) LiOH.</p></p></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structures of THIQs <b>9</b> (green) and <b>40</b> (yellow) (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T92">5T92</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T97">5T97</a>, respectively).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Model of <b>(</b><i><b>S</b></i><b>)-40</b> (yellow) superimposed onto the cocrystal of <b>(</b><i><b>R</b></i><b>)-40</b> (orange) and the ERαLBD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0014.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0005.jpeg" id="rightTab-GRAPHIC-d88e2185-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Stability of <b>(</b><i><b>R</b></i><b>)</b>-<b>40</b> in aqueous buffer at pH 6.8 and 7.4 and methanol. (b) Stability of <b>(</b><i><b>R</b></i><b>)-40</b> in mouse, human, rat, dog, and monkey plasma.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0015.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0016.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 8. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) 1-bromo-4-iodobenzene (3 equiv), 2.5 M <i>n</i>-BuLi in hexanes (3.01 equiv), pentanes (0.12 M), 1 h, rt; (ii) <b>58</b> in THF (0.2 M), −78 °C, 1 h; (iii) HClO<sub>4</sub>, 1 h; (b) KF (3 equiv), 0.38 M 2,2-difluoro-2-(trimethylsilyl)acetate in DMF, 30 min, rt, 77% yield; (c) 1 M LiOH (2.5 equiv), 1,4-dioxane (0.1 M), 2 h, 40 °C (carried forward crude); (d) CsF (5 equiv), NMP (0.2 M), 192 °C, 24 h, 80% yield; (e) methyl acrylate (20 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (50 mol %), NEt<sub>3</sub> (5 equiv), DMF (0.15 M), 130 °C, 1 h, 15% yield; (f) AlCl<sub>3</sub> (8 equiv), EtSH (20 equiv), DCM (0.01 M), 2 h, rt, 84% yield; (g) 1 M LiOH (10 equiv), 1,4-dioxane (0.02 M), 3 h, rt, 44% yield.</p></p></figure><figure data-id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0006.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Measurement of ERα reduction by THIQ <b>40</b>, fulvestrant, and 4-hydroxytamoxifen in MCF-7 cells grown in 10% charcoal dextran-stripped serum supplemented media. For the in-cell Western, cells were incubated with compounds for 18 h followed by fixation and processing to determine the amount of ERα protein remaining.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0007.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Insulin-mediated proliferation of MCF-7 cells. Cells were incubated in DMEM (without phenol red) plus 8% charcoal dextran-stripped serum with insulin (20 nM) and compound treatment for 6 d. Cellular proliferation was quantified by measuring DNA content. IC<sub>50</sub> values were determined using GraphPad Prism software and are defined as the inflection point of the fitted inhibition curves.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/medium/jm-2016-014689_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0008.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo efficacy and ERα degradation by <b>40</b> in the MCF-7 xenograft model in female nude mice. Tumors were established by injection of 10 million cells in 50% Matrigel into the axillary mammary fat pad area. Mice were implanted with a 0.36 mg estradiol/90-day release pellet 2 days prior to cell implantation. When tumors reached an average of approximately 230 mm<sup>3</sup>, mice were randomized according to tumor volume into treatment groups (<i>n</i> = 6). THIQ <b>40</b> (20 mg/kg) or its vehicle alone were orally (po) treated once daily, and tamoxifen was orally treated (60 mg/kg) 5 times a week. Fulvestrant was administered subcutaneously (sc) once a week (250 mg/mouse). (a) Caliper measurements of tumor length and width were used to determine tumor volumes of treatment groups, which are graphed over time: (∗) <i>p</i> < 0.05, Kruskal–Wallis ANOVA, Dunn’s pos thoc test, versus vehicle control on day 108 after implantation. (b) Individual tumor volumes are plotted for values on day 108. (c) At the end of the efficacy study on day 108, MCF-7 tumors (<i>n</i> = 3–5) were collected at 7 and 24 h after last dose of THIQ <b>40</b> or 24 h after last dose of fulvestrant, and ER-α protein levels were analyzed from tumor lysates by ELISA (DuoSet, R&D System, catalog no. DYC5715-5) to detect ERα levels. The percent of ERα remaining was determined by comparing tumors from the treated mice versus those from the vehicle control group ((∗) <i>p</i> < 0.05, one-way ANOVA, Holm–Sidak method post hoc test, versus vehicle control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01468/20170407/images/large/jm-2016-014689_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01468&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40047" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40047" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 31 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fedele, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlando, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiavone, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caliolo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaranta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cinieri, S.</span><span> </span><span class="NLM_article-title">Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1016/j.critrevonc.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.critrevonc.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=25624176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A280%3ADC%252BC2MvpvVeisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2015&pages=291-301&author=P.+Fedeleauthor=L.+Orlandoauthor=P.+Schiavoneauthor=N.+Calvaniauthor=C.+Calioloauthor=A.+Quarantaauthor=A.+Nacciauthor=S.+Cinieri&title=Recent+advances+in+the+treatment+of+hormone+receptor+positive+HER2+negative+metastatic+breast+cancer&doi=10.1016%2Fj.critrevonc.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer</span></div><div class="casAuthors">Fedele Palma; Orlando Laura; Schiavone Paola; Calvani Nicola; Caliolo Chiara; Quaranta Annamaria; Nacci Angelo; Cinieri Saverio</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-301</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Endocrine therapy is the recommended systemic therapy for hormone receptor (HR) positive metastatic breast cancer (MBC).  However so far the limited number of endocrine agents and the onset of endocrine resistance have severely limited the therapeutic options for this patients.  In the last years many targeted agents have been investigated to prevent or overcome endocrine resistance; only a few of them have been found effective in HR positive MBC, such as everolimus, CK4/6 inhibitors and HDAC inhibitors.  Furthermore, translational medicine studies using next generation sequencing technologies have evaluated genetic variations of a broad panel of cancer-related genes and explored their correlations with targeted agents benefit.  In some studies predictive biomarkers have been identified and many ongoing studies are evaluating the efficacy of targeted drugs in HR positive MBC patients selected for biomarkers or stratified by pathways amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZOhFUzosBFP6xYuD7tu2XfW6udTcc2eaIeFMY9C0WNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvpvVeisA%253D%253D&md5=28a33613eeb8f3c3ee1b60e3043c64bf</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DFedele%26aufirst%3DP.%26aulast%3DOrlando%26aufirst%3DL.%26aulast%3DSchiavone%26aufirst%3DP.%26aulast%3DCalvani%26aufirst%3DN.%26aulast%3DCaliolo%26aufirst%3DC.%26aulast%3DQuaranta%26aufirst%3DA.%26aulast%3DNacci%26aufirst%3DA.%26aulast%3DCinieri%26aufirst%3DS.%26atitle%3DRecent%2520advances%2520in%2520the%2520treatment%2520of%2520hormone%2520receptor%2520positive%2520HER2%2520negative%2520metastatic%2520breast%2520cancer%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2015%26volume%3D94%26spage%3D291%26epage%3D301%26doi%3D10.1016%2Fj.critrevonc.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ryerson, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eheman, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altekruse, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holtzman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lake, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noone, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penberthy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohler, B. A.</span><span> </span><span class="NLM_article-title">Annual report to the nation on the status of cancer 1975–2012, featuring the increasing incidence of liver cancer</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1312</span><span class="NLM_x">–</span> <span class="NLM_lpage">1337</span><span class="refDoi"> DOI: 10.1002/cncr.29936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1002%2Fcncr.29936" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2016&pages=1312-1337&author=A.+B.+Ryersonauthor=C.+R.+Ehemanauthor=S.+F.+Altekruseauthor=J.+W.+Wardauthor=A.+Jemalauthor=R.+L.+Shermanauthor=S.+J.+Henleyauthor=D.+Holtzmanauthor=A.+Lakeauthor=A.-M.+Nooneauthor=R.+N.+Andersonauthor=J.+Maauthor=K.+N.+Lyauthor=K.+A.+Croninauthor=L.+Penberthyauthor=B.+A.+Kohler&title=Annual+report+to+the+nation+on+the+status+of+cancer+1975%E2%80%932012%2C+featuring+the+increasing+incidence+of+liver+cancer&doi=10.1002%2Fcncr.29936"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29936%26sid%3Dliteratum%253Aachs%26aulast%3DRyerson%26aufirst%3DA.%2BB.%26aulast%3DEheman%26aufirst%3DC.%2BR.%26aulast%3DAltekruse%26aufirst%3DS.%2BF.%26aulast%3DWard%26aufirst%3DJ.%2BW.%26aulast%3DJemal%26aufirst%3DA.%26aulast%3DSherman%26aufirst%3DR.%2BL.%26aulast%3DHenley%26aufirst%3DS.%2BJ.%26aulast%3DHoltzman%26aufirst%3DD.%26aulast%3DLake%26aufirst%3DA.%26aulast%3DNoone%26aufirst%3DA.-M.%26aulast%3DAnderson%26aufirst%3DR.%2BN.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLy%26aufirst%3DK.%2BN.%26aulast%3DCronin%26aufirst%3DK.%2BA.%26aulast%3DPenberthy%26aufirst%3DL.%26aulast%3DKohler%26aufirst%3DB.%2BA.%26atitle%3DAnnual%2520report%2520to%2520the%2520nation%2520on%2520the%2520status%2520of%2520cancer%25201975%25E2%2580%25932012%252C%2520featuring%2520the%2520increasing%2520incidence%2520of%2520liver%2520cancer%26jtitle%3DCancer%26date%3D2016%26volume%3D122%26spage%3D1312%26epage%3D1337%26doi%3D10.1002%2Fcncr.29936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">R235</span><span class="NLM_x">–</span> <span class="NLM_lpage">R246</span><span class="refDoi"> DOI: 10.1530/ERC-14-0092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1530%2FERC-14-0092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=24659478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlOmsbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=R235-R246&author=V.+C.+Jordan&title=Tamoxifen+as+the+first+targeted+long-term+adjuvant+therapy+for+breast+cancer&doi=10.1530%2FERC-14-0092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer</span></div><div class="casAuthors">Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">R235-R246</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">A review.  Tamoxifen is an unlikely pioneering medicine in medical oncol.  Nevertheless, the medicine has continued to surprise us, perform, and save lives for the past 40 years.  Unlike any other medicine in oncol., it is used to treat all stages of breast cancer, ductal carcinoma in situ, and male breast cancer and pioneered the use of chemoprevention by reducing the incidence of breast cancer in women at high risk and induces ovulation in subfertile women!  The impact of tamoxifen is ubiquitous.  However, the power to save lives from this unlikely success story came from the first lab. studies which defined that 'longer was going to be better' when tamoxifen was being considered as an adjuvant therapy.  This is that success story, with a focus on the interdependent components of: excellence in drug discovery, investment in self-selecting young investigators, a conversation with Nature, a conversation between the lab. and the clinic, and the creation of the Oxford Overview Anal.  Each of these factors was essential to propel the progress of tamoxifen to evolve as an essential part of the fabric of society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDHcUccrokKrVg90H21EOLACvtfcHk0ljTAvsPOk2UMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlOmsbrI&md5=1ce0dc42b512c264d8a20278e582ef59</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1530%2FERC-14-0092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-14-0092%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DTamoxifen%2520as%2520the%2520first%2520targeted%2520long-term%2520adjuvant%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2014%26volume%3D21%26spage%3DR235%26epage%3DR246%26doi%3D10.1530%2FERC-14-0092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Osborne, C. K.</span><span> </span><span class="NLM_article-title">Tamoxifen in the treatment of breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">1609</span><span class="NLM_x">–</span> <span class="NLM_lpage">1618</span><span class="refDoi"> DOI: 10.1056/NEJM199811263392207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1056%2FNEJM199811263392207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=9828250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFOitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=1998&pages=1609-1618&author=C.+K.+Osborne&title=Tamoxifen+in+the+treatment+of+breast+cancer&doi=10.1056%2FNEJM199811263392207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen in the treatment of breast cancer</span></div><div class="casAuthors">Osborne, C. Kent</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1609-1618</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review with 111 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXdjwzJ2N3sLVg90H21EOLACvtfcHk0liNd7e4LC06mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFOitLs%253D&md5=04c33aef97d8087d0afaa1d868019925</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1056%2FNEJM199811263392207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199811263392207%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26atitle%3DTamoxifen%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1998%26volume%3D339%26spage%3D1609%26epage%3D1618%26doi%3D10.1056%2FNEJM199811263392207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Clarke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyson, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, J. M.</span><span> </span><span class="NLM_article-title">Endrocrine resistance in breast cancer – an overview and update</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">418</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.mce.2015.09.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.mce.2015.09.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=26455641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1KisbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=2015&pages=220-234&author=R.+Clarkeauthor=J.+J.+Tysonauthor=J.+M.+Dixon&title=Endrocrine+resistance+in+breast+cancer+%E2%80%93+an+overview+and+update&doi=10.1016%2Fj.mce.2015.09.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine resistance in breast cancer - An overview and update</span></div><div class="casAuthors">Clarke, Robert; Tyson, John J.; Dixon, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue">Part_3</span>),
    <span class="NLM_cas:pages">220-234</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Tumors that express detectable levels of the product of the ESR1 gene (estrogen receptor-α; ERα) represent the single largest mol. subtype of breast cancer.  More women eventually die from ERα+ breast cancer than from either HER2+ disease (almost half of which also express ERα) and/or from triple neg. breast cancer (ERα-neg., progesterone receptor-neg., and HER2-neg.).  Antiestrogens and aromatase inhibitors are largely indistinguishable from each other in their abilities to improve overall survival and almost 50% of ERα+ breast cancers will eventually fail one or more of these endocrine interventions.  The precise reasons why these therapies fail in ERα+ breast cancer remain largely unknown.  Pharmacogenetic explanations for Tamoxifen resistance are controversial.  The role of ERα mutations in endocrine resistance remains unclear.  Targeting the growth factors and oncogenes most strongly correlated with endocrine resistance has proven mostly disappointing in their abilities to improve overall survival substantially, particularly in the metastatic setting.  Nonetheless, there are new concepts in endocrine resistance that integrate mol. signaling, cellular metab., and stress responses including endoplasmic reticulum stress and the unfolded protein response (UPR) that provide novel insights and suggest innovative therapeutic targets.  Encouraging evidence that drug combinations with CDK4/CDK6 inhibitors can extend recurrence free survival may yet translate to improvements in overall survival.  Whether the improvements seen with immunotherapy in other cancers can be achieved in breast cancer remains to be detd., particularly for ERα+ breast cancers.  This review explores the basic mechanisms of resistance to endocrine therapies, concluding with some new insights from systems biol. approaches further implicating autophagy and the UPR in detail, and a brief discussion of exciting new avenues and future prospects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHhMBDWyJnLLVg90H21EOLACvtfcHk0liNd7e4LC06mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1KisbzO&md5=dc6a3084f11f5c7d0fbe04968752bc27</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2015.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2015.09.035%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DR.%26aulast%3DTyson%26aufirst%3DJ.%2BJ.%26aulast%3DDixon%26aufirst%3DJ.%2BM.%26atitle%3DEndrocrine%2520resistance%2520in%2520breast%2520cancer%2520%25E2%2580%2593%2520an%2520overview%2520and%2520update%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2015%26volume%3D418%26spage%3D220%26epage%3D234%26doi%3D10.1016%2Fj.mce.2015.09.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Goss, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingle, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muss, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccart, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castiglione, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livingston, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therasse, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pater, J. L.</span><span> </span><span class="NLM_article-title">A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">1793</span><span class="NLM_x">–</span> <span class="NLM_lpage">1802</span><span class="refDoi"> DOI: 10.1056/NEJMoa032312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1056%2FNEJMoa032312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=14551341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosl2gtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=1793-1802&author=P.+E.+Gossauthor=J.+N.+Ingleauthor=S.+Martinoauthor=N.+J.+Robertauthor=H.+B.+Mussauthor=M.+J.+Piccartauthor=M.+Castiglioneauthor=D.+Tuauthor=L.+E.+Shepherdauthor=K.+I.+Pritchardauthor=R.+B.+Livingstonauthor=N.+E.+Davidsonauthor=L.+Nortonauthor=E.+A.+Perezauthor=J.+S.+Abramsauthor=P.+Therasseauthor=M.+J.+Palmerauthor=J.+L.+Pater&title=A+randomized+trial+of+letrozole+in+postmenopausal+women+after+five+years+of+tamoxifen+therapy+for+early-stage+breast+cancer&doi=10.1056%2FNEJMoa032312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer</span></div><div class="casAuthors">Goss, Paul E.; Ingle, James N.; Martino, Silvana; Robert, Nicholas J.; Muss, Hyman B.; Piccart, Martine J.; Castiglione, Monica; Tu, Dongsheng; Shepherd, Lois E.; Pritchard, Kathleen I.; Livingston, Robert B.; Davidson, Nancy E.; Norton, Larry; Perez, Edith A.; Abrams, Jeffrey S.; Therasse, Patrick; Palmer, Michael J.; Pater, Joseph L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy - but not tamoxifen therapy of longer duration - prolongs disease-free and overall survival.  The aromatase inhibitor letrozole, by suppressing estrogen prodn., might improve the outcome after the discontinuation of tamoxifen therapy.  Methods: We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy.  The primary end point was disease-free survival.  Results: A total of 5187 women were enrolled (median follow-up, 2.4 yr).  At the first interim anal., there were 207 local or metastatic recurrences of breast cancer or new primary cancers in the contralateral breast - 75 in the letrozole group and 132 in the placebo group - with estd. four-year disease-free survival rates of 93% and 87%, resp., in the two groups (p ≤ 0.001 for the comparison of disease-free survival).  A total of 42 women in the placebo group and 31 women in the letrozole group died (P = 0.25 for the comparison of overall survival).  Low-grade hot flashes, arthritis, arthralgia, and myalgia were more frequent in the letrozole group, but vaginal bleeding was less frequent.  There were new diagnoses of osteoporosis in 5.8% of the women in the letrozole group and 4.5% of the women in the placebo group (P = 0.07); the rates of fracture were similar.  After the first interim anal., the independent data and safety monitoring committee recommended termination of the trial and prompt communication of the results to the participants.  Conclusions: As compared with placebo, letrozole therapy after the completion of std. tamoxifen treatment significantly improves disease-free survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn8Yeh_0VFRbVg90H21EOLACvtfcHk0liNd7e4LC06mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosl2gtbc%253D&md5=b7ccc0fb80f769bc70d2768567a4c31f</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032312%26sid%3Dliteratum%253Aachs%26aulast%3DGoss%26aufirst%3DP.%2BE.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DMartino%26aufirst%3DS.%26aulast%3DRobert%26aufirst%3DN.%2BJ.%26aulast%3DMuss%26aufirst%3DH.%2BB.%26aulast%3DPiccart%26aufirst%3DM.%2BJ.%26aulast%3DCastiglione%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DShepherd%26aufirst%3DL.%2BE.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DLivingston%26aufirst%3DR.%2BB.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DAbrams%26aufirst%3DJ.%2BS.%26aulast%3DTherasse%26aufirst%3DP.%26aulast%3DPalmer%26aufirst%3DM.%2BJ.%26aulast%3DPater%26aufirst%3DJ.%2BL.%26atitle%3DA%2520randomized%2520trial%2520of%2520letrozole%2520in%2520postmenopausal%2520women%2520after%2520five%2520years%2520of%2520tamoxifen%2520therapy%2520for%2520early-stage%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D1793%26epage%3D1802%26doi%3D10.1056%2FNEJMoa032312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paridaens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolé, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildiers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiche, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clément, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köberle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldhirsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thürlimann, B.</span><span> </span><span class="NLM_article-title">Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss group for clinical cancer research trial (SAKK 21/00)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">64</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span><span class="refDoi"> DOI: 10.1093/annonc/mdl341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1093%2Fannonc%2Fmdl341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=17030543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FisVWntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=64-69&author=L.+Pereyauthor=R.+Paridaensauthor=H.+Hawleauthor=K.+Zamanauthor=F.+Nol%C3%A9author=H.+Wildiersauthor=M.+Ficheauthor=D.+Dietrichauthor=P.+Cl%C3%A9mentauthor=D.+K%C3%B6berleauthor=A.+Goldhirschauthor=B.+Th%C3%BCrlimann&title=Clinical+benefit+of+fulvestrant+in+postmenopausal+women+with+advanced+breast+cancer+and+primary+or+acquired+resistance+to+aromatase+inhibitors%3A+final+results+of+phase+II+Swiss+group+for+clinical+cancer+research+trial+%28SAKK+21%2F00%29&doi=10.1093%2Fannonc%2Fmdl341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)</span></div><div class="casAuthors">Perey L; Hawle H; Fiche M; Dietrich D; Koberle D; Thurlimann B; Paridaens R; Wildiers H; Clement P; Zaman K; Nole F; Goldhirsch A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-69</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment.  PATIENTS AND METHODS:  This is a phase II, open, multicenter, noncomparative study.  Two patient groups were prospectively considered: group A (n=70) with AI-responsive disease and group B (n=20) with AI-resistant disease.  Fulvestrant 250 mg was administered as intramuscular injection every 28 (+/-3) days.  RESULTS:  All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases.  Fulvestrant administration was well tolerated and yielded a clinical benefit (CB; defined as objective response or stable disease [SD] for >or=24 weeks) in 28% (90% confidence interval [CI] 19% to 39%) of patients in group A and 37% (90% CI 19% to 58%) of patients in group B.  Median time to progression (TTP) was 3.6 (95% CI 3.0 to 4.8) months in group A and 3.4 (95% CI 2.5 to 6.7) months in group B.  CONCLUSIONS:  Overall, 30% of patients who had progressed following prior AI treatment gained CB with fulvestrant, thereby delaying indication to start chemotherapy.  Prior response to an AI did not appear to be predictive for benefit with fulvestrant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgdgcuVoVvhr7NkxioyDXTfW6udTcc2eYHDiMF3PN8a7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FisVWntQ%253D%253D&md5=33f52d40ebeba134195a6311c0e8d854</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdl341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdl341%26sid%3Dliteratum%253Aachs%26aulast%3DPerey%26aufirst%3DL.%26aulast%3DParidaens%26aufirst%3DR.%26aulast%3DHawle%26aufirst%3DH.%26aulast%3DZaman%26aufirst%3DK.%26aulast%3DNol%25C3%25A9%26aufirst%3DF.%26aulast%3DWildiers%26aufirst%3DH.%26aulast%3DFiche%26aufirst%3DM.%26aulast%3DDietrich%26aufirst%3DD.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DP.%26aulast%3DK%25C3%25B6berle%26aufirst%3DD.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DTh%25C3%25BCrlimann%26aufirst%3DB.%26atitle%3DClinical%2520benefit%2520of%2520fulvestrant%2520in%2520postmenopausal%2520women%2520with%2520advanced%2520breast%2520cancer%2520and%2520primary%2520or%2520acquired%2520resistance%2520to%2520aromatase%2520inhibitors%253A%2520final%2520results%2520of%2520phase%2520II%2520Swiss%2520group%2520for%2520clinical%2520cancer%2520research%2520trial%2520%2528SAKK%252021%252F00%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2007%26volume%3D18%26spage%3D64%26epage%3D69%26doi%3D10.1093%2Fannonc%2Fmdl341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Deshmane, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melemed, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzdar, A. U.</span><span> </span><span class="NLM_article-title">Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">4967</span><span class="NLM_x">–</span> <span class="NLM_lpage">4973</span><span class="refDoi"> DOI: 10.1200/JCO.2006.09.5992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1200%2FJCO.2006.09.5992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=17971595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOhtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=4967-4973&author=V.+Deshmaneauthor=S.+Krishnamurthyauthor=A.+S.+Melemedauthor=P.+Petersonauthor=A.+U.+Buzdar&title=Phase+III+double-blind+trial+of+arzoxifene+compared+with+tamoxifen+for+locally+advanced+or+metastic+breast+cancer&doi=10.1200%2FJCO.2006.09.5992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer</span></div><div class="casAuthors">Deshmane, VijayaLaxmi; Krishnamurthy, S.; Melemed, Allen S.; Peterson, Patrick; Buzdar, Aman U.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">4967-4973</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To compare the efficacy of arzoxifene with tamoxifen for the treatment of locally advanced or metastatic breast cancer.  Patients and Methods: Women with estrogen- or progesterone-receptor-pos. breast cancer who had not received prior systemic therapy, or who had relapsed more than 12 mo after stopping adjuvant hormonal therapy, were randomly assigned to receive 20 mg arzoxifene or 20 mg tamoxifen daily.  Each treatment arm was to have 240 patients enrolled.  The primary end point was progression-free survival.  Secondary end points included other measures of tumor response, overall survival, and safety.  Results: Enrollment was stopped when a planned interim anal. of the first 200 patients suggested arzoxifene to be significantly inferior to tamoxifen.  The median progression-free survival for the 352 patients who had been randomly assigned when enrollment was stopped was 4.0 mo (95% CI, 3.4 to 5.6 mo) for the arzoxifene group and 7.5 mo (95% CI, 5.9 to 8.8 mo) for the tamoxifen group.  On-study progression-free survival (P = .011) and time to treatment failure (P = .029) also favored tamoxifen.  Overall tumor response rate and median response duration were comparable between the groups.  Adverse events were similar between the treatments, except for nausea (more frequent with arzoxifene) and vaginal discharge (more frequent with tamoxifen).  Conclusion: Tamoxifen produced significantly longer progression-free survival and time to treatment failure compared with arzoxifene in the treatment of locally advanced and metastatic breast cancer.  There were no significant differences between tumor response rate, clin. benefit rate, or median response duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0TBBdzHZWMbVg90H21EOLACvtfcHk0ljl0P-bptjlOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOhtbfK&md5=464ad5ce1273cc4210417b6e85f763e7</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.09.5992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.09.5992%26sid%3Dliteratum%253Aachs%26aulast%3DDeshmane%26aufirst%3DV.%26aulast%3DKrishnamurthy%26aufirst%3DS.%26aulast%3DMelemed%26aufirst%3DA.%2BS.%26aulast%3DPeterson%26aufirst%3DP.%26aulast%3DBuzdar%26aufirst%3DA.%2BU.%26atitle%3DPhase%2520III%2520double-blind%2520trial%2520of%2520arzoxifene%2520compared%2520with%2520tamoxifen%2520for%2520locally%2520advanced%2520or%2520metastic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D4967%26epage%3D4973%26doi%3D10.1200%2FJCO.2006.09.5992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Johnston, S. R. D.</span><span> </span><span class="NLM_article-title">Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">4376s</span><span class="NLM_x">–</span> <span class="NLM_lpage">4387s</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=11916228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD38Xltlyjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=4376s-4387s&author=S.+R.+D.+Johnston&title=Endocrine+manipulation+in+advanced+breast+cancer%3A+recent+advances+with+SERM+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine manipulation in advanced breast cancer: Recent advances with SERM therapies</span></div><div class="casAuthors">Johnston, Stephen R. D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12, Suppl.</span>),
    <span class="NLM_cas:pages">4376S-4387S</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Tamoxifen is one of the most effective treatments for breast cancer through its ability to antagonize estrogen-dependent growth by binding estrogen receptors (ERs) and inhibiting breast epithelial cell proliferation.  However, tamoxifen has estrogenic agonist effects in other tissues such as bone and endometrium because of liganded ER-activating target genes in these different cell types.  Several novel antiestrogen compds. have been developed that are also selective ER modulators (SERMs) but that have a reduced agonist profile on breast and gynecol. tissues.  These SERMs offer the potential for enhanced efficacy and reduced toxicity compared with tamoxifen.  In advanced breast cancer clin. data exist for three first-generation SERMs (toremifene, droloxifene, idoxifene), which are related to the triphenylethylene structure of tamoxifen.  In Phase II trials in a total of 263 patients resistant to tamoxifen, the median objective response rate to these SERMs way only 5% (range, 0-15%), with stable disease for 6 mo in an addnl. 18% (range, 9-23%).  As first-line therapy for advanced breast cancer, the median response rate was 31% (range, 20-68%) with a median time to progression of 7 mo.  Randomized Phase III trials for toremifene and idoxifene in more than 1500 patients showed no significant difference compared with tamoxifen.  Fewer clin. data exist for the structurally distinct second- and third-generation SERMs (raloxifene, arzoxifene, EM-800, and ERA-923), although a similarly low median response rate of 6% (range, 0-14%) was seen in Phase II trials in tamoxifen-resistant patients.  It remains unclear whether any clin. advantage exists for second- and third-generation SERMs over tamoxifen as first-line therapy.  With the emergence of potent aromatase inhibitors (AIs) that are superior to tamoxifen, the clin. questions in advanced disease have shifted to which antiestrogen (including SERMs) may be effective following failure of AIs, and whether any merit exists for combined AI/SERM therapy.  The main advantage for SERM therapy probably remains in early stage-disease (adjuvant therapy or prevention), in which the estrogenic effects on bone and reduced gynecol. side effects may prove more beneficial than either tamoxifen or AI.  The issue is whether the current clin. data for SERMs in advanced breast cancer are sufficiently strong to encourage that further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpF6hXEfwfYLVg90H21EOLACvtfcHk0ljl0P-bptjlOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xltlyjug%253D%253D&md5=e8213625c91f3c25c9fbdcccab013aa2</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26atitle%3DEndocrine%2520manipulation%2520in%2520advanced%2520breast%2520cancer%253A%2520recent%2520advances%2520with%2520SERM%2520therapies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D4376s%26epage%3D4387s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradishar, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauriac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bines, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amant, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romieu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzdar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brufsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possinger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapunar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccart, M.</span><span> </span><span class="NLM_article-title">Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1664</span><span class="NLM_x">–</span> <span class="NLM_lpage">1670</span><span class="refDoi"> DOI: 10.1200/JCO.2007.13.5822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1200%2FJCO.2007.13.5822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=18316794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWhsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1664-1670&author=S.+Chiaauthor=W.+Gradisharauthor=L.+Mauriacauthor=J.+Binesauthor=F.+Amantauthor=M.+Federicoauthor=L.+Feinauthor=G.+Romieuauthor=A.+Buzdarauthor=J.+F.+R.+Robertsonauthor=A.+Brufskyauthor=K.+Possingerauthor=P.+Rennieauthor=F.+Sapunarauthor=E.+Loweauthor=M.+Piccart&title=Double-blind%2C+randomized+placebo+controlled+trial+of+fulvestrant+compared+with+exemestane+after+prior+nonsteroidal+aromatase+inhibitor+therapy+in+postmenopausal+women+with+hormone+receptor-positive%2C+advanced+breast+cancer%3A+results+from+EFECT&doi=10.1200%2FJCO.2007.13.5822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from Effect</span></div><div class="casAuthors">Chia, Stephen; Gradishar, William; Mauriac, Louis; Bines, Jose; Amant, Frederic; Federico, Miriam; Fein, Luis; Romieu, Gilles; Buzdar, Aman; Robertson, John F. R.; Brufsky, Adam; Possinger, Kurt; Rennie, Pamela; Sapunar, Francisco; Lowe, Elizabeth; Piccart, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1664-1670</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The third-generation nonsteroidal aromatase inhibitors (AIs) are increasingly used as adjuvant and first-line advanced therapy for postmenopausal, hormone receptor-pos. (HR+) breast cancer.  Because many patients subsequently experience progression or relapse, it is important to identify agents with efficacy after Al failure.  Materials and Methods: Evaluation of Faslodex vs. Exemestane Clin. Trial (Effect) is a randomized, double-blind, placebo controlled, multicenter phase III trial of fulvestrant vs. exemestane in postmenopausal women with HR+ advanced breast cancer (ABC) progressing or recurring after nonsteroidal AI.  The primary end point was time to progression (TTP).  A fulvestrant loading-dose (LD) regimen was used: 500 mg i.m. on day 0, 250 mg on days 14, 28, and 250 mg every 28 days thereafter.  Exemestane 25 mg orally was administered once daily.  Results: A total of 693 women were randomly assigned to fulvestrant (n = 351) or exemestane (n = 342).  Approx. 60% of patients had received at least two prior endocrine therapies.  Median TTP was 3.7 mo in both groups (hazard ratio = 0.963; 95% CI, 0.819 to 1.133; P = .6531).  The overall response rate (7.4% v 6.7%; P = .736) and clin. benefit rate (32.2% v 31.5%; P = .853) were similar between fulvestrant and exemestane resp.  Median duration of clin. benefit was 9.3 and 8.3 mo, resp.  Both treatments were well tolerated, with no significant differences in the incidence of adverse events or quality of life.  Pharmacokinetic data confirm that steady-state was reached within 1 mo with the LD schedule of fulvestrant.  Conclusion: Fulvestrant LD and exemestane are equally active and well-tolerated in a meaningful proportion of postmenopausal women with ABC who have experienced progression or recurrence during treatment with a nonsteroidal AI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWaXOCyTBWnrVg90H21EOLACvtfcHk0ljbJ5ON9i7_nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWhsrg%253D&md5=6c92d61eb60518a1fee2a82e8f9b892c</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.5822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.5822%26sid%3Dliteratum%253Aachs%26aulast%3DChia%26aufirst%3DS.%26aulast%3DGradishar%26aufirst%3DW.%26aulast%3DMauriac%26aufirst%3DL.%26aulast%3DBines%26aufirst%3DJ.%26aulast%3DAmant%26aufirst%3DF.%26aulast%3DFederico%26aufirst%3DM.%26aulast%3DFein%26aufirst%3DL.%26aulast%3DRomieu%26aufirst%3DG.%26aulast%3DBuzdar%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DBrufsky%26aufirst%3DA.%26aulast%3DPossinger%26aufirst%3DK.%26aulast%3DRennie%26aufirst%3DP.%26aulast%3DSapunar%26aufirst%3DF.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DPiccart%26aufirst%3DM.%26atitle%3DDouble-blind%252C%2520randomized%2520placebo%2520controlled%2520trial%2520of%2520fulvestrant%2520compared%2520with%2520exemestane%2520after%2520prior%2520nonsteroidal%2520aromatase%2520inhibitor%2520therapy%2520in%2520postmenopausal%2520women%2520with%2520hormone%2520receptor-positive%252C%2520advanced%2520breast%2520cancer%253A%2520results%2520from%2520EFECT%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D1664%26epage%3D1670%26doi%3D10.1200%2FJCO.2007.13.5822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wittmann, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9549</span><span class="NLM_x">–</span> <span class="NLM_lpage">9560</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1158%2F0008-5472.CAN-07-1590" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9549-9560&author=B.+M.+Wittmannauthor=A.+Sherkauthor=D.+P.+McDonnell&title=Definition+of+functionally+important+mechanistic+differences+among+selective+estrogen+receptor+down-regulators&doi=10.1158%2F0008-5472.CAN-07-1590"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1590%26sid%3Dliteratum%253Aachs%26aulast%3DWittmann%26aufirst%3DB.%2BM.%26aulast%3DSherk%26aufirst%3DA.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DDefinition%2520of%2520functionally%2520important%2520mechanistic%2520differences%2520among%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9549%26epage%3D9560%26doi%3D10.1158%2F0008-5472.CAN-07-1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Howell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapunar, F.</span><span> </span><span class="NLM_article-title">Fulvestrant revisited: efficacy and safety of the 500-mg dose</span> <span class="citation_source-journal">Clin. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">204</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1016/j.clbc.2011.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.clbc.2011.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=21729658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKisr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=204-210&author=A.+Howellauthor=F.+Sapunar&title=Fulvestrant+revisited%3A+efficacy+and+safety+of+the+500-mg+dose&doi=10.1016%2Fj.clbc.2011.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant revisited: efficacy and safety of the 500-mg dose</span></div><div class="casAuthors">Howell, Anthony; Sapunar, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">204-210</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Postmenopausal women with hormone receptor-pos. advanced breast cancer are candidates for endocrine therapy.  As the disease will eventually progress in most patients, it is important to investigate agents with novel modes of action to reduce the likelihood of treatment cross-resistance.  Fulvestrant is an estrogen receptor antagonist with no known agonist effects that has been shown to be as effective as anastrozole following failure on tamoxifen, at the approved dose of 250 mg/mo.  However, pharmacokinetic modeling and evidence of clin. efficacy in early trials, together with the favorable tolerability profile of fulvestrant 250 mg, led to suggestions that increasing the fulvestrant dose would lead to an improved benefit-risk profile.  This review describes the rationale behind the development of a 500 mg/mo higher dose of fulvestrant and details relevant clin. trials, including the pivotal phase III COmparisoN of Faslodex In Recurrent or Metastatic breast cancer (CONFIRM) study.  CONFIRM demonstrated a significant improvement in progression-free survival for fulvestrant 500 mg vs. 250 mg in postmenopausal patients who had progressed on previous endocrine therapy.  Here, we present and discuss a pooled safety anal. of CONFIRM and three further clin. studies demonstrating fulvestrant 500 mg to be well-tolerated with no evidence of dose-related adverse events.  Overall, these data indicate an improved benefit-risk profile for fulvestrant 500 mg vs. 250 mg following failure on prior endocrine therapy, and suggest that fulvestrant 500 mg may be considered in future as initial endocrine treatment for advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4U1d7Q6edlbVg90H21EOLACvtfcHk0ljbJ5ON9i7_nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKisr7E&md5=0d1063c9546320294193e92d3f2097dd</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2011.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2011.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DHowell%26aufirst%3DA.%26aulast%3DSapunar%26aufirst%3DF.%26atitle%3DFulvestrant%2520revisited%253A%2520efficacy%2520and%2520safety%2520of%2520the%2520500-mg%2520dose%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D204%26epage%3D210%26doi%3D10.1016%2Fj.clbc.2011.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">van Kruchten</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaudemans, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Lanschot, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Faassen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kema, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schröder, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hospers, G. A.</span><span> </span><span class="NLM_article-title">Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1158%2F2159-8290.CD-14-0697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=25380844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-81&author=+van+Kruchtenauthor=E.+G.+de+Vriesauthor=A.+W.+Glaudemansauthor=M.+C.+van+Lanschotauthor=M.+van+Faassenauthor=I.+P.+Kemaauthor=M.+Brownauthor=C.+P.+Schr%C3%B6derauthor=E.+F.+de+Vriesauthor=G.+A.+Hospers&title=Measuring+residual+estrogen+receptor+availability+during+fulvestrant+therapy+in+patients+with+metastatic+breast+cancer&doi=10.1158%2F2159-8290.CD-14-0697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">van Kruchten, Michel; de Vries, Elisabeth G.; Glaudemans, Andor W.; van Lanschot, Meta C.; van Faassen, Martijn; Kema, Ido P.; Brown, Myles; Schroeder, Carolien P.; de Vries, Erik F.; Hospers, Geke A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-81</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Decreased [18F]fluoroestradiol uptake visualized by PET/CT provides a measure of tumor ER availability and correlates with fulvestrant treatment outcome in patients with metastatic breast cancer.  It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer.  We performed a feasibility study to assess ER availability before and during fulvestrant.  Sixteen patients with ER-pos. metastatic breast cancer underwent positron emission tomog./computed tomog. (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18F]fluoroestradiol (FES) uptake.  Incomplete redn. in ER availability was predefined as <75% decrease in median tumor FES uptake and a residual standardized uptake value (SUVmax) of ≥1.5.  In total, 131 FES-pos. lesions were identified (median SUVmax of 2.9; range, 1.7-6.5).  The median change in patients during fulvestrant treatment was -85% at scan 2, but varied widely (-99% to +60%).  Fulvestrant reduced tumor FES uptake incompletely at scan 2 in 6 (38%) of the 16 patients, which was assocd. with early progression.  Significance: Serial imaging of tumor estrogen uptake by FES-PET can give insight into the dose needed for ER antagonists to completely abolish ER.  FES-PET showed significant residual ER availability in tumors during fulvestrant therapy in 38% of patients, which was assocd. with early progression.  Cancer Discov; 5(1); 72-81. ©2014 AACR.  This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAIvv5LaIyrVg90H21EOLACvtfcHk0lhDdmhJ2XE4AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D&md5=c5e8291be59caa5bf772cb6da80d52fb</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0697%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BKruchten%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3DGlaudemans%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLanschot%26aufirst%3DM.%2BC.%26aulast%3Dvan%2BFaassen%26aufirst%3DM.%26aulast%3DKema%26aufirst%3DI.%2BP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DC.%2BP.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DHospers%26aufirst%3DG.%2BA.%26atitle%3DMeasuring%2520residual%2520estrogen%2520receptor%2520availability%2520during%2520fulvestrant%2520therapy%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D72%26epage%3D81%26doi%3D10.1158%2F2159-8290.CD-14-0697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Robertson, J. F. R.</span><span> </span><span class="NLM_article-title">Fulvestrant (Faslodex)- how to make a good drug better</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">774</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span><span class="refDoi"> DOI: 10.1634/theoncologist.12-7-774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1634%2Ftheoncologist.12-7-774" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=774-784&author=J.+F.+R.+Robertson&title=Fulvestrant+%28Faslodex%29-+how+to+make+a+good+drug+better&doi=10.1634%2Ftheoncologist.12-7-774"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-7-774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-7-774%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%2BR.%26atitle%3DFulvestrant%2520%2528Faslodex%2529-%2520how%2520to%2520make%2520a%2520good%2520drug%2520better%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D774%26epage%3D784%26doi%3D10.1634%2Ftheoncologist.12-7-774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ma, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielewska, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M. J.</span><span> </span><span class="NLM_article-title">Mechanisms of aromatase inhibitor resistance</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1038/nrc3920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1038%2Fnrc3920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=25907219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wrur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=261-275&author=C.+X.+Maauthor=T.+Reinertauthor=I.+Chmielewskaauthor=M.+J.+Ellis&title=Mechanisms+of+aromatase+inhibitor+resistance&doi=10.1038%2Fnrc3920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of aromatase inhibitor resistance</span></div><div class="casAuthors">Ma, Cynthia X.; Reinert, Tomas; Chmielewska, Izabela; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">261-275</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Estrogen receptor-pos. (ER+) breast cancer is a major cause of cancer death in women.  Although aromatase inhibitors suppress the function of ER and reduce the risk of recurrence, therapeutic resistance is common and essentially inevitable in advanced disease.  This Review considers both genomic and cell biol. explanations as to why ER+ breast cancer cells persist, progress and cause an incurable, lethal, systemic disease.  The design and outcomes of clin. trials are considered with the perspective that resistance mechanisms are heterogeneous, and therefore biomarker and somatic mutation-based stratification and eligibility will be essential for improvements in patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFQZc2ZDe2yrVg90H21EOLACvtfcHk0lhDdmhJ2XE4AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wrur3F&md5=8873908dbbf917eece0cdc51d19efea1</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1038%2Fnrc3920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3920%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%2BX.%26aulast%3DReinert%26aufirst%3DT.%26aulast%3DChmielewska%26aufirst%3DI.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DMechanisms%2520of%2520aromatase%2520inhibitor%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D261%26epage%3D275%26doi%3D10.1038%2Fnrc3920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Masamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitjan, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santen, R. J.</span><span> </span><span class="NLM_article-title">Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">2918</span><span class="NLM_x">–</span> <span class="NLM_lpage">2925</span><span class="refDoi"> DOI: 10.1210/jcem.80.10.7559875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1210%2Fjcem.80.10.7559875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=7559875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK2MXoslCns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=2918-2925&author=S.+Masamuraauthor=S.+J.+Santnerauthor=D.+F.+Heitjanauthor=R.+J.+Santen&title=Estrogen+deprivation+causes+estradiol+hypersensitivity+in+human+breast+cancer+cells&doi=10.1210%2Fjcem.80.10.7559875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells</span></div><div class="casAuthors">Masamura, Shigeru; Santner, Steven J.; Heitjan, Daniel F.; Santen, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2918-25</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Genetic and environmental factors can modulate the level of sensitivity to various hormones, including estrogens.  Enhanced sensitivity to estradiol (E2) has been demonstrated in several biol. conditions, such as in sheep during the nonbreeding season, in untreated patients with Turner's syndrome, and in the prepubertal state in normal girls.  The authors postulated that secondary responses to hormonal therapy in patients with breast cancer could also result from enhanced E2 sensitivity, developing as an adaptive mechanism to E2 deprivation.  The present study used the MCF-7 human breast cancer cell line as a model system to test the concept that enhanced sensitivity to E2 may occur as a result of adaptation to low E2 levels.  After depriving MCF-7 cells of estrogens in tissue culture medium for periods of 1-6 mo, the authors established conditions under which replication could be stimulated maximally by 10-14-10-15M E2.  In contrast, wild-type cells not exposed to estrogen deprivation required 10-10M E2 to grow at the same rate.  Further, the concn. of the antiestrogen, ICI 164384, needed to inhibit growth by 50% in estrogen-deprived cells was much lower than that required in wild-type cells (i.e. 10-15 vs. 10-9M).  Nude mice implanted with these estrogen-deprived cells demonstrated an earlier appearance of palpable tumors in response to E2 than animals bearing wild-type cells.  Reexposure to 10-10-10-9M E2, either in vivo or in vitro, returned these cells to the level of estrogen sensitivity obsd. in wild-type cells.  Apparently, breast cancer cells can adapt to low levels of estrogens by enhancing their sensitivity to E2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcOoAZDaWphbVg90H21EOLACvtfcHk0lhDdmhJ2XE4AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslCns7Y%253D&md5=e61b1298d67a65bc5854b1afc3376af3</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1210%2Fjcem.80.10.7559875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.80.10.7559875%26sid%3Dliteratum%253Aachs%26aulast%3DMasamura%26aufirst%3DS.%26aulast%3DSantner%26aufirst%3DS.%2BJ.%26aulast%3DHeitjan%26aufirst%3DD.%2BF.%26aulast%3DSanten%26aufirst%3DR.%2BJ.%26atitle%3DEstrogen%2520deprivation%2520causes%2520estradiol%2520hypersensitivity%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1995%26volume%3D80%26spage%3D2918%26epage%3D2925%26doi%3D10.1210%2Fjcem.80.10.7559875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Jeselsohn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwalter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, R.</span><span> </span><span class="NLM_article-title"><i>ESR1</i> mutations—a mechanism for acquired endocrine resistance in breast cancer. <i>Nat. Rev</i></span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2015.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1038%2Fnrclinonc.2015.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=26122181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOju77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=573-583&author=R.+Jeselsohnauthor=G.+Buchwalterauthor=C.+De+Angelisauthor=M.+Brownauthor=R.+Schiff&title=ESR1+mutations%E2%80%94a+mechanism+for+acquired+endocrine+resistance+in+breast+cancer.+Nat.+Rev&doi=10.1038%2Fnrclinonc.2015.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer</span></div><div class="casAuthors">Jeselsohn, Rinath; Buchwalter, Gilles; De Angelis, Carmine; Brown, Myles; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">573-583</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Approx. 70% of breast cancers are estrogen receptor α (ER) pos., and are, therefore, treated with endocrine therapies.  However, about 25% of patients with primary disease and almost all patients with metastases will present with or eventually develop endocrine resistance.  Despite the magnitude of this clin. challenge, the mechanisms underlying the development of resistance remain largely unknown.  In the past 2 years, several studies unveiled gain-of-function mutations in ESR1, the gene encoding the ER, in approx. 20% of patients with metastatic ER-pos. disease who received endocrine therapies, such as tamoxifen and aromatase inhibitors.  These mutations are clustered in a 'hotspot' within the ligand-binding domain (LBD) of the ER and lead to ligand-independent ER activity that promotes tumor growth, partial resistance to endocrine therapy, and potentially enhanced metastatic capacity; thus, ER LBD mutations might account for a mechanism of acquired endocrine resistance in a substantial fraction of patients with metastatic disease.  In general, the absence of detectable ESR1 mutations in patients with treatment-naive disease, and the correlation between the frequency of patients with tumors harbouring these mutations and the no. of endocrine treatments received suggest that, under selective treatment pressure, clonal expansion of rare mutant clones occurs, leading to resistance.  Preclin. and clin. development of rationale-based novel therapeutic strategies that inhibit these ER mutants has the potential to substantially improve treatment outcomes.  We discuss the contribution of ESR1 mutations to the development of acquired resistance to endocrine therapy, and evaluate how mutated ER can be detected and targeted to overcome resistance and improve patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIrcfX3mOHgLVg90H21EOLACvtfcHk0lhNFM_3sKM51g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOju77E&md5=76da7da110c253410b40853bbf3b1be6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.117%26sid%3Dliteratum%253Aachs%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DBuchwalter%26aufirst%3DG.%26aulast%3DDe%2BAngelis%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DESR1%2520mutations%25E2%2580%2594a%2520mechanism%2520for%2520acquired%2520endocrine%2520resistance%2520in%2520breast%2520cancer.%2520Nat.%2520Rev%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26spage%3D573%26epage%3D583%26doi%3D10.1038%2Fnrclinonc.2015.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">McDonnell, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span> </span><span class="NLM_article-title">Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4883</span><span class="NLM_x">–</span> <span class="NLM_lpage">4887</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4883-4887&author=D.+P.+McDonnellauthor=S.+E.+Wardellauthor=J.+D.+Norris&title=Oral+selective+estrogen+receptor+downregulators+%28SERDs%29%2C+a+breakthrough+endocrine+therapy+for+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.; Norris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4883-4887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drugs that inhibit estrogen receptor alpha (ERα) or that block the prodn. of estrogens remain frontline interventions in the treatment and management of breast cancer at all stages.  However, resistance to endocrine therapies, esp. in the setting of advanced disease, remains an impediment to durable clin. responses.  Although the mechanisms underlying resistance to existing agents are complex, preclin. studies suggest that selective estrogen receptor downregulators (SERDs), mols. which eliminate ERα expression, may have particular utility in the treatment of breast cancers that have progressed on tamoxifen and/or aromatase inhibitors.  The discovery and development of orally bioavailable SERDs provide the opportunity to evaluate the utility of eliminating ERα expression in advanced metastatic breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQkRKbmjeJdLVg90H21EOLACvtfcHk0lhNFM_3sKM51g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D&md5=127869f40034451832a82fb2d7816528</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00760%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26atitle%3DOral%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%252C%2520a%2520breakthrough%2520endocrine%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4883%26epage%3D4887%26doi%3D10.1021%2Facs.jmedchem.5b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Wu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span> </span><span class="NLM_article-title">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.molcel.2005.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=15893725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=413-424&author=Y.-L.+Wuauthor=X.+Yangauthor=Z.+Renauthor=D.+P.+McDonnellauthor=J.+D.+Norrisauthor=T.+M.+Willsonauthor=G.+L.+Greene&title=Structural+basis+for+an+unexpected+mode+of+SERM-mediated+ER+antagonism&doi=10.1016%2Fj.molcel.2005.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span></div><div class="casAuthors">Wu, Ya-Ling; Yang, Xiaojing; Ren, Zhong; McDonnell, Donald P.; Norris, John D.; Willson, Timothy M.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-424</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tamoxifen is effective for the prevention and treatment of estrogen-dependent breast cancers, but is assocd. with an increased incidence of endometrial tumors.  The authors report the crystal structure of the estrogen receptor α (ERα) ligand binding domain (LBD) bound to the structurally similar compd. GW5638, which has therapeutic potential and does not stimulate the uterus.  Like tamoxifen, GW5638 relocates the carboxy-terminal helix (H12) to the known coactivator-docking site in the ERα LBD.  However, GW5638 repositions residues in H12 through specific contacts with the N terminus of this helix.  In contrast to tamoxifen, the resulting increase in exposed hydrophobic surface of ERα LBD correlates with a significant destabilization of ERα in MCF-7 cells.  Thus, the GW5638-ERα LBD structure reveals an unexpected mode of SERM-mediated ER antagonism, in which the stability of ERα is decreased through an altered position of H12.  This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBuyhLNSdbQbVg90H21EOLACvtfcHk0lhNFM_3sKM51g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D&md5=c60e01b31b57c07b934da01a34efb255</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DStructural%2520basis%2520for%2520an%2520unexpected%2520mode%2520of%2520SERM-mediated%2520ER%2520antagonism%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26spage%3D413%26epage%3D424%26doi%3D10.1016%2Fj.molcel.2005.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henke, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Momtahen, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charifson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batchelor, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubahn, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauls, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Triantafillou, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, P. G.</span><span> </span><span class="NLM_article-title">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1550</span><span class="NLM_x">–</span> <span class="NLM_lpage">1552</span><span class="refDoi"> DOI: 10.1021/jm00037a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00037a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1550-1552&author=T.+M.+Willsonauthor=B.+R.+Henkeauthor=T.+M.+Momtahenauthor=P.+S.+Charifsonauthor=K.+W.+Batchelorauthor=D.+B.+Lubahnauthor=L.+B.+Mooreauthor=B.+B.+Oliverauthor=H.+R.+Saulsauthor=J.+A.+Triantafillouauthor=S.+G.+Wolfeauthor=P.+G.+Baer&title=3-%5B4-%281%2C2-Diphenylbut-1-enyl%29phenyl%5Dacrylic+acid%3A+a+non-steroidal+estrogen+with+functional+selectivity+for+bone+over+uterus+in+rats&doi=10.1021%2Fjm00037a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats</span></div><div class="casAuthors">Willson, Timothy M.; Henke, Brad R.; Momtahen, Tanya M.; Charifson, Paul S.; Batchelor, Kenneth W.; Lubahn, Dennis B.; Moore, Linda B.; Oliver, Beverly B.; Sauls, Howard R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1550-2</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Exploiting knowledge of the mol. biol. of the estrogen receptor and the existence of two independent transcription activation domains, a series of tissue-selective non-steroidal estrogens was designed.  The ethanolamine side-chain of tamoxifen was targeted for modification, resulting in the identification of a series of α,β-unsatd. acid and amide analogs I [R = OH, NEt2, morpholino, NH(CH2)3OMe, dicyclohexylamino, NEtCH2CH2NMe2, NH(CH2)3OH, N-methyloctylamino, NHEt,NH2].  I [R = OH] profiled as an estrogen with full agonist activity in bone while maintaining antagonist activity in the uterus of rats.  The demonstration that different parts of the triphenylethylene structure control expression of estrogenic activity in bone and uterus has implications in the design of tissue selective ligands for other members of the steroid/retinoid family of intracellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4iuXq4R8fm7Vg90H21EOLACvtfcHk0lhmKeurJyw9Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D&md5=721906b3513f7e8cdc9ae08ecd99a93b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm00037a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00037a002%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DHenke%26aufirst%3DB.%2BR.%26aulast%3DMomtahen%26aufirst%3DT.%2BM.%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26aulast%3DBatchelor%26aufirst%3DK.%2BW.%26aulast%3DLubahn%26aufirst%3DD.%2BB.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26aulast%3DTriantafillou%26aufirst%3DJ.%2BA.%26aulast%3DWolfe%26aufirst%3DS.%2BG.%26aulast%3DBaer%26aufirst%3DP.%2BG.%26atitle%3D3-%255B4-%25281%252C2-Diphenylbut-1-enyl%2529phenyl%255Dacrylic%2520acid%253A%2520a%2520non-steroidal%2520estrogen%2520with%2520functional%2520selectivity%2520for%2520bone%2520over%2520uterus%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1550%26epage%3D1552%26doi%3D10.1021%2Fjm00037a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asplin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauls, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Dissection of the molecular mechanism of action of GW5368, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">3901</span><span class="NLM_x">–</span> <span class="NLM_lpage">3911</span><span class="refDoi"> DOI: 10.1210/endo.138.9.5358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1210%2Fendo.138.9.5358" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1997&pages=3901-3911&author=T.+M.+Willsonauthor=J.+D.+Norrisauthor=B.+L.+Wagnerauthor=I.+Asplinauthor=P.+Baerauthor=H.+R.+Brownauthor=S.+A.+Jonesauthor=B.+Henkeauthor=H.+Saulsauthor=S.+Wolfeauthor=D.+C.+Morrisauthor=D.+P.+McDonnell&title=Dissection+of+the+molecular+mechanism+of+action+of+GW5368%2C+a+novel+estrogen+receptor+ligand%2C+provides+insights+into+the+role+of+estrogen+receptor&doi=10.1210%2Fendo.138.9.5358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1210%2Fendo.138.9.5358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.138.9.5358%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWagner%26aufirst%3DB.%2BL.%26aulast%3DAsplin%26aufirst%3DI.%26aulast%3DBaer%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DH.%2BR.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DHenke%26aufirst%3DB.%26aulast%3DSauls%26aufirst%3DH.%26aulast%3DWolfe%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DD.%2BC.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DDissection%2520of%2520the%2520molecular%2520mechanism%2520of%2520action%2520of%2520GW5368%252C%2520a%2520novel%2520estrogen%2520receptor%2520ligand%252C%2520provides%2520insights%2520into%2520the%2520role%2520of%2520estrogen%2520receptor%26jtitle%3DEndocrinology%26date%3D1997%26volume%3D138%26spage%3D3901%26epage%3D3911%26doi%3D10.1210%2Fendo.138.9.5358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowler, J.</span><span> </span><span class="NLM_article-title">Novel antioestrogens without partial agonist activity</span> <span class="citation_source-journal">J. Steroid Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">653</span><span class="refDoi"> DOI: 10.1016/0022-4731(88)90014-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2F0022-4731%2888%2990014-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=3199810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=645-653&author=A.+E.+Wakelingauthor=J.+Bowler&title=Novel+antioestrogens+without+partial+agonist+activity&doi=10.1016%2F0022-4731%2888%2990014-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antiestrogens without partial agonist activity</span></div><div class="casAuthors">Wakeling, A. E.; Bowler, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4B</span>),
    <span class="NLM_cas:pages">645-53</span>CODEN:
                <span class="NLM_cas:coden">JSTBBK</span>;
        ISSN:<span class="NLM_cas:issn">0022-4731</span>.
    </div><div class="casAbstract">The estrogenic and antiestrogenic properties of some novel 7α-alkyl amide derivs. of 17β-estradiol have been measured in rats and mice.  The compd. ICI 164384 (I) was devoid of estrogenic activity in the uterus and vagina of both species and on the hypothalamic-pituitary axis of the rat.  ICI 164384 blocked completely the uterotrophic action of exogenous and endogenous estradiol and of the partial agonist antiestrogens typified by tamoxifen.  Unlike tamoxifen, ICI 164384 did not promote premature vaginal opening in neonatal rats.  The affinity of ICI 164384 for the rat uterus estrogen receptor was substantially greater than that of tamoxifen.  In MCF-7 and ZR-75-1 breast cancer cells in tissue culture, ICI 164384 was a more potent inhibitor of cell growth than was tamoxifen and growth inhibition was reversed by estradiol.  The properties of ICI 164384 satisfy many of the criteria which define pure antiestrogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSFknFn53ejrVg90H21EOLACvtfcHk0lhmKeurJyw9Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCjtw%253D%253D&md5=038d59b06202ab394d535e1bf20a8577</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2F0022-4731%2888%2990014-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-4731%252888%252990014-3%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DNovel%2520antioestrogens%2520without%2520partial%2520agonist%2520activity%26jtitle%3DJ.%2520Steroid%2520Biochem.%26date%3D1988%26volume%3D31%26spage%3D645%26epage%3D653%26doi%3D10.1016%2F0022-4731%2888%2990014-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pike, A. C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brzozowski, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsell, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafsson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlquist, M.</span><span> </span><span class="NLM_article-title">Structural insights into the mode of action of a pure antiestrogen</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.1016/S0969-2126(01)00568-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2FS0969-2126%2801%2900568-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=11250199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslKgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2001&pages=145-153&author=A.+C.+W.+Pikeauthor=A.+M.+Brzozowskiauthor=J.+Waltonauthor=R.+E.+Hubbardauthor=A.+G.+Thorsellauthor=Y.+L.+Liauthor=J.+A.+Gustafssonauthor=M.+Carlquist&title=Structural+insights+into+the+mode+of+action+of+a+pure+antiestrogen&doi=10.1016%2FS0969-2126%2801%2900568-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the mode of action of a pure antiestrogen</span></div><div class="casAuthors">Pike, Ashley C. W.; Brzozowski, A. Marek; Walton, Julia; Hubbard, Roderick E.; Thorsell, Ann-Gerd; Li, Yi-Lin; Gustafsson, Jan-Ake; Carlquist, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-153</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Background: Estrogens exert their effects on target tissues by binding to a nuclear transcription factor termed the estrogen receptor (ER).  Previous structural studies have demonstrated that each class of ER ligand (agonist, partial agonist, and SERM antagonist) induces distinctive orientations in the receptor's carboxy-terminal transactivation helix.  The conformation of this portion of the receptor dets. whether ER can recruit and interact with the components of the transcriptional machinery, thereby facilitating target gene expression.  Results: We have detd. the structure of rat ERβ ligand binding domain (LBD) in complex with the pure antiestrogen ICI 164,384 at 2.3 Å resoln.  The binding of this compd. to the receptor completely abolishes the assocn. between the transactivation helix (H12) and the rest of the LBD.  The structure reveals that the terminal portion of ICI's bulky side chain substituent protrudes from the hormone binding pocket, binds along the coactivator recruitment site, and phys. prevents H12 from adopting either its characteristic agonist or AF2 antagonist orientation.  Conclusions: The binding mode adopted by the pure antiestrogen is similar to that seen for other ER antagonists.  However, the size and resultant positioning of the ligand's side chain substituent produces a receptor conformation that is distinct from that adopted in the presence of other classes of ER ligands.  The novel observation that binding of ICI results in the complete destabilization of H12 provides some indications as to a possible mechanism for pure receptor antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_dBAqpVZPtrVg90H21EOLACvtfcHk0li26ehY9hWHbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslKgsrg%253D&md5=ac139f6c39a2605e15314176397f11d4</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2801%2900568-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252801%252900568-8%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DA.%2BC.%2BW.%26aulast%3DBrzozowski%26aufirst%3DA.%2BM.%26aulast%3DWalton%26aufirst%3DJ.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DThorsell%26aufirst%3DA.%2BG.%26aulast%3DLi%26aufirst%3DY.%2BL.%26aulast%3DGustafsson%26aufirst%3DJ.%2BA.%26aulast%3DCarlquist%26aufirst%3DM.%26atitle%3DStructural%2520insights%2520into%2520the%2520mode%2520of%2520action%2520of%2520a%2520pure%2520antiestrogen%26jtitle%3DStructure%26date%3D2001%26volume%3D9%26spage%3D145%26epage%3D153%26doi%3D10.1016%2FS0969-2126%2801%2900568-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Shiau, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barstad, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loria, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agard, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span> </span><span class="NLM_article-title">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">927</span><span class="NLM_x">–</span> <span class="NLM_lpage">937</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81717-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2FS0092-8674%2800%2981717-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=9875847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=927-937&author=A.+K.+Shiauauthor=D.+Barstadauthor=P.+M.+Loriaauthor=L.+Chengauthor=P.+J.+Kushnerauthor=D.+A.+Agardauthor=G.+L.+Greene&title=The+structural+basis+of+estrogen+receptor%2Fcoactivator+recognition+and+the+antagonism+of+this+interaction+by+tamoxifen&doi=10.1016%2FS0092-8674%2800%2981717-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</span></div><div class="casAuthors">Shiau, Andrew K.; Barstad, Danielle; Loria, Paula M.; Cheng, Lin; Kushner, Peter J.; Agard, David A.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">927-937</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by interactions with coactivators.  Receptor agonists promote coactivator binding, and antagonists block coactivator binding.  Here we report the crystal structure of the human estrogen receptor α (hERα) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hERα LBD bound to the selective antagonist 4-hydroxytamoxifen (OHT).  In the DES-LBD-peptide complex, the peptide binds as a short α helix to a hydrophobic groove on the surface of the LBD.  In the OHT-LBD complex, helix 12 occludes the coactivator recognition groove by mimicking the interactions of the NR box peptide with the LBD.  These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrjqf40oHhE7Vg90H21EOLACvtfcHk0li26ehY9hWHbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D&md5=074d616cf353f0d98cea5b26c4595c10</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981717-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981717-1%26sid%3Dliteratum%253Aachs%26aulast%3DShiau%26aufirst%3DA.%2BK.%26aulast%3DBarstad%26aufirst%3DD.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DThe%2520structural%2520basis%2520of%2520estrogen%2520receptor%252Fcoactivator%2520recognition%2520and%2520the%2520antagonism%2520of%2520this%2520interaction%2520by%2520tamoxifen%26jtitle%3DCell%26date%3D1998%26volume%3D95%26spage%3D927%26epage%3D937%26doi%3D10.1016%2FS0092-8674%2800%2981717-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Renaud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floersheim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halleux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaeppi, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, W.</span><span> </span><span class="NLM_article-title">Estrogen receptor modulators: identification and structure-activity relationships of potent ERα-selective tetrahydroisoquinoline ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2945</span><span class="NLM_x">–</span> <span class="NLM_lpage">2957</span><span class="refDoi"> DOI: 10.1021/jm030086h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030086h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2945-2957&author=J.+Renaudauthor=S.+F.+Bischoffauthor=T.+Buhlauthor=P.+Floersheimauthor=B.+Fournierauthor=C.+Halleuxauthor=J.+Kallenauthor=H.+Kellerauthor=J.-M.+Schlaeppiauthor=W.+Stark&title=Estrogen+receptor+modulators%3A+identification+and+structure-activity+relationships+of+potent+ER%CE%B1-selective+tetrahydroisoquinoline+ligands&doi=10.1021%2Fjm030086h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm030086h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030086h%26sid%3Dliteratum%253Aachs%26aulast%3DRenaud%26aufirst%3DJ.%26aulast%3DBischoff%26aufirst%3DS.%2BF.%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DFloersheim%26aufirst%3DP.%26aulast%3DFournier%26aufirst%3DB.%26aulast%3DHalleux%26aufirst%3DC.%26aulast%3DKallen%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DH.%26aulast%3DSchlaeppi%26aufirst%3DJ.-M.%26aulast%3DStark%26aufirst%3DW.%26atitle%3DEstrogen%2520receptor%2520modulators%253A%2520identification%2520and%2520structure-activity%2520relationships%2520of%2520potent%2520ER%25CE%25B1-selective%2520tetrahydroisoquinoline%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2945%26epage%3D2957%26doi%3D10.1021%2Fjm030086h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Renaud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floersheim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geiser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halleux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramage, P.</span><span> </span><span class="NLM_article-title">Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERα-Selective tetrahydroisoquinoline ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">364</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span><span class="refDoi"> DOI: 10.1021/jm040858p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040858p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=364-379&author=J.+Renaudauthor=S.+F.+Bischoffauthor=T.+Buhlauthor=P.+Floersheimauthor=B.+Fournierauthor=M.+Geiserauthor=C.+Halleuxauthor=J.+Kallenauthor=H.+Kellerauthor=P.+Ramage&title=Selective+estrogen+receptor+modulators+with+conformationally+restricted+side+chains.+Synthesis+and+structure-activity+relationship+of+ER%CE%B1-Selective+tetrahydroisoquinoline+ligands&doi=10.1021%2Fjm040858p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm040858p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040858p%26sid%3Dliteratum%253Aachs%26aulast%3DRenaud%26aufirst%3DJ.%26aulast%3DBischoff%26aufirst%3DS.%2BF.%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DFloersheim%26aufirst%3DP.%26aulast%3DFournier%26aufirst%3DB.%26aulast%3DGeiser%26aufirst%3DM.%26aulast%3DHalleux%26aufirst%3DC.%26aulast%3DKallen%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DH.%26aulast%3DRamage%26aufirst%3DP.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulators%2520with%2520conformationally%2520restricted%2520side%2520chains.%2520Synthesis%2520and%2520structure-activity%2520relationship%2520of%2520ER%25CE%25B1-Selective%2520tetrahydroisoquinoline%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D364%26epage%3D379%26doi%3D10.1021%2Fjm040858p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Govek, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasawa, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnefous, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darimont, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillot, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudente, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hager, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. D.</span><span> </span><span class="NLM_article-title">Optimization of an indazole series of selective estrogen receptor degraders: tumor regression in a tamoxifen-resistent breast cancer xenograft</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5163</span><span class="NLM_x">–</span> <span class="NLM_lpage">5167</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.bmcl.2015.09.074" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5163-5167&author=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=K.+L.+Douglasauthor=A.+G.+Laiauthor=M.+Kahramanauthor=C.+Bonnefousauthor=A.+M.+Aparicioauthor=B.+D.+Darimontauthor=K.+L.+Grillotauthor=J.+D.+Josephauthor=J.+A.+Kaufmanauthor=K.-J.+Leeauthor=N.+Luauthor=M.+J.+Moonauthor=R.+Y.+Prudenteauthor=J.+Sensintaffarauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Optimization+of+an+indazole+series+of+selective+estrogen+receptor+degraders%3A+tumor+regression+in+a+tamoxifen-resistent+breast+cancer+xenograft&doi=10.1016%2Fj.bmcl.2015.09.074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DAparicio%26aufirst%3DA.%2BM.%26aulast%3DDarimont%26aufirst%3DB.%2BD.%26aulast%3DGrillot%26aufirst%3DK.%2BL.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DKaufman%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DPrudente%26aufirst%3DR.%2BY.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DOptimization%2520of%2520an%2520indazole%2520series%2520of%2520selective%2520estrogen%2520receptor%2520degraders%253A%2520tumor%2520regression%2520in%2520a%2520tamoxifen-resistent%2520breast%2520cancer%2520xenograft%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5163%26epage%3D5167%26doi%3D10.1016%2Fj.bmcl.2015.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Savi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Almeida, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callis, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donald, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feron, L. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayter, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karoutchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, Z.</span><span> </span><span class="NLM_article-title">Optimization of a novel binding motif to (<i>E</i>)-3-(3,5-difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8128</span><span class="NLM_x">–</span> <span class="NLM_lpage">8140</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&author=C.+De+Saviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+L.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+novel+binding+motif+to+%28E%29-3-%283%2C5-difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C3%2C4%2C9-tetrahydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+acid+%28AZD9496%29%2C+a+potent+and+orally+bioavailable+selective+estrogen+receptor+downregulator+and+antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span></div><div class="casAuthors">De Savi, Chris; Bradbury, Robert H.; Rabow, Alfred A.; Norman, Richard A.; de Almeida, Camila; Andrews, David M.; Ballard, Peter; Buttar, David; Callis, Rowena J.; Currie, Gordon S.; Curwen, Jon O.; Davies, Chris D.; Donald, Craig S.; Feron, Lyman J. L.; Gingell, Helen; Glossop, Steven C.; Hayter, Barry R.; Hussain, Syeed; Karoutchi, Galith; Lamont, Scott G.; MacFaul, Philip; Moss, Thomas A.; Pearson, Stuart E.; Tonge, Michael; Walker, Graeme E.; Weir, Hazel M.; Wilson, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8128-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equiv. potency and preclin. pharmacol. to the i.m. SERD fulvestrant is described.  A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand.  Aided by crystal structures of novel ligands bound to an ER construct, medicinal chem. iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clin. candidate with high oral bioavailability across preclin. species that is currently being evaluated in phase I clin. trials for the treatment of advanced estrogen receptor (ER) pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP-ZYYxmMtg7Vg90H21EOLACvtfcHk0liYrmmogQysyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK&md5=df7eee70ca783a2933cd494b53f71488</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%2BL.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520novel%2520binding%2520motif%2520to%2520%2528E%2529-3-%25283%252C5-difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C3%252C4%252C9-tetrahydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520acid%2520%2528AZD9496%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520and%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasawa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnefous, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudente, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darimont, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillot, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hager, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. D.</span><span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4888</span><span class="NLM_x">–</span> <span class="NLM_lpage">4904</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&author=A.+Laiauthor=M.+Kahramanauthor=G.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.-J.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0liYrmmogQysyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DG.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Scott, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, R. D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degorce, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">Tetrahydroisoquinoline phenols: selective estrogen receptor downregulator antagonists with oral bioavailability in rat</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=94-99&author=J.+S.+Scottauthor=A.+Baileyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=P.+A.+MacFaulauthor=H.+Gingellauthor=T.+Mossauthor=R.+A.+Normanauthor=J.+H.+Pinkauthor=A.+A.+Rabowauthor=B.+Robertsauthor=P.+D.+Smith&title=Tetrahydroisoquinoline+phenols%3A+selective+estrogen+receptor+downregulator+antagonists+with+oral+bioavailability+in+rat&doi=10.1021%2Facsmedchemlett.5b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18dR"><div class="casContent"><span class="casTitleNuber">18d</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Davies, Robert D. M.; Degorce, Sebastien L.; MacFaul, Philip A.; Gingell, Helen; Moss, Thomas; Norman, Richard A.; Pink, Jennifer H.; Rabow, Alfred A.; Roberts, Bryan; Smith, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile.  Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compds. I [R = Ph, PhCH2, i-Bu, etc.] with subnanomolar levels of potency.  The phenol functionality was shown to be required to achieve highly potent compds., but unusually this was compatible with obtaining high oral bioavailabilities in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXOiEPK5ofVLVg90H21EOLACvtfcHk0livuUH181HVRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK&md5=8c573b4e96e70cf61d40f349a7c19967</span></div><a href="/servlet/linkout?suffix=cit18d&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00413%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DTetrahydroisoquinoline%2520phenols%253A%2520selective%2520estrogen%2520receptor%2520downregulator%2520antagonists%2520with%2520oral%2520bioavailability%2520in%2520rat%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D94%26epage%3D99%26doi%3D10.1021%2Facsmedchemlett.5b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Wardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">–</span> <span class="NLM_lpage">724</span><span class="refDoi"> DOI: 10.1530/ERC-15-0287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1530%2FERC-15-0287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=26162914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=713-724&author=S.+E.+Wardellauthor=E.+R.+Nelsonauthor=C.+A.+Chaoauthor=H.+M.+Alleyauthor=D.+P.+McDonnell&title=Evaluation+of+the+pharmacological+activities+of+RAD1901%2C+a+selective+estrogen+receptor+degrader&doi=10.1530%2FERC-15-0287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18eR"><div class="casContent"><span class="casTitleNuber">18e</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader</span></div><div class="casAuthors">Wardell, Suzanne E.; Nelson, Erik R.; Chao, Christina A.; Alley, Holly M.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">713-724</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains a first-line treatment for estrogen receptor 1 (ESR1) pos. breast cancer.  However, tumor resistance limits the duration of response.  The clin. efficacy of fulvestrant, a selective ER degrader (SERD) that triggers receptor degrdn., has confirmed that ESR1 often remains engaged in endocrine therapy resistant cancers.  Recently developed, selective ER modulators (SERMs)/SERD hybrids (SSHs) that facilitate ESR1 degrdn. in breast cancer cells and reproductive tissues have been advanced as an alternative treatment for advanced breast cancer, particularly in the metastatic setting.  RAD1901 is one SSH currently being evaluated clin. that is unique among ESR1 modulators in that it readily enters the brain, a common site of breast cancer metastasis.  In this study, RAD1901 inhibited estrogen activation of ESR1 in vitro and in vivo, inhibited estrogen-dependent breast cancer cell proliferation and xenograft tumor growth, and mediated dose-dependent downregulation of ESR1 protein.  However, doses of RAD1901 insufficient to induce ESR1 degrdn. were shown to result in the activation of ESR1 target genes and in the stimulation of xenograft tumor growth.  RAD1901 is an SSH that exhibits complex pharmacol. in breast cancer models, having dose-dependent agonist/antagonist activity displayed in a tissue-selective manner.  It remains unclear how this unique pharmacol. will impact the utility of RAD1901 for breast cancer treatment.  However, being the only SERD currently known to access the brain, RAD1901 merits evaluation as a targeted therapy for the treatment of breast cancer brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZozvILn25g7Vg90H21EOLACvtfcHk0lj7CYBuESfU0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D&md5=0749b230c2a16355345c884438681d47</span></div><a href="/servlet/linkout?suffix=cit18e&amp;dbid=16384&amp;doi=10.1530%2FERC-15-0287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-15-0287%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNelson%26aufirst%3DE.%2BR.%26aulast%3DChao%26aufirst%3DC.%2BA.%26aulast%3DAlley%26aufirst%3DH.%2BM.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520pharmacological%2520activities%2520of%2520RAD1901%252C%2520a%2520selective%2520estrogen%2520receptor%2520degrader%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2015%26volume%3D22%26spage%3D713%26epage%3D724%26doi%3D10.1530%2FERC-15-0287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Wander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hausoul, P. J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliedregt, L. A. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Steen, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Koten, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein Gebbink, R. J. M. K.</span><span> </span><span class="NLM_article-title">Synthesis of polyaryl rigid-core carbosilane dendrimers for supported organic synthesis</span> <span class="citation_source-journal">Organometallics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4415</span><span class="refDoi"> DOI: 10.1021/om900265v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/om900265v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFCmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=4406-4415&author=M.+Wanderauthor=P.+J.+C.+Hausoulauthor=L.+A.+J.+M.+Sliedregtauthor=B.+J.+van+Steenauthor=G.+van+Kotenauthor=R.+J.+M.+K.+Klein+Gebbink&title=Synthesis+of+polyaryl+rigid-core+carbosilane+dendrimers+for+supported+organic+synthesis&doi=10.1021%2Fom900265v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Polyaryl Rigid-Core Carbosilane Dendrimers for Supported Organic Synthesis</span></div><div class="casAuthors">Wander, Maaike; Hausoul, Peter J. C.; Sliedregt, Leo A. J. M.; van Steen, Bart J.; van Koten, Gerard; Klein Gebbink, Robertus J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Organometallics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4415</span>CODEN:
                <span class="NLM_cas:coden">ORGND7</span>;
        ISSN:<span class="NLM_cas:issn">0276-7333</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carbosilane dendrimers can be used as sol. supports for org. synthesis, since their structure allows sepn. of excess reagents from the supported products, eventually yielding products of high purity and in high yield, as in solid-phase org. synthesis (SPOS).  In previous studies often loss of dendritic material during filtration was obsd., due to the rather flexible structure of the conventional dendrimers.  In order to improve the diafiltration retention of the carbosilane dendrimers, the synthesis of carbosilane dendrimers based on more rigid-core mols. was investigated.  Both 1,3,5-tris(4-bromophenyl)benzene 1 and tetrakis(4-bromophenyl)silane 2 were selected on the basis of their rigid structure and suitable functional groups for further functionalization using organolithium chem.  An optimized halogen lithium exchange (HLE) protocol was developed for the synthesis of 2 via 1-bromo-4-lithiobenzene.  This protocol involves reaction of an aryl bromide with n-BuLi at room temp., followed by partial removal of the solvent by evapn. (∼70%, vol./vol.), addn. of pentane to promote pptn. of the aryl lithium compd., and centrifugation and removal of the solvent to obtain, after repeating the last two steps once, the wet aryl lithium compd. in pure form.  This HLE protocol was proven to be effective for mono- and dilithiation, as well as for polylithiation reactions of aryl bromides.  Furthermore, the rigid tris(4-bromophenyl)chlorosilane wedge 3 was synthesized to add a rigid generation to the prepd. core mols., and bromotriallylsilane 4 was synthesized for the introduction of triallylsilyl moieties on the periphery of the core mols.  With these four building blocks several rigid-core carbosilane dendrimers were synthesized, which can be applied as better retainable sol. supports for org. synthesis in a diafiltration setup.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ABOwsTdgL7Vg90H21EOLACvtfcHk0lj7CYBuESfU0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFCmu7c%253D&md5=d1f0861282cb40a1a2e3f55fcfa9f358</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fom900265v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fom900265v%26sid%3Dliteratum%253Aachs%26aulast%3DWander%26aufirst%3DM.%26aulast%3DHausoul%26aufirst%3DP.%2BJ.%2BC.%26aulast%3DSliedregt%26aufirst%3DL.%2BA.%2BJ.%2BM.%26aulast%3Dvan%2BSteen%26aufirst%3DB.%2BJ.%26aulast%3Dvan%2BKoten%26aufirst%3DG.%26aulast%3DKlein%2BGebbink%26aufirst%3DR.%2BJ.%2BM.%2BK.%26atitle%3DSynthesis%2520of%2520polyaryl%2520rigid-core%2520carbosilane%2520dendrimers%2520for%2520supported%2520organic%2520synthesis%26jtitle%3DOrganometallics%26date%3D2009%26volume%3D28%26spage%3D4406%26epage%3D4415%26doi%3D10.1021%2Fom900265v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wittenberger, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donner, B. G.</span><span> </span><span class="NLM_article-title">Dialkyltin oxide mediated addition of trimethylsilyl azide to nitriles. A novel preparation of 5-substituted tetrazols</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4139</span><span class="NLM_x">–</span> <span class="NLM_lpage">4141</span><span class="refDoi"> DOI: 10.1021/jo00067a058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00067a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK3sXkvFGnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1993&pages=4139-4141&author=S.+J.+Wittenbergerauthor=B.+G.+Donner&title=Dialkyltin+oxide+mediated+addition+of+trimethylsilyl+azide+to+nitriles.+A+novel+preparation+of+5-substituted+tetrazols&doi=10.1021%2Fjo00067a058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dialkyltin oxide mediated addition of trimethylsilyl azide to nitriles.  A novel preparation of 5-substituted tetrazols</span></div><div class="casAuthors">Wittenberger, Steven J.; Donner, B. Gregory</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4139-41</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">A new method for the conversion of nitriles into 5-substituted tetrazoles is presented.  Aryl and aliph. nitriles, R2CN (R2 = Ph, 2-, 3-BrC6H4, Bu, 4'methyl-1,1'-biphenyl-2-yl, etc.), were treated with trimethylsilyl azide in the presence of catalytic dialkyltin oxide, R12SnO (R1 = Me, n-Bu) in toluene at 93-110° to produce the tetrazoles I.  A tetracoordinate dialkyl(O-trimethylsilyl) azidostannylhydrin, Me3SiOSn(N3)R12, was implicated as the reactive intermediate.  The 5-substituted tetrazoles were isolated in good to excellent yield.  The procedure is esp. useful for the prepn. of 5-[4'-methyl-1,1'-biphenyl-2-yl]-1H-tetrazole, a subunit that has become ubiquitous in the most potent and bioavailable angiotensin II antagonists disclosed to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphNY7eA5hllLVg90H21EOLACvtfcHk0lhx8rMUDmw1XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkvFGnsb8%253D&md5=1ca082880c6a390baae06845f6312431</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjo00067a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00067a058%26sid%3Dliteratum%253Aachs%26aulast%3DWittenberger%26aufirst%3DS.%2BJ.%26aulast%3DDonner%26aufirst%3DB.%2BG.%26atitle%3DDialkyltin%2520oxide%2520mediated%2520addition%2520of%2520trimethylsilyl%2520azide%2520to%2520nitriles.%2520A%2520novel%2520preparation%2520of%25205-substituted%2520tetrazols%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1993%26volume%3D58%26spage%3D4139%26epage%3D4141%26doi%3D10.1021%2Fjo00067a058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Milinkevich, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparks, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorsbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurth, M. J.</span><span> </span><span class="NLM_article-title">Synthesis and biological activity of 2-(4,5-dihydroisoxazol-5-yl)-1,3,4-oxadiazoles</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5796</span><span class="NLM_x">–</span> <span class="NLM_lpage">5798</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.07.139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.bmcl.2009.07.139" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5796-5798&author=K.+A.+Milinkevichauthor=C.+L.+Yooauthor=T.+C.+Sparksauthor=B.+A.+Lorsbachauthor=M.+J.+Kurth&title=Synthesis+and+biological+activity+of+2-%284%2C5-dihydroisoxazol-5-yl%29-1%2C3%2C4-oxadiazoles&doi=10.1016%2Fj.bmcl.2009.07.139"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.139%26sid%3Dliteratum%253Aachs%26aulast%3DMilinkevich%26aufirst%3DK.%2BA.%26aulast%3DYoo%26aufirst%3DC.%2BL.%26aulast%3DSparks%26aufirst%3DT.%2BC.%26aulast%3DLorsbach%26aufirst%3DB.%2BA.%26aulast%3DKurth%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%25202-%25284%252C5-dihydroisoxazol-5-yl%2529-1%252C3%252C4-oxadiazoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5796%26epage%3D5798%26doi%3D10.1016%2Fj.bmcl.2009.07.139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Brzozowski, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauter, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engström, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Öhman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafsson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlquist, M.</span><span> </span><span class="NLM_article-title">Molecular basis of agonism and antagonism in the oestrogen receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">389</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">758</span><span class="refDoi"> DOI: 10.1038/39645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1038%2F39645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=9338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=753-758&author=A.+M.+Brzozowskiauthor=A.+C.+Pikeauthor=Z.+Dauterauthor=R.+E.+Hubbardauthor=T.+Bonnauthor=O.+Engstr%C3%B6mauthor=L.+%C3%96hmanauthor=G.+L.+Greeneauthor=J.+A.+Gustafssonauthor=M.+Carlquist&title=Molecular+basis+of+agonism+and+antagonism+in+the+oestrogen+receptor&doi=10.1038%2F39645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of agonism and antagonism in the estrogen receptor</span></div><div class="casAuthors">Brzozowski, Andrzej M.; Pike, Ashley C. W.; Dauter, Zbigniew; Hubbard, Roderick E.; Bonn, Tomas; Engstrom, Owe; Ohman, Lars; Greene, Geoffrey L.; Gustafsson, Jan-Ake; Carlquist, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6652</span>),
    <span class="NLM_cas:pages">753-758</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Estrogens are involved in the growth, development and homeostasis of a no. of tissues.  The physiol. effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the estrogen receptor (ER).  Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of mol. events culminating in the activation or repression of target genes.  Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery.  Here we report the crystal structures of the LBD of ER in complex with the endogenous estrogen, 17β-estradiol, and the selective antagonist raloxifene, at resolns. of 3.1 and 2.6Å, resp.  The structures provide a mol. basis for the distinctive pharmacophore of the ER and its catholic binding properties.  Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes.  In addn., each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAXbSo66V1LrVg90H21EOLACvtfcHk0lhx8rMUDmw1XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D&md5=2a63951b881b329ff142c9fbc82a13e3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2F39645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F39645%26sid%3Dliteratum%253Aachs%26aulast%3DBrzozowski%26aufirst%3DA.%2BM.%26aulast%3DPike%26aufirst%3DA.%2BC.%26aulast%3DDauter%26aufirst%3DZ.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DBonn%26aufirst%3DT.%26aulast%3DEngstr%25C3%25B6m%26aufirst%3DO.%26aulast%3D%25C3%2596hman%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DGustafsson%26aufirst%3DJ.%2BA.%26aulast%3DCarlquist%26aufirst%3DM.%26atitle%3DMolecular%2520basis%2520of%2520agonism%2520and%2520antagonism%2520in%2520the%2520oestrogen%2520receptor%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D753%26epage%3D758%26doi%3D10.1038%2F39645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Shiau, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barstad, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loria, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agard, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span> </span><span class="NLM_article-title">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">927</span><span class="NLM_x">–</span> <span class="NLM_lpage">937</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81717-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2FS0092-8674%2800%2981717-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=9875847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=927-937&author=A.+K.+Shiauauthor=D.+Barstadauthor=P.+M.+Loriaauthor=L.+Chengauthor=P.+J.+Kushnerauthor=D.+A.+Agardauthor=G.+L.+Greene&title=The+structural+basis+of+estrogen+receptor%2Fcoactivator+recognition+and+the+antagonism+of+this+interaction+by+tamoxifen&doi=10.1016%2FS0092-8674%2800%2981717-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</span></div><div class="casAuthors">Shiau, Andrew K.; Barstad, Danielle; Loria, Paula M.; Cheng, Lin; Kushner, Peter J.; Agard, David A.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">927-937</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by interactions with coactivators.  Receptor agonists promote coactivator binding, and antagonists block coactivator binding.  Here we report the crystal structure of the human estrogen receptor α (hERα) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hERα LBD bound to the selective antagonist 4-hydroxytamoxifen (OHT).  In the DES-LBD-peptide complex, the peptide binds as a short α helix to a hydrophobic groove on the surface of the LBD.  In the OHT-LBD complex, helix 12 occludes the coactivator recognition groove by mimicking the interactions of the NR box peptide with the LBD.  These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrjqf40oHhE7Vg90H21EOLACvtfcHk0ljmwvSJcmXdkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D&md5=074d616cf353f0d98cea5b26c4595c10</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981717-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981717-1%26sid%3Dliteratum%253Aachs%26aulast%3DShiau%26aufirst%3DA.%2BK.%26aulast%3DBarstad%26aufirst%3DD.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DThe%2520structural%2520basis%2520of%2520estrogen%2520receptor%252Fcoactivator%2520recognition%2520and%2520the%2520antagonism%2520of%2520this%2520interaction%2520by%2520tamoxifen%26jtitle%3DCell%26date%3D1998%26volume%3D95%26spage%3D927%26epage%3D937%26doi%3D10.1016%2FS0092-8674%2800%2981717-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span>Department of Health and Human Services, Food and Drug Administration: FDA’s Policy Statement for the Development of New Stereoisomeric Drugs, Washington, DC,<span class="NLM_x"> </span><span class="NLM_year">1992</span>. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122883.htm" class="extLink">http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122883.htm</a> (accessed September 30, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Department+of+Health+and+Human+Services%2C+Food+and+Drug+Administration%3A+FDA%E2%80%99s+Policy+Statement+for+the+Development+of+New+Stereoisomeric+Drugs%2C+Washington%2C+DC%2C+1992.+http%3A%2F%2Fwww.fda.gov%2FDrugs%2FGuidanceComplianceRegulatoryInformation%2FGuidances%2Fucm122883.htm+%28accessed+September+30%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span>Configuration of enantiomers was randomly assigned.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Configuration+of+enantiomers+was+randomly+assigned."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J.</span><span> </span><span class="NLM_article-title">Nucleophilic difluoromethylation of C═N bonds in heterocycles with difluoromethyl silane reagents</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">5137</span><span class="NLM_x">–</span> <span class="NLM_lpage">5144</span><span class="refDoi"> DOI: 10.1016/j.tet.2012.04.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.tet.2012.04.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=5137-5144&author=W.+Huangauthor=C.+Niauthor=Y.+Zhaoauthor=W.+Zhangauthor=A.+D.+Dilmanauthor=J.+Hu&title=Nucleophilic+difluoromethylation+of+C%E2%95%90N+bonds+in+heterocycles+with+difluoromethyl+silane+reagents&doi=10.1016%2Fj.tet.2012.04.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2012.04.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2012.04.039%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DNi%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDilman%26aufirst%3DA.%2BD.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DNucleophilic%2520difluoromethylation%2520of%2520C%25E2%2595%2590N%2520bonds%2520in%2520heterocycles%2520with%2520difluoromethyl%2520silane%2520reagents%26jtitle%3DTetrahedron%26date%3D2012%26volume%3D68%26spage%3D5137%26epage%3D5144%26doi%3D10.1016%2Fj.tet.2012.04.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Fujikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amii, H.</span><span> </span><span class="NLM_article-title">A new method for aromatic difluoromethylation: copper-catalyzed cross-coupling and decarboxylation sequence from aryl iodides</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">5560</span><span class="NLM_x">–</span> <span class="NLM_lpage">5563</span><span class="refDoi"> DOI: 10.1021/ol202289z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol202289z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ClsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=5560-5563&author=K.+Fujikawaauthor=Y.+Fujiokaauthor=A.+Kobayashiauthor=H.+Amii&title=A+new+method+for+aromatic+difluoromethylation%3A+copper-catalyzed+cross-coupling+and+decarboxylation+sequence+from+aryl+iodides&doi=10.1021%2Fol202289z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A new method for aromatic difluoromethylation: copper-catalyzed cross-coupling and decarboxylation sequence from aryl iodides</span></div><div class="casAuthors">Fujikawa, Kenichi; Fujioka, Yasutaka; Kobayashi, Akira; Amii, Hideki</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5560-5563</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new methodol. for arom. difluoromethylation is described.  Aryl iodides reacted with α-silyldifluoroacetates upon treatment with copper catalyst in DMSO or DME to give the corresponding aryldifluoroacetates in moderate to good yields.  The subsequent hydrolysis of aryldifluoroacetates and KF-promoted decarboxylation afforded a variety of difluoromethyl aroms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGUe51qOd-PrVg90H21EOLACvtfcHk0liCsTUxuZhLlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ClsLjP&md5=c9f174dfbb2fc3a39e18968e5b2d678a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fol202289z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol202289z%26sid%3Dliteratum%253Aachs%26aulast%3DFujikawa%26aufirst%3DK.%26aulast%3DFujioka%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DA.%26aulast%3DAmii%26aufirst%3DH.%26atitle%3DA%2520new%2520method%2520for%2520aromatic%2520difluoromethylation%253A%2520copper-catalyzed%2520cross-coupling%2520and%2520decarboxylation%2520sequence%2520from%2520aryl%2520iodides%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D5560%26epage%3D5563%26doi%3D10.1021%2Fol202289z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Connor, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadwater, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewhirst, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2917</span><span class="NLM_x">–</span> <span class="NLM_lpage">2922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=11306468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2917-2922&author=C.+E.+Connorauthor=J.+D.+Norrisauthor=G.+Broadwaterauthor=T.+M.+Willsonauthor=M.+M.+Gottardisauthor=M.+W.+Dewhirstauthor=D.+P.+McDonnell&title=Circumventing+tamoxifen+resistance+in+breast+cancers+using+antiestrogens+that+induce+unique+conformational+changes+in+the+estrogen+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span></div><div class="casAuthors">Connor, Caroline E.; Norris, John D.; Broadwater, Gloria; Willson, Timothy M.; Gottardis, Marco M.; Dewhirst, Mark W.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2917-2922</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tamoxifen inhibits estrogen receptor (ER) transcriptional activity by competitively inhibiting estradiol binding and inducing conformational changes in the receptor that may prevent its interaction with coactivators.  In bone, the cardiovascular system, and some breast tumors, however, tamoxifen exhibits agonist activity, suggesting that the tamoxifen-ER complex is not recognized identically in all cells.  We used phage display to demonstrate that the antiestrogen GW5638 induces a unique structural change in the ER.  The biol. significance of this conformational change was revealed in studies that demonstrated that tamoxifen-resistant breast tumor explants are not cross-resistant to GW5638.  Because of these properties, this drug is currently being developed as a potential therapeutic for tamoxifen-resistant breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2YSN94iysMbVg90H21EOLACvtfcHk0liCsTUxuZhLlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D&md5=d7ecae7d445901e2f2c4f133ebbacdc5</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DC.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DBroadwater%26aufirst%3DG.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DCircumventing%2520tamoxifen%2520resistance%2520in%2520breast%2520cancers%2520using%2520antiestrogens%2520that%2520induce%2520unique%2520conformational%2520changes%2520in%2520the%2520estrogen%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2917%26epage%3D2922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiRenzo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span> </span><span class="NLM_article-title">Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">843</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)00188-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2FS0092-8674%2800%2900188-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=11136970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFCjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=843-852&author=Y.+Shangauthor=X.+Huauthor=J.+DiRenzoauthor=M.+A.+Lazarauthor=M.+Brown&title=Cofactor+dynamics+and+sufficiency+in+estrogen+receptor-regulated+transcription&doi=10.1016%2FS0092-8674%2800%2900188-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription</span></div><div class="casAuthors">Shang, Yongfeng; Hu, Xiao; DiRenzo, James; Lazar, Mitchell A.; Brown, Myles</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">843-852</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Many cofactors bind the hormone-activated estrogen receptor (ER), yet the specific regulators of endogenous ER-mediated gene transcription are unknown.  Using chromatin immunopptn. (ChIP), we find that ER and a no. of coactivators rapidly assoc. with estrogen responsive promoters following estrogen treatment in a cyclic fashion that is not predicted by current models of hormone activation.  Cycles of ER complex assembly are followed by transcription.  In contrast, the anti-estrogen tamoxifen (TAM) recruits corepressors but not coactivators.  Using a genetic approach, we show that recruitment of the p160 class of coactivators is sufficient for gene activation and for the growth stimulatory actions of estrogen in breast cancer supporting a model in which ER cofactors play unique roles in estrogen signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6m5Mq-rPwB7Vg90H21EOLACvtfcHk0liCsTUxuZhLlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFCjt7s%253D&md5=6f5af3762620dfd880758ba9fafcba25</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900188-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900188-4%26sid%3Dliteratum%253Aachs%26aulast%3DShang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDiRenzo%26aufirst%3DJ.%26aulast%3DLazar%26aufirst%3DM.%2BA.%26aulast%3DBrown%26aufirst%3DM.%26atitle%3DCofactor%2520dynamics%2520and%2520sufficiency%2520in%2520estrogen%2520receptor-regulated%2520transcription%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D843%26epage%3D852%26doi%3D10.1016%2FS0092-8674%2800%2900188-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Wardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">122</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span><span class="refDoi"> DOI: 10.1016/j.bcp.2011.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1016%2Fj.bcp.2011.03.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=122-130&author=S.+E.+Wardellauthor=J.+R.+Marksauthor=D.+P.+McDonnell&title=The+turnover+of+estrogen+receptor+%CE%B1+by+the+selective+estrogen+receptor+degrader+%28SERD%29+fulvestrant+is+a+saturable+process+that+is+not+required+for+antagonist+efficacy&doi=10.1016%2Fj.bcp.2011.03.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DMarks%26aufirst%3DJ.%2BR.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DThe%2520turnover%2520of%2520estrogen%2520receptor%2520%25CE%25B1%2520by%2520the%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520fulvestrant%2520is%2520a%2520saturable%2520process%2520that%2520is%2520not%2520required%2520for%2520antagonist%2520efficacy%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D122%26epage%3D130%26doi%3D10.1016%2Fj.bcp.2011.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Johnston, S. R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowsett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benz, C. C.</span><span> </span><span class="NLM_article-title">Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3723</span><span class="NLM_x">–</span> <span class="NLM_lpage">3727</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3723-3727&author=S.+R.+D.+Johnstonauthor=B.+Luauthor=M.+Dowsettauthor=X.+Liangauthor=M.+Kaufmannauthor=G.+K.+Scottauthor=C.+K.+Osborneauthor=C.+C.+Benz&title=Comparison+of+estrogen+receptor+DNA+binding+in+untreated+and+acquired+antiestrogen-resistant+human+breast+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DKaufmann%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DG.%2BK.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DBenz%26aufirst%3DC.%2BC.%26atitle%3DComparison%2520of%2520estrogen%2520receptor%2520DNA%2520binding%2520in%2520untreated%2520and%2520acquired%2520antiestrogen-resistant%2520human%2520breast%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3723%26epage%3D3727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Campbell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat-Nakshatri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinidou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakshatri, H.</span><span> </span><span class="NLM_article-title">Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">9817</span><span class="NLM_x">–</span> <span class="NLM_lpage">9824</span><span class="refDoi"> DOI: 10.1074/jbc.M010840200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1074%2Fjbc.M010840200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=9817-9824&author=R.+A.+Campbellauthor=P.+Bhat-Nakshatriauthor=N.+M.+Patelauthor=D.+Constantinidouauthor=S.+Aliauthor=H.+Nakshatri&title=Phosphatidylinositol+3-kinase%2FAKT-mediated+activation+of+estrogen+receptor+%CE%B1&doi=10.1074%2Fjbc.M010840200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010840200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010840200%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DR.%2BA.%26aulast%3DBhat-Nakshatri%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DN.%2BM.%26aulast%3DConstantinidou%26aufirst%3DD.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DNakshatri%26aufirst%3DH.%26atitle%3DPhosphatidylinositol%25203-kinase%252FAKT-mediated%2520activation%2520of%2520estrogen%2520receptor%2520%25CE%25B1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D9817%26epage%3D9824%26doi%3D10.1074%2Fjbc.M010840200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Regan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cisneros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacGregor, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muenzner, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assikis, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilimoria, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piette, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragan, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitot, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">1552</span><span class="NLM_x">–</span> <span class="NLM_lpage">1558</span><span class="refDoi"> DOI: 10.1093/jnci/90.20.1552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=10.1093%2Fjnci%2F90.20.1552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=9790548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK1cXntVKru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1998&pages=1552-1558&author=R.+M.+O%E2%80%99Reganauthor=A.+Cisnerosauthor=G.+M.+Englandauthor=J.+I.+MacGregorauthor=H.+D.+Muenznerauthor=V.+J.+Assikisauthor=M.+M.+Bilimoriaauthor=M.+Pietteauthor=Y.+P.+Draganauthor=H.+C.+Pitotauthor=R.+Chattertonauthor=V.+C.+Jordan&title=Effects+of+the+antiestrogens+tamoxifen%2C+toremifene%2C+and+ICI+182%2C780+on+endometrial+cancer+growth&doi=10.1093%2Fjnci%2F90.20.1552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth</span></div><div class="casAuthors">O'Regan, Ruth M.; Cisneros, Angela; England, Gale M.; MacGregor, Jennifer I.; Muenzner, Henry D.; Assikis, Vasikios J.; Bilimoria, Malcolm M.; Piette, Michael; Dragan, Yvonne P.; Pitot, Henry C.; Chatterton, Robert; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Tamoxifen has been shown to promote the growth of human endometrial tumors implanted in athymic mice, and it has been assocd. with a twofold to threefold increase in endometrial cancer.  Toremifene, a chlorinated deriv. of tamoxifen, and ICI 182,780, a pure antiestrogen, are two new antiestrogens being developed for the treatment of breast cancer.  The effects of these drugs on endometrial cancer are currently unknown.  Our objective was to evaluate the effects of toremifene and ICI 182,780 on the growth of human endometrial cancer in athymic mice.  The effects of tamoxifen and toremifene on the growth of either tamoxifen-stimulated or tamoxifen-naive endometrial tumors in athymic mice were not substantially different.  ICI 182,780 inhibited the growth of tamoxifen-stimulated endometrial cancer, in both the presence and the absence of estrogen.  Conclusions: Toremifene and tamoxifen produce identical effects in our endometrial cancer models.  Therefore, it is possible that toremifene, like tamoxifen, may be assocd. with an increased incidence of endometrial cancer.  In contrast, ICI 182,780 inhibited tamoxifen-stimulated endometrial cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF1twx_YIjK7Vg90H21EOLACvtfcHk0ljrXL8XTUHVYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntVKru7c%253D&md5=a9f77649d62eee3db3ae1480ba6980d4</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F90.20.1552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F90.20.1552%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DR.%2BM.%26aulast%3DCisneros%26aufirst%3DA.%26aulast%3DEngland%26aufirst%3DG.%2BM.%26aulast%3DMacGregor%26aufirst%3DJ.%2BI.%26aulast%3DMuenzner%26aufirst%3DH.%2BD.%26aulast%3DAssikis%26aufirst%3DV.%2BJ.%26aulast%3DBilimoria%26aufirst%3DM.%2BM.%26aulast%3DPiette%26aufirst%3DM.%26aulast%3DDragan%26aufirst%3DY.%2BP.%26aulast%3DPitot%26aufirst%3DH.%2BC.%26aulast%3DChatterton%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DEffects%2520of%2520the%2520antiestrogens%2520tamoxifen%252C%2520toremifene%252C%2520and%2520ICI%2520182%252C780%2520on%2520endometrial%2520cancer%2520growth%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1998%26volume%3D90%26spage%3D1552%26epage%3D1558%26doi%3D10.1093%2Fjnci%2F90.20.1552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowler, J.</span><span> </span><span class="NLM_article-title">A potent specific pure antiestrogen with clinical potential</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3867</span><span class="NLM_x">–</span> <span class="NLM_lpage">3873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1855205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=3867-3873&author=A.+E.+Wakelingauthor=M.+Dukesauthor=J.+Bowler&title=A+potent+specific+pure+antiestrogen+with+clinical+potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">A potent specific pure antiestrogen with clinical potential</span></div><div class="casAuthors">Wakeling, Alan E.; Dukes, Michael; Bowler, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3867-73</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Previous studies from this lab. have described a series of 7α-alkylamide analogs of estradiol with pure antiestrogenic activity, exemplified by ICI 164,384.  A new compd., 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol (ICI 182,780) has now been identified which has significantly increased antiestrogenic potency and retains pure estrogen antagonist activity.  The antiuterotropic potency of ICI 182,780 in the immature rat was more than 10-fold greater than that of ICI 164,384 (50% EDs of 0.06 and 0.9 mg/kg, resp.).  This order of magnitude increase of in vivo potency was also reflected, in part, by intrinsic activity at the estrogen receptor.  The relative binding affinities of ICI 182,780 and ICI 164,384 were 0.89 and 0.19, resp., compared with that of estradiol (1.0).  Similarly, the in vitro growth-inhibitory potency of ICI 182,780 exceeded that of ICI 164,384 in MCF-7 human breast cancer cells, where 50% inhibitory concns. of 0.29 and 1.3 nM, resp., were recorded.  ICI 182,780 was a more effective inhibitor of MCF-7 growth than 4'-hydroxytamoxifen, producing an 80% redn. of cell no. under conditions where 4'-hydroxytamoxifen achieved a max. of 50% inhibition.  This increased efficacy was reflected by a greater redn. of the proportion of cells engaged in DNA synthesis in ICI 182,780-treated cell cultures compared with tamoxifen-treated cells.  Sustained antiestrogenic effects, following a single parental dose of ICI 182,780 in oil suspension, were apparent in both rats and pigtail monkeys.  In vivo, antitumor activity of ICI 182,780 was demonstrated with xenografts of MCF-7 and Br10 human breast cancers in nude mice.  A single injection of ICI 182,780 provided antitumor efficacy equiv. to that of daily tamoxifen treatment for at least 4 wk.  The properties of ICI 182,780 identify this pure antiestrogen as a prime candidate with which to evaluate the potential therapeutic benefits of complete estrogen withdrawal in endocrine-responsive human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsBbUoU0rp-LVg90H21EOLACvtfcHk0ljrXL8XTUHVYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D&md5=f73c3ea7810ce4780789bc69096f43ea</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DA%2520potent%2520specific%2520pure%2520antiestrogen%2520with%2520clinical%2520potential%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26spage%3D3867%26epage%3D3873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=IR5K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=IR5K','PDB','IR5K'); return false;">PDB: IR5K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=IHJ1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=IHJ1','PDB','IHJ1'); return false;">PDB: IHJ1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T92" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T92','PDB','5T92'); return false;">PDB: 5T92</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T97" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T97','PDB','5T97'); return false;">PDB: 5T97</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i76"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01468">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_28067"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01468">10.1021/acs.jmedchem.6b01468</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthesis of <b>52</b>, <b>66</b>, <b>69</b>–<b>82</b>, 1-methyl-4-vinyl-1<i>H</i>-imidazole, and 1-methyl-5-vinyl-1<i>H</i>-imidazole in addition to the chiral separation of <b>rac-10</b>, <b>rac-40</b>, <b>rac-59</b>, and <b>rac-63</b>, solution and plasma stability of <b>(<i>R</i>)-</b> and <b>(<i>S</i>)-40</b>, crystallographic parameters, pharmacokinetic studies, and methods for solubility and permeability determination (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01468/suppl_file/jm6b01468_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01468/suppl_file/jm6b01468_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01468/suppl_file/jm6b01468_si_001.pdf">jm6b01468_si_001.pdf (1.67 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01468/suppl_file/jm6b01468_si_002.csv">jm6b01468_si_002.csv (6.52 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB code for compound <b>9</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T92">5T92</a> and for <b>40</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T97">5T97</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01468%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-7" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01468" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799cee94fd83d94","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
